U.S. patent application number 10/831620 was filed with the patent office on 2005-07-07 for rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina).
This patent application is currently assigned to Sirna Therapeutics, Inc.. Invention is credited to Beigelman, Leonid, McSwiggen, James, Pavco, Pamela.
Application Number | 20050148530 10/831620 |
Document ID | / |
Family ID | 49510602 |
Filed Date | 2005-07-07 |
United States Patent
Application |
20050148530 |
Kind Code |
A1 |
McSwiggen, James ; et
al. |
July 7, 2005 |
RNA interference mediated inhibition of vascular endothelial growth
factor and vascular endothelial growth factor receptor gene
expression using short interfering nucleic acid (siNA)
Abstract
The present invention concerns methods and reagents useful in
modulating vascular endothelial growth factor (VEGF, VEGF-A,
VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor
receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a
variety of applications, including use in therapeutic, diagnostic,
target validation, and genomic discovery applications.
Specifically, the invention relates to small nucleic acid
molecules, such as short interfering nucleic acid (siNA), short
interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
(mRNA), and short hairpin RNA (shRNA) molecules capable of
mediating RNA interference (RNAi) against VEGF and/or VEGFr gene
expression and/or activity. The small nucleic acid molecules are
useful in the diagnosis and treatment of cancer, proliferative
diseases, and any other disease or condition that responds to
modulation of VEGF and/or VEGFr expression or activity.
Inventors: |
McSwiggen, James; (Boulder,
CO) ; Beigelman, Leonid; (Longmont, CO) ;
Pavco, Pamela; (Lafayette, CO) |
Correspondence
Address: |
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 S. WACKER DRIVE
32ND FLOOR
CHICAGO
IL
60606
US
|
Assignee: |
Sirna Therapeutics, Inc.
Boulder
CO
|
Family ID: |
49510602 |
Appl. No.: |
10/831620 |
Filed: |
April 23, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10764957 |
Jan 26, 2004 |
|
|
|
10764957 |
Jan 26, 2004 |
|
|
|
10670011 |
Sep 23, 2003 |
|
|
|
10670011 |
Sep 23, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
PCT/US03/05022 |
Feb 20, 2003 |
|
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10758155 |
Jan 12, 2004 |
|
|
|
10758155 |
Jan 12, 2004 |
|
|
|
10665951 |
Sep 18, 2003 |
|
|
|
10665951 |
Sep 18, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
PCT/US03/05022 |
Feb 20, 2003 |
|
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10664668 |
Sep 18, 2003 |
|
|
|
10664668 |
Sep 18, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
10665255 |
Sep 16, 2003 |
|
|
|
PCT/US03/05028 |
Feb 20, 2003 |
|
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10757803 |
Jan 14, 2004 |
|
|
|
10757803 |
Jan 14, 2004 |
|
|
|
10720448 |
Nov 24, 2003 |
|
|
|
10720448 |
Nov 24, 2003 |
|
|
|
10693059 |
Oct 23, 2003 |
|
|
|
10693059 |
Oct 23, 2003 |
|
|
|
10444853 |
May 23, 2003 |
|
|
|
10444853 |
May 23, 2003 |
|
|
|
PCT/US03/05346 |
Feb 20, 2003 |
|
|
|
10444853 |
May 23, 2003 |
|
|
|
PCT/US03/05028 |
Feb 20, 2003 |
|
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10427160 |
Apr 30, 2003 |
|
|
|
10427160 |
Apr 30, 2003 |
|
|
|
PCT/US02/15876 |
May 17, 2002 |
|
|
|
10831620 |
Apr 23, 2004 |
|
|
|
10712633 |
Nov 13, 2003 |
|
|
|
10712633 |
Nov 13, 2003 |
|
|
|
PCT/US02/17674 |
May 29, 2002 |
|
|
|
60393796 |
Jul 3, 2002 |
|
|
|
60399348 |
Jul 29, 2002 |
|
|
|
60393796 |
Jul 3, 2002 |
|
|
|
60399348 |
Jul 29, 2002 |
|
|
|
60393796 |
Jul 3, 2002 |
|
|
|
60399348 |
Jul 29, 2002 |
|
|
|
60358580 |
Feb 20, 2002 |
|
|
|
60358580 |
Feb 20, 2002 |
|
|
|
60363124 |
Mar 11, 2002 |
|
|
|
60363124 |
Mar 11, 2002 |
|
|
|
60386782 |
Jun 6, 2002 |
|
|
|
60386782 |
Jun 6, 2002 |
|
|
|
60406784 |
Aug 29, 2002 |
|
|
|
60406784 |
Aug 29, 2002 |
|
|
|
60408378 |
Sep 5, 2002 |
|
|
|
60408378 |
Sep 5, 2002 |
|
|
|
60409293 |
Sep 9, 2002 |
|
|
|
60409293 |
Sep 9, 2002 |
|
|
|
60440129 |
Jan 15, 2003 |
|
|
|
60440129 |
Jan 15, 2003 |
|
|
|
Current U.S.
Class: |
514/44A ;
536/23.1 |
Current CPC
Class: |
C12N 2310/3521 20130101;
C12N 2310/3533 20130101; C12N 15/1136 20130101; C12N 2310/315
20130101; C12N 15/111 20130101; C12N 2310/322 20130101; C12N
2310/317 20130101; C12N 2310/321 20130101; C12N 15/1138 20130101;
C12N 2310/51 20130101; C12N 2310/14 20130101 |
Class at
Publication: |
514/044 ;
536/023.1 |
International
Class: |
C07H 021/02; A61K
048/00 |
Claims
What we claim is:
1. A chemically synthesized double stranded short interfering
nucleic acid (siNA) molecule that directs cleavage of a vascular
endothelial growth factor receptor 1 (VEGFR1) via RNA interference
(RNAi), wherein: a. each strand of said siNA molecule is about 19
to about 23 nucleotides in length; and b. one strand of said siNA
molecule comprises nucleotide sequence having sufficient
complementarity to said VEGFR1 RNA for the siNA molecule to direct
cleavage of the VEGFR1 RNA via RNA interference.
2. The siNA molecule of claim 1, wherein said siNA molecule
comprises no ribonucleotides.
3. The siNA molecule of claim 1, wherein said siNA molecule
comprises one or more ribonucleotides.
4. The siNA molecule of claim 1, wherein one strand of said
double-stranded siNA molecule comprises a nucleotide sequence that
is complementary to a nucleotide sequence of a VEGFR1 gene or a
portion thereof, and wherein a second strand of said
double-stranded siNA molecule comprises a nucleotide sequence
substantially similar to the nucleotide sequence or a portion
thereof of said VEGFR1 RNA.
5. The siNA molecule of claim 4, wherein each strand of the siNA
molecule comprises about 19 to about 23 nucleotides, and wherein
each strand comprises at least about 19 nucleotides that are
complementary to the nucleotides of the other strand.
6. The siNA molecule of claim 1, wherein said siNA molecule
comprises an antisense region comprising a nucleotide sequence that
is complementary to a nucleotide sequence of a VEGFR1 gene or a
portion thereof, and wherein said siNA further comprises a sense
region, wherein said sense region comprises a nucleotide sequence
substantially similar to the nucleotide sequence of said VEGFR1
gene or a portion thereof.
7. The siNA molecule of claim 6, wherein said antisense region and
said sense region comprise about 19 to about 23 nucleotides, and
wherein said antisense region comprises at least about 19
nucleotides that are complementary to nucleotides of the sense
region.
8. The siNA molecule of claim 1, wherein said siNA molecule
comprises a sense region and an antisense region, and wherein said
antisense region comprises a nucleotide sequence that is
complementary to a nucleotide sequence of RNA encoded by a VEGFR1
gene, or a portion thereof, and said sense region comprises a
nucleotide sequence that is complementary to said antisense
region.
9. The siNA molecule of claim 6, wherein said siNA molecule is
assembled from two separate oligonucleotide fragments wherein one
fragment comprises the sense region and a second fragment comprises
the antisense region of said siNA molecule.
10. The siNA molecule of claim 6, wherein said sense region is
connected to the antisense region via a linker molecule.
11. The siNA molecule of claim 10, wherein said linker molecule is
a polynucleotide linker.
12. The siNA molecule of claim 10, wherein said linker molecule is
a non-nucleotide linker.
13. The siNA molecule of claim 6, wherein pyrimidine nucleotides in
the sense region are 2'-O-methylpyrimidine nucleotides.
14. The siNA molecule of claim 6, wherein purine nucleotides in the
sense region are 2'-deoxy purine nucleotides.
15. The siNA molecule of claim 6, wherein pyrimidine nucleotides
present in the sense region are 2'-deoxy-2'-fluoro pyrimidine
nucleotides.
16. The siNA molecule of claim 9, wherein the fragment comprising
said sense region includes a terminal cap moiety at the 5'-end, the
3'-end, or both of the 5' and 3' ends of the fragment comprising
said sense region.
17. The siNA molecule of claim 16, wherein said terminal cap moiety
is an inverted deoxy abasic moiety.
18. The siNA molecule of claim 6, wherein pyrimidine nucleotides of
said antisense region are 2'-deoxy-2'-fluoro pyrimidine
nucleotides
19. The siNA molecule of claim 6, wherein purine nucleotides of
said antisense region are 2'-O-methyl purine nucleotides.
20. The siNA molecule of claim 6, wherein purine nucleotides
present in said antisense region comprise 2'-deoxy-purine
nucleotides.
21. The siNA molecule of claim 18, wherein said antisense region
comprises a phosphorothioate internucleotide linkage at the 3' end
of said antisense region.
22. The siNA molecule of claim 6, wherein said antisense region
comprises a glyceryl modification at the 3' end of said antisense
region.
23. The siNA molecule of claim 9, wherein each of the two fragments
of said siNA molecule comprise about 21 nucleotides.
24. The siNA molecule of claim 23, wherein about 19 nucleotides of
each fragment of the siNA molecule are base-paired to the
complementary nucleotides of the other fragment of the siNA
molecule and wherein at least two 3' terminal nucleotides of each
fragment of the siNA molecule are not base-paired to the
nucleotides of the other fragment of the siNA molecule.
25. The siNA molecule of claim 24, wherein each of the two 3'
terminal nucleotides of each fragment of the siNA molecule are
2'-deoxy-pyrimidines.
26. The siNA molecule of claim 25, wherein said 2'-deoxy-pyrimidine
is 2'-deoxy-thymidine.
27. The siNA molecule of claim 23, wherein all about 21 nucleotides
of each fragment of the siNA molecule are base-paired to the
complementary nucleotides of the other fragment of the siNA
molecule.
28. The siNA molecule of claim 23, wherein about 19 nucleotides of
the antisense region are base-paired to the nucleotide sequence of
the RNA encoded by a VEGFR1 gene or a portion thereof.
29. The siNA molecule of claim 23, wherein about 21 nucleotides of
the antisense region are base-paired to the nucleotide sequence of
the RNA encoded by a VEGFR1 gene or a portion thereof.
30. The siNA molecule of claim 9, wherein the 5'-end of the
fragment comprising said antisense region optionally includes a
phosphate group.
31. A composition comprising the siNA molecule of claim 1 in an
pharmaceutically acceptable carrier or diluent.
32. A siNA according to claim 1 wherein the VEGFR1 RNA comprises
Genebank Accession No. NM.sub.--002019.
33. A siNA according to claim 1 wherein said siNA comprises SEQ ID
NO: 2185 and SEQ ID NO: 2188.
34. A composition comprising the siNA of claim 32 and a
pharmaceutically acceptable carrier or diluent.
35. A composition comprising the siNA of claim 33 and a
pharmaceutically acceptable carrier or diluent.
Description
[0001] This application is a continuation-in-part of U.S. patent
application Ser. No. 10/764,957, filed Jan. 26, 2004, which is a
continuation-in-part of U.S. Ser. No. 10/670,011, filed Sep. 23,
2003, which is a continuation-in-part of U.S. Ser. No. 10/665,255,
filed Sep. 16, 2003, which is a continuation-in-part of
PCT/US03/05022, filed Feb. 20, 2003, which claims the benefit of
U.S. Provisional Application No. 60/393,796 filed Jul. 3, 2002 and
claims the benefit of U.S. Provisional Application No. 60/399,348
filed Jul. 29, 2002. This application is also a
continuation-in-part of U.S. patent application Ser. No.
10/758,155, filed Jan. 12, 2004, which is a continuation-in-part of
U.S. Ser. No. 10/665,951, filed Sep. 18, 2003, which is a
continuation-in-part of U.S. Ser. No. 10/665,255, filed Sep. 16,
2003, which is a continuation-in-part of PCT/US03/05022, filed Feb.
20, 2003 which claims the benefit of U.S. Provisional Application
No. 60/393,796 filed Jul. 3, 2002 and claims the benefit of U.S.
Provisional Application No. 60/399,348 filed Jul. 29, 2002. This
application is also a continuation-in-part of U.S. patent
application Ser. No. 10/664,668, filed Sep. 18, 2003, which is a
continuation-in-part of U.S. Ser. No. 10/665,255, filed Sep. 16,
2003, which is a continuation-in-part of PCT/US03/05022, filed Feb.
20, 2003 which claims the benefit of U.S. Provisional Application
No. 60/393,796 filed Jul. 3, 2002 and claims the benefit of U.S.
Provisional Application No. 60/399,348 filed Jul. 29, 2002. This
application is also a continuation-in-part of U.S. patent
application Ser. No. 10/757,803, filed Jan. 14, 2004, which is a
continuation-in-part of U.S. patent application Ser. No.
10/720,448, filed Nov. 24, 2003, which is a continuation-in-part of
U.S. patent application Ser. No. 10/693,059, filed Oct. 23, 2003,
which is a continuation-in-part of U.S. patent application Ser. No.
10/444,853, filed May 23, 2003, which is a continuation-in-part of
International Patent Application No. PCT/US03/05346, filed Feb. 20,
2003, and a continuation-in-part of International Patent
Application No. PCT/US03/05028, filed Feb. 20, 2003, both of which
International Patent Applications claim the benefit of U.S.
Provisional Application No. 60/358,580 filed Feb. 20, 2002, U.S.
Provisional Application No. 60/363,124 filed Mar. 11, 2002, U.S.
Provisional Application No. 60/386,782 filed Jun. 6, 2002, U.S.
Provisional Application No. 60/406,784 filed Aug. 29, 2002, U.S.
Provisional Application No. 60/408,378 filed Sep. 5, 2002, U.S.
Provisional Application No. 60/409,293 filed Sep. 9, 2002, and U.S.
Provisional Application No. 60/440,129 filed Jan. 15, 2003. This
application is also a continuation-in-part of U.S. patent
application Ser. No. 10/427,160, filed Apr. 30, 2003 which is a
continuation-in-part of International Patent Application No.
PCT/US02/15876 filed May 17, 2002. This application is also a
continuation-in-part of U.S. patent application Ser. No.
10/712,633, filed Nov. 13, 2003 which is a continuation of
International Patent Application No. PCT/US02/17674 filed May 29,
2002. The instant application claims the benefit of all the listed
applications, which are hereby incorporated by reference herein in
their entireties, including the drawings.
FIELD OF THE INVENTION
[0002] The present invention relates to compounds, compositions,
and methods for the study, diagnosis, and treatment of conditions
and diseases that respond to the modulation of vascular endothelial
growth factor (VEGF) and/or vascular endothelial growth factor
receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression
and/or activity. The present invention is also directed to
compounds, compositions, and methods relating to conditions and
diseases that respond to the modulation of expression and/or
activity of genes involved in VEGF and VEGF receptor pathways.
Specifically, the invention relates to small nucleic acid
molecules, such as short interfering nucleic acid (siNA), short
interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
(mRNA), and short hairpin RNA (shRNA) molecules capable of
mediating RNA interference (RNAi) against VEGF and VEGF receptor
gene expression.
BACKGROUND OF THE INVENTION
[0003] The following is a discussion of relevant art pertaining to
RNAi. The discussion is provided only for understanding of the
invention that follows. The summary is not an admission that any of
the work described below is prior art to the claimed invention.
[0004] RNA interference refers to the process of sequence-specific
post-transcriptional gene silencing in animals mediated by short
interfering RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33;
Fire et al., 1998, Nature, 391, 806; Hamilton et al., 1999,
Science, 286, 950-951; Lin et al., 1999, Nature, 402, 128-129;
Sharp, 1999, Genes & Dev., 13:139-141; and Strauss, 1999,
Science, 286, 886). The corresponding process in plants (Heifetz et
al., International PCT Publication No. WO 99/61631) is commonly
referred to as post-transcriptional gene silencing or RNA silencing
and is also referred to as quelling in fungi. The process of
post-transcriptional gene silencing is thought to be an
evolutionarily-conserved cellular defense mechanism used to prevent
the expression of foreign genes and is commonly shared by diverse
flora and phyla (Fire et al., 1999, Trends Genet., 15, 358). Such
protection from foreign gene expression may have evolved in
response to the production of double-stranded RNAs (dsRNAs) derived
from viral infection or from the random integration of transposon
elements into a host genome via a cellular response that
specifically destroys homologous single-stranded RNA or viral
genomic RNA. The presence of dsRNA in cells triggers the RNAi
response through a mechanism that has yet to be fully
characterized. This mechanism appears to be different from other
known mechanisms involving double stranded RNA-specific
ribonucleases, such as the interferon response that results from
dsRNA-mediated activation of protein kinase PKR and
2',5'-oligoadenylate synthetase resulting in non-specific cleavage
of mRNA by ribonuclease L (see for example U.S. Pat. Nos.
6,107,094; 5,898,031; Clemens et al., 1997, J. Interferon &
Cytokine Res., 17, 503-524; Adah et al., 2001, Curr. Med. Chem., 8,
1189).
[0005] The presence of long dsRNAs in cells stimulates the activity
of a ribonuclease III enzyme referred to as dicer (Bass, 2000,
Cell, 101, 235; Zamore et al., 2000, Cell, 101, 25-33; Hammond et
al., 2000, Nature, 404, 293). Dicer is involved in the processing
of the dsRNA into short pieces of dsRNA known as short interfering
RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33; Bass, 2000,
Cell, 101, 235; Berstein et al., 2001, Nature, 409, 363). Short
interfering RNAs derived from dicer activity are typically about 21
to about 23 nucleotides in length and comprise about 19 base pair
duplexes (Zamore et al., 2000, Cell, 101, 25-33; Elbashir et al.,
2001, Genes Dev., 15, 188). Dicer has also been implicated in the
excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from
precursor RNA of conserved structure that are implicated in
translational control (Hutvagner et al., 2001, Science, 293, 834).
The RNAi response also features an endonuclease complex, commonly
referred to as an RNA-induced silencing complex (RISC), which
mediates cleavage of single-stranded RNA having sequence
complementary to the antisense strand of the siRNA duplex. Cleavage
of the target RNA takes place in the middle of the region
complementary to the antisense strand of the siRNA duplex (Elbashir
et al., 2001, Genes Dev., 15, 188).
[0006] RNAi has been studied in a variety of systems. Fire et al.,
1998, Nature, 391, 806, were the first to observe RNAi in C.
elegans. Bahramian and Zarbl, 1999, Molecular and Cellular Biology,
19, 274-283 and Wianny and Goetz, 1999, Nature Cell Biol., 2, 70,
describe RNAi mediated by dsRNA in mammalian systems. Hammond et
al., 2000, Nature, 404, 293, describe RNAi in Drosophila cells
transfected with dsRNA. Elbashir et al., 2001, Nature, 411, 494 and
Tuschl et al., International PCT Publication No. WO 01/75164,
describe RNAi induced by introduction of duplexes of synthetic
21-nucleotide RNAs in cultured mammalian cells including human
embryonic kidney and HeLa cells. Recent work in Drosophila
embryonic lysates (Elbashir et al., 2001, EMBO J, 20, 6877 and
Tuschl et al., International PCT Publication No. WO 01/75164) has
revealed certain requirements for siRNA length, structure, chemical
composition, and sequence that are essential to mediate efficient
RNAi activity. These studies have shown that 21-nucleotide siRNA
duplexes are most active when containing 3'-terminal dinucleotide
overhangs. Furthermore, complete substitution of one or both siRNA
strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes
RNAi activity, whereas substitution of the 3'-terminal siRNA
overhang nucleotides with 2'-deoxy nucleotides (2'-H) was shown to
be tolerated. Single mismatch sequences in the center of the siRNA
duplex were also shown to abolish RNAi activity. In addition, these
studies also indicate that the position of the cleavage site in the
target RNA is defined by the 5'-end of the siRNA guide sequence
rather than the 3'-end of the guide sequence (Elbashir et al.,
2001, EMBO J, 20, 6877). Other studies have indicated that a
5'-phosphate on the target-complementary strand of a siRNA duplex
is required for siRNA activity and that ATP is utilized to maintain
the 5'-phosphate moiety on the siRNA (Nykanen et al., 2001, Cell,
107, 309).
[0007] Studies have shown that replacing the 3'-terminal nucleotide
overhanging segments of a 21-mer siRNA duplex having two-nucleotide
3'-overhangs with deoxyribonucleotides does not have an adverse
effect on RNAi activity. Replacing up to four nucleotides on each
end of the siRNA with deoxyribonucleotides has been reported to be
well tolerated, whereas complete substitution with
deoxyribonucleotides results in no RNAi activity (Elbashir et al.,
2001, EMBO J., 20, 6877 and Tuschl et al., International PCT
Publication No. WO 01/75164). In addition, Elbashir et al., supra,
also report that substitution of siRNA with 2'-O-methyl nucleotides
completely abolishes RNAi activity. Li et al., International PCT
Publication No. WO 00/44914, and Beach et al., International PCT
Publication No. WO 01/68836 preliminarily suggest that siRNA may
include modifications to either the phosphate-sugar backbone or the
nucleoside to include at least one of a nitrogen or sulfur
heteroatom, however, neither application postulates to what extent
such modifications would be tolerated in siRNA molecules, nor
provides any further guidance or examples of such modified siRNA.
Kreutzer et al., Canadian Patent Application No. 2,359,180, also
describe certain chemical modifications for use in dsRNA constructs
in order to counteract activation of double-stranded RNA-dependent
protein kinase PKR, specifically 2'-amino or 2'-O-methyl
nucleotides, and nucleotides containing a 2'-O or 4'-C methylene
bridge. However, Kreutzer et al. similarly fails to provide
examples or guidance as to what extent these modifications would be
tolerated in dsRNA molecules.
[0008] Parrish et al., 2000, Molecular Cell, 6, 1077-1087, tested
certain chemical modifications targeting the unc-22 gene in C.
elegans using long (>25 nt) siRNA transcripts. The authors
describe the introduction of thiophosphate residues into these
siRNA transcripts by incorporating thiophosphate nucleotide analogs
with T7 and T3 RNA polymerase and observed that RNAs with two
phosphorothioate modified bases also had substantial decreases in
effectiveness as RNAi. Further, Parrish et al. reported that
phosphorothioate modification of more than two residues greatly
destabilized the RNAs in vitro such that interference activities
could not be assayed. Id. at 1081. The authors also tested certain
modifications at the 2'-position of the nucleotide sugar in the
long siRNA transcripts and found that substituting deoxynucleotides
for ribonucleotides produced a substantial decrease in interference
activity, especially in the case of Uridine to Thymidine and/or
Cytidine to deoxy-Cytidine substitutions. Id. In addition, the
authors tested certain base modifications, including substituting,
in sense and antisense strands of the siRNA, 4-thiouracil,
5-bromouracil, 5-iodouracil, and 3-(aminoallyl) uracil for uracil,
and inosine for guanosine. Whereas 4-thiouracil and 5-bromouracil
substitution appeared to be tolerated, Parrish reported that
inosine produced a substantial decrease in interference activity
when incorporated in either strand. Parrish also reported that
incorporation of 5-iodouracil and 3-(aminoallyl) uracil in the
antisense strand resulted in a substantial decrease in RNAi
activity as well.
[0009] The use of longer dsRNA has been described. For example,
Beach et al., International PCT Publication No. WO 01/68836,
describes specific methods for attenuating gene expression using
endogenously-derived dsRNA. Tuschl et al., International PCT
Publication No. WO 01/75164, describe a Drosophila in vitro RNAi
system and the use of specific siRNA molecules for certain
functional genomic and certain therapeutic applications; although
Tuschl, 2001, Chem. Biochem., 2, 239-245, doubts that RNAi can be
used to cure genetic diseases or viral infection due to the danger
of activating interferon response. Li et al., International PCT
Publication No. WO 00/44914, describe the use of specific long (141
bp-488 bp) enzymatically synthesized or vector expressed dsRNAs for
attenuating the expression of certain target genes. Zernicka-Goetz
et al., International PCT Publication No. WO 01/36646, describes
certain methods for inhibiting the expression of particular genes
in mammalian cells using certain long (550 bp-714 bp),
enzymatically synthesized or vector expressed dsRNA molecules. Fire
et al., International PCT Publication No. WO 99/32619, describe
particular methods for introducing certain long dsRNA molecules
into cells for use in inhibiting gene expression in nematodes.
Plaetinck et al., International PCT Publication No. WO 00/01846,
describe certain methods for identifying specific genes responsible
for conferring a particular phenotype in a cell using specific long
dsRNA molecules. Mello et al., International PCT Publication No. WO
01/29058, describe the identification of specific genes involved in
dsRNA-mediated RNAi. Pachuck et al., International PCT Publication
No. WO 00/63364, describe certain long (at least 200 nucleotide)
dsRNA constructs. Deschamps Depaillette et al., International PCT
Publication No. WO 99/07409, describe specific compositions
consisting of particular dsRNA molecules combined with certain
anti-viral agents. Waterhouse et al., International PCT Publication
No. 99/53050 and 1998, PNAS, 95, 13959-13964, describe certain
methods for decreasing the phenotypic expression of a nucleic acid
in plant cells using certain dsRNAs. Driscoll et al., International
PCT Publication No. WO 01/49844, describe specific DNA expression
constructs for use in facilitating gene silencing in targeted
organisms.
[0010] Others have reported on various RNAi and gene-silencing
systems. For example, Parrish et al., 2000, Molecular Cell, 6,
1077-1087, describe specific chemically-modified dsRNA constructs
targeting the unc-22 gene of C. elegans. Grossniklaus,
International PCT Publication No. WO 01/38551, describes certain
methods for regulating polycomb gene expression in plants using
certain dsRNAs. Churikov et al., International PCT Publication No.
WO 01/42443, describe certain methods for modifying genetic
characteristics of an organism using certain dsRNAs. Cogoni et al.,
International PCT Publication No. WO 01/53475, describe certain
methods for isolating a Neurospora silencing gene and uses thereof.
Reed et al., International PCT Publication No. WO 01/68836,
describe certain methods for gene silencing in plants. Honer et
al., International PCT Publication No. WO 01/70944, describe
certain methods of drug screening using transgenic nematodes as
Parkinson's Disease models using certain dsRNAs. Deak et al.,
International PCT Publication No. WO 01/72774, describe certain
Drosophila-derived gene products that may be related to RNAi in
Drosophila. Arndt et al., International PCT Publication No. WO
01/92513 describes certain methods for mediating gene suppression
by using factors that enhance RNAi. Tuschl et al., International
PCT Publication No. WO 02/44321, describe certain synthetic siRNA
constructs. Pachuk et al., International PCT Publication No. WO
00/63364, and Satishchandran et al., International PCT Publication
No. WO 01/04313, describe certain methods and compositions for
inhibiting the function of certain polynucleotide sequences using
certain long (over 250 bp), vector expressed dsRNAs. Echeverri et
al., International PCT Publication No. WO 02/38805, describe
certain C. elegans genes identified via RNAi. Kreutzer et al.,
International PCT Publications Nos. WO 02/055692, WO 02/055693, and
EP 1144623 B1 describe certain methods for inhibiting gene
expression using dsRNA. Graham et al, International PCT
Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501
describe certain vector expressed siRNA molecules. Fire et al.,
U.S. Pat. No. 6,506,559, describe certain methods for inhibiting
gene expression in vitro using certain long dsRNA (299 bp-1033 bp)
constructs that mediate RNAi. Martinez et al., 2002, Cell, 110,
563-574, describe certain single stranded siRNA constructs,
including certain 5'-phosphorylated single stranded siRNAs that
mediate RNA interference in Hela cells. Harborth et al., 2003,
Antisense & Nucleic Acid Drug Development, 13, 83-105, describe
certain chemically and structurally modified siRNA molecules. Chiu
and Rana, 2003, RNA, 9, 1034-1048, describe certain chemically and
structurally modified siRNA molecules. Woolf et al., International
PCT Publication Nos. WO 03/064626 and WO 03/064625 describe certain
chemically modified dsRNA constructs.
SUMMARY OF THE INVENTION
[0011] This invention relates to compounds, compositions, and
methods useful for modulating the expression of genes, such as
those genes associated with angiogenesis and proliferation, using
short interfering nucleic acid (siNA) molecules. This invention
further relates to compounds, compositions, and methods useful for
modulating the expression and activity of vascular endothelial
growth factor (VEGF) and/or vascular endothelial growth factor
receptor (e.g., VEGFR1, VEGFR2, VEGFr3) genes, or genes involved in
VEGF and/or VEGFr pathways of gene expression and/or VEGF activity
by RNA interference (RNAi) using small nucleic acid molecules. In
particular, the instant invention features small nucleic acid
molecules, such as short interfering nucleic acid (siNA), short
interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
(mRNA), and short hairpin RNA (shRNA) molecules and methods used to
modulate the expression of VEGF and/or VEGFr genes. A siNA of the
invention can be unmodified or chemically-modified. A siNA of the
instant invention can be chemically synthesized, expressed from a
vector or enzymatically synthesized. The instant invention also
features various chemically-modified synthetic short interfering
nucleic acid (siNA) molecules capable of modulating VEGF and/or
VEGFr gene expression or activity in cells by RNA interference
(RNAi). The use of chemically-modified siNA improves various
properties of native siNA molecules through increased resistance to
nuclease degradation in vivo and/or through improved cellular
uptake. Further, contrary to earlier published studies, siNA having
multiple chemical modifications retains its RNAi activity. The siNA
molecules of the instant invention provide useful reagents and
methods for a variety of therapeutic, diagnostic, target
validation, genomic discovery, genetic engineering, and
pharmacogenomic applications.
[0012] In one embodiment, the invention features one or more siNA
molecules and methods that independently or in combination modulate
the expression of gene(s) encoding proteins, such as vascular
endothelial growth factor (VEGF) and/or vascular endothelial growth
factor receptors (e.g., VEGFR1, VEGFR2, VEGFr3), associated with
the maintenance and/or development of cancer and other
proliferative diseases, such as genes encoding sequences comprising
those sequences referred to by GenBank Accession Nos. shown in
Table I, referred to herein generally as VEGF and/or VEGFr. The
description below of the various aspects and embodiments of the
invention is provided with reference to the exemplary VEGF and
VEGFr (e.g., VEGFR1, VEGFR2, VEGFr3) genes referred to herein as
VEGF and VEGFr respectively. However, the various aspects and
embodiments are also directed to other VEGF and/or VEGFr genes,
such as mutant VEGF and/or VEGFr genes, splice variants of VEGF
and/or VEGFr genes, other VEGF and/or VEGFr ligands and receptors.
The various aspects and embodiments are also directed to other
genes that are involved in VEGF and/or VEGFr mediated pathways of
signal transduction or gene expression that are involved in the
progression, development, and/or maintenance of disease (e.g.,
cancer). These additional genes can be analyzed for target sites
using the methods described for VEGF and/or VEGFr genes herein.
Thus, the modulation of other genes and the effects of such
modulation of the other genes can be performed, determined, and
measured as described herein.
[0013] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a vascular endothelial growth factor (e.g., VEGF,
VEGF-A, VEGF-B, VEGF-C, VEGF-D) gene, wherein said siNA molecule
comprises about 19 to about 21 base pairs.
[0014] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a vascular endothelial growth factor receptor (e.g.,
VEGFR1, VEGFR2, and/or VEGFr3) gene, wherein said siNA molecule
comprises about 19 to about 21 base pairs.
[0015] In one embodiment, the invention features a siNA molecule
that down-regulates expression of a VEGF gene, for example, a VEGF
gene comprising VEGF encoding sequence.
[0016] In one embodiment, the invention features a siNA molecule
that down-regulates expression of a VEGFr gene, for example, a
VEGFr gene comprising VEGFr encoding sequence.
[0017] In one embodiment, the invention features a siNA molecule
having RNAi activity against VEGF and/or VEGFr RNA, wherein the
siNA molecule comprises a sequence complementary to any RNA having
VEGF and/or VEGFr or other VEGF and/or VEGFr encoding sequence,
such as those sequences having GenBank Accession Nos. shown in
Table I. In another embodiment, the invention features a siNA
molecule having RNAi activity against VEGF and/or VEGFr RNA,
wherein the siNA molecule comprises a sequence complementary to an
RNA having variant VEGF and/or VEGFr encoding sequence, for example
mutant VEGF and/or VEGFr genes, splice variants of VEGF and/or
VEGFr genes, variants of VEGF and/or VEGFr genes with conservative
substitutions, and homologous VEGF and/or VEGFr ligands and
receptors. Chemical modifications as shown in Tables III and IV or
otherwise described herein can be applied to any siNA construct of
the invention.
[0018] In one embodiment, the invention features a siNA molecule
having RNAi activity against VEGF and/or VEGFr RNA, wherein the
siNA molecule comprises a sequence complementary to any RNA having
VEGF and/or VEGFr encoding sequence, such as those sequences having
VEGF and/or VEGFr GenBank Accession Nos. shown in Table I. In
another embodiment, the invention features a siNA molecule having
RNAi activity against VEGF and/or VEGFr RNA, wherein the siNA
molecule comprises a sequence complementary to an RNA having other
VEGF and/or VEGFr encoding sequence, for example, mutant VEGF
and/or VEGFr genes, splice variants of VEGF and/or VEGFr genes,
VEGF and/or VEGFr variants with conservative substitutions, and
homologous VEGF and/or VEGFr ligands and receptors. Chemical
modifications as shown in Tables III and IV or otherwise described
herein can be applied to any siNA construct of the invention.
[0019] In another embodiment, the invention features a siNA
molecule having RNAi activity against a VEGF and/or VEGFr gene,
wherein the siNA molecule comprises nucleotide sequence
complementary to nucleotide sequence of a VEGF and/or VEGFr gene,
such as those VEGF and/or VEGFr sequences having GenBank Accession
Nos. shown in Table I or other VEGF and/or VEGFr encoding sequence,
such as mutant VEGF and/or VEGFr genes, splice variants of VEGF
and/or VEGFr genes, variants with conservative substitutions, and
homologous VEGF and/or VEGFr ligands and receptors. In another
embodiment, a siNA molecule of the invention includes nucleotide
sequence that can interact with nucleotide sequence of a VEGF
and/or VEGFr gene and thereby mediate silencing of VEGF and/or
VEGFr gene expression, for example, wherein the siNA mediates
regulation of VEGF and/or VEGFr gene expression by cellular
processes that modulate the chromatin structure of the VEGF and/or
VEGFr gene and prevent transcription of the VEGF and/or VEGFr
gene.
[0020] In one embodiment, siNA molecules of the invention are used
to down regulate or inhibit the expression of soluble VEGF
receptors (e.g. sVEGFR1 or sVEGFR2). Analysis of soluble VEGF
receptor levels can be used to identify subjects with certain
cancer types. These cancers can be amenable to treatment, for
example, treatment with siNA molecules of the invention and any
other chemotherapeutic composition. As such, analysis of soluble
VEGF receptor levels can be used to determine treatment type and
the course of therapy in treating a subject. Monitoring of soluble
VEGF receptor levels can be used to predict treatment outcome and
to determine the efficacy of compounds and compositions that
modulate the level and/or activity of VEGF receptors (see for
example Pavco U.S. Ser. No. 10/438,493, incorporated by reference
herein in its entirety including the drawings).
[0021] In another embodiment, the invention features a siNA
molecule comprising nucleotide sequence, for example, nucleotide
sequence in the antisense region of the siNA molecule that is
complementary to a nucleotide sequence or portion of sequence of a
VEGF and/or VEGFr gene. In another embodiment, the invention
features a siNA molecule comprising a region, for example, the
antisense region of the siNA construct, complementary to a sequence
comprising a VEGF and/or VEGFr gene sequence or a portion
thereof.
[0022] In one embodiment, the antisense region of VEGFR1 siNA
constructs comprises a sequence complementary to sequence having
any of SEQ ID NOs. 1-427, 1997-2000, 2009-2012, or 2244-2255. In
one embodiment, the antisense region can also comprise sequence
having any of SEQ ID NOs. 428-854, 2024-2027, 2032-2035, 2040-2043,
2188-2190, 2197-2200, 2203, 2217, 2278-2280, 2292-2298, 2313-2318,
2326-2332, 2347-2364, 2444-2448, 2451-2452, 2455-2456, 2564, 2566,
2568, or 2571. In another embodiment, the sense region of VEGFR1
constructs can comprise sequence having any of SEQ ID NOs. 1-427,
1997-2000, 2009-2012, 2020-2023, 2028-2031, 2036-2039, 2185-2187,
2201-2202, 2218, 2220, 2222, 2224, 2244-2255, 2275-2277, 2281-2291,
2299-2305, 2319-2325, 2333-2339, 2347-2364, 2438-2439, 2449-2450,
2563, 2565, 2567, 2569, or 2570. The sense region can comprise a
sequence of SEQ ID NO. 2554 and the antisense region can comprise a
sequence of SEQ ID NO. 2555. The sense region can comprise a
sequence of SEQ ID NO. 2556 and the antisense region can comprise a
sequence of SEQ ID NO. 2557. The sense region can comprise a
sequence of SEQ ID NO. 2558 and the antisense region can comprise a
sequence of SEQ ID NO. 2559. The sense region can comprise a
sequence of SEQ ID NO. 2560 and the antisense region can comprise a
sequence of SEQ ID NO. 2557. The sense region can comprise a
sequence of SEQ ID NO. 2561 and the antisense region can comprise a
sequence of SEQ ID NO. 2557. The sense region can comprise a
sequence of SEQ ID NO. 2560 and the antisense region can comprise a
sequence of SEQ ID NO. 2562.
[0023] In one embodiment, the antisense region of VEGFR2 siNA
constructs can comprise a sequence complementary to sequence having
any of SEQ ID NOs. 855-1178, 2001-2004, or 2017-2019 or 2256-2271.
In one embodiment, the antisense region can also comprise sequence
having any of SEQ ID NOs. 1179-1502, 2048-2051, 2056-2059,
2064-2067, 2208-2210, 2214-2216, 2226-2227, 2230-2231, 2377-2388,
2391-2392, 2401-2405, 2420-2423, 2498-2501, or 2506-2509. In
another embodiment, the sense region of VEGFR2 constructs can
comprise sequence having any of SEQ ID NOs. 855-1178, 2001-2004,
2017-2019, 2256-2271, 2044-2047, 2052-2055, 2060-2063, 2205-2207,
2211-2213, 2228-2229, 2365-2376, 2389-2390, 2393-2394, 2397-2400,
2406-2410, 2416-2419, 2424-2427, 2494-2497, or 2502-2505. The sense
region can comprise a sequence of SEQ ID NO. 2438 and the antisense
region can comprise a sequence of SEQ ID NO. 2439. The sense region
can comprise a sequence of SEQ ID NO. 2554 and the antisense region
can comprise a sequence of SEQ ID NO. 2555. The sense region can
comprise a sequence of SEQ ID NO. 2556 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2558 and the antisense region can
comprise a sequence of SEQ ID NO. 2559. The sense region can
comprise a sequence of SEQ ID NO. 2560 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2561 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2560 and the antisense region can
comprise a sequence of SEQ ID NO. 2562.
[0024] In one embodiment, the antisense region of VEGFr3 siNA
constructs can comprise a sequence complementary to sequence having
any of SEQ ID NOs. 1503-1749, 2005-2008, or 2272-2274. In one
embodiment, the antisense region can also comprise sequence having
any of SEQ ID NOs. 1750-1996, 2072-2075, 2080-2083, 2088-2091,
2435-2437, or 2534-2548. In another embodiment, the sense region of
VEGFr3 constructs can comprise sequence having any of SEQ ID NOs.
1503-1749, 2005-2008, 2068-2071, 2076-2079, or 2084-2087,
2272-2274, 2432-2434, 2440-2443, or 2526-2533. The sense region can
comprise a sequence of SEQ ID NO. 2554 and the antisense region can
comprise a sequence of SEQ ID NO. 2555. The sense region can
comprise a sequence of SEQ ID NO. 2556 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2558 and the antisense region can
comprise a sequence of SEQ ID NO. 2559. The sense region can
comprise a sequence of SEQ ID NO. 2560 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2561 and the antisense region can
comprise a sequence of SEQ ID NO. 2557. The sense region can
comprise a sequence of SEQ ID NO. 2560 and the antisense region can
comprise a sequence of SEQ ID NO. 2562.
[0025] In one embodiment, a siNA molecule of the invention
comprises any of SEQ ID NOs. 1-2562. The sequences shown in SEQ ID
NOs: 1-2562 are not limiting. A siNA molecule of the invention can
comprise any contiguous VEGF and/or VEGFr sequence (e.g., about 19
to about 25, or about 19, 20, 21, 22, 23, 24 or 25 contiguous VEGF
and/or VEGFr nucleotides).
[0026] In yet another embodiment, the invention features a siNA
molecule comprising a sequence, for example, the antisense sequence
of the siNA construct, complementary to a sequence or portion of
sequence comprising sequence represented by GenBank Accession Nos.
shown in Table I. Chemical modifications in Tables III and IV and
described herein can be applied to any siNA construct of the
invention.
[0027] In one embodiment of the invention a siNA molecule comprises
an antisense strand having about 19 to about 29 (e.g., about 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, wherein the
antisense strand is complementary to a RNA sequence encoding a VEGF
and/or VEGFr protein, and wherein said siNA further comprises a
sense strand having about 19 to about 29 (e.g., about 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, or 29) nucleotides, and wherein said
sense strand and said antisense strand are distinct nucleotide
sequences with at least about 19 complementary nucleotides.
[0028] In another embodiment of the invention a siNA molecule of
the invention comprises an antisense region having about 19 to
about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or
29) nucleotides, wherein the antisense region is complementary to a
RNA sequence encoding a VEGF and/or VEGFr protein, and wherein said
siNA further comprises a sense region having about 19 to about 29
(e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29)
nucleotides, wherein said sense region and said antisense region
comprise a linear molecule with at least about 19 complementary
nucleotides.
[0029] In one embodiment, a siNA molecule of the invention has RNAi
activity that modulates expression of RNA encoded by a VEGF and/or
VEGFr gene. Because VEGF and/or VEGFr genes can share some degree
of sequence homology with each other, siNA molecules can be
designed to target a class of VEGF and/or VEGFr genes or
alternately specific VEGF and/or VEGFr genes (e.g., polymorphic
variants) by selecting sequences that are either shared amongst
different VEGF and/or VEGFr targets or alternatively that are
unique for a specific VEGF and/or VEGFr target. Therefore, in one
embodiment, the siNA molecule can be designed to target conserved
regions of VEGF and/or VEGFr RNA sequence having homology between
several VEGF and/or VEGFr gene variants so as to target a class of
VEGF and/or VEGFr genes with one siNA molecule. Accordingly, in one
embodiment, the siNA molecule of the invention modulates the
expression of one or both VEGF and/or VEGFr alleles in a subject.
In another embodiment, the siNA molecule can be designed to target
a sequence that is unique to a specific VEGF and/or VEGFr RNA
sequence (e.g., a single VEGF and/or VEGFr allele or VEGF and/or
VEGFr single nucleotide polymorphism (SNP)) due to the high degree
of specificity that the siNA molecule requires to mediate RNAi
activity.
[0030] In one embodiment, a siNA molecule of the invention has RNAi
activity that modulates expression of RNA encoded by a VEGFr gene.
Because VEGFr genes can share some degree of sequence homology with
each other, siNA molecules can be designed to target a class of
VEGFr genes (and associated receptor or ligand genes) or
alternately specific VEGFr genes by selecting sequences that are
either shared amongst different VEGFr targets or alternatively that
are unique for a specific VEGFr target. Therefore, in one
embodiment, the siNA molecule can be designed to target conserved
regions of VEGFr RNA sequence having homology between several VEGFr
genes so as to target several VEGFr genes (e.g., VEGFR1, VEGFR2
and/or VEGFr3, different VEGFr isoforms, splice variants, mutant
genes etc.) with one siNA molecule. In one embodiment, the siNA
molecule can be designed to target conserved regions of VEGFR1 and
VEGFR2 RNA sequence having shared sequence homology (see for
example Table III). Accordingly, in one embodiment, the siNA
molecule of the invention modulates the expression of more than one
VEGFr gene, i.e., VEGFR1, VEGFR2, and VEGFr3, or any combination
thereof. In another embodiment, the siNA molecule can be designed
to target a sequence that is unique to a specific VEGFr RNA
sequence due to the high degree of specificity that the siNA
molecule requires to mediate RNAi activity.
[0031] In one embodiment, a siNA molecule of the invention has RNAi
activity that modulates expression of RNA encoded by a VEGF gene.
Because VEGF genes can share some degree of sequence homology with
each other, siNA molecules can be designed to target a class of
VEGF genes (and associated receptor or ligand genes) or alternately
specific VEGF genes by selecting sequences that are either shared
amongst different VEGF targets or alternatively that are unique for
a specific VEGF target. Therefore, in one embodiment, the siNA
molecule can be designed to target conserved regions of VEGF RNA
sequence having homology between several VEGF genes so as to target
several VEGF genes (e.g., VEGF-A, VEGF-B, VEGF-C and/or VEGF-D,
different VEGF isoforms, splice variants, mutant genes etc.) with
one siNA molecule. Accordingly, in one embodiment, the siNA
molecule of the invention modulates the expression of more than one
VEGF gene, i.e., VEGF-A, VEGF-B, VRGF-C, and VEGF-D or any
combination thereof. In another embodiment, the siNA molecule can
be designed to target a sequence that is unique to a specific VEGF
RNA sequence due to the high degree of specificity that the siNA
molecule requires to mediate RNAi activity.
[0032] In one embodiment, a siNA molecule of the invention
targeting one or more VEGF receptor genes (e.g., VEGFR1, VEGFR2,
and/or VEGFr3) is used in combination with a siNA molecule of the
invention targeting a VEGF gene (e.g., VEGF-A, VEGF-B, VEGF-C
and/or VEGF-D) according to a use described herein, such as
treating a subject with an angiogenesis or neovascularization
related disease, such as tumor angiogenesis and cancer, including
but not limited to breast cancer, lung cancer (including non-small
cell lung carcinoma), prostate cancer, colorectal cancer, brain
cancer, esophageal cancer, bladder cancer, pancreatic cancer,
cervical cancer, head and neck cancer, skin cancers, nasopharyngeal
carcinoma, liposarcoma, epithelial carcinoma, renal cell carcinoma,
gallbladder adeno carcinoma, parotid adenocarcinoma, ovarian
cancer, melanoma, lymphoma, glioma, endometrial sarcoma, multidrug
resistant cancers, diabetic retinopathy, macular degeneration,
neovascular glaucoma, myopic degeneration, arthritis, psoriasis,
endometriosis, female reproduction, verruca vulgaris, angiofibroma
of tuberous sclerosis, pot-wine stains, Sturge Weber syndrome,
Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome, renal
disease such as Autosomal dominant polycystic kidney disease
(ADPKD), and any other diseases or conditions that are related to
or will respond to the levels of VEGF, VEGFR1, and VEGFR2 in a cell
or tissue, alone or in combination with other therapies.
[0033] In another embodiment, a siNA molecule of the invention that
targets homologous VEGFR1 and VEGFR2 sequence is used in
combination with a siNA molecule that targets VEGF-A according to a
use described herein, such as treating a subject with an
angiogenesis or neovascularization related disease such as tumor
angiogenesis and cancer, including but not limited to breast
cancer, lung cancer (including non-small cell lung carcinoma),
prostate cancer, colorectal cancer, brain cancer, esophageal
cancer, bladder cancer, pancreatic cancer, cervical cancer, head
and neck cancer, skin cancers, nasopharyngeal carcinoma,
liposarcoma, epithelial carcinoma, renal cell carcinoma,
gallbladder adeno carcinoma, parotid adenocarcinoma, ovarian
cancer, melanoma, lymphoma, glioma, endometrial sarcoma, multidrug
resistant cancers, diabetic retinopathy, macular degeneration,
neovascular glaucoma, myopic degeneration, arthritis, psoriasis,
endometriosis, female reproduction, verruca vulgaris, angiofibroma
of tuberous sclerosis, pot-wine stains, Sturge Weber syndrome,
Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome, renal
disease such as Autosomal dominant polycystic kidney disease
(ADPKD), and any other diseases or conditions that are related to
or will respond to the levels of VEGF, VEGFR1, and VEGFR2 in a cell
or tissue, alone or in combination with other therapies.
[0034] In one embodiment, a siNA of the invention is used to
inhibit the expression of VEGFR1, VEGFR2, and/or VEGFr3 genes,
wherein the VEGFR1, VEGFR2, and/or VEGFr3 sequences share sequence
homology. Such homologous sequences can be identified as is known
in the art, for example using sequence alignments. siNA molecules
can be designed to target such homologous sequences, for example
using perfectly complementary sequences or by incorporating
mismatches and/or wobble base pairs that can provide additional
target sequences One advantage of using siNAs of the invention is
that a single siNA can be designed to include nucleic acid sequence
that is complementary to the nucleotide sequence that is conserved
between the VEGF receptors (i.e., VEGFR1, VEGFR2, and/or VEGFr3)
such that the siNA can interact with RNAs of the receptors and
mediate RNAi to achieve inhibition of expression of the VEGF
receptors. In this approach, a single siNA can be used to inhibit
expression of more than one VEGF receptor instead of using more
than one siNA molecule to target the different receptors.
[0035] In one embodiment, the invention features a method of
designing a single siNA to inhibit the expression of both VEGFR1
and VEGFR2 genes comprising designing an siNA having nucleotide
sequence that is complementary to nucleotide sequence encoded by or
present in both VEGFR1 and VEGFR2 genes or a portion thereof,
wherein the siNA mediates RNAi to inhibit the expression of both
VEGFR1 and VEGFR2 genes. For example, a single siNA can inhibit the
expression of two genes by binding to conserved or homologous
sequence present in RNA encoded by VEGFR1 and VEGFR2 genes or a
portion thereof.
[0036] In one embodiment, the invention features a method of
designing a single siNA to inhibit the expression of both VEGFR1
and VEGFr3 genes comprising designing an siNA having nucleotide
sequence that is complementary to nucleotide sequence encoded by or
present in both VEGFR1 and VEGFr3 genes or a portion thereof,
wherein the siNA mediates RNAi to inhibit the expression of both
VEGFR1 and VEGFr3 genes. For example, a single siNA can inhibit the
expression of two genes by binding to conserved or homologous
sequence present in RNA encoded by VEGFR1 and VEGFr3 genes or a
portion thereof.
[0037] In one embodiment, the invention features a method of
designing a single siNA to inhibit the expression of both VEGFR2
and VEGFr3 genes comprising designing an siNA having nucleotide
sequence that is complementary to nucleotide sequence encoded by or
present in both VEGFR2 and VEGFr3 genes or a portion thereof,
wherein the siNA mediates RNAi to inhibit the expression of both
VEGFR2 and VEGFr3 genes. For example, a single siNA can inhibit the
expression of two genes by binding to conserved or homologous
sequence present in RNA encoded by VEGFR2 and VEGFr3 genes or a
portion thereof.
[0038] In one embodiment, the invention features a method of
designing a single siNA to inhibit the expression of VEGFR1, VEGFR2
and VEGFr3 genes comprising designing an siNA having nucleotide
sequence that is complementary to nucleotide sequence encoded by or
present in VEGFR1, VEGFR2 and VEGFr3 genes or a portion thereof,
wherein the siNA mediates RNAi to inhibit the expression of VEGFR1,
VEGFR2 and VEGFr3 genes. For example, a single siNA can inhibit the
expression of two genes by binding to conserved or homologous
sequence present in RNA encoded by VEGFR1, VEGFR2 and VEGFr3 genes
or a portion thereof.
[0039] In one embodiment, nucleic acid molecules of the invention
that act as mediators of the RNA interference gene silencing
response are double-stranded nucleic acid molecules. In another
embodiment, the siNA molecules of the invention consist of duplex
nucleic acid molecules containing about 19 base pairs between
oligonucleotides comprising about 19 to about 25 (e.g., about 19,
20, 21, 22, 23, 24, or 25) nucleotides. In yet another embodiment,
siNA molecules of the invention comprise duplex nucleic acid
molecules with overhanging ends of about 1 to about 3 (e.g., about
1, 2, or 3) nucleotides, for example, about 21-nucleotide duplexes
with about 19 base pairs and 3'-terminal mononucleotide,
dinucleotide, or trinucleotide overhangs.
[0040] In one embodiment, the invention features one or more
chemically-modified siNA constructs having specificity for VEGF
and/or VEGFr expressing nucleic acid molecules, such as RNA
encoding a VEGF and/or VEGFr protein. Non-limiting examples of such
chemical modifications include without limitation phosphorothioate
internucleotide linkages, 2'-deoxyribonucleotides, 2'-O-methyl
ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal
base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides,
and terminal glyceryl and/or inverted deoxy abasic residue
incorporation. These chemical modifications, when used in various
siNA constructs, are shown to preserve RNAi activity in cells while
at the same time, dramatically increasing the serum stability of
these compounds. Furthermore, contrary to the data published by
Parrish et al., supra, applicant demonstrates that multiple
(greater than one) phosphorothioate substitutions are
well-tolerated and confer substantial increases in serum stability
for modified siNA constructs.
[0041] In one embodiment, a siNA molecule of the invention
comprises modified nucleotides while maintaining the ability to
mediate RNAi. The modified nucleotides can be used to improve in
vitro or in vivo characteristics such as stability, activity,
and/or bioavailability. For example, a siNA molecule of the
invention can comprise modified nucleotides as a percentage of the
total number of nucleotides present in the siNA molecule. As such,
a siNA molecule of the invention can generally comprise about 5% to
about 100% modified nucleotides (e.g., about 5%, 10%, 15%, 20%,
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95% or 100% modified nucleotides). The actual percentage of
modified nucleotides present in a given siNA molecule will depend
on the total number of nucleotides present in the siNA. If the siNA
molecule is single stranded, the percent modification can be based
upon the total number of nucleotides present in the single stranded
siNA molecules. Likewise, if the siNA molecule is double stranded,
the percent modification can be based upon the total number of
nucleotides present in the sense strand, antisense strand, or both
the sense and antisense strands.
[0042] One aspect of the invention features a double-stranded short
interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene. In one embodiment, the
double stranded siNA molecule comprises one or more chemical
modifications and each strand of the double-stranded siNA is about
21 nucleotides long. In one embodiment, the double-stranded siNA
molecule does not contain any ribonucleotides. In another
embodiment, the double-stranded siNA molecule comprises one or more
ribonucleotides. In one embodiment, each strand of the
double-stranded siNA molecule comprises about 19 to about 29 (e.g.,
about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29) nucleotides,
wherein each strand comprises about 19 nucleotides that are
complementary to the nucleotides of the other strand. In one
embodiment, one of the strands of the double-stranded siNA molecule
comprises a nucleotide sequence that is complementary to a
nucleotide sequence, or a portion thereof, of the VEGF and/or VEGFr
gene, and the second strand of the double-stranded siNA molecule
comprises a nucleotide sequence substantially similar to the
nucleotide sequence of the VEGF and/or VEGFr gene, or a portion
thereof.
[0043] In another embodiment, the invention features a
double-stranded short interfering nucleic acid (siNA) molecule that
down-regulates expression of a VEGF and/or VEGFr gene comprising an
antisense region, wherein the antisense region comprises a
nucleotide sequence that is complementary to a nucleotide sequence
of the VEGF and/or VEGFr gene or a portion thereof, and a sense
region, wherein the sense region comprises a nucleotide sequence
substantially similar to the nucleotide sequence of the VEGF and/or
VEGFr gene or a portion thereof. In one embodiment, the antisense
region and the sense region each comprise about 19 to about 23
(e.g. about 19, 20, 21, 22, or 23) nucleotides, wherein the
antisense region comprises about 19 nucleotides that are
complementary to nucleotides of the sense region.
[0044] In another embodiment, the invention features a
double-stranded short interfering nucleic acid (siNA) molecule that
down-regulates expression of a VEGF and/or VEGFr gene comprising a
sense region and an antisense region, wherein the antisense region
comprises a nucleotide sequence that is complementary to a
nucleotide sequence of RNA encoded by the VEGF and/or VEGFr gene or
a portion thereof and the sense region comprises a nucleotide
sequence that is complementary to the antisense region.
[0045] In one embodiment, a siNA molecule of the invention
comprises blunt ends, i.e., ends that do not include any
overhanging nucleotides. For example, a siNA molecule comprising
modifications described herein (e.g., comprising nucleotides having
Formulae I-VII or siNA constructs comprising Stab00-Stab22 or any
combination thereof (see Table IV)) and/or any length described
herein can comprise blunt ends or ends with no overhanging
nucleotides.
[0046] In one embodiment, any siNA molecule of the invention can
comprise one or more blunt ends, i.e. where a blunt end does not
have any overhanging nucleotides. In one embodiment, the blunt
ended siNA molecule has a number of base pairs equal to the number
of nucleotides present in each strand of the siNA molecule. In
another embodiment, the siNA molecule comprises one blunt end, for
example, wherein the 5'-end of the antisense strand and the 3'-end
of the sense strand do not have any overhanging nucleotides. In
another example, the siNA molecule comprises one blunt end, for
example, wherein the 3'-end of the antisense strand and the 5'-end
of the sense strand do not have any overhanging nucleotides. In
another example, a siNA molecule comprises two blunt ends, for
example wherein the 3'-end of the antisense strand and the 5'-end
of the sense strand as well as the 5'-end of the antisense strand
and 3'-end of the sense strand do not have any overhanging
nucleotides. A blunt ended siNA molecule can comprise, for example,
from about 18 to about 30 nucleotides (e.g., about 18, 19, 20, 21,
22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). Other
nucleotides present in a blunt ended siNA molecule can comprise
mismatches, bulges, loops, or wobble base pairs, for example, to
modulate the activity of the siNA molecule to mediate RNA
interference.
[0047] By "blunt ends" is meant symmetric termini or termini of a
double stranded siNA molecule having no overhanging nucleotides.
The two strands of a double stranded siNA molecule align with each
other without over-hanging nucleotides at the termini. For example,
a blunt ended siNA construct comprises terminal nucleotides that
are complementary between the sense and antisense regions of the
siNA molecule.
[0048] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene, wherein the siNA molecule
is assembled from two separate oligonucleotide fragments wherein
one fragment comprises the sense region and the second fragment
comprises the antisense region of the siNA molecule. The sense
region can be connected to the antisense region via a linker
molecule, such as a polynucleotide linker or a non-nucleotide
linker.
[0049] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene, wherein the siNA molecule
comprises about 19 to about 21 base pairs, and wherein each strand
of the siNA molecule comprises one or more chemical modifications.
In another embodiment, one of the strands of the double-stranded
siNA molecule comprises a nucleotide sequence that is complementary
to a nucleotide sequence of a VEGF and/or VEGFr gene or portion
thereof, and the second strand of the double-stranded siNA molecule
comprises a nucleotide sequence substantially similar to the
nucleotide sequence or a portion thereof of the VEGF and/or VEGFr
gene. In another embodiment, one of the strands of the
double-stranded siNA molecule comprises a nucleotide sequence that
is complementary to a nucleotide sequence of a VEGF and/or VEGFr
gene or portion thereof, and the second strand of the
double-stranded siNA molecule comprises a nucleotide sequence
substantially similar to the nucleotide sequence or a portion
thereof of the VEGF and/or VEGFr gene. In another embodiment, each
strand of the siNA molecule comprises about 19 to about 23
nucleotides, and each strand comprises at least about 19
nucleotides that are complementary to the nucleotides of the other
strand. The VEGF and/or VEGFr gene can comprise, for example,
sequences referred to in Table I.
[0050] In one embodiment, a siNA molecule of the invention
comprises no ribonucleotides. In another embodiment, a siNA
molecule of the invention comprises ribonucleotides.
[0051] In one embodiment, a siNA molecule of the invention
comprises an antisense region comprising a nucleotide sequence that
is complementary to a nucleotide sequence of a VEGF and/or VEGFr
gene or a portion thereof, and the siNA further comprises a sense
region comprising a nucleotide sequence substantially similar to
the nucleotide sequence of the VEGF and/or VEGFr gene or a portion
thereof. In another embodiment, the antisense region and the sense
region each comprise about 19 to about 23 nucleotides and the
antisense region comprises at least about 19 nucleotides that are
complementary to nucleotides of the sense region. The VEGF and/or
VEGFr gene can comprise, for example, sequences referred to in
Table I.
[0052] In one embodiment, a siNA molecule of the invention
comprises a sense region and an antisense region, wherein the
antisense region comprises a nucleotide sequence that is
complementary to a nucleotide sequence of RNA encoded by a VEGF
and/or VEGFr gene, or a portion thereof, and the sense region
comprises a nucleotide sequence that is complementary to the
antisense region. In one embodiment, the siNA molecule is assembled
from two separate oligonucleotide fragments, wherein one fragment
comprises the sense region and the second fragment comprises the
antisense region of the siNA molecule. In another embodiment, the
sense region is connected to the antisense region via a linker
molecule. In another embodiment, the sense region is connected to
the antisense region via a linker molecule, such as a nucleotide or
non-nucleotide linker. The VEGF and/or VEGFr gene can comprise, for
example, sequences referred in to Table I.
[0053] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene comprising a sense region
and an antisense region, wherein the antisense region comprises a
nucleotide sequence that is complementary to a nucleotide sequence
of RNA encoded by the VEGF and/or VEGFr gene or a portion thereof
and the sense region comprises a nucleotide sequence that is
complementary to the antisense region, and wherein the siNA
molecule has one or more modified pyrimidine and/or purine
nucleotides. In one embodiment, the pyrimidine nucleotides in the
sense region are 2'-O-methyl pyrimidine nucleotides or
2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine
nucleotides present in the sense region are 2'-deoxy purine
nucleotides. In another embodiment, the pyrimidine nucleotides in
the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides and
the purine nucleotides present in the sense region are 2'-O-methyl
purine nucleotides. In another embodiment, the pyrimidine
nucleotides in the sense region are 2'-deoxy-2'-fluoro pyrimidine
nucleotides and the purine nucleotides present in the sense region
are 2'-deoxy purine nucleotides. In one embodiment, the pyrimidine
nucleotides in the antisense region are 2'-deoxy-2'-fluoro
pyrimidine nucleotides and the purine nucleotides present in the
antisense region are 2'-O-methyl or 2'-deoxy purine nucleotides. In
another embodiment of any of the above-described siNA molecules,
any nucleotides present in a non-complementary region of the sense
strand (e.g. overhang region) are 2'-deoxy nucleotides.
[0054] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene, wherein the siNA molecule
is assembled from two separate oligonucleotide fragments wherein
one fragment comprises the sense region and the second fragment
comprises the antisense region of the siNA molecule, and wherein
the fragment comprising the sense region includes a terminal cap
moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of
the fragment. In one embodiment, the terminal cap moiety is an
inverted deoxy abasic moiety or glyceryl moiety. In one embodiment,
each of the two fragments of the siNA molecule comprise about 21
nucleotides.
[0055] In one embodiment, the invention features a siNA molecule
comprising at least one modified nucleotide, wherein the modified
nucleotide is a 2'-deoxy-2'-fluoro nucleotide. The siNA can be, for
example, of length between about 12 and about 36 nucleotides. In
one embodiment, all pyrimidine nucleotides present in the siNA are
2'-deoxy-2'-fluoro pyrimidine nucleotides. In one embodiment, the
modified nucleotides in the siNA include at least one
2'-deoxy-2'-fluoro cytidine or 2'-deoxy-2'-fluoro uridine
nucleotide. In one embodiment, the modified nucleotides in the siNA
include at least one 2'-fluoro cytidine and at least one
2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all
uridine nucleotides present in the siNA are 2'-deoxy-2'-fluoro
uridine nucleotides. In one embodiment, all cytidine nucleotides
present in the siNA are 2'-deoxy-2'-fluoro cytidine nucleotides. In
one embodiment, all adenosine nucleotides present in the siNA are
2'-deoxy-2'-fluoro adenosine nucleotides. In one embodiment, all
guanosine nucleotides present in the siNA are 2'-deoxy-2'-fluoro
guanosine nucleotides. The siNA can further comprise at least one
modified internucleotidic linkage, such as phosphorothioate
linkage. In another embodiment, the 2'-deoxy-2'-fluoronucleotides
are present at specifically selected locations in the siNA that are
sensitive to cleavage by ribonucleases, such as locations having
pyrimidine nucleotides.
[0056] In one embodiment, the invention features a method of
increasing the stability of a siNA molecule against cleavage by
ribonucleases comprising introducing at least one modified
nucleotide into the siNA molecule, wherein the modified nucleotide
is a 2'-deoxy-2'-fluoro nucleotide. In one embodiment, all
pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro
pyrimidine nucleotides. In one embodiment, the modified nucleotides
in the siNA include at least one 2'-deoxy-2'-fluoro cytidine or
2'-deoxy-2'-fluoro uridine nucleotide. In one embodiment, the
modified nucleotides in the siNA include at least one 2'-fluoro
cytidine and at least one 2'-deoxy-2'-fluoro uridine nucleotides.
In one embodiment, all uridine nucleotides present in the siNA are
2'-deoxy-2'-fluoro uridine nucleotides. In one embodiment, all
cytidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro
cytidine nucleotides. In one embodiment, all adenosine nucleotides
present in the siNA are 2'-deoxy-2'-fluoro adenosine nucleotides.
In one embodiment, all guanosine nucleotides present in the siNA
are 2'-deoxy-2'-fluoro guanosine nucleotides. The siNA can further
comprise at least one modified internucleotidic linkage, such as
phosphorothioate linkage. In one embodiment, the
2'-deoxy-2'-fluoronucleotides are present at specifically selected
locations in the siNA that are sensitive to cleavage by
ribonucleases, such as locations having pyrimidine nucleotides.
[0057] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene comprising a sense region
and an antisense region, wherein the antisense region comprises a
nucleotide sequence that is complementary to a nucleotide sequence
of RNA encoded by the VEGF and/or VEGFr gene or a portion thereof
and the sense region comprises a nucleotide sequence that is
complementary to the antisense region, and wherein the purine
nucleotides present in the antisense region comprise
2'-deoxy-purine nucleotides. In an alternative embodiment, the
purine nucleotides present in the antisense region comprise
2'-O-methyl purine nucleotides. In either of the above embodiments,
the antisense region can comprise a phosphorothioate
internucleotide linkage at the 3' end of the antisense region.
Alternatively, in either of the above embodiments, the antisense
region can comprise a glyceryl modification at the 3' end of the
antisense region. In another embodiment of any of the
above-described siNA molecules, any nucleotides present in a
non-complementary region of the antisense strand (e.g. overhang
region) are 2'-deoxy nucleotides.
[0058] In one embodiment, the antisense region of a siNA molecule
of the invention comprises sequence complementary to a portion of a
VEGF and/or VEGFr transcript having sequence unique to a particular
VEGF and/or VEGFr disease related allele, such as sequence
comprising a single nucleotidepolymorphism (SNP) associated with
the disease specific allele. As such, the antisense region of a
siNA molecule of the invention can comprise sequence complementary
to sequences that are unique to a particular allele to provide
specificity in mediating selective RNAi against the disease related
allele.
[0059] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that down-regulates
expression of a VEGF and/or VEGFr gene, wherein the siNA molecule
is assembled from two separate oligonucleotide fragments wherein
one fragment comprises the sense region and the second fragment
comprises the antisense region of the siNA molecule. In another
embodiment about 19 nucleotides of each fragment of the siNA
molecule are base-paired to the complementary nucleotides of the
other fragment of the siNA molecule and wherein at least two 3'
terminal nucleotides of each fragment of the siNA molecule are not
base-paired to the nucleotides of the other fragment of the siNA
molecule. In one embodiment, each of the two 3' terminal
nucleotides of each fragment of the siNA molecule is a
2'-deoxy-pyrimidine nucleotide, such as a 2'-deoxy-thymidine. In
another embodiment, all 21 nucleotides of each fragment of the siNA
molecule are base-paired to the complementary nucleotides of the
other fragment of the siNA molecule. In another embodiment, about
19 nucleotides of the antisense region are base-paired to the
nucleotide sequence or a portion thereof of the RNA encoded by the
VEGF and/or VEGFr gene. In another embodiment, about 21 nucleotides
of the antisense region are base-paired to the nucleotide sequence
or a portion thereof of the RNA encoded by the VEGF and/or VEGFr
gene. In any of the above embodiments, the 5'-end of the fragment
comprising said antisense region can optionally includes a
phosphate group.
[0060] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits the
expression of a VEGF and/or VEGFr RNA sequence (e.g., wherein said
target RNA sequence is encoded by a VEGF and/or VEGFr gene involved
in the VEGF and/or VEGFr pathway), wherein the siNA molecule does
not contain any ribonucleotides and wherein each strand of the
double-stranded siNA molecule is about 21 nucleotides long.
Examples of non-ribonucleotide containing siNA constructs are
combinations of stabilization chemistries shown in Table IV in any
combination of Sense/Antisense chemistries, such as Stab 7/8, Stab
7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13, Stab
18/13, Stab 7/19, Stab 8/19, Stab 18/19, Stab 7/20, Stab 8/20, or
Stab 18/20.
[0061] In one embodiment, the invention features a chemically
synthesized double stranded RNA molecule that directs cleavage of a
VEGF and/or VEGFr RNA via RNA interference, wherein each strand of
said RNA molecule is about 21 to about 23 nucleotides in length;
one strand of the RNA molecule comprises nucleotide sequence having
sufficient complementarity to the VEGF and/or VEGFr RNA for the RNA
molecule to direct cleavage of the VEGF and/or VEGFr RNA via RNA
interference; and wherein at least one strand of the RNA molecule
comprises one or more chemically modified nucleotides described
herein, such as deoxynucleotides, 2'-O-methyl nucleotides,
2'-deoxy-2'-fluoro nucloetides, 2'-O-methoxyethyl nucleotides
etc.
[0062] In one embodiment, the invention features a medicament
comprising a siNA molecule of the invention.
[0063] In one embodiment, the invention features an active
ingredient comprising a siNA molecule of the invention.
[0064] In one embodiment, the invention features the use of a
double-stranded short interfering nucleic acid (siNA) molecule to
down-regulate expression of a VEGF and/or VEGFr gene, wherein the
siNA molecule comprises one or more chemical modifications and each
strand of the double-stranded siNA is about 18 to about 28 or more
(e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or more)
nucleotides long.
[0065] In one embodiment, the invention features the use of a
double-stranded short interfering nucleic acid (siNA) molecule to
down-regulate expression of a VEGF and/or VEGFr gene, wherein the
siNA molecule comprises one or more chemical modifications and each
strand of the double-stranded siNA is about 21 nucleotides
long.
[0066] In one embodiment, a VEGFr gene contemplated by the
invention is a VEGFR1, VEGFR2, or VEGFr3 gene.
[0067] In one embodiment, the invention features the use of a
double-stranded short interfering nucleic acid (siNA) molecule that
inhibits expression of a VEGF and/or VEGFr gene, wherein one of the
strands of the double-stranded siNA molecule is an antisense strand
which comprises nucleotide sequence that is complementary to
nucleotide sequence of VEGF and/or VEGFr RNA or a portion thereof,
the other strand is a sense strand which comprises nucleotide
sequence that is complementary to a nucleotide sequence of the
antisense strand and wherein a majority of the pyrimidine
nucleotides present in the double-stranded siNA molecule comprises
a sugar modification. In one embodiment, the VEGFr gene is VEGFR2.
In one embodiment, the VEGFr gene is VEGFR1.
[0068] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits
expression of a VEGF and/or VEGFr gene, wherein one of the strands
of the double-stranded siNA molecule is an antisense strand which
comprises nucleotide sequence that is complementary to nucleotide
sequence of VEGF and/or VEGFr RNA or a portion thereof, wherein the
other strand is a sense strand which comprises nucleotide sequence
that is complementary to a nucleotide sequence of the antisense
strand and wherein a majority of the pyrimidine nucleotides present
in the double-stranded siNA molecule comprises a sugar
modification. In one embodiment, the VEGFr gene is VEGFR2. In one
embodiment, the VEGFr gene is VEGFR1.
[0069] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits
expression of a VEGF and/or VEGFr gene, wherein one of the strands
of the double-stranded siNA molecule is an antisense strand which
comprises nucleotide sequence that is complementary to nucleotide
sequence of VEGF and/or VEGFr RNA or a portion thereof, the other
strand is a sense strand which comprises nucleotide sequence that
is complementary to a nucleotide sequence of the antisense strand
and wherein a majority of the pyrimidine nucleotides present in the
double-stranded siNA molecule comprises a sugar modification. In
one embodiment, each strand of the siNA molecule comprises about 18
to about 29 or more (e.g., about 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29 or more) nucleotides, wherein each strand comprises
at least about 18 nucleotides that are complementary to the
nucleotides of the other strand. In another embodiment, the siNA
molecule is assembled from two oligonucleotide fragments, wherein
one fragment comprises the nucleotide sequence of the antisense
strand of the siNA molecule and a second fragment comprises
nucleotide sequence of the sense region of the siNA molecule. In
one embodiment, the sense strand is connected to the antisense
strand via a linker molecule, such as a polynucleotide linker or a
non-nucleotide linker. In a further embodiment, the pyrimidine
nucleotides present in the sense strand are 2'-deoxy-2'-fluoro
pyrimidine nucleotides and the purine nucleotides present in the
sense region are 2'-deoxy purine nucleotides. In another
embodiment, the pyrimidine nucleotides present in the sense strand
are 2'-deoxy-2'-fluoro pyrimidine nucleotides and the purine
nucleotides present in the sense region are 2'-O-methyl purine
nucleotides. In still another embodiment, the pyrimidine
nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro
pyrimidine nucleotides and any purine nucleotides present in the
antisense strand are 2'-deoxy purine nucleotides. In one
embodiment, the antisense strand comprises one or more
2'-deoxy-2'-fluoro pyrimidine nucleotides and one or more
2'-O-methyl purine nucleotides. In another embodiment, the
pyrimidine nucleotides present in the antisense strand are
2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine
nucleotides present in the antisense strand are 2'-O-methyl purine
nucleotides. In a further embodiment the sense strand comprises a
3'-end and a 5'-end, wherein a terminal cap moiety (e.g., an
inverted deoxy abasic moiety or inverted deoxy nucleotide moiety
such as inverted thymidine) is present at the 5'-end, the 3'-end,
or both of the 5' and 3' ends of the sense strand. In another
embodiment, the antisense strand comprises a phosphorothioate
internucleotide linkage at the 3' end of the antisense strand. In
another embodiment, the antisense strand comprises a glyceryl
modification at the 3' end. In another embodiment, the 5'-end of
the antisense strand optionally includes a phosphate group.
[0070] In any of the above-described embodiments of a
double-stranded short interfering nucleic acid (siNA) molecule that
inhibits expression of a VEGF and/or VEGFr gene, wherein a majority
of the pyrimidine nucleotides present in the double-stranded siNA
molecule comprises a sugar modification, each of the two strands of
the siNA molecule can comprise about 21 nucleotides. In one
embodiment, about 21 nucleotides of each strand of the siNA
molecule are base-paired to the complementary nucleotides of the
other strand of the siNA molecule. In another embodiment, about 19
nucleotides of each strand of the siNA molecule are base-paired to
the complementary nucleotides of the other strand of the siNA
molecule, wherein at least two 3' terminal nucleotides of each
strand of the siNA molecule are not base-paired to the nucleotides
of the other strand of the siNA molecule. In one embodiment, each
of the two 3' terminal nucleotides of each fragment of the siNA
molecule is a 2'-deoxy-pyrimidine, such as 2'-deoxy-thymidine. In
one embodiment, each strand of the siNA molecule is base-paired to
the complementary nucleotides of the other strand of the siNA
molecule. In one embodiment, about 19 nucleotides of the antisense
strand are base-paired to the nucleotide sequence of the VEGF
and/or VEGFr RNA or a portion thereof. In another embodiment, about
21 nucleotides of the antisense strand are base-paired to the
nucleotide sequence of the VEGF and/or VEGFr RNA or a portion
thereof.
[0071] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits
expression of a VEGF and/or VEGFr gene, wherein one of the strands
of the double-stranded siNA molecule is an antisense strand which
comprises nucleotide sequence that is complementary to nucleotide
sequence of VEGF and/or VEGFr RNA or a portion thereof, the other
strand is a sense strand which comprises nucleotide sequence that
is complementary to a nucleotide sequence of the antisense strand
and wherein a majority of the pyrimidine nucleotides present in the
double-stranded siNA molecule comprises a sugar modification, and
wherein the 5'-end of the antisense strand optionally includes a
phosphate group.
[0072] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits
expression of a VEGF and/or VEGFr gene, wherein one of the strands
of the double-stranded siNA molecule is an antisense strand which
comprises nucleotide sequence that is complementary to nucleotide
sequence of VEGF and/or VEGFr RNA or a portion thereof, the other
strand is a sense strand which comprises nucleotide sequence that
is complementary to a nucleotide sequence of the antisense strand
and wherein a majority of the pyrimidine nucleotides present in the
double-stranded siNA molecule comprises a sugar modification, and
wherein the nucleotide sequence or a portion thereof of the
antisense strand is complementary to a nucleotide sequence of the
untranslated region or a portion thereof of the VEGF and/or VEGFr
RNA.
[0073] In one embodiment, the invention features a double-stranded
short interfering nucleic acid (siNA) molecule that inhibits
expression of a VEGF and/or VEGFr gene, wherein one of the strands
of the double-stranded siNA molecule is an antisense strand which
comprises nucleotide sequence that is complementary to nucleotide
sequence of VEGF and/or VEGFr RNA or a portion thereof, wherein the
other strand is a sense strand which comprises nucleotide sequence
that is complementary to a nucleotide sequence of the antisense
strand, wherein a majority of the pyrimidine nucleotides present in
the double-stranded siNA molecule comprises a sugar modification,
and wherein the nucleotide sequence of the antisense strand is
complementary to a nucleotide sequence of the VEGF and/or VEGFr RNA
or a portion thereof that is present in the VEGF and/or VEGFr
RNA.
[0074] In one embodiment, the invention features a composition
comprising a siNA molecule of the invention in a pharmaceutically
acceptable carrier or diluent.
[0075] In a non-limiting example, the introduction of
chemically-modified nucleotides into nucleic acid molecules
provides a powerful tool in overcoming potential limitations of in
vivo stability and bioavailability inherent to native RNA molecules
that are delivered exogenously. For example, the use of
chemically-modified nucleic acid molecules can enable a lower dose
of a particular nucleic acid molecule for a given therapeutic
effect since chemically-modified nucleic acid molecules tend to
have a longer half-life in serum. Furthermore, certain chemical
modifications can improve the bioavailability of nucleic acid
molecules by targeting particular cells or tissues and/or improving
cellular uptake of the nucleic acid molecule. Therefore, even if
the activity of a chemically-modified nucleic acid molecule is
reduced as compared to a native nucleic acid molecule, for example,
when compared to an all-RNA nucleic acid molecule, the overall
activity of the modified nucleic acid molecule can be greater than
that of the native molecule due to improved stability and/or
delivery of the molecule. Unlike native unmodified siNA,
chemically-modified siNA can also minimize the possibility of
activating interferon activity in humans.
[0076] In any of the embodiments of siNA molecules described
herein, the antisense region of a siNA molecule of the invention
can comprise a phosphorothioate internucleotide linkage at the
3'-end of said antisense region. In any of the embodiments of siNA
molecules described herein, the antisense region can comprise about
one to about five phosphorothioate internucleotide linkages at the
5'-end of said antisense region. In any of the embodiments of siNA
molecules described herein, the 3'-terminal nucleotide overhangs of
a siNA molecule of the invention can comprise ribonucleotides or
deoxyribonucleotides that are chemically-modified at a nucleic acid
sugar, base, or backbone. In any of the embodiments of siNA
molecules described herein, the 3'-terminal nucleotide overhangs
can comprise one or more universal base ribonucleotides. In any of
the embodiments of siNA molecules described herein, the 3'-terminal
nucleotide overhangs can comprise one or more acyclic
nucleotides.
[0077] One embodiment of the invention provides an expression
vector comprising a nucleic acid sequence encoding at least one
siNA molecule of the invention in a manner that allows expression
of the nucleic acid molecule. Another embodiment of the invention
provides a mammalian cell comprising such an expression vector. The
mammalian cell can be a human cell. The siNA molecule of the
expression vector can comprise a sense region and an antisense
region. The antisense region can comprise sequence complementary to
a RNA or DNA sequence encoding VEGF and/or VEGFr and the sense
region can comprise sequence complementary to the antisense region.
The siNA molecule can comprise two distinct strands having
complementary sense and antisense regions. The siNA molecule can
comprise a single strand having complementary sense and antisense
regions.
[0078] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone
modified internucleotide linkage having Formula I: 1
[0079] wherein each R1 and R2 is independently any nucleotide,
non-nucleotide, or polynucleotide which can be naturally-occurring
or chemically-modified, each X and Y is independently O, S, N,
alkyl, or substituted alkyl, each Z and W is independently O, S, N,
alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or
acetyl and wherein W, X, Y, and Z are optionally not all O. In
another embodiment, a backbone modification of the invention
comprises a phosphonoacetate and/or thiophosphonoacetate
internucleotide linkage (see for example Sheehan et al., 2003,
Nucleic Acids Research, 31, 4109-4118).
[0080] The chemically-modified internucleotide linkages having
Formula I, for example, wherein any Z, W, X, and/or Y independently
comprises a sulphur atom, can be present in one or both
oligonucleotide strands of the siNA duplex, for example, in the
sense strand, the antisense strand, or both strands. The siNA
molecules of the invention can comprise one or more (e.g., about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified
internucleotide linkages having Formula I at the 3'-end, the
5'-end, or both of the 3' and 5'-ends of the sense strand, the
antisense strand, or both strands. For example, an exemplary siNA
molecule of the invention can comprise about 1 to about 5 or more
(e.g., about 1, 2, 3, 4, 5, or more) chemically-modified
internucleotide linkages having Formula I at the 5'-end of the
sense strand, the antisense strand, or both strands. In another
non-limiting example, an exemplary siNA molecule of the invention
can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, or more) pyrimidine nucleotides with chemically-modified
internucleotide linkages having Formula I in the sense strand, the
antisense strand, or both strands. In yet another non-limiting
example, an exemplary siNA molecule of the invention can comprise
one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more)
purine nucleotides with chemically-modified internucleotide
linkages having Formula I in the sense strand, the antisense
strand, or both strands. In another embodiment, a siNA molecule of
the invention having internucleotide linkage(s) of Formula I also
comprises a chemically-modified nucleotide or non-nucleotide having
any of Formulae I-VII.
[0081] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides
having Formula II: 2
[0082] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is
independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl,
F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl,
O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH,
O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl,
alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid,
aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl,
heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalklylamino, substituted silyl, or group having Formula I or
II; R9 is O, S, CH2, S.dbd.O, CHF, or CF2, and B is a nucleosidic
base such as adenine, guanine, uracil, cytosine, thymine,
2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other
non-naturally occurring base that can be complementary or
non-complementary to target RNA or a non-nucleosidic base such as
phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine,
pyridone, pyridinone, or any other non-naturally occurring
universal base that can be complementary or non-complementary to
target RNA.
[0083] The chemically-modified nucleotide or non-nucleotide of
Formula II can be present in one or both oligonucleotide strands of
the siNA duplex, for example in the sense strand, the antisense
strand, or both strands. The siNA molecules of the invention can
comprise one or more chemically-modified nucleotide or
non-nucleotide of Formula II at the 3'-end, the 5'-end, or both of
the 3' and 5'-ends of the sense strand, the antisense strand, or
both strands. For example, an exemplary siNA molecule of the
invention can comprise about 1 to about 5 or more (e.g., about 1,
2, 3, 4, 5, or more) chemically-modified nucleotides or
non-nucleotides of Formula II at the 5'-end of the sense strand,
the antisense strand, or both strands. In anther non-limiting
example, an exemplary siNA molecule of the invention can comprise
about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more)
chemically-modified nucleotides or non-nucleotides of Formula II at
the 3'-end of the sense strand, the antisense strand, or both
strands.
[0084] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, or more) nucleotides or non-nucleotides
having Formula III: 3
[0085] wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is
independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl,
F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl,
O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH,
O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl,
alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid,
aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl,
heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalklylamino, substituted silyl, or group having Formula I or
II; R9 is O, S, CH2, S.dbd.O, CHF, or CF2, and B is a nucleosidic
base such as adenine, guanine, uracil, cytosine, thymine,
2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other
non-naturally occurring base that can be employed to be
complementary or non-complementary to target RNA or a
non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole,
5-nitroindole, nebularine, pyridone, pyridinone, or any other
non-naturally occurring universal base that can be complementary or
non-complementary to target RNA.
[0086] The chemically-modified nucleotide or non-nucleotide of
Formula III can be present in one or both oligonucleotide strands
of the siNA duplex, for example, in the sense strand, the antisense
strand, or both strands. The siNA molecules of the invention can
comprise one or more chemically-modified nucleotide or
non-nucleotide of Formula III at the 3'-end, the 5'-end, or both of
the 3' and 5'-ends of the sense strand, the antisense strand, or
both strands. For example, an exemplary siNA molecule of the
invention can comprise about 1 to about 5 or more (e.g., about 1,
2, 3, 4, 5, or more) chemically-modified nucleotide(s) or
non-nucleotide(s) of Formula III at the 5'-end of the sense strand,
the antisense strand, or both strands. In anther non-limiting
example, an exemplary siNA molecule of the invention can comprise
about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more)
chemically-modified nucleotide or non-nucleotide of Formula III at
the 3'-end of the sense strand, the antisense strand, or both
strands.
[0087] In another embodiment, a siNA molecule of the invention
comprises a nucleotide having Formula II or III, wherein the
nucleotide having Formula II or III is in an inverted
configuration. For example, the nucleotide having Formula II or III
is connected to the siNA construct in a 3'-3',3'-2',2'-3', or 5'-5'
configuration, such as at the 3'-end, the 5'-end, or both of the 3'
and 5'-ends of one or both siNA strands.
[0088] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises a 5'-terminal phosphate group
having Formula IV: 4
[0089] wherein each X and Y is independently O, S, N, alkyl,
substituted alkyl, or alkylhalo; wherein each Z and W is
independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl,
alkaryl, aralkyl, alkylhalo, or acetyl; and wherein W, X, Y and Z
are not all O.
[0090] In one embodiment, the invention features a siNA molecule
having a 5'-terminal phosphate group having Formula IV on the
target-complementary strand, for example, a strand complementary to
a target RNA, wherein the siNA molecule comprises an all RNA siNA
molecule. In another embodiment, the invention features a siNA
molecule having a 5'-terminal phosphate group having Formula IV on
the target-complementary strand wherein the siNA molecule also
comprises about 1 to about 3 (e.g., about 1, 2, or 3) nucleotide
3'-terminal nucleotide overhangs having about 1 to about 4 (e.g.,
about 1, 2, 3, or 4) deoxyribonucleotides on the 3'-end of one or
both strands. In another embodiment, a 5'-terminal phosphate group
having Formula IV is present on the target-complementary strand of
a siNA molecule of the invention, for example a siNA molecule
having chemical modifications having any of Formulae I-VII.
[0091] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises one or more phosphorothioate
internucleotide linkages. For example, in a non-limiting example,
the invention features a chemically-modified short interfering
nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more
phosphorothioate internucleotide linkages in one siNA strand. In
yet another embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA)
individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more
phosphorothioate internucleotide linkages in both siNA strands. The
phosphorothioate internucleotide linkages can be present in one or
both oligonucleotide strands of the siNA duplex, for example in the
sense strand, the antisense strand, or both strands. The siNA
molecules of the invention can comprise one or more
phosphorothioate internucleotide linkages at the 3'-end, the
5'-end, or both of the 3'- and 5'-ends of the sense strand, the
antisense strand, or both strands. For example, an exemplary siNA
molecule of the invention can comprise about 1 to about 5 or more
(e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate
internucleotide linkages at the 5'-end of the sense strand, the
antisense strand, or both strands. In another non-limiting example,
an exemplary siNA molecule of the invention can comprise one or
more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more)
pyrimidine phosphorothioate internucleotide linkages in the sense
strand, the antisense strand, or both strands. In yet another
non-limiting example, an exemplary siNA molecule of the invention
can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, or more) purine phosphorothioate internucleotide linkages in
the sense strand, the antisense strand, or both strands.
[0092] In one embodiment, the invention features a siNA molecule,
wherein the sense strand comprises one or more, for example, about
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate
internucleotide linkages, and/or one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl,
2'-deoxy-2'-fluoro, and/or about one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides,
and optionally a terminal cap molecule at the 3'-end, the 5'-end,
or both of the 3'- and 5'-ends of the sense strand; and wherein the
antisense strand comprises about 1 to about 10 or more,
specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more
phosphorothioate internucleotide linkages, and/or one or more
(e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy,
2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified
nucleotides, and optionally a terminal cap molecule at the 3'-end,
the 5'-end, or both of the 3'- and 5'-ends of the antisense strand.
In another embodiment, one or more, for example about 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense
and/or antisense siNA strand are chemically-modified with 2'-deoxy,
2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without
one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
more, phosphorothioate internucleotide linkages and/or a terminal
cap molecule at the 3'-end, the 5'-end, or both of the 3'- and
5'-ends, being present in the same or different strand.
[0093] In another embodiment, the invention features a siNA
molecule, wherein the sense strand comprises about 1 to about 5,
specifically about 1, 2, 3, 4, or 5 phosphorothioate
internucleotide linkages, and/or one or more (e.g., about 1, 2, 3,
4, 5, or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or
one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base
modified nucleotides, and optionally a terminal cap molecule at the
3-end, the 5'-end, or both of the 3'- and 5'-ends of the sense
strand; and wherein the antisense strand comprises about 1 to about
5 or more, specifically about 1, 2, 3, 4, 5, or more
phosphorothioate internucleotide linkages, and/or one or more
(e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy,
2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified
nucleotides, and optionally a terminal cap molecule at the 3'-end,
the 5'-end, or both of the 3'- and 5'-ends of the antisense strand.
In another embodiment, one or more, for example about 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense
and/or antisense siNA strand are chemically-modified with 2'-deoxy,
2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without
about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or
more phosphorothioate internucleotide linkages and/or a terminal
cap molecule at the 3'-end, the 5'-end, or both of the 3'- and
5'-ends, being present in the same or different strand.
[0094] In one embodiment, the invention features a siNA molecule,
wherein the antisense strand comprises one or more, for example,
about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate
internucleotide linkages, and/or about one or more (e.g., about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl,
2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5,
6, 7, 8, 9, 10 or more) universal base modified nucleotides, and
optionally a terminal cap molecule at the 3'-end, the 5'-end, or
both of the 3'- and 5'-ends of the sense strand; and wherein the
antisense strand comprises about 1 to about 10 or more,
specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more
phosphorothioate internucleotide linkages, and/or one or more
(e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy,
2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified
nucleotides, and optionally a terminal cap molecule at the 3'-end,
the 5'-end, or both of the 3'- and 5'-ends of the antisense strand.
In another embodiment, one or more, for example about 1, 2, 3, 4,
5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense
and/or antisense siNA strand are chemically-modified with 2'-deoxy,
2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without
one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or
more phosphorothioate internucleotide linkages and/or a terminal
cap molecule at the 3'-end, the 5'-end, or both of the 3' and
5'-ends, being present in the same or different strand.
[0095] In another embodiment, the invention features a siNA
molecule, wherein the antisense strand comprises about 1 to about 5
or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate
internucleotide linkages, and/or one or more (e.g., about 1, 2, 3,
4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl,
2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5,
6, 7, 8, 9, 10 or more) universal base modified nucleotides, and
optionally a terminal cap molecule at the 3'-end, the 5'-end, or
both of the 3'- and 5'-ends of the sense strand; and wherein the
antisense strand comprises about 1 to about 5 or more, specifically
about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide
linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8,
9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or
one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more)
universal base modified nucleotides, and optionally a terminal cap
molecule at the 3'end, the 5'-end, or both of the 3'- and 5'-ends
of the antisense strand. In another embodiment, one or more, for
example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine
nucleotides of the sense and/or antisense siNA strand are
chemically-modified with 2'-deoxy, 2'-O-methyl and/or
2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5,
for example about 1, 2, 3, 4, 5 or more phosphorothioate
internucleotide linkages and/or a terminal cap molecule at the
3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present
in the same or different strand.
[0096] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
having about 1 to about 5, specifically about 1, 2, 3, 4, 5 or more
phosphorothioate internucleotide linkages in each strand of the
siNA molecule.
[0097] In another embodiment, the invention features a siNA
molecule comprising 2'-5' internucleotide linkages. The 2'-5'
internucleotide linkage(s) can be at the 3'-end, the 5'-end, or
both of the 3'- and 5'-ends of one or both siNA sequence strands.
In addition, the 2'-5' internucleotide linkage(s) can be present at
various other positions within one or both siNA sequence strands,
for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including
every internucleotide linkage of a pyrimidine nucleotide in one or
both strands of the siNA molecule can comprise a 2'-5'
internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
more including every internucleotide linkage of a purine nucleotide
in one or both strands of the siNA molecule can comprise a 2'-5'
internucleotide linkage.
[0098] In another embodiment, a chemically-modified siNA molecule
of the invention comprises a duplex having two strands, one or both
of which can be chemically-modified, wherein each strand is about
18 to about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or
27) nucleotides in length, wherein the duplex has about 18 to about
23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein
the chemical modification comprises a structure having any of
Formulae I-VII. For example, an exemplary chemically-modified siNA
molecule of the invention comprises a duplex having two strands,
one or both of which can be chemically-modified with a chemical
modification having any of Formulae I-VII or any combination
thereof, wherein each strand consists of about 21 nucleotides, each
having a 2-nucleotide 3'-terminal nucleotide overhang, and wherein
the duplex has about 19 base pairs. In another embodiment, a siNA
molecule of the invention comprises a single stranded hairpin
structure, wherein the siNA is about 36 to about 70 (e.g., about
36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having
about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base
pairs, and wherein the siNA can include a chemical modification
comprising a structure having any of Formulae I-VII or any
combination thereof. For example, an exemplary chemically-modified
siNA molecule of the invention comprises a linear oligonucleotide
having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47,
48, 49, or 50) nucleotides that is chemically-modified with a
chemical modification having any of Formulae I-VII or any
combination thereof, wherein the linear oligonucleotide forms a
hairpin structure having about 19 base pairs and a 2-nucleotide
3'-terminal nucleotide overhang. In another embodiment, a linear
hairpin siNA molecule of the invention contains a stem loop motif,
wherein the loop portion of the siNA molecule is biodegradable. For
example, a linear hairpin siNA molecule of the invention is
designed such that degradation of the loop portion of the siNA
molecule in vivo can generate a double-stranded siNA molecule with
3'-terminal overhangs, such as 3'-terminal nucleotide overhangs
comprising about 2 nucleotides.
[0099] In another embodiment, a siNA molecule of the invention
comprises a hairpin structure, wherein the siNA is about 25 to
about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50)
nucleotides in length having about 3 to about 25 (e.g., about 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, or 25) base pairs, and wherein the siNA can include one or
more chemical modifications comprising a structure having any of
Formulae I-VII or any combination thereof. For example, an
exemplary chemically-modified siNA molecule of the invention
comprises a linear oligonucleotide having about 25 to about 35
(e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35)
nucleotides that is chemically-modified with one or more chemical
modifications having any of Formulae I-VII or any combination
thereof, wherein the linear oligonucleotide forms a hairpin
structure having about 3 to about 23 (e.g., about 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) base
pairs and a 5'-terminal phosphate group that can be chemically
modified as described herein (for example a 5'-terminal phosphate
group having Formula IV). In one embodiment, a linear hairpin siNA
molecule of the invention contains a stem loop motif, wherein the
loop portion of the siNA molecule is biodegradable. In another
embodiment, a linear hairpin siNA molecule of the invention
comprises a loop portion comprising a non-nucleotide linker.
[0100] In another embodiment, a siNA molecule of the invention
comprises an asymmetric hairpin structure, wherein the siNA is
about 25 to about 50 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
or 50) nucleotides in length having about 3 to about 20 (e.g.,
about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
or 20) base pairs, and wherein the siNA can include one or more
chemical modifications comprising a structure having any of
Formulae I-VII or any combination thereof. For example, an
exemplary chemically-modified siNA molecule of the invention
comprises a linear oligonucleotide having about 25 to about 35
(e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35)
nucleotides that is chemically-modified with one or more chemical
modifications having any of Formulae I-VII or any combination
thereof, wherein the linear oligonucleotide forms an asymmetric
hairpin structure having about 3 to about 18 (e.g., about 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) base pairs and a
5'-terminal phosphate group that can be chemically modified as
described herein (for example a 5'-terminal phosphate group having
Formula IV). In one embodiment, an asymmetric hairpin siNA molecule
of the invention contains a stem loop motif, wherein the loop
portion of the siNA molecule is biodegradable. In another
embodiment, an asymmetric hairpin siNA molecule of the invention
comprises a loop portion comprising a non-nucleotide linker.
[0101] In another embodiment, a siNA molecule of the invention
comprises an asymmetric double stranded structure having separate
polynucleotide strands comprising sense and antisense regions,
wherein the antisense region is about 16 to about 25 (e.g., about
16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length,
wherein the sense region is about 3 to about 18 (e.g., about 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) nucleotides
in length, wherein the sense region and the antisense region have
at least 3 complementary nucleotides, and wherein the siNA can
include one or more chemical modifications comprising a structure
having any of Formulae I-VII or any combination thereof. For
example, an exemplary chemically-modified siNA molecule of the
invention comprises an asymmetric double stranded structure having
separate polynucleotide strands comprising sense and antisense
regions, wherein the antisense region is about 18 to about 22
(e.g., about 18, 19, 20, 21, or 22) nucleotides in length and
wherein the sense region is about 3 to about 15 (e.g., about 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) nucleotides in length,
wherein the sense region the antisense region have at least 3
complementary nucleotides, and wherein the siNA can include one or
more chemical modifications comprising a structure having any of
Formulae I-VII or any combination thereof. In another embodiment,
the asymmetic double stranded siNA molecule can also have a
5'-terminal phosphate group that can be chemically modified as
described herein (for example a 5'-terminal phosphate group having
Formula IV).
[0102] In another embodiment, a siNA molecule of the invention
comprises a circular nucleic acid molecule, wherein the siNA is
about 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or
70) nucleotides in length having about 18 to about 23 (e.g., about
18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can
include a chemical modification, which comprises a structure having
any of Formulae I-VII or any combination thereof. For example, an
exemplary chemically-modified siNA molecule of the invention
comprises a circular oligonucleotide having about 42 to about 50
(e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides
that is chemically-modified with a chemical modification having any
of Formulae I-VII or any combination thereof, wherein the circular
oligonucleotide forms a dumbbell shaped structure having about 19
base pairs and 2 loops.
[0103] In another embodiment, a circular siNA molecule of the
invention contains two loop motifs, wherein one or both loop
portions of the siNA molecule is biodegradable. For example, a
circular siNA molecule of the invention is designed such that
degradation of the loop portions of the siNA molecule in vivo can
generate a double-stranded siNA molecule with 3'-terminal
overhangs, such as 3'-terminal nucleotide overhangs comprising
about 2 nucleotides.
[0104] In one embodiment, a siNA molecule of the invention
comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or more) abasic moiety, for example a compound having Formula V:
5
[0105] wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13
is independently H, OH, alkyl, substituted alkyl, alkaryl or
aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl,
O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH,
O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl,
alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid,
aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl,
heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalklylamino, substituted silyl, or group having Formula I or
II; R9 is O, S, CH2, S.dbd.O, CHF, or CF2.
[0106] In one embodiment, a siNA molecule of the invention
comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or more) inverted abasic moiety, for example a compound having
Formula VI: 6
[0107] wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13
is independently H, OH, alkyl, substituted alkyl, alkaryl or
aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl,
O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH,
O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl,
alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid,
aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl,
heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalklylamino, substituted silyl, or group having Formula I or
II; R9 is O, S, CH2, S.dbd.O, CHF, or CF2, and either R2, R3, R8 or
R13 serve as points of attachment to the siNA molecule of the
invention.
[0108] In another embodiment, a siNA molecule of the invention
comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or more) substituted polyalkyl moieties, for example a compound
having Formula VII: 7
[0109] wherein each n is independently an integer from 1 to 12,
each R1, R2 and R3 is independently H, OH, alkyl, substituted
alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl,
S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl,
alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH,
S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2,
aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid,
O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalklylamino, substituted silyl, or a group having Formula I,
and R1, R2 or R3 serves as points of attachment to the siNA
molecule of the invention.
[0110] In another embodiment, the invention features a compound
having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups,
n=1, and R3 comprises O and is the point of attachment to the
3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both
strands of a double-stranded siNA molecule of the invention or to a
single-stranded siNA molecule of the invention. This modification
is referred to herein as "glyceryl" (for example modification 6 in
FIG. 10).
[0111] In another embodiment, a moiety having any of Formula V, VI
or VII of the invention is at the 3'-end, the 5'-end, or both of
the 3' and 5'-ends of a siNA molecule of the invention. For
example, a moiety having Formula V, VI or VII can be present at the
3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense
strand, the sense strand, or both antisense and sense strands of
the siNA molecule. In addition, a moiety having Formula VII can be
present at the 3'-end or the 5'-end of a hairpin siNA molecule as
described herein.
[0112] In another embodiment, a siNA molecule of the invention
comprises an abasic residue having Formula V or VI, wherein the
abasic residue having Formula VI or VI is connected to the siNA
construct in a 3'-3',3'-2',2'-3', or 5'-5' configuration, such as
at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or
both siNA strands.
[0113] In one embodiment, a siNA molecule of the invention
comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or more) locked nucleic acid (LNA) nucleotides, for example at the
5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination
thereof, of the siNA molecule.
[0114] In another embodiment, a siNA molecule of the invention
comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
or more) acyclic nucleotides, for example at the 5'-end, the
3'-end, both of the 5' and 3'-ends, or any combination thereof, of
the siNA molecule.
[0115] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising a sense region, wherein any (e.g., one
or more or all) pyrimidine nucleotides present in the sense region
are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all
pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the sense
region are 2'-deoxy purine nucleotides (e.g., wherein all purine
nucleotides are 2'-deoxy purine nucleotides or alternately a
plurality of purine nucleotides are 2'-deoxy purine
nucleotides).
[0116] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising a sense region, wherein any (e.g., one
or more or all) pyrimidine nucleotides present in the sense region
are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all
pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the sense
region are 2'-deoxy purine nucleotides (e.g., wherein all purine
nucleotides are 2'-deoxy purine nucleotides or alternately a
plurality of purine nucleotides are 2'-deoxy purine nucleotides),
wherein any nucleotides comprising a 3'-terminal nucleotide
overhang that are present in said sense region are 2'-deoxy
nucleotides.
[0117] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising a sense region, wherein any (e.g., one
or more or all) pyrimidine nucleotides present in the sense region
are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all
pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the sense
region are 2'-O-methyl purine nucleotides (e.g., wherein all purine
nucleotides are 2'-O-methyl purine nucleotides or alternately a
plurality of purine nucleotides are 2'-O-methyl purine
nucleotides).
[0118] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising a sense region, wherein any (e.g., one
or more or all) pyrimidine nucleotides present in the sense region
are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all
pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), wherein any (e.g.,
one or more or all) purine nucleotides present in the sense region
are 2'-O-methyl purine nucleotides (e.g., wherein all purine
nucleotides are 2'-O-methyl purine nucleotides or alternately a
plurality of purine nucleotides are 2'-O-methyl purine
nucleotides), and wherein any nucleotides comprising a 3'-terminal
nucleotide overhang that are present in said sense region are
2'-deoxy nucleotides.
[0119] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising an antisense region, wherein any (e.g.,
one or more or all) pyrimidine nucleotides present in the antisense
region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein
all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the
antisense region are 2'-O-methyl purine nucleotides (e.g., wherein
all purine nucleotides are 2'-O-methyl purine nucleotides or
alternately a plurality of purine nucleotides are 2'-O-methyl
purine nucleotides).
[0120] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising an antisense region, wherein any (e.g.,
one or more or all) pyrimidine nucleotides present in the antisense
region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein
all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), wherein any (e.g.,
one or more or all) purine nucleotides present in the antisense
region are 2'-O-methyl purine nucleotides (e.g., wherein all purine
nucleotides are 2'-O-methyl purine nucleotides or alternately a
plurality of purine nucleotides are 2'-O-methyl purine
nucleotides), and wherein any nucleotides comprising a 3'-terminal
nucleotide overhang that are present in said antisense region are
2'-deoxy nucleotides.
[0121] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising an antisense region, wherein any (e.g.,
one or more or all) pyrimidine nucleotides present in the antisense
region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein
all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the
antisense region are 2'-deoxy purine nucleotides (e.g., wherein all
purine nucleotides are 2'-deoxy purine nucleotides or alternately a
plurality of purine nucleotides are 2'-deoxy purine
nucleotides).
[0122] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention comprising an antisense region, wherein any (e.g.,
one or more or all) pyrimidine nucleotides present in the antisense
region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein
all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
(e.g., one or more or all) purine nucleotides present in the
antisense region are 2'-O-methyl purine nucleotides (e.g., wherein
all purine nucleotides are 2'-O-methyl purine nucleotides or
alternately a plurality of purine nucleotides are 2'-O-methyl
purine nucleotides).
[0123] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid (siNA) molecule
of the invention capable of mediating RNA interference (RNAi)
against VEGF and/or VEGFr inside a cell or reconstituted in vitro
system comprising a sense region, wherein one or more pyrimidine
nucleotides present in the sense region are 2'-deoxy-2'-fluoro
pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a
plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro
pyrimidine nucleotides), and one or more purine nucleotides present
in the sense region are 2'-deoxy purine nucleotides (e.g., wherein
all purine nucleotides are 2'-deoxy purine nucleotides or
alternately a plurality of purine nucleotides are 2'-deoxy purine
nucleotides), and an antisense region, wherein one or more
pyrimidine nucleotides present in the antisense region are
2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all
pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and one or more
purine nucleotides present in the antisense region are 2'-O-methyl
purine nucleotides (e.g., wherein all purine nucleotides are
2'-O-methyl purine nucleotides or alternately a plurality of purine
nucleotides are 2'-O-methyl purine nucleotides). The sense region
and/or the antisense region can have a terminal cap modification,
such as any modification described herein or shown in FIG. 10, that
is optionally present at the 3'-end, the 5'-end, or both of the 3'
and 5'-ends of the sense and/or antisense sequence. The sense
and/or antisense region can optionally further comprise a
3'-terminal nucleotide overhang having about 1 to about 4 (e.g.,
about 1, 2, 3, or 4) 2'-deoxynucleotides. The overhang nucleotides
can further comprise one or more (e.g., about 1, 2, 3, 4 or more)
phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate
internucleotide linkages. Non-limiting examples of these
chemically-modified siNAs are shown in FIGS. 4 and 5 and Tables III
and IV herein. In any of these described embodiments, the purine
nucleotides present in the sense region are alternatively
2'-O-methyl purine nucleotides (e.g., wherein all purine
nucleotides are 2'-O-methyl purine nucleotides or alternately a
plurality of purine nucleotides are 2'-O-methyl purine nucleotides)
and one or more purine nucleotides present in the antisense region
are 2'-O-methyl purine nucleotides (e.g., wherein all purine
nucleotides are 2'-O-methyl purine nucleotides or alternately a
plurality of purine nucleotides are 2'-O-methyl purine
nucleotides). Also, in any of these embodiments, one or more purine
nucleotides present in the sense region are alternatively purine
ribonucleotides (e.g., wherein all purine nucleotides are purine
ribonucleotides or alternately a plurality of purine nucleotides
are purine ribonucleotides) and any purine nucleotides present in
the antisense region are 2'-O-methyl purine nucleotides (e.g.,
wherein all purine nucleotides are 2'-O-methyl purine nucleotides
or alternately a plurality of purine nucleotides are 2'-O-methyl
purine nucleotides). Additionally, in any of these embodiments, one
or more purine nucleotides present in the sense region and/or
present in the antisense region are alternatively selected from the
group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA)
nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and
2'-O-methyl nucleotides (e.g., wherein all purine nucleotides are
selected from the group consisting of 2'-deoxy nucleotides, locked
nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides,
4'-thionucleotides, and 2'-O-methyl nucleotides or alternately a
plurality of purine nucleotides are selected from the group
consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA)
nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and
2'-O-methyl nucleotides).
[0124] In another embodiment, any modified nucleotides present in
the siNA molecules of the invention, preferably in the antisense
strand of the siNA molecules of the invention, but also optionally
in the sense and/or both antisense and sense strands, comprise
modified nucleotides having properties or characteristics similar
to naturally occurring ribonucleotides. For example, the invention
features siNA molecules including modified nucleotides having a
Northern conformation (e.g., Northern pseudorotation cycle, see for
example Saenger, Principles of Nucleic Acid Structure,
Springer-Verlag ed., 1984). As such, chemically modified
nucleotides present in the siNA molecules of the invention,
preferably in the antisense strand of the siNA molecules of the
invention, but also optionally in the sense and/or both antisense
and sense strands, are resistant to nuclease degradation while at
the same time maintaining the capacity to mediate RNAi.
Non-limiting examples of nucleotides having a northern
configuration include locked nucleic acid (LNA) nucleotides (e.g.,
2'-O, 4'-C-methylene-(D-ribofuranosyl) nucleotides);
2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio-ethyl,
2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-chloro nucleotides,
2'-azido nucleotides, and 2'-O-methyl nucleotides.
[0125] In one embodiment, the sense strand of a double stranded
siNA molecule of the invention comprises a terminal cap moiety,
(see for example FIG. 10) such as an inverted deoxyabaisc moiety,
at the 3'-end, 5'-end, or both 3' and 5'-ends of the sense
strand.
[0126] In one embodiment, the invention features a
chemically-modified short interfering nucleic acid molecule (siNA)
capable of mediating RNA interference (RNAi) against VEGF and/or
VEGFr inside a cell or reconstituted in vitro system, wherein the
chemical modification comprises a conjugate covalently attached to
the chemically-modified siNA molecule. Non-limiting examples of
conjugates contemplated by the invention include conjugates and
ligands described in Vargeese et al., U.S. Ser. No. 10/427,160,
filed Apr. 30, 2003, incorporated by reference herein in its
entirety, including the drawings. In another embodiment, the
conjugate is covalently attached to the chemically-modified siNA
molecule via a biodegradable linker. In one embodiment, the
conjugate molecule is attached at the 3'-end of either the sense
strand, the antisense strand, or both strands of the
chemically-modified siNA molecule. In another embodiment, the
conjugate molecule is attached at the 5'-end of either the sense
strand, the antisense strand, or both strands of the
chemically-modified siNA molecule. In yet another embodiment, the
conjugate molecule is attached both the 3'-end and 5'-end of either
the sense strand, the antisense strand, or both strands of the
chemically-modified siNA molecule, or any combination thereof. In
one embodiment, a conjugate molecule of the invention comprises a
molecule that facilitates delivery of a chemically-modified siNA
molecule into a biological system, such as a cell. In another
embodiment, the conjugate molecule attached to the
chemically-modified siNA molecule is a polyethylene glycol, human
serum albumin, or a ligand for a cellular receptor that can mediate
cellular uptake. Examples of specific conjugate molecules
contemplated by the instant invention that can be attached to
chemically-modified siNA molecules are described in Vargeese et
al., U.S. Ser. No. 10/201,394, filed Jul. 22, 2002 incorporated by
reference herein. The type of conjugates used and the extent of
conjugation of siNA molecules of the invention can be evaluated for
improved pharmacokinetic profiles, bioavailability, and/or
stability of siNA constructs while at the same time maintaining the
ability of the siNA to mediate RNAi activity. As such, one skilled
in the art can screen siNA constructs that are modified with
various conjugates to determine whether the siNA conjugate complex
possesses improved properties while maintaining the ability to
mediate RNAi, for example in animal models as are generally known
in the art.
[0127] In one embodiment, the invention features a short
interfering nucleic acid (siNA) molecule of the invention, wherein
the siNA further comprises a nucleotide, non-nucleotide, or mixed
nucleotide/non-nucleotid- e linker that joins the sense region of
the siNA to the antisense region of the siNA. In one embodiment, a
nucleotide linker of the invention can be a linker of .gtoreq.2
nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10
nucleotides in length. In another embodiment, the nucleotide linker
can be a nucleic acid aptamer. By "aptamer" or "nucleic acid
aptamer" as used herein is meant a nucleic acid molecule that binds
specifically to a target molecule wherein the nucleic acid molecule
has sequence that comprises a sequence recognized by the target
molecule in its natural setting. Alternately, an aptamer can be a
nucleic acid molecule that binds to a target molecule where the
target molecule does not naturally bind to a nucleic acid. The
target molecule can be any molecule of interest. For example, the
aptamer can be used to bind to a ligand-binding domain of a
protein, thereby preventing interaction of the naturally occurring
ligand with the protein. This is a non-limiting example and those
in the art will recognize that other embodiments can be readily
generated using techniques generally known in the art. (See, for
example, Gold et al., 1995, Annu. Rev. Biochem., 64, 763; Brody and
Gold, 2000, J. Biotechnol., 74, 5; Sun, 2000, Curr. Opin. Mol.
Ther., 2, 100; Kusser, 2000, J Biotechnol., 74, 27; Hermann and
Patel, 2000, Science, 287, 820; and Jayasena, 1999, Clinical
Chemistry, 45, 1628.)
[0128] In yet another embodiment, a non-nucleotide linker of the
invention comprises abasic nucleotide, polyether, polyamine,
polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other
polymeric compounds (e.g. polyethylene glycols such as those having
between 2 and 100 ethylene glycol units). Specific examples include
those described by Seela and Kaiser, Nucleic Acids Res. 1990,
18:6353 and Nucleic Acids Res. 1987, 15:3113; Cload and Schepartz,
J. Am. Chem. Soc. 1991, 113:6324; Richardson and Schepartz, J. Am.
Chem. Soc. 1991, 113:5109; Ma et al., Nucleic Acids Res. 1993,
21:2585 and Biochemistry 1993, 32:1751; Durand et al., Nucleic
Acids Res. 1990, 18:6353; McCurdy et al., Nucleosides &
Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993,
34:301; Ono et al., Biochemistry 1991, 30:9914; Arnold et al.,
International Publication No. WO 89/02439; Usman et al.,
International Publication No. WO 95/06731; Dudycz et al.,
International Publication No. WO 95/11910 and Ferentz and Verdine,
J. Am. Chem. Soc. 1991, 113:4000, all hereby incorporated by
reference herein. A "non-nucleotide" further means any group or
compound that can be incorporated into a nucleic acid chain in the
place of one or more nucleotide units, including either sugar
and/or phosphate substitutions, and allows the remaining bases to
exhibit their enzymatic activity. The group or compound can be
abasic in that it does not contain a commonly recognized nucleotide
base, such as adenosine, guanine, cytosine, uracil or thymine, for
example at the C1 position of the sugar.
[0129] In one embodiment, the invention features a short
interfering nucleic acid (siNA) molecule capable of mediating RNA
interference (RNAi) inside a cell or reconstituted in vitro system,
wherein one or both strands of the siNA molecule that are assembled
from two separate oligonucleotides do not comprise any
ribonucleotides. For example, a siNA molecule can be assembled from
a single oligonculeotide where the sense and antisense regions of
the siNA comprise separate oligonucleotides that do not have any
ribonucleotides (e.g., nucleotides having a 2'-OH group) present in
the oligonucleotides. In another example, a siNA molecule can be
assembled from a single oligonculeotide where the sense and
antisense regions of the siNA are linked or circularized by a
nucleotide or non-nucleotide linker as described herein, wherein
the oligonucleotide does not have any ribonucleotides (e.g.,
nucleotides having a 2'-OH group) present in the oligonucleotide.
Applicant has surprisingly found that the presense of
ribonucleotides (e.g., nucleotides having a 2'-hydroxyl group)
within the siNA molecule is not required or essential to support
RNAi activity. As such, in one embodiment, all positions within the
siNA can include chemically modified nucleotides and/or
non-nucleotides such as nucleotides and or non-nucleotides having
Formula I, II, III, IV, V, VI, or VII or any combination thereof to
the extent that the ability of the siNA molecule to support RNAi
activity in a cell is maintained.
[0130] In one embodiment, a siNA molecule of the invention is a
single stranded siNA molecule that mediates RNAi activity in a cell
or reconstituted in vitro system comprising a single stranded
polynucleotide having complementarity to a target nucleic acid
sequence. In another embodiment, the single stranded siNA molecule
of the invention comprises a 5'-terminal phosphate group. In
another embodiment, the single stranded siNA molecule of the
invention comprises a 5'-terminal phosphate group and a 3'-terminal
phosphate group (e.g., a 2',3'-cyclic phosphate). In another
embodiment, the single stranded siNA molecule of the invention
comprises about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, or 29) nucleotides. In yet another embodiment, the
single stranded siNA molecule of the invention comprises one or
more chemically modified nucleotides or non-nucleotides described
herein. For example, all the positions within the siNA molecule can
include chemically-modified nucleotides such as nucleotides having
any of Formulae I-VII, or any combination thereof to the extent
that the ability of the siNA molecule to support RNAi activity in a
cell is maintained.
[0131] In one embodiment, a siNA molecule of the invention is a
single stranded siNA molecule that mediates RNAi activity in a cell
or reconstituted in vitro system comprising a single stranded
polynucleotide having complementarity to a target nucleic acid
sequence, wherein one or more pyrimidine nucleotides present in the
siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein
all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine
nucleotides or alternately a plurality of pyrimidine nucleotides
are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any
purine nucleotides present in the antisense region are 2'-O-methyl
purine nucleotides (e.g., wherein all purine nucleotides are
2'-O-methyl purine nucleotides or alternately a plurality of purine
nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap
modification, such as any modification described herein or shown in
FIG. 10, that is optionally present at the 3'-end, the 5'-end, or
both of the 3' and 5'-ends of the antisense sequence. The siNA
optionally further comprises about 1 to about 4 or more (e.g.,
about 1, 2, 3, 4 or more) terminal 2'-deoxynucleotides at the
3'-end of the siNA molecule, wherein the terminal nucleotides can
further comprise one or more (e.g., 1, 2, 3, 4 or more)
phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate
internucleotide linkages, and wherein the siNA optionally further
comprises a terminal phosphate group, such as a 5'-terminal
phosphate group. In any of these embodiments, any purine
nucleotides present in the antisense region are alternatively
2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides
are 2'-deoxy purine nucleotides or alternately a plurality of
purine nucleotides are 2'-deoxy purine nucleotides). Also, in any
of these embodiments, any purine nucleotides present in the siNA
(i.e., purine nucleotides present in the sense and/or antisense
region) can alternatively be locked nucleic acid (LNA) nucleotides
(e.g., wherein all purine nucleotides are LNA nucleotides or
alternately a plurality of purine nucleotides are LNA nucleotides).
Also, in any of these embodiments, any purine nucleotides present
in the siNA are alternatively 2'-methoxyethyl purine nucleotides
(e.g., wherein all purine nucleotides are 2'-methoxyethyl purine
nucleotides or alternately a plurality of purine nucleotides are
2'-methoxyethyl purine nucleotides). In another embodiment, any
modified nucleotides present in the single stranded siNA molecules
of the invention comprise modified nucleotides having properties or
characteristics similar to naturally occurring ribonucleotides. For
example, the invention features siNA molecules including modified
nucleotides having a Northern conformation (e.g., Northern
pseudorotation cycle, see for example Saenger, Principles of
Nucleic Acid Structure, Springer-Verlag ed., 1984). As such,
chemically modified nucleotides present in the single stranded siNA
molecules of the invention are preferably resistant to nuclease
degradation while at the same time maintaining the capacity to
mediate RNAi.
[0132] In one embodiment, the invention features a method for
modulating the expression of a VEGF and/or VEGFr gene within a cell
comprising: (a) synthesizing a siNA molecule of the invention,
which can be chemically-modified, wherein one of the siNA strands
comprises a sequence complementary to RNA of the VEGF and/or VEGFr
gene; and (b) introducing the siNA molecule into a cell under
conditions suitable to modulate the expression of the VEGF and/or
VEGFr gene in the cell.
[0133] In one embodiment, the invention features a method for
modulating the expression of a VEGF and/or VEGFr gene within a cell
comprising: (a) synthesizing a siNA molecule of the invention,
which can be chemically-modified, wherein one of the siNA strands
comprises a sequence complementary to RNA of the VEGF and/or VEGFr
gene and wherein the sense strand sequence of the siNA comprises a
sequence identical or substantially similar to the sequence of the
target RNA; and (b) introducing the siNA molecule into a cell under
conditions suitable to modulate the expression of the VEGF and/or
VEGFr gene in the cell.
[0134] In another embodiment, the invention features a method for
modulating the expression of more than one VEGF and/or VEGFr gene
within a cell comprising: (a) synthesizing siNA molecules of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr genes; and (b) introducing the siNA molecules into a
cell under conditions suitable to modulate the expression of the
VEGF and/or VEGFr genes in the cell.
[0135] In another embodiment, the invention features a method for
modulating the expression of two or more VEGF and/or VEGFr genes
within a cell comprising: (a) synthesizing one or more siNA
molecules of the invention, which can be chemically-modified,
wherein the siNA strands comprise sequences complementary to RNA of
the VEGF and/or VEGFr genes and wherein the sense strand sequences
of the siNAs comprise sequences identical or substantially similar
to the sequences of the target RNAs; and (b) introducing the siNA
molecules into a cell under conditions suitable to modulate the
expression of the VEGF and/or VEGFr genes in the cell.
[0136] In another embodiment, the invention features a method for
modulating the expression of more than one VEGF and/or VEGFr gene
within a cell comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr gene and wherein the sense strand sequence of the siNA
comprises a sequence identical or substantially similar to the
sequences of the target RNAs; and (b) introducing the siNA molecule
into a cell under conditions suitable to modulate the expression of
the VEGF and/or VEGFr genes in the cell.
[0137] In one embodiment, siNA molecules of the invention are used
as reagents in ex vivo applications. For example, siNA reagents are
introduced into tissue or cells that are transplanted into a
subject for therapeutic effect. The cells and/or tissue can be
derived from an organism or subject that later receives the
explant, or can be derived from another organism or subject prior
to transplantation. The siNA molecules can be used to modulate the
expression of one or more genes in the cells or tissue, such that
the cells or tissue obtain a desired phenotype or are able to
perform a function when transplanted in vivo. In one embodiment,
certain target cells from a patient are extracted. These extracted
cells are contacted with siNAs targeting a specific nucleotide
sequence within the cells under conditions suitable for uptake of
the siNAs by these cells (e.g. using delivery reagents such as
cationic lipids, liposomes and the like or using techniques such as
electroporation to facilitate the delivery of siNAs into cells).
The cells are then reintroduced back into the same patient or other
patients. In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in a tissue
explant comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr gene; and (b) introducing the siNA molecule into a
cell of the tissue explant derived from a particular organism under
conditions suitable to modulate the expression of the VEGF and/or
VEGFr gene in the tissue explant. In another embodiment, the method
further comprises introducing the tissue explant back into the
organism the tissue was derived from or into another organism under
conditions suitable to modulate the expression of the VEGF and/or
VEGFr gene in that organism.
[0138] In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in a tissue
explant comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr gene and wherein the sense strand sequence of the siNA
comprises a sequence identical or substantially similar to the
sequence of the target RNA; and (b) introducing the siNA molecule
into a cell of the tissue explant derived from a particular
organism under conditions suitable to modulate the expression of
the VEGF and/or VEGFr gene in the tissue explant. In another
embodiment, the method further comprises introducing the tissue
explant back into the organism the tissue was derived from or into
another organism under conditions suitable to modulate the
expression of the VEGF and/or VEGFr gene in that organism.
[0139] In another embodiment, the invention features a method of
modulating the expression of more than one VEGF and/or VEGFr gene
in a tissue explant comprising: (a) synthesizing siNA molecules of
the invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr genes; and (b) introducing the siNA molecules into a
cell of the tissue explant derived from a particular organism under
conditions suitable to modulate the expression of the VEGF and/or
VEGFr genes in the tissue explant. In another embodiment, the
method further comprises introducing the tissue explant back into
the organism the tissue was derived from or into another organism
under conditions suitable to modulate the expression of the VEGF
and/or VEGFr genes in that organism.
[0140] In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in an
organism comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr gene; and (b) introducing the siNA molecule into the
organism under conditions suitable to modulate the expression of
the VEGF and/or VEGFr gene in the organism. The level of VEGF or
VEGFr can be determined as is known in the art or as described in
Pavco U.S. Ser. No. 10/438,493, incorporated by reference herein in
its entirety including the drawings.
[0141] In another embodiment, the invention features a method of
modulating the expression of more than one VEGF and/or VEGFr gene
in an organism comprising: (a) synthesizing siNA molecules of the
invention, which can be chemically-modified, wherein one of the
siNA strands comprises a sequence complementary to RNA of the VEGF
and/or VEGFr genes; and (b) introducing the siNA molecules into the
organism under conditions suitable to modulate the expression of
the VEGF and/or VEGFr genes in the organism. The level of VEGF or
VEGFr can be determined as is known in the art or as described in
Pavco U.S. Ser. No. 10/438,493, incorporated by reference herein in
its entirety including the drawings.
[0142] In one embodiment, the invention features a method for
modulating the expression of a VEGF and/or VEGFr gene within a cell
comprising: (a) synthesizing a siNA molecule of the invention,
which can be chemically-modified, wherein the siNA comprises a
single stranded sequence having complementarity to RNA of the VEGF
and/or VEGFr gene; and (b) introducing the siNA molecule into a
cell under conditions suitable to modulate the expression of the
VEGF and/or VEGFr gene in the cell.
[0143] In another embodiment, the invention features a method for
modulating the expression of more than one VEGF and/or VEGFr gene
within a cell comprising: (a) synthesizing siNA molecules of the
invention, which can be chemically-modified, wherein the siNA
comprises a single stranded sequence having complementarity to RNA
of the VEGF and/or VEGFr gene; and (b) contacting the cell in vitro
or in vivo with the siNA molecule under conditions suitable to
modulate the expression of the VEGF and/or VEGFr genes in the
cell.
[0144] In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in a tissue
explant comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein the siNA
comprises a single stranded sequence having complementarity to RNA
of the VEGF and/or VEGFr gene; and (b) contacting the cell of the
tissue explant derived from a particular organism with the siNA
molecule under conditions suitable to modulate the expression of
the VEGF and/or VEGFr gene in the tissue explant. In another
embodiment, the method further comprises introducing the tissue
explant back into the organism the tissue was derived from or into
another organism under conditions suitable to modulate the
expression of the VEGF and/or VEGFr gene in that organism.
[0145] In another embodiment, the invention features a method of
modulating the expression of more than one VEGF and/or VEGFr gene
in a tissue explant comprising: (a) synthesizing siNA molecules of
the invention, which can be chemically-modified, wherein the siNA
comprises a single stranded sequence having complementarity to RNA
of the VEGF and/or VEGFr gene; and (b) introducing the siNA
molecules into a cell of the tissue explant derived from a
particular organism under conditions suitable to modulate the
expression of the VEGF and/or VEGFr genes in the tissue explant. In
another embodiment, the method further comprises introducing the
tissue explant back into the organism the tissue was derived from
or into another organism under conditions suitable to modulate the
expression of the VEGF and/or VEGFr genes in that organism.
[0146] In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in an
organism comprising: (a) synthesizing a siNA molecule of the
invention, which can be chemically-modified, wherein the siNA
comprises a single stranded sequence having complementarity to RNA
of the VEGF and/or VEGFr gene; and (b) introducing the siNA
molecule into the organism under conditions suitable to modulate
the expression of the VEGF and/or VEGFr gene in the organism.
[0147] In another embodiment, the invention features a method of
modulating the expression of more than one VEGF and/or VEGFr gene
in an organism comprising: (a) synthesizing siNA molecules of the
invention, which can be chemically-modified, wherein the siNA
comprises a single stranded sequence having complementarity to RNA
of the VEGF and/or VEGFr gene; and (b) introducing the siNA
molecules into the organism under conditions suitable to modulate
the expression of the VEGF and/or VEGFr genes in the organism.
[0148] In one embodiment, the invention features a method of
modulating the expression of a VEGF and/or VEGFr gene in an
organism comprising contacting the organism with a siNA molecule of
the invention under conditions suitable to modulate the expression
of the VEGF and/or VEGFr gene in the organism.
[0149] In another embodiment, the invention features a method of
modulating the expression of more than one VEGF and/or VEGFr gene
in an organism comprising contacting the organism with one or more
siNA molecules of the invention under conditions suitable to
modulate the expression of the VEGF and/or VEGFr genes in the
organism.
[0150] The siNA molecules of the invention can be designed to down
regulate or inhibit target (e.g., VEGF and/or VEGFr) gene
expression through RNAi targeting of a variety of RNA molecules. In
one embodiment, the siNA molecules of the invention are used to
target various RNAs corresponding to a target gene. Non-limiting
examples of such RNAs include messenger RNA (mRNA), alternate RNA
splice variants of target gene(s), post-transcriptionally modified
RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA
templates. If alternate splicing produces a family of transcripts
that are distinguished by usage of appropriate exons, the instant
invention can be used to inhibit gene expression through the
appropriate exons to specifically inhibit or to distinguish among
the functions of gene family members. For example, a protein that
contains an alternatively spliced transmembrane domain can be
expressed in both membrane bound and secreted forms. Use of the
invention to target the exon containing the transmembrane domain
can be used to determine the functional consequences of
pharmaceutical targeting of membrane bound as opposed to the
secreted form of the protein. Non-limiting examples of applications
of the invention relating to targeting these RNA molecules include
therapeutic pharmaceutical applications, pharmaceutical discovery
applications, molecular diagnostic and gene function applications,
and gene mapping, for example using single nucleotide polymorphism
mapping with siNA molecules of the invention. Such applications can
be implemented using known gene sequences or from partial sequences
available from an expressed sequence tag (EST).
[0151] In another embodiment, the siNA molecules of the invention
are used to target conserved sequences corresponding to a gene
family or gene families such as VEGF and/or VEGFr family genes. As
such, siNA molecules targeting multiple VEGF and/or VEGFr targets
can provide increased therapeutic effect. In addition, siNA can be
used to characterize pathways of gene function in a variety of
applications. For example, the present invention can be used to
inhibit the activity of target gene(s) in a pathway to determine
the function of uncharacterized gene(s) in gene function analysis,
mRNA function analysis, or translational analysis. The invention
can be used to determine potential target gene pathways involved in
various diseases and conditions toward pharmaceutical development.
The invention can be used to understand pathways of gene expression
involved in, for example, the progression and/or maintenance of
cancer.
[0152] In one embodiment, siNA molecule(s) and/or methods of the
invention are used to down regulate the expression of gene(s) that
encode RNA referred to by Genbank Accession, for example VEGF
and/or VEGFr genes encoding RNA sequence(s) referred to herein by
Genbank Accession number, for example, Genbank Accession Nos. shown
in Table I.
[0153] In one embodiment, the invention features a method
comprising: (a) generating a library of siNA constructs having a
predetermined complexity; and (b) assaying the siNA constructs of
(a) above, under conditions suitable to determine RNAi target sites
within the target RNA sequence. In one embodiment, the siNA
molecules of (a) have strands of a fixed length, for example, about
23 nucleotides in length. In another embodiment, the siNA molecules
of (a) are of differing length, for example having strands of about
19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25)
nucleotides in length. In one embodiment, the assay can comprise a
reconstituted in vitro siNA assay as described herein. In another
embodiment, the assay can comprise a cell culture system in which
target RNA is expressed. In another embodiment, fragments of target
RNA are analyzed for detectable levels of cleavage, for example by
gel electrophoresis, northern blot analysis, or RNAse protection
assays, to determine the most suitable target site(s) within the
target RNA sequence. The target RNA sequence can be obtained as is
known in the art, for example, by cloning and/or transcription for
in vitro systems, and by cellular expression in in vivo
systems.
[0154] In one embodiment, the invention features a method
comprising: (a) generating a randomized library of siNA constructs
having a predetermined complexity, such as of 4N, where N
represents the number of base paired nucleotides in each of the
siNA construct strands (eg. for a siNA construct having 21
nucleotide sense and antisense strands with 19 base pairs, the
complexity would be 419); and (b) assaying the siNA constructs of
(a) above, under conditions suitable to determine RNAi target sites
within the target VEGF and/or VEGFr RNA sequence. In another
embodiment, the siNA molecules of (a) have strands of a fixed
length, for example about 23 nucleotides in length. In yet another
embodiment, the siNA molecules of (a) are of differing length, for
example having strands of about 19 to about 25 (e.g., about 19, 20,
21, 22, 23, 24, or 25) nucleotides in length. In one embodiment,
the assay can comprise a reconstituted in vitro siNA assay as
described in Example 7 herein. In another embodiment, the assay can
comprise a cell culture system in which target RNA is expressed. In
another embodiment, fragments of VEGF and/or VEGFr RNA are analyzed
for detectable levels of cleavage, for example by gel
electrophoresis, northern blot analysis, or RNAse protection
assays, to determine the most suitable target site(s) within the
target VEGF and/or VEGFr RNA sequence. The target VEGF and/or VEGFr
RNA sequence can be obtained as is known in the art, for example,
by cloning and/or transcription for in vitro systems, and by
cellular expression in in vivo systems.
[0155] In another embodiment, the invention features a method
comprising: (a) analyzing the sequence of a RNA target encoded by a
target gene; (b) synthesizing one or more sets of siNA molecules
having sequence complementary to one or more regions of the RNA of
(a); and (c) assaying the siNA molecules of (b) under conditions
suitable to determine RNAi targets within the target RNA sequence.
In one embodiment, the siNA molecules of (b) have strands of a
fixed length, for example about 23 nucleotides in length. In
another embodiment, the siNA molecules of (b) are of differing
length, for example having strands of about 19 to about 25 (e.g.,
about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one
embodiment, the assay can comprise a reconstituted in vitro siNA
assay as described herein. In another embodiment, the assay can
comprise a cell culture system in which target RNA is expressed.
Fragments of target RNA are analyzed for detectable levels of
cleavage, for example by gel electrophoresis, northern blot
analysis, or RNAse protection assays, to determine the most
suitable target site(s) within the target RNA sequence. The target
RNA sequence can be obtained as is known in the art, for example,
by cloning and/or transcription for in vitro systems, and by
expression in in vivo systems.
[0156] By "target site" is meant a sequence within a target RNA
that is "targeted" for cleavage mediated by a siNA construct which
contains sequences within its antisense region that are
complementary to the target sequence.
[0157] By "detectable level of cleavage" is meant cleavage of
target RNA (and formation of cleaved product RNAs) to an extent
sufficient to discern cleavage products above the background of
RNAs produced by random degradation of the target RNA. Production
of cleavage products from 1-5% of the target RNA is sufficient to
detect above the background for most methods of detection.
[0158] In one embodiment, the invention features a composition
comprising a siNA molecule of the invention, which can be
chemically-modified, in a pharmaceutically acceptable carrier or
diluent. In another embodiment, the invention features a
pharmaceutical composition comprising siNA molecules of the
invention, which can be chemically-modified, targeting one or more
genes in a pharmaceutically acceptable carrier or diluent. In
another embodiment, the invention features a method for diagnosing
a disease or condition in a subject comprising administering to the
subject a composition of the invention under conditions suitable
for the diagnosis of the disease or condition in the subject. In
another embodiment, the invention features a method for treating or
preventing a disease or condition in a subject, comprising
administering to the subject a composition of the invention under
conditions suitable for the treatment or prevention of the disease
or condition in the subject, alone or in conjunction with one or
more other therapeutic compounds. In yet another embodiment, the
invention features a method for reducing or preventing tissue
rejection in a subject comprising administering to the subject a
composition of the invention under conditions suitable for the
reduction or prevention of tissue rejection in the subject.
[0159] In another embodiment, the invention features a method for
validating a VEGF and/or VEGFr gene target, comprising: (a)
synthesizing a siNA molecule of the invention, which can be
chemically-modified, wherein one of the siNA strands includes a
sequence complementary to RNA of a VEGF and/or VEGFr target gene;
(b) introducing the siNA molecule into a cell, tissue, or organism
under conditions suitable for modulating expression of the VEGF
and/or VFGFr target gene in the cell, tissue, or organism; and (c)
determining the function of the gene by assaying for any phenotypic
change in the cell, tissue, or organism.
[0160] In another embodiment, the invention features a method for
validating a VEGF and/or VEGFr target comprising: (a) synthesizing
a siNA molecule of the invention, which can be chemically-modified,
wherein one of the siNA strands includes a sequence complementary
to RNA of a VEGF and/or VEGFr target gene; (b) introducing the siNA
molecule into a biological system under conditions suitable for
modulating expression of the VEGF and/or VEGFr target gene in the
biological system; and (c) determining the function of the gene by
assaying for any phenotypic change in the biological system.
[0161] By "biological system" is meant, material, in a purified or
unpurified form, from biological sources, including but not limited
to human or animal, wherein the system comprises the components
required for RNAi activity. The term "biological system" includes,
for example, a cell, tissue, or organism, or extract thereof. The
term biological system also includes reconstituted RNAi systems
that can be used in an in vitro setting.
[0162] By "phenotypic change" is meant any detectable change to a
cell that occurs in response to contact or treatment with a nucleic
acid molecule of the invention (e.g., siNA). Such detectable
changes include, but are not limited to, changes in shape, size,
proliferation, motility, protein expression or RNA expression or
other physical or chemical changes as can be assayed by methods
known in the art. The detectable change can also include expression
of reporter genes/molecules such as Green Florescent Protein (GFP)
or various tags that are used to identify an expressed protein or
any other cellular component that can be assayed.
[0163] In one embodiment, the invention features a kit containing a
siNA molecule of the invention, which can be chemically-modified,
that can be used to modulate the expression of a VEGF and/or VEGFr
target gene in a biological system, including, for example, in a
cell, tissue, or organism. In another embodiment, the invention
features a kit containing more than one siNA molecule of the
invention, which can be chemically-modified, that can be used to
modulate the expression of more than one VEGF and/or VEGFr target
gene in a biological system, including, for example, in a cell,
tissue, or organism.
[0164] In one embodiment, the invention features a cell containing
one or more siNA molecules of the invention, which can be
chemically-modified. In another embodiment, the cell containing a
siNA molecule of the invention is a mammalian cell. In yet another
embodiment, the cell containing a siNA molecule of the invention is
a human cell.
[0165] In one embodiment, the synthesis of a siNA molecule of the
invention, which can be chemically-modified, comprises: (a)
synthesis of two complementary strands of the siNA molecule; (b)
annealing the two complementary strands together under conditions
suitable to obtain a double-stranded siNA molecule. In another
embodiment, synthesis of the two complementary strands of the siNA
molecule is by solid phase oligonucleotide synthesis. In yet
another embodiment, synthesis of the two complementary strands of
the siNA molecule is by solid phase tandem oligonucleotide
synthesis.
[0166] In one embodiment, the invention features a method for
synthesizing a siNA duplex molecule comprising: (a) synthesizing a
first oligonucleotide sequence strand of the siNA molecule, wherein
the first oligonucleotide sequence strand comprises a cleavable
linker molecule that can be used as a scaffold for the synthesis of
the second oligonucleotide sequence strand of the siNA; (b)
synthesizing the second oligonucleotide sequence strand of siNA on
the scaffold of the first oligonucleotide sequence strand, wherein
the second oligonucleotide sequence strand further comprises a
chemical moiety than can be used to purify the siNA duplex; (c)
cleaving the linker molecule of (a) under conditions suitable for
the two siNA oligonucleotide strands to hybridize and form a stable
duplex; and (d) purifying the siNA duplex utilizing the chemical
moiety of the second oligonucleotide sequence strand. In one
embodiment, cleavage of the linker molecule in (c) above takes
place during deprotection of the oligonucleotide, for example under
hydrolysis conditions using an alkylamine base such as methylamine.
In one embodiment, the method of synthesis comprises solid phase
synthesis on a solid support such as controlled pore glass (CPG) or
polystyrene, wherein the first sequence of (a) is synthesized on a
cleavable linker, such as a succinyl linker, using the solid
support as a scaffold. The cleavable linker in (a) used as a
scaffold for synthesizing the second strand can comprise similar
reactivity as the solid support derivatized linker, such that
cleavage of the solid support derivatized linker and the cleavable
linker of (a) takes place concomitantly. In another embodiment, the
chemical moiety of (b) that can be used to isolate the attached
oligonucleotide sequence comprises a trityl group, for example a
dimethoxytrityl group, which can be employed in a trityl-on
synthesis strategy as described herein. In yet another embodiment,
the chemical moiety, such as a dimethoxytrityl group, is removed
during purification, for example, using acidic conditions.
[0167] In a further embodiment, the method for siNA synthesis is a
solution phase synthesis or hybrid phase synthesis wherein both
strands of the siNA duplex are synthesized in tandem using a
cleavable linker attached to the first sequence which acts a
scaffold for synthesis of the second sequence. Cleavage of the
linker under conditions suitable for hybridization of the separate
siNA sequence strands results in formation of the double-stranded
siNA molecule.
[0168] In another embodiment, the invention features a method for
synthesizing a siNA duplex molecule comprising: (a) synthesizing
one oligonucleotide sequence strand of the siNA molecule, wherein
the sequence comprises a cleavable linker molecule that can be used
as a scaffold for the synthesis of another oligonucleotide
sequence; (b) synthesizing a second oligonucleotide sequence having
complementarity to the first sequence strand on the scaffold of
(a), wherein the second sequence comprises the other strand of the
double-stranded siNA molecule and wherein the second sequence
further comprises a chemical moiety than can be used to isolate the
attached oligonucleotide sequence; (c) purifying the product of (b)
utilizing the chemical moiety of the second oligonucleotide
sequence strand under conditions suitable for isolating the
full-length sequence comprising both siNA oligonucleotide strands
connected by the cleavable linker and under conditions suitable for
the two siNA oligonucleotide strands to hybridize and form a stable
duplex. In one embodiment, cleavage of the linker molecule in (c)
above takes place during deprotection of the oligonucleotide, for
example under hydrolysis conditions. In another embodiment,
cleavage of the linker molecule in (c) above takes place after
deprotection of the oligonucleotide. In another embodiment, the
method of synthesis comprises solid phase synthesis on a solid
support such as controlled pore glass (CPG) or polystyrene, wherein
the first sequence of (a) is synthesized on a cleavable linker,
such as a succinyl linker, using the solid support as a scaffold.
The cleavable linker in (a) used as a scaffold for synthesizing the
second strand can comprise similar reactivity or differing
reactivity as the solid support derivatized linker, such that
cleavage of the solid support derivatized linker and the cleavable
linker of (a) takes place either concomitantly or sequentially. In
one embodiment, the chemical moiety of (b) that can be used to
isolate the attached oligonucleotide sequence comprises a trityl
group, for example a dimethoxytrityl group.
[0169] In another embodiment, the invention features a method for
making a double-stranded siNA molecule in a single synthetic
process comprising: (a) synthesizing an oligonucleotide having a
first and a second sequence, wherein the first sequence is
complementary to the second sequence, and the first oligonucleotide
sequence is linked to the second sequence via a cleavable linker,
and wherein a terminal 5'-protecting group, for example, a
5'-O-dimethoxytrityl group (5'-O-DMT) remains on the
oligonucleotide having the second sequence; (b) deprotecting the
oligonucleotide whereby the deprotection results in the cleavage of
the linker joining the two oligonucleotide sequences; and (c)
purifying the product of (b) under conditions suitable for
isolating the double-stranded siNA molecule, for example using a
trityl-on synthesis strategy as described herein.
[0170] In another embodiment, the method of synthesis of siNA
molecules of the invention comprises the teachings of Scaringe et
al., U.S. Pat. Nos. 5,889,136; 6,008,400; and 6,111,086,
incorporated by reference herein in their entirety.
[0171] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications, for
example, one or more chemical modifications having any of Formulae
I-VII or any combination thereof that increases the nuclease
resistance of the siNA construct.
[0172] In another embodiment, the invention features a method for
generating siNA molecules with increased nuclease resistance
comprising (a) introducing nucleotides having any of Formula I-VII
or any combination thereof into a siNA molecule, and (b) assaying
the siNA molecule of step (a) under conditions suitable for
isolating siNA molecules having increased nuclease resistance.
[0173] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that modulates the binding affinity between the sense and
antisense strands of the siNA construct.
[0174] In another embodiment, the invention features a method for
generating siNA molecules with increased binding affinity between
the sense and antisense strands of the siNA molecule comprising (a)
introducing nucleotides having any of Formula I-VII or any
combination thereof into a siNA molecule, and (b) assaying the siNA
molecule of step (a) under conditions suitable for isolating siNA
molecules having increased binding affinity between the sense and
antisense strands of the siNA molecule.
[0175] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that modulates the binding affinity between the antisense
strand of the siNA construct and a complementary target RNA
sequence within a cell.
[0176] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that modulates the binding affinity between the antisense
strand of the siNA construct and a complementary target DNA
sequence within a cell.
[0177] In another embodiment, the invention features a method for
generating siNA molecules with increased binding affinity between
the antisense strand of the siNA molecule and a complementary
target RNA sequence comprising (a) introducing nucleotides having
any of Formula I-VII or any combination thereof into a siNA
molecule, and (b) assaying the siNA molecule of step (a) under
conditions suitable for isolating siNA molecules having increased
binding affinity between the antisense strand of the siNA molecule
and a complementary target RNA sequence.
[0178] In another embodiment, the invention features a method for
generating siNA molecules with increased binding affinity between
the antisense strand of the siNA molecule and a complementary
target DNA sequence comprising (a) introducing nucleotides having
any of Formula I-VII or any combination thereof into a siNA
molecule, and (b) assaying the siNA molecule of step (a) under
conditions suitable for isolating siNA molecules having increased
binding affinity between the antisense strand of the siNA molecule
and a complementary target DNA sequence.
[0179] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that modulate the polymerase activity of a cellular
polymerase capable of generating additional endogenous siNA
molecules having sequence homology to the chemically-modified siNA
construct.
[0180] In another embodiment, the invention features a method for
generating siNA molecules capable of mediating increased polymerase
activity of a cellular polymerase capable of generating additional
endogenous siNA molecules having sequence homology to a
chemically-modified siNA molecule comprising (a) introducing
nucleotides having any of Formula I-VII or any combination thereof
into a siNA molecule, and (b) assaying the siNA molecule of step
(a) under conditions suitable for isolating siNA molecules capable
of mediating increased polymerase activity of a cellular polymerase
capable of generating additional endogenous siNA molecules having
sequence homology to the chemically-modified siNA molecule.
[0181] In one embodiment, the invention features
chemically-modified siNA constructs that mediate RNAi against VEGF
and/or VEGFr in a cell, wherein the chemical modifications do not
significantly effect the interaction of siNA with a target RNA
molecule, DNA molecule and/or proteins or other factors that are
essential for RNAi in a manner that would decrease the efficacy of
RNAi mediated by such siNA constructs.
[0182] In another embodiment, the invention features a method for
generating siNA molecules with improved RNAi activity against VEGF
and/or VEGFr comprising (a) introducing nucleotides having any of
Formula I-VII or any combination thereof into a siNA molecule, and
(b) assaying the siNA molecule of step (a) under conditions
suitable for isolating siNA molecules having improved RNAi
activity.
[0183] In yet another embodiment, the invention features a method
for generating siNA molecules with improved RNAi activity against
VEGF and/or VEGFr target RNA comprising (a) introducing nucleotides
having any of Formula I-VII or any combination thereof into a siNA
molecule, and (b) assaying the siNA molecule of step (a) under
conditions suitable for isolating siNA molecules having improved
RNAi activity against the target RNA.
[0184] In yet another embodiment, the invention features a method
for generating siNA molecules with improved RNAi activity against
VEGF and/or VEGFr target DNA comprising (a) introducing nucleotides
having any of Formula I-VII or any combination thereof into a siNA
molecule, and (b) assaying the siNA molecule of step (a) under
conditions suitable for isolating siNA molecules having improved
RNAi activity against the target DNA.
[0185] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that modulates the cellular uptake of the siNA
construct.
[0186] In another embodiment, the invention features a method for
generating siNA molecules against VEGF and/or VEGFr with improved
cellular uptake comprising (a) introducing nucleotides having any
of Formula I-VII or any combination thereof into a siNA molecule,
and (b) assaying the siNA molecule of step (a) under conditions
suitable for isolating siNA molecules having improved cellular
uptake.
[0187] In one embodiment, the invention features siNA constructs
that mediate RNAi against VEGF and/or VEGFr, wherein the siNA
construct comprises one or more chemical modifications described
herein that increases the bioavailability of the siNA construct,
for example, by attaching polymeric conjugates such as
polyethyleneglycol or equivalent conjugates that improve the
pharmacokinetics of the siNA construct, or by attaching conjugates
that target specific tissue types or cell types in vivo.
Non-limiting examples of such conjugates are described in Vargeese
et al., U.S. Ser. No. 10/201,394 incorporated by reference
herein.
[0188] In one embodiment, the invention features a method for
generating siNA molecules of the invention with improved
bioavailability, comprising (a) introducing a conjugate into the
structure of a siNA molecule, and (b) assaying the siNA molecule of
step (a) under conditions suitable for isolating siNA molecules
having improved bioavailability. Such conjugates can include
ligands for cellular receptors, such as peptides derived from
naturally occurring protein ligands; protein localization
sequences, including cellular ZIP code sequences; antibodies;
nucleic acid aptamers; vitamins and other co-factors, such as
folate and N-acetylgalactosamine; polymers, such as
polyethyleneglycol (PEG); phospholipids; cholesterol; polyamines,
such as spermine or spermidine; and others.
[0189] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein said second sequence is chemically
modified in a manner that it can no longer act as a guide sequence
for efficiently mediating RNA interference and/or be recognized by
cellular proteins that facilitate RNAi.
[0190] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein the second sequence is designed or
modified in a manner that prevents its entry into the RNAi pathway
as a guide sequence or as a sequence that is complementary to a
target nucleic acid (e.g., RNA) sequence. Such design or
modifications are expected to enhance the activity of siNA and/or
improve the specificity of siNA molecules of the invention. These
modifications are also expected to minimize any off-target effects
and/or associated toxicity.
[0191] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein said second sequence is incapable of
acting as a guide sequence for mediating RNA interference.
[0192] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein said second sequence does not have a
terminal 5'-hydroxyl (5'-OH) or 5'-phosphate group.
[0193] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein said second sequence comprises a
terminal cap moiety at the 5'-end of said second sequence. In one
embodiment, the terminal cap moiety comprises an inverted abasic,
inverted deoxy abasic, inverted nucleotide moiety, a group shown in
FIG. 10, an alkyl or cycloalkyl group, a heterocycle, or any other
group that prevents RNAi activity in which the second sequence
serves as a guide sequence or template for RNAi.
[0194] In one embodiment, the invention features a double stranded
short interfering nucleic acid (siNA) molecule that comprises a
first nucleotide sequence complementary to a target RNA sequence or
a portion thereof, and a second sequence having complementarity to
said first sequence, wherein said second sequence comprises a
terminal cap moiety at the 5'-end and 3'-end of said second
sequence. In one embodiment, each terminal cap moiety individually
comprises an inverted abasic, inverted deoxy abasic, inverted
nucleotide moiety, a group shown in FIG. 10, an alkyl or cycloalkyl
group, a heterocycle, or any other group that prevents RNAi
activity in which the second sequence serves as a guide sequence or
template for RNAi.
[0195] In one embodiment, the invention features a method for
generating siNA molecules of the invention with improved
specificity for down regulating or inhibiting the expression of a
target nucleic acid (e.g., a DNA or RNA such as a gene or its
corresponding RNA), comprising (a) introducing one or more chemical
modifications into the structure of a siNA molecule, and (b)
assaying the siNA molecule of step (a) under conditions suitable
for isolating siNA molecules having improved specificity. In
another embodiment, the chemical modification used to improve
specificity comprises terminal cap modifications at the 5'-end,
3'-end, or both 5' and 3'-ends of the siNA molecule. The terminal
cap modifications can comprise, for example, structures shown in
FIG. 10 (e.g. inverted deoxyabasic moieties) or any other chemical
modification that renders a portion of the siNA molecule (e.g. the
sense strand) incapable of mediating RNA interference against an
off target nucleic acid sequence. In a non-limiting example, a siNA
molecule is designed such that only the antisense sequence of the
siNA molecule can serve as a guide sequence for RISC mediated
degradation of a corresponding target RNA sequence. This can be
accomplished by rendering the sense sequence of the siNA inactive
by introducing chemical modifications to the sense strand that
preclude recognition of the sense strand as a guide sequence by
RNAi machinery. In one embodiment, such chemical modifications
comprise any chemical group at the 5'-end of the sense strand of
the siNA, or any other group that serves to render the sense strand
inactive as a guide sequence for mediating RNA interference. These
modifications, for example, can result in a molecule where the
5'-end of the sense strand no longer has a free 5'-hydroxyl (5'-OH)
or a free 5'-phosphate group (e.g., phosphate, diphosphate,
triphosphate, cyclic phosphate etc.). Non-limiting examples of such
siNA constructs are described herein, such as "Stab 9/10", "Stab
7/8", "Stab 7/19" and "Stab 17/22" chemistries and variants thereof
(see Table 4) wherein the 5'-end and 3'-end of the sense strand of
the siNA do not comprise a hydroxyl group or phosphate group.
[0196] In one embodiment, the invention features a method for
generating siNA molecules of the invention with improved
specificity for down regulating or inhibiting the expression of a
target nucleic acid (e.g., a DNA or RNA such as a gene or its
corresponding RNA), comprising introducing one or more chemical
modifications into the structure of a siNA molecule that prevent a
strand or portion of the siNA molecule from acting as a template or
guide sequence for RNAi activity. In one embodiment, the inactive
strand or sense region of the siNA molecule is the sense strand or
sense region of the siNA molecule, i.e. the strand or region of the
siNA that does not have complementarity to the target nucleic acid
sequence. In one embodiment, such chemical modifications comprise
any chemical group at the 5'-end of the sense strand or region of
the siNA that does not comprise a 5'-hydroxyl (5'-OH) or
5'-phosphate group, or any other group that serves to render the
sense strand or sense region inactive as a guide sequence for
mediating RNA interference. Non-limiting examples of such siNA
constructs are described herein, such as "Stab 9/10", "Stab 7/8",
"Stab 7/19" and "Stab 17/22" chemistries and variants thereof (see
Table IV) wherein the 5'-end and 3'-end of the sense strand of the
siNA do not comprise a hydroxyl group or phosphate group.
[0197] In one embodiment, the invention features a method for
screening siNA molecules that are active in mediating RNA
interference against a target nucleic acid sequence comprising (a)
generating a plurality of unmodified siNA molecules, (b) screening
the siNA molecules of step (a) under conditions suitable for
isolating siNA molecules that are active in mediating RNA
interference against the target nucleic acid sequence, and (c)
introducing chemical modifications (e.g. chemical modifications as
described herein or as otherwise known in the art) into the active
siNA molecules of (b). In one embodiment, the method further
comprises re-screening the chemically modified siNA molecules of
step (c) under conditions suitable for isolating chemically
modified siNA molecules that are active in mediating RNA
interference against the target nucleic acid sequence.
[0198] In one embodiment, the invention features a method for
screening chemically modified siNA molecules that are active in
mediating RNA interference against a target nucleic acid sequence
comprising (a) generating a plurality of chemically modified siNA
molecules (e.g. siNA molecules as described herein or as otherwise
known in the art), and (b) screening the siNA molecules of step (a)
under conditions suitable for isolating chemically modified siNA
molecules that are active in mediating RNA interference against the
target nucleic acid sequence.
[0199] The term "ligand" refers to any compound or molecule, such
as a drug, peptide, hormone, or neurotransmitter, that is capable
of interacting with another compound, such as a receptor, either
directly or indirectly. The receptor that interacts with a ligand
can be present on the surface of a cell or can alternately be an
intercullular receptor. Interaction of the ligand with the receptor
can result in a biochemical reaction, or can simply be a physical
interaction or association.
[0200] In another embodiment, the invention features a method for
generating siNA molecules of the invention with improved
bioavailability comprising (a) introducing an excipient formulation
to a siNA molecule, and (b) assaying the siNA molecule of step (a)
under conditions suitable for isolating siNA molecules having
improved bioavailability. Such excipients include polymers such as
cyclodextrins, lipids, cationic lipids, polyamines, phospholipids,
nanoparticles, receptors, ligands, and others.
[0201] In another embodiment, the invention features a method for
generating siNA molecules of the invention with improved
bioavailability comprising (a) introducing nucleotides having any
of Formulae I-VII or any combination thereof into a siNA molecule,
and (b) assaying the siNA molecule of step (a) under conditions
suitable for isolating siNA molecules having improved
bioavailability.
[0202] In another embodiment, polyethylene glycol (PEG) can be
covalently attached to siNA compounds of the present invention. The
attached PEG can be any molecular weight, preferably from about
2,000 to about 50,000 daltons (Da).
[0203] The present invention can be used alone or as a component of
a kit having at least one of the reagents necessary to carry out
the in vitro or in vivo introduction of RNA to test samples and/or
subjects. For example, preferred components of the kit include a
siNA molecule of the invention and a vehicle that promotes
introduction of the siNA into cells of interest as described herein
(e.g., using lipids and other methods of transfection known in the
art, see for example Beigelman et al, U.S. Pat. No. 6,395,713). The
kit can be used for target validation, such as in determining gene
function and/or activity, or in drug optimization, and in drug
discovery (see for example Usman et al., U.S. Ser. No. 60/402,996).
Such a kit can also include instructions to allow a user of the kit
to practice the invention.
[0204] The term "short interfering nucleic acid", "siNA", "short
interfering RNA", "siRNA", "short interfering nucleic acid
molecule", "short interfering oligonucleotide molecule", or
"chemically-modified short interfering nucleic acid molecule" as
used herein refers to any nucleic acid molecule capable of
inhibiting or down regulating gene expression or viral replication,
for example by mediating RNA interference "RNAi" or gene silencing
in a sequence-specific manner; see for example Zamore et al., 2000,
Cell, 101, 25-33; Bass, 2001, Nature, 411, 428-429; Elbashir et
al., 2001, Nature, 411, 494-498; and Kreutzer et al., International
PCT Publication No. WO 00/44895; Zernicka-Goetz et al.,
International PCT Publication No. WO 01/36646; Fire, International
PCT Publication No. WO 99/32619; Plaetinck et al., International
PCT Publication No. WO 00/01846; Mello and Fire, International PCT
Publication No. WO 01/29058; Deschamps-Depaillette, International
PCT Publication No. WO 99/07409; and Li et al., International PCT
Publication No. WO 00/44914; Allshire, 2002, Science, 297,
1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein,
2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297,
2232-2237; Hutvagner and Zamore, 2002, Science, 297, 2056-60;
McManus et al., 2002, RNA, 8, 842-850; Reinhart et al., 2002, Gene
& Dev., 16, 1616-1626; and Reinhart & Bartel, 2002,
Science, 297, 1831). Non limiting examples of siNA molecules of the
invention are shown in FIGS. 4-6, and Tables II and III herein. For
example the siNA can be a double-stranded polynucleotide molecule
comprising self-complementary sense and antisense regions, wherein
the antisense region comprises nucleotide sequence that is
complementary to nucleotide sequence in a target nucleic acid
molecule or a portion thereof and the sense region having
nucleotide sequence corresponding to the target nucleic acid
sequence or a portion thereof. The siNA can be assembled from two
separate oligonucleotides, where one strand is the sense strand and
the other is the antisense strand, wherein the antisense and sense
strands are self-complementary (i.e. each strand comprises
nucleotide sequence that is complementary to nucleotide sequence in
the other strand; such as where the antisense strand and sense
strand form a duplex or double stranded structure, for example
wherein the double stranded region is about 19 base pairs); the
antisense strand comprises nucleotide sequence that is
complementary to nucleotide sequence in a target nucleic acid
molecule or a portion thereof and the sense strand comprises
nucleotide sequence corresponding to the target nucleic acid
sequence or a portion thereof. Alternatively, the siNA is assembled
from a single oligonucleotide, where the self-complementary sense
and antisense regions of the siNA are linked by means of a nucleic
acid based or non-nucleic acid-based linker(s). The siNA can be a
polynucleotide with a duplex, asymmetric duplex, hairpin or
asymmetric hairpin secondary structure, having self-complementary
sense and antisense regions, wherein the antisense region comprises
nucleotide sequence that is complementary to nucleotide sequence in
a separate target nucleic acid molecule or a portion thereof and
the sense region having nucleotide sequence corresponding to the
target nucleic acid sequence or a portion thereof. The siNA can be
a circular single-stranded polynucleotide having two or more loop
structures and a stem comprising self-complementary sense and
antisense regions, wherein the antisense region comprises
nucleotide sequence that is complementary to nucleotide sequence in
a target nucleic acid molecule or a portion thereof and the sense
region having nucleotide sequence corresponding to the target
nucleic acid sequence or a portion thereof, and wherein the
circular polynucleotide can be processed either in vivo or in vitro
to generate an active siNA molecule capable of mediating RNAi. The
siNA can also comprise a single stranded polynucleotide having
nucleotide sequence complementary to nucleotide sequence in a
target nucleic acid molecule or a portion thereof (for example,
where such siNA molecule does not require the presence within the
siNA molecule of nucleotide sequence corresponding to the target
nucleic acid sequence or a portion thereof), wherein the single
stranded polynucleotide can further comprise a terminal phosphate
group, such as a 5'-phosphate (see for example Martinez et al.,
2002, Cell., 110, 563-574 and Schwarz et al., 2002, Molecular Cell,
10, 537-568), or 5',3'-diphosphate. In certain embodiments, the
siNA molecule of the invention comprises separate sense and
antisense sequences or regions, wherein the sense and antisense
regions are covalently linked by nucleotide or non-nucleotide
linkers molecules as is known in the art, or are alternately
non-covalently linked by ionic interactions, hydrogen bonding, van
der waals interactions, hydrophobic intercations, and/or stacking
interactions. In certain embodiments, the siNA molecules of the
invention comprise nucleotide sequence that is complementary to
nucleotide sequence of a target gene. In another embodiment, the
siNA molecule of the invention interacts with nucleotide sequence
of a target gene in a manner that causes inhibition of expression
of the target gene. As used herein, siNA molecules need not be
limited to those molecules containing only RNA, but further
encompasses chemically-modified nucleotides and non-nucleotides. In
certain embodiments, the short interfering nucleic acid molecules
of the invention lack 2'-hydroxy (2'-OH) containing nucleotides.
Applicant describes in certain embodiments short interfering
nucleic acids that do not require the presence of nucleotides
having a 2'-hydroxy group for mediating RNAi and as such, short
interfering nucleic acid molecules of the invention optionally do
not include any ribonucleotides (e.g., nucleotides having a 2'-OH
group). Such siNA molecules that do not require the presence of
ribonucleotides within the siNA molecule to support RNAi can
however have an attached linker or linkers or other attached or
associated groups, moieties, or chains containing one or more
nucleotides with 2'-OH groups. Optionally, siNA molecules can
comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the
nucleotide positions. The modified short interfering nucleic acid
molecules of the invention can also be referred to as short
interfering modified oligonucleotides "siMON." As used herein, the
term siNA is meant to be equivalent to other terms used to describe
nucleic acid molecules that are capable of mediating sequence
specific RNAi, for example short interfering RNA (siRNA),
double-stranded RNA (dsRNA), micro-RNA (mRNA), short hairpin RNA
(shRNA), short interfering oligonucleotide, short interfering
nucleic acid, short interfering modified oligonucleotide,
chemically-modified siRNA, post-transcriptional gene silencing RNA
(ptgsRNA), and others. In addition, as used herein, the term RNAi
is meant to be equivalent to other terms used to describe sequence
specific RNA interference, such as post transcriptional gene
silencing, translational inhibition, or epigenetics. For example,
siNA molecules of the invention can be used to epigenetically
silence genes at both the post-transcriptional level or the
pre-transcriptional level. In a non-limiting example, epigenetic
regulation of gene expression by siNA molecules of the invention
can result from siNA mediated modification of chromatin structure
to alter gene expression (see, for example, Verdel et al., 2004,
Science, 303, 672-676; Pal-Bhadra et al., 2004, Science, 303,
669-672; Allshire, 2002, Science, 297, 1818-1819; Volpe et al.,
2002, Science, 297, 1833-1837; Jenuwein, 2002, Science, 297,
2215-2218; and Hall et al., 2002, Science, 297, 2232-2237).
[0205] In one embodiment, a siNA molecule of the invention is a
duplex forming oligonucleotide "DFO", (see for example FIGS. 14-15
and Vaish et al., U.S. Ser. No. 10/727,780 filed Dec. 3, 2003).
[0206] In one embodiment, a siNA molecule of the invention is a
multifunctional siNA, (see for example FIGS. 16-22 and Jadhav et
al., U.S. Ser. No. 60/543,480 filed Feb. 10, 2004). The
multifunctional siNA of the invention can comprise sequence
targeting, for example, two regions of VEGF and/or VEGFr RNA (see
for example target sequences in Tables II and III).
[0207] By "asymmetric hairpin" as used herein is meant a linear
siNA molecule comprising an antisense region, a loop portion that
can comprise nucleotides or non-nucleotides, and a sense region
that comprises fewer nucleotides than the antisense region to the
extent that the sense region has enough complementary nucleotides
to base pair with the antisense region and form a duplex with loop.
For example, an asymmetric hairpin siNA molecule of the invention
can comprise an antisense region having length sufficient to
mediate RNAi in a cell or in vitro system (e.g. about 19 to about
22, or about 19, 20, 21, or 22) nucleotides) and a loop region
comprising about 4 to about 8 (e.g., about 4, 5, 6, 7, or 8)
nucleotides, and a sense region having about 3 to about 18 (e.g.,
about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18)
nucleotides that are complementary to the antisense region. The
asymmetric hairpin siNA molecule can also comprise a 5'-terminal
phosphate group that can be chemically modified. The loop portion
of the asymmetric hairpin siNA molecule can comprise nucleotides,
non-nucleotides, linker molecules, or conjugate molecules as
described herein.
[0208] By "asymmetric duplex" as used herein is meant a siNA
molecule having two separate strands comprising a sense region and
an antisense region, wherein the sense region comprises fewer
nucleotides than the antisense region to the extent that the sense
region has enough complementary nucleotides to base pair with the
antisense region and form a duplex. For example, an asymmetric
duplex siNA molecule of the invention can comprise an antisense
region having length sufficient to mediate RNAi in a cell or in
vitro system e.g. about 19 to about 22 (e.g. about 19, 20, 21, or
22) nucleotides and a sense region having about 3 to about 18
(e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
or 18) nucleotides that are complementary to the antisense
region.
[0209] By "modulate" is meant that the expression of the gene, or
level of RNA molecule or equivalent RNA molecules encoding one or
more proteins or protein subunits, or activity of one or more
proteins or protein subunits is up regulated or down regulated,
such that expression, level, or activity is greater than or less
than that observed in the absence of the modulator. For example,
the term "modulate" can mean "inhibit," but the use of the word
"modulate" is not limited to this definition.
[0210] By "inhibit", "down-regulate", or "reduce", it is meant that
the expression of the gene, or level of RNA molecules or equivalent
RNA molecules encoding one or more proteins or protein subunits, or
activity of one or more proteins or protein subunits, is reduced
below that observed in the absence of the nucleic acid molecules
(e.g., siNA) of the invention. In one embodiment, inhibition,
down-regulation or reduction with an siNA molecule is below that
level observed in the presence of an inactive or attenuated
molecule. In another embodiment, inhibition, down-regulation, or
reduction with siNA molecules is below that level observed in the
presence of, for example, an siNA molecule with scrambled sequence
or with mismatches. In another embodiment, inhibition,
down-regulation, or reduction of gene expression with a nucleic
acid molecule of the instant invention is greater in the presence
of the nucleic acid molecule than in its absence.
[0211] By "gene", or "target gene", is meant, a nucleic acid that
encodes an RNA, for example, nucleic acid sequences including, but
not limited to, structural genes encoding a polypeptide. A gene or
target gene can also encode a functional RNA (fRNA) or non-coding
RNA (ncRNA), such as small temporal RNA (stRNA), micro RNA (mRNA),
small nuclear RNA (snRNA), short interfering RNA (siRNA), small
nucleolar RNA (snRNA), ribosomal RNA (rRNA), transfer RNA (tRNA)
and precursor RNAs thereof. Such non-coding RNAs can serve as
target nucleic acid molecules for siNA mediated RNA interference in
modulating the activity of fRNA or ncRNA involved in functional or
regulatory cellular processes. Abberant fRNA or ncRNA activity
leading to disease can therefore be modulated by siNA molecules of
the invention. siNA molecules targeting fRNA and ncRNA can also be
used to manipulate or alter the genotype or phenotype of an
organism or cell, by intervening in cellular processes such as
genetic imprinting, transcription, translation, or nucleic acid
processing (e.g., transamination, methylation etc.). The target
gene can be a gene derived from a cell, an endogenous gene, a
transgene, or exogenous genes such as genes of a pathogen, for
example a virus, which is present in the cell after infection
thereof. The cell containing the target gene can be derived from or
contained in any organism, for example a plant, animal, protozoan,
virus, bacterium, or fungus. Non-limiting examples of plants
include monocots, dicots, or gymnosperms. Non-limiting examples of
animals include vertebrates or invertebrates. Non-limiting examples
of fungi include molds or yeasts.
[0212] By "VEGF" as used herein is meant, any vascular endothelial
growth factor (e.g., VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) protein,
peptide, or polypeptide having vascular endothelial growth factor
activity, such as encoded by VEGF Genbank Accession Nos. shown in
Table I. The term VEGF also refers to nucleic acid sequences
encloding any vascular endothelial growth factor protein, peptide,
or polypeptide having vascular endothelial growth factor
activity.
[0213] By "VEGF-B" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--003377, having vascular endothelial growth
factor type B activity. The term VEGF-B also refers to nucleic acid
sequences encloding any VEGF-B protein, peptide, or polypeptide
having VEGF-B activity.
[0214] By "VEGF-C" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--005429, having vascular endothelial growth
factor type C activity. The term VEGF-C also refers to nucleic acid
sequences encloding any VEGF-C protein, peptide, or polypeptide
having VEGF-C activity.
[0215] By "VEGF-D" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--004469, having vascular endothelial growth
factor type D activity. The term VEGF-D also refers to nucleic acid
sequences encloding any VEGF-D protein, peptide, or polypeptide
having VEGF-D activity.
[0216] By "VEGFr" as used herein is meant, any vascular endothelial
growth factor receptor protein, peptide, or polypeptide (e.g.,
VEGFR1, VEGFR2, or VEGFr3, including both membrane bound and/or
soluble forms thereof) having vascular endothelial growth factor
receptor activity, such as encoded by VEGFr Genbank Accession Nos.
shown in Table I. The term VEGFr also refers to nucleic acid
sequences encloding any vascular endothelial growth factor receptor
protein, peptide, or polypeptide having vascular endothelial growth
factor receptor activity.
[0217] By "VEGFR1" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--002019, having vascular endothelial growth
factor receptor type 1 (flt) activity, for example, having the
ability to bind a vascular endothelial growth factor. The term
VEGF1 also refers to nucleic acid sequences encloding any VEGFR1
protein, peptide, or polypeptide having VEGFR1 activity.
[0218] By "VEGFR2" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--002253, having vascular endothelial growth
factor receptor type 2 (kdr) activity, for example, having the
ability to bind a vascular endothelial growth factor. The term
VEGF2 also refers to nucleic acid sequences encloding any VEGFR2
protein, peptide, or polypeptide having VEGFR2 activity.
[0219] By "VEGFr3" is meant, protein, peptide, or polypeptide
receptor or a derivative thereof, such as encoded by Genbank
Accession No. NM.sub.--002020 having vascular endothelial growth
factor receptor type 3 (kdr) activity, for example, having the
ability to bind a vascular endothelial growth factor. The term
VEGF3 also refers to nucleic acid sequences encloding any VEGFr3
protein, peptide, or polypeptide having VEGFr3 activity.
[0220] By "proliferative disease" or "cancer" as used herein is
meant, any disease or condition characterized by unregulated cell
growth or replication as is known in the art; including breast
cancer, cancers of the head and neck including various lymphomas
such as mantle cell lymphoma, non-Hodgkins lymphoma, adenoma,
squamous cell carcinoma, laryngeal carcinoma, cancers of the
retina, cancers of the esophagus, multiple myeloma, ovarian cancer,
uterine cancer, melanoma, colorectal cancer, lung cancer, bladder
cancer, prostate cancer, glioblastoma, lung cancer (including
non-small cell lung carcinoma), pancreatic cancer, cervical cancer,
head and neck cancer, skin cancers, nasopharyngeal carcinoma,
liposarcoma, epithelial carcinoma, renal cell carcinoma,
gallbladder adeno carcinoma, parotid adenocarcinoma, endometrial
sarcoma, multidrug resistant cancers; and proliferative diseases
and conditions, such as neovascularization associated with tumor
angiogenesis, macular degeneration (e.g., wet/dry AMD), corneal
neovascularization, diabetic retinopathy, neovascular glaucoma,
myopic degeneration and other proliferative diseases and conditions
such as restenosis and polycystic kidney disease, and any other
cancer or proliferative disease or condition that can respond to
the level of VEGF and/or VEGFr in a cell or tissue, alone or in
combination with other therapies.
[0221] By "homologous sequence" is meant, a nucleotide sequence
that is shared by one or more polynucleotide sequences, such as
genes, gene transcripts and/or non-coding polynucleotides. For
example, a homologous sequence can be a nucleotide sequence that is
shared by two or more genes encoding related but different
proteins, such as different members of a gene family, different
protein epitopes, different protein isoforms or completely
divergent genes, such as a cytokine and its corresponding
receptors. A homologous sequence can be a nucleotide sequence that
is shared by two or more non-coding polynucleotides, such as
noncoding DNA or RNA, regulatory sequences, introns, and sites of
transcriptional control or regulation. Homologous sequences can
also include conserved sequence regions shared by more than one
polynucleotide sequence. Homology does not need to be perfect
homology (e.g., 100%), as partially homologous sequences are also
contemplated by the instant invention (e.g., 99%, 98%, 97%, 96%,
95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%,
82%, 81%, 80% etc.).
[0222] By "conserved sequence region" is meant, a nucleotide
sequence of one or more regions in a polynucleotide does not vary
significantly between generations or from one biological system or
organism to another biological system or organism. The
polynucleotide can include both coding and non-coding DNA and
RNA.
[0223] By "sense region" is meant a nucleotide sequence of a siNA
molecule having complementarity to an antisense region of the siNA
molecule. In addition, the sense region of a siNA molecule can
comprise a nucleic acid sequence having homology with a target
nucleic acid sequence.
[0224] By "antisense region" is meant a nucleotide sequence of a
siNA molecule having complementarity to a target nucleic acid
sequence. In addition, the antisense region of a siNA molecule can
optionally comprise a nucleic acid sequence having complementarity
to a sense region of the siNA molecule.
[0225] By "target nucleic acid" is meant any nucleic acid sequence
whose expression or activity is to be modulated. The target nucleic
acid can be DNA or RNA.
[0226] By "complementarity" is meant that a nucleic acid can form
hydrogen bond(s) with another nucleic acid sequence by either
traditional Watson-Crick or other non-traditional types. In
reference to the nucleic molecules of the present invention, the
binding free energy for a nucleic acid molecule with its
complementary sequence is sufficient to allow the relevant function
of the nucleic acid to proceed, e.g., RNAi activity. Determination
of binding free energies for nucleic acid molecules is well known
in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol.
LII pp. 123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA
83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc.
109:3783-3785). A percent complementarity indicates the percentage
of contiguous residues in a nucleic acid molecule that can form
hydrogen bonds (e.g., Watson-Crick base pairing) with a second
nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out
of a total of 10 nucleotides in the first oligonuelcotide being
based paired to a second nucleic acid sequence having 10
nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100%
complementary respectively). "Perfectly complementary" means that
all the contiguous residues of a nucleic acid sequence will
hydrogen bond with the same number of contiguous residues in a
second nucleic acid sequence.
[0227] The siNA molecules of the invention represent a novel
therapeutic approach to treat a variety of disease and conditions
such as proliferative diseases and conditions and/or cancer
including breast cancer, cancers of the head and neck including
various lymphomas such as mantle cell lymphoma, non-Hodgkins
lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma,
cancers of the retina, cancers of the esophagus, multiple myeloma,
ovarian cancer, uterine cancer, melanoma, colorectal cancer, lung
cancer, bladder cancer, prostate cancer, glioblastoma, lung cancer
(including non-small cell lung carcinoma), pancreatic cancer,
cervical cancer, head and neck cancer, skin cancers, nasopharyngeal
carcinoma, liposarcoma, epithelial carcinoma, renal cell carcinoma,
gallbladder adeno carcinoma, parotid adenocarcinoma, endometrial
sarcoma, multidrug resistant cancers; and proliferative diseases
and conditions, such as neovascularization associated with tumor
angiogenesis, macular degeneration (e.g., wet/dry AMD), corneal
neovascularization, diabetic retinopathy, neovascular glaucoma,
myopic degeneration and other proliferative diseases and conditions
such as arthritis, psoriasis, endometriosis, female reproduction,
verruca vulgaris, angiofibroma of tuberous sclerosis, pot-wine
stains, Sturge Weber syndrome, Kippel-Trenaunay-Weber syndrome,
Osler-Weber-Rendu syndrome, restenosis and polycystic kidney
disease; and any other diseases or conditions that are related to
or will respond to the levels of VEGF and/or VEGFr in a cell or
tissue, alone or in combination with other therapies. The reduction
of VEGF and/or VEGFr expression and thus reduction in the level of
the respective protein relieves, to some extent, the symptoms of
the disease or condition.
[0228] In one embodiment of the present invention, each sequence of
a siNA molecule of the invention is independently about 18 to about
24 nucleotides in length, in specific embodiments about 18, 19, 20,
21, 22, 23, or 24 nucleotides in length. In another embodiment, the
siNA duplexes of the invention independently comprise about 17 to
about 23 base pairs (e.g., about 17, 18, 19, 20, 21, 22, or 23). In
yet another embodiment, siNA molecules of the invention comprising
hairpin or circular structures are about 35 to about 55 (e.g.,
about 35, 40, 45, 50 or 55) nucleotides in length, or about 38 to
about 44 (e.g., 38, 39, 40, 41, 42, 43, or 44) nucleotides in
length and comprising about 16 to about 22 (e.g., about 16, 17, 18,
19, 20, 21 or 22) base pairs. Exemplary siNA molecules of the
invention are shown in Table II. Exemplary synthetic siNA molecules
of the invention are shown in Table III and/or FIGS. 4-5.
[0229] As used herein "cell" is used in its usual biological sense,
and does not refer to an entire multicellular organism, e.g.,
specifically does not refer to a human. The cell can be present in
an organism, e.g., birds, plants and mammals such as humans, cows,
sheep, apes, monkeys, swine, dogs, and cats. The cell can be
prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian
or plant cell). The cell can be of somatic or germ line origin,
totipotent or pluripotent, dividing or non-dividing. The cell can
also be derived from or can comprise a gamete or embryo, a stem
cell, or a fully differentiated cell.
[0230] The siNA molecules of the invention are added directly, or
can be complexed with cationic lipids, packaged within liposomes,
or otherwise delivered to target cells or tissues. The nucleic acid
or nucleic acid complexes can be locally administered to relevant
tissues ex vivo, or in vivo through injection, infusion pump or
stent, with or without their incorporation in biopolymers. In
particular embodiments, the nucleic acid molecules of the invention
comprise sequences shown in Tables II-III and/or FIGS. 4-5.
Examples of such nucleic acid molecules consist essentially of
sequences defined in these tables and figures. Furthermore, the
chemically modified constructs described in Table IV can be applied
to any siNA sequence of the invention.
[0231] In another aspect, the invention provides mammalian cells
containing one or more siNA molecules of this invention. The one or
more siNA molecules can independently be targeted to the same or
different sites.
[0232] By "RNA" is meant a molecule comprising at least one
ribonucleotide residue. By "ribonucleotide" is meant a nucleotide
with a hydroxyl group at the 2' position of a .beta.-D-ribofuranose
moiety. The terms include double-stranded RNA, single-stranded RNA,
isolated RNA such as partially purified RNA, essentially pure RNA,
synthetic RNA, recombinantly produced RNA, as well as altered RNA
that differs from naturally occurring RNA by the addition,
deletion, substitution and/or alteration of one or more
nucleotides. Such alterations can include addition of
non-nucleotide material, such as to the end(s) of the siNA or
internally, for example at one or more nucleotides of the RNA.
Nucleotides in the RNA molecules of the instant invention can also
comprise non-standard nucleotides, such as non-naturally occurring
nucleotides or chemically synthesized nucleotides or
deoxynucleotides. These altered RNAs can be referred to as analogs
or analogs of naturally-occurring RNA.
[0233] By "subject" is meant an organism, which is a donor or
recipient of explanted cells or the cells themselves. "Subject"
also refers to an organism to which the nucleic acid molecules of
the invention can be administered. A subject can be a mammal or
mammalian cells, including a human or human cells.
[0234] The term "phosphorothioate" as used herein refers to an
internucleotide linkage having Formula I, wherein Z and/or W
comprise a sulfur atom. Hence, the term phosphorothioate refers to
both phosphorothioate and phosphorodithioate internucleotide
linkages.
[0235] The term "phosphonoacetate" as used herein refers to an
internucleotide linkage having Formula I, wherein Z and/or W
comprise an acetyl or protected acetyl group.
[0236] The term "thiophosphonoacetate" as used herein refers to an
internucleotide linkage having Formula I, wherein Z comprises an
acetyl or protected acetyl group and W comprises a sulfur atom or
alternately W comprises an acetyl or protected acetyl group and Z
comprises a sulfur atom.
[0237] The term "universal base" as used herein refers to
nucleotide base analogs that form base pairs with each of the
natural DNA/RNA bases with little discrimination between them.
Non-limiting examples of universal bases include C-phenyl,
C-naphthyl and other aromatic derivatives, inosine, azole
carboxamides, and nitroazole derivatives such as 3-nitropyrrole,
4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art
(see for example Loakes, 2001, Nucleic Acids Research, 29,
2437-2447).
[0238] The term "acyclic nucleotide" as used herein refers to any
nucleotide having an acyclic ribose sugar, for example where any of
the ribose carbons (C1, C2, C3, C4, or C5), are independently or in
combination absent from the nucleotide.
[0239] The nucleic acid molecules of the instant invention,
individually, or in combination or in conjunction with other drugs,
can be used to treat diseases or conditions discussed herein (e.g.,
cancers and other proliferative conditions, inflammatory diseases
and conditions, and/or autoimmune diseases and conditions). For
example, to treat a particular disease or condition, the siNA
molecules can be administered to a subject or can be administered
to other appropriate cells evident to those skilled in the art,
individually or in combination with one or more drugs under
conditions suitable for the treatment.
[0240] In a further embodiment, the siNA molecules can be used in
combination with other known treatments to treat conditions or
diseases discussed above. For example, the described molecules
could be used in combination with one or more known therapeutic
agents to treat a disease or condition. Non-limiting examples of
other therapeutic agents that can be readily combined with a siNA
molecule of the invention are enzymatic nucleic acid molecules,
allosteric nucleic acid molecules, antisense, decoy, or aptamer
nucleic acid molecules, antibodies such as monoclonal antibodies,
small molecules, and other organic and/or inorganic compounds
including metals, salts and ions.
[0241] In one embodiment, the invention features an expression
vector comprising a nucleic acid sequence encoding at least one
siNA molecule of the invention, in a manner which allows expression
of the siNA molecule. For example, the vector can contain
sequence(s) encoding both strands of a siNA molecule comprising a
duplex. The vector can also contain sequence(s) encoding a single
nucleic acid molecule that is self-complementary and thus forms a
siNA molecule. Non-limiting examples of such expression vectors are
described in Paul et al., 2002, Nature Biotechnology, 19, 505;
Miyagishi and Taira, 2002, Nature Biotechnology, 19, 497; Lee et
al., 2002, Nature Biotechnology, 19, 500; and Novina et al., 2002,
Nature Medicine, advance online publication doi: 10.1038/nm725.
[0242] In another embodiment, the invention features a mammalian
cell, for example, a human cell, including an expression vector of
the invention.
[0243] In yet another embodiment, the expression vector of the
invention comprises a sequence for a siNA molecule having
complementarity to a RNA molecule referred to by a Genbank
Accession numbers, for example Genbank Accession Nos. shown in
Table I.
[0244] In one embodiment, an expression vector of the invention
comprises a nucleic acid sequence encoding two or more siNA
molecules, which can be the same or different.
[0245] In another aspect of the invention, siNA molecules that
interact with target RNA molecules and down-regulate gene encoding
target RNA molecules (for example target RNA molecules referred to
by Genbank Accession numbers herein) are expressed from
transcription units inserted into DNA or RNA vectors. The
recombinant vectors can be DNA plasmids or viral vectors. siNA
expressing viral vectors can be constructed based on, but not
limited to, adeno-associated virus, retrovirus, adenovirus, or
alphavirus. The recombinant vectors capable of expressing the siNA
molecules can be delivered as described herein, and persist in
target cells. Alternatively, viral vectors can be used that provide
for transient expression of siNA molecules. Such vectors can be
repeatedly administered as necessary. Once expressed, the siNA
molecules bind and down-regulate gene function or expression via
RNA interference (RNAi). Delivery of siNA expressing vectors can be
systemic, such as by intravenous or intramuscular administration,
by administration to target cells ex-planted from a subject
followed by reintroduction into the subject, or by any other means
that would allow for introduction into the desired target cell.
[0246] By "vectors" is meant any nucleic acid- and/or viral-based
technique used to deliver a desired nucleic acid.
[0247] Other features and advantages of the invention will be
apparent from the following description of the preferred
embodiments thereof, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0248] FIG. 1 shows a non-limiting example of a scheme for the
synthesis of siNA molecules. The complementary siNA sequence
strands, strand 1 and strand 2, are synthesized in tandem and are
connected by a cleavable linkage, such as a nucleotide succinate or
abasic succinate, which can be the same or different from the
cleavable linker used for solid phase synthesis on a solid support.
The synthesis can be either solid phase or solution phase, in the
example shown, the synthesis is a solid phase synthesis. The
synthesis is performed such that a protecting group, such as a
dimethoxytrityl group, remains intact on the terminal nucleotide of
the tandem oligonucleotide. Upon cleavage and deprotection of the
oligonucleotide, the two siNA strands spontaneously hybridize to
form a siNA duplex, which allows the purification of the duplex by
utilizing the properties of the terminal protecting group, for
example by applying a trityl on purification method wherein only
duplexes/oligonucleotides with the terminal protecting group are
isolated.
[0249] FIG. 2 shows a MALDI-TOF mass spectrum of a purified siNA
duplex synthesized by a method of the invention. The two peaks
shown correspond to the predicted mass of the separate siNA
sequence strands. This result demonstrates that the siNA duplex
generated from tandem synthesis can be purified as a single entity
using a simple trityl-on purification methodology.
[0250] FIG. 3 shows a non-limiting proposed mechanistic
representation of target RNA degradation involved in RNAi.
Double-stranded RNA (dsRNA), which is generated by RNA-dependent
RNA polymerase (RdRP) from foreign single-stranded RNA, for example
viral, transposon, or other exogenous RNA, activates the DICER
enzyme that in turn generates siNA duplexes. Alternately, synthetic
or expressed siNA can be introduced directly into a cell by
appropriate means. An active siNA complex forms which recognizes a
target RNA, resulting in degradation of the target RNA by the RISC
endonuclease complex or in the synthesis of additional RNA by
RNA-dependent RNA polymerase (RdRP), which can activate DICER and
result in additional siNA molecules, thereby amplifying the RNAi
response.
[0251] FIG. 4A-F shows non-limiting examples of chemically-modified
siNA constructs of the present invention. In the figure, N stands
for any nucleotide (adenosine, guanosine, cytosine, uridine, or
optionally thymidine, for example thymidine can be substituted in
the overhanging regions designated by parenthesis (N N). Various
modifications are shown for the sense and antisense strands of the
siNA constructs.
[0252] FIG. 4A: The sense strand comprises 21 nucleotides wherein
the two terminal 3'-nucleotides are optionally base paired and
wherein all nucleotides present are ribonucleotides except for (N
N) nucleotides, which can comprise ribonucleotides,
deoxynucleotides, universal bases, or other chemical modifications
described herein. The antisense strand comprises 21 nucleotides,
optionally having a 3'-terminal glyceryl moiety wherein the two
terminal 3'-nucleotides are optionally complementary to the target
RNA sequence, and wherein all nucleotides present are
ribonucleotides except for (N N) nucleotides, which can comprise
ribonucleotides, deoxynucleotides, universal bases, or other
chemical modifications described herein. A modified internucleotide
linkage, such as a phosphorothioate, phosphorodithioate or other
modified internucleotide linkage as described herein, shown as "s",
optionally connects the (N N) nucleotides in the antisense
strand.
[0253] FIG. 4B: The sense strand comprises 21 nucleotides wherein
the two terminal 3'-nucleotides are optionally base paired and
wherein all pyrimidine nucleotides that may be present are
2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides
that may be present are 2'-O-methyl modified nucleotides except for
(N N) nucleotides, which can comprise ribonucleotides,
deoxynucleotides, universal bases, or other chemical modifications
described herein. The antisense strand comprises 21 nucleotides,
optionally having a 3'-terminal glyceryl moiety and wherein the two
terminal 3'-nucleotides are optionally complementary to the target
RNA sequence, and wherein all pyrimidine nucleotides that may be
present are 2'-deoxy-2'-fluoro modified nucleotides and all purine
nucleotides that may be present are 2'-O-methyl modified
nucleotides except for (N N) nucleotides, which can comprise
ribonucleotides, deoxynucleotides, universal bases, or other
chemical modifications described herein. A modified internucleotide
linkage, such as a phosphorothioate, phosphorodithioate or other
modified internucleotide linkage as described herein, shown as "s",
optionally connects the (N N) nucleotides in the sense and
antisense strand.
[0254] FIG. 4C: The sense strand comprises 21 nucleotides having
5'- and 3'-terminal cap moieties wherein the two terminal
3'-nucleotides are optionally base paired and wherein all
pyrimidine nucleotides that may be present are 2'-O-methyl or
2'-deoxy-2'-fluoro modified nucleotides except for (N N)
nucleotides, which can comprise ribonucleotides, deoxynucleotides,
universal bases, or other chemical modifications described herein.
The antisense strand comprises 21 nucleotides, optionally having a
3'-terminal glyceryl moiety and wherein the two terminal
3'-nucleotides are optionally complementary to the target RNA
sequence, and wherein all pyrimidine nucleotides that may be
present are 2'-deoxy-2'-fluoro modified nucleotides except for (N
N) nucleotides, which can comprise ribonucleotides,
deoxynucleotides, universal bases, or other chemical modifications
described herein. A modified internucleotide linkage, such as a
phosphorothioate, phosphorodithioate or other modified
internucleotide linkage as described herein, shown as "s",
optionally connects the (N N) nucleotides in the antisense
strand.
[0255] FIG. 4D: The sense strand comprises 21 nucleotides having
5'- and 3'-terminal cap moieties wherein the two terminal
3'-nucleotides are optionally base paired and wherein all
pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro
modified nucleotides except for (N N) nucleotides, which can
comprise ribonucleotides, deoxynucleotides, universal bases, or
other chemical modifications described herein and wherein and all
purine nucleotides that may be present are 2'-deoxy nucleotides.
The antisense strand comprises 21 nucleotides, optionally having a
3'-terminal glyceryl moiety and wherein the two terminal
3'-nucleotides are optionally complementary to the target RNA
sequence, wherein all pyrimidine nucleotides that may be present
are 2'-deoxy-2'-fluoro modified nucleotides and all purine
nucleotides that may be present are 2'-O-methyl modified
nucleotides except for (N N) nucleotides, which can comprise
ribonucleotides, deoxynucleotides, universal bases, or other
chemical modifications described herein. A modified internucleotide
linkage, such as a phosphorothioate, phosphorodithioate or other
modified internucleotide linkage as described herein, shown as "s",
optionally connects the (N N) nucleotides in the antisense
strand.
[0256] FIG. 4E: The sense strand comprises 21 nucleotides having
5'- and 3'-terminal cap moieties wherein the two terminal
3'-nucleotides are optionally base paired and wherein all
pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro
modified nucleotides except for (N N) nucleotides, which can
comprise ribonucleotides, deoxynucleotides, universal bases, or
other chemical modifications described herein. The antisense strand
comprises 21 nucleotides, optionally having a 3'-terminal glyceryl
moiety and wherein the two terminal 3'-nucleotides are optionally
complementary to the target RNA sequence, and wherein all
pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro
modified nucleotides and all purine nucleotides that may be present
are 2'-O-methyl modified nucleotides except for (N N) nucleotides,
which can comprise ribonucleotides, deoxynucleotides, universal
bases, or other chemical modifications described herein. A modified
internucleotide linkage, such as a phosphorothioate,
phosphorodithioate or other modified internucleotide linkage as
described herein, shown as "s", optionally connects the (N N)
nucleotides in the antisense strand.
[0257] FIG. 4F: The sense strand comprises 21 nucleotides having
5'- and 3'-terminal cap moieties wherein the two terminal
3'-nucleotides are optionally base paired and wherein all
pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro
modified nucleotides except for (N N) nucleotides, which can
comprise ribonucleotides, deoxynucleotides, universal bases, or
other chemical modifications described herein and wherein and all
purine nucleotides that may be present are 2'-deoxy nucleotides.
The antisense strand comprises 21 nucleotides, optionally having a
3'-terminal glyceryl moiety and wherein the two terminal
3'-nucleotides are optionally complementary to the target RNA
sequence, and having one 3'-terminal phosphorothioate
internucleotide linkage and wherein all pyrimidine nucleotides that
may be present are 2'-deoxy-2'-fluoro modified nucleotides and all
purine nucleotides that may be present are 2'-deoxy nucleotides
except for (N N) nucleotides, which can comprise ribonucleotides,
deoxynucleotides, universal bases, or other chemical modifications
described herein. A modified internucleotide linkage, such as a
phosphorothioate, phosphorodithioate or other modified
internucleotide linkage as described herein, shown as "s",
optionally connects the (N N) nucleotides in the antisense strand.
The antisense strand of constructs A-F comprise sequence
complementary to any target nucleic acid sequence of the invention.
Furthermore, when a glyceryl moiety (L) is present at the 3'-end of
the antisense strand for any construct shown in FIG. 4A-F, the
modified internucleotide linkage is optional.
[0258] FIG. 5A-F shows non-limiting examples of specific
chemically-modified siNA sequences of the invention. A-F applies
the chemical modifications described in FIG. 4A-F to a VEGFR1 siNA
sequence. Such chemical modifications can be applied to any VEGF
and/or VEGFr sequence.
[0259] FIG. 6 shows non-limiting examples of different siNA
constructs of the invention. The examples shown (constructs 1, 2,
and 3) have 19 representative base pairs; however, different
embodiments of the invention include any number of base pairs
described herein. Bracketed regions represent nucleotide overhangs,
for example comprising about 1, 2, 3, or 4 nucleotides in length,
preferably about 2 nucleotides. Constructs 1 and 2 can be used
independently for RNAi activity. Construct 2 can comprise a
polynucleotide or non-nucleotide linker, which can optionally be
designed as a biodegradable linker. In one embodiment, the loop
structure shown in construct 2 can comprise a biodegradable linker
that results in the formation of construct 1 in vivo and/or in
vitro. In another example, construct 3 can be used to generate
construct 2 under the same principle wherein a linker is used to
generate the active siNA construct 2 in vivo and/or in vitro, which
can optionally utilize another biodegradable linker to generate the
active siNA construct 1 in vivo and/or in vitro. As such, the
stability and/or activity of the siNA constructs can be modulated
based on the design of the siNA construct for use in vivo or in
vitro and/or in vitro.
[0260] FIG. 7A-C is a diagrammatic representation of a scheme
utilized in generating an expression cassette to generate siNA
hairpin constructs.
[0261] FIG. 7A: A DNA oligomer is synthesized with a 5'-restriction
site (R1) sequence followed by a region having sequence identical
(sense region of siNA) to a predetermined VEGF and/or VEGFr target
sequence, wherein the sense region comprises, for example, about
19, 20, 21, or 22 nucleotides (N) in length, which is followed by a
loop sequence of defined sequence (X), comprising, for example,
about 3 to about 10 nucleotides.
[0262] FIG. 7B: The synthetic construct is then extended by DNA
polymerase to generate a hairpin structure having
self-complementary sequence that will result in a siNA transcript
having specificity for a VEGF and/or VEGFr target sequence and
having self-complementary sense and antisense regions.
[0263] FIG. 7C: The construct is heated (for example to about
95.degree. C.) to linearize the sequence, thus allowing extension
of a complementary second DNA strand using a primer to the
3'-restriction sequence of the first strand. The double-stranded
DNA is then inserted into an appropriate vector for expression in
cells. The construct can be designed such that a 3'-terminal
nucleotide overhang results from the transcription, for example by
engineering restriction sites and/or utilizing a poly-U termination
region as described in Paul et al., 2002, Nature Biotechnology, 29,
505-508.
[0264] FIG. 8A-C is a diagrammatic representation of a scheme
utilized in generating an expression cassette to generate
double-stranded siNA constructs.
[0265] FIG. 8A: A DNA oligomer is synthesized with a 5'-restriction
(R1) site sequence followed by a region having sequence identical
(sense region of siNA) to a predetermined VEGF and/or VEGFr target
sequence, wherein the sense region comprises, for example, about
19, 20, 21, or 22 nucleotides (N) in length, and which is followed
by a 3'-restriction site (R2) which is adjacent to a loop sequence
of defined sequence (X).
[0266] FIG. 8B: The synthetic construct is then extended by DNA
polymerase to generate a hairpin structure having
self-complementary sequence.
[0267] FIG. 8C: The construct is processed by restriction enzymes
specific to R1 and R2 to generate a double-stranded DNA which is
then inserted into an appropriate vector for expression in cells.
The transcription cassette is designed such that a U6 promoter
region flanks each side of the dsDNA which generates the separate
sense and antisense strands of the siNA. Poly T termination
sequences can be added to the constructs to generate U overhangs in
the resulting transcript.
[0268] FIG. 9A-E is a diagrammatic representation of a method used
to determine target sites for siNA mediated RNAi within a
particular target nucleic acid sequence, such as messenger RNA.
[0269] FIG. 9A: A pool of siNA oligonucleotides are synthesized
wherein the antisense region of the siNA constructs has
complementarity to target sites across the target nucleic acid
sequence, and wherein the sense region comprises sequence
complementary to the antisense region of the siNA.
[0270] FIGS. 9B&C: (FIG. 9B) The sequences are pooled and are
inserted into vectors such that (FIG. 9C) transfection of a vector
into cells results in the expression of the siNA.
[0271] FIG. 9D: Cells are sorted based on phenotypic change that is
associated with modulation of the target nucleic acid sequence.
[0272] FIG. 9E: The siNA is isolated from the sorted cells and is
sequenced to identify efficacious target sites within the target
nucleic acid sequence.
[0273] FIG. 10 shows non-limiting examples of different
stabilization chemistries (1-10) that can be used, for example, to
stabilize the 3'-end of siNA sequences of the invention, including
(1) [3-3']-inverted deoxyribose; (2) deoxyribonucleotide; (3)
[5'-3']-3'-deoxyribonucleotide; (4) [5'-3']-ribonucleotide; (5)
[5'-3']-3'-O-methyl ribonucleotide; (6) 3'-glyceryl; (7)
[3'-5']-3'-deoxyribonucleotide; (8) [3'-3']-deoxyribonucleotide;
(9) [5'-2']-deoxyribonucleotide; and (10)
[5-3']-dideoxyribonucleotide. In addition to modified and
unmodified backbone chemistries indicated in the figure, these
chemistries can be combined with different backbone modifications
as described herein, for example, backbone modifications having
Formula I. In addition, the 2'-deoxy nucleotide shown 5' to the
terminal modifications shown can be another modified or unmodified
nucleotide or non-nucleotide described herein, for example
modifications having any of Formulae I-VII or any combination
thereof.
[0274] FIG. 11 shows a non-limiting example of a strategy used to
identify chemically modified siNA constructs of the invention that
are nuclease resistance while preserving the ability to mediate
RNAi activity. Chemical modifications are introduced into the siNA
construct based on educated design parameters (e.g. introducing
2'-mofications, base modifications, backbone modifications,
terminal cap modifications etc). The modified construct in tested
in an appropriate system (e.g. human serum for nuclease resistance,
shown, or an animal model for PK/delivery parameters). In parallel,
the siNA construct is tested for RNAi activity, for example in a
cell culture system such as a luciferase reporter assay). Lead siNA
constructs are then identified which possess a particular
characteristic while maintaining RNAi activity, and can be further
modified and assayed once again. This same approach can be used to
identify siNA-conjugate molecules with improved pharmacokinetic
profiles, delivery, and RNAi activity.
[0275] FIG. 12 shows non-limiting examples of phosphorylated siNA
molecules of the invention, including linear and duplex constructs
and asymmetric derivatives thereof.
[0276] FIG. 13 shows non-limiting examples of chemically modified
terminal phosphate groups of the invention.
[0277] FIG. 14A shows a non-limiting example of methodology used to
design self complementary DFO constructs utilizing palidrome and/or
repeat nucleic acid sequences that are identifed in a target
nucleic acid sequence. (i) A palindrome or repeat sequence is
identified in a nucleic acid target sequence. (ii) A sequence is
designed that is complementary to the target nucleic acid sequence
and the palindrome sequence. (iii) An inverse repeat sequence of
the non-palindrome/repeat portion of the complementary sequence is
appended to the 3'-end of the complementary sequence to generate a
self complmentary DFO molecule comprising sequence complementary to
the nucleic acid target. (iv) The DFO molecule can self-assemble to
form a double stranded oligonucleotide. FIG. 14B shows a
non-limiting representative example of a duplex forming
oligonucleotide sequence. FIG. 14C shows a non-limiting example of
the self assembly schematic of a representative duplex forming
oligonucleotide sequence. FIG. 14D shows a non-limiting example of
the self assembly schematic of a representative duplex forming
oligonucleotide sequence followed by interaction with a target
nucleic acid sequence resulting in modulation of gene
expression.
[0278] FIG. 15 shows a non-limiting example of the design of self
complementary DFO constructs utilizing palidrome and/or repeat
nucleic acid sequences that are incorporated into the DFO
constructs that have sequence complementary to any target nucleic
acid sequence of interest. Incorporation of these palindrome/repeat
sequences allow the design of DFO constructs that form duplexes in
which each strand is capable of mediating modulation of target gene
expression, for example by RNAi. First, the target sequence is
identified. A complementary sequence is then generated in which
nucleotide or non-nucleotide modifications (shown as X or Y) are
introduced into the complementary sequence that generate an
artificial palindrome (shown as XYXYXY in the Figure). An inverse
repeat of the non-palindrome/repeat complementary sequence is
appended to the 3'-end of the complementary sequence to generate a
self complmentary DFO comprising sequence complementary to the
nucleic acid target. The DFO can self-assemble to form a double
stranded oligonucleotide.
[0279] FIG. 16 shows non-limiting examples of multifunctional siNA
molecules of the invention comprising two separate polynucleotide
sequences that are each capable of mediating RNAi directed cleavage
of differing target nucleic acid sequences. FIG. 16A shows a
non-limiting example of a multifunctional siNA molecule having a
first region that is complementary to a first target nucleic acid
sequence (complementary region 1) and a second region that is
complementary to a second target nucleic acid sequence
(complementary region 2), wherein the first and second
complementary regions are situated at the 3'-ends of each
polynucleotide sequence in the multifunctional siNA. The dashed
portions of each polynucleotide sequence of the multifunctional
siNA construct have complementarity with regard to corresponding
portions of the siNA duplex, but do not have complementarity to the
target nucleic acid sequences. FIG. 16B shows a non-limiting
example of a multifunctional siNA molecule having a first region
that is complementary to a first target nucleic acid sequence
(complementary region 1) and a second region that is complementary
to a second target nucleic acid sequence (complementary region 2),
wherein the first and second complementary regions are situated at
the 5'-ends of each polynucleotide sequence in the multifunctional
siNA. The dashed portions of each polynucleotide sequence of the
multifunctional siNA construct have complementarity with regard to
corresponding portions of the siNA duplex, but do not have
complementarity to the target nucleic acid sequences.
[0280] FIG. 17 shows non-limiting examples of multifunctional siNA
molecules of the invention comprising a single polynucleotide
sequence comprising distinct regions that are each capable of
mediating RNAi directed cleavage of differing target nucleic acid
sequences. FIG. 17A shows a non-limiting example of a
multifunctional siNA molecule having a first region that is
complementary to a first target nucleic acid sequence
(complementary region 1) and a second region that is complementary
to a second target nucleic acid sequence (complementary region 2),
wherein the second complementary region is situated at the 3'-end
of the polynucleotide sequence in the multifunctional siNA. The
dashed portions of each polynucleotide sequence of the
multifunctional siNA construct have complementarity with regard to
corresponding portions of the siNA duplex, but do not have
complementarity to the target nucleic acid sequences. FIG. 17B
shows a non-limiting example of a multifunctional siNA molecule
having a first region that is complementary to a first target
nucleic acid sequence (complementary region 1) and a second region
that is complementary to a second target nucleic acid sequence
(complementary region 2), wherein the first complementary region is
situated at the 5'-end of the polynucleotide sequence in the
multifunctional siNA. The dashed portions of each polynucleotide
sequence of the multifunctional siNA construct have complementarity
with regard to corresponding portions of the siNA duplex, but do
not have complementarity to the target nucleic acid sequences. In
one embodiment, these multifunctional siNA constructs are processed
in vivo or in vitro to generate multifunctional siNA constructs as
shown in FIG. 16.
[0281] FIG. 18 shows non-limiting examples of multifunctional siNA
molecules of the invention comprising two separate polynucleotide
sequences that are each capable of mediating RNAi directed cleavage
of differing target nucleic acid sequences and wherein the
multifunctional siNA construct further comprises a self
complementary, palindrome, or repeat region, thus enabling shorter
bifuctional siNA constructs that can mediate RNA interference
against differing target nucleic acid sequences. FIG. 18A shows a
non-limiting example of a multifunctional siNA molecule having a
first region that is complementary to a frist target nucleic acid
sequence (complementary region 1) and a second region that is
complementary to a second target nucleic acid sequence
(complementary region 2), wherein the first and second
complementary regions are situated at the 3'-ends of each
polynucleotide sequence in the multifunctional siNA, and wherein
the first and second complementary regions further comprise a self
complementary, palindrome, or repeat region. The dashed portions of
each polynucleotide sequence of the multifunctional siNA construct
have complementarity with regard to corresponding portions of the
siNA duplex, but do not have complementarity to the target nucleic
acid sequences. FIG. 18B shows a non-limiting example of a
multifunctional siNA molecule having a first region that is
complementary to a frist target nucleic acid sequence
(complementary region 1) and a second region that is complementary
to a second target nucleic acid sequence (complementary region 2),
wherein the first and second complementary regions are situated at
the 5'-ends of each polynucleotide sequence in the multifunctional
siNA, and wherein the first and second complementary regions
further comprise a self complementary, palindrome, or repeat
region. The dashed portions of each polynucleotide sequence of the
multifunctional siNA construct have complementarity with regard to
corresponding portions of the siNA duplex, but do not have
complementarity to the target nucleic acid sequences.
[0282] FIG. 19 shows non-limiting examples of multifunctional siNA
molecules of the invention comprising a single polynucleotide
sequence comprising distinct regions that are each capable of
mediating RNAi directed cleavage of differing target nucleic acid
sequences and wherein the multifunctional siNA construct further
comprises a self complementary, palindrome, or repeat region, thus
enabling shorter bifuctional siNA constructs that can mediate RNA
interference against differing target nucleic acid sequences. FIG.
19A shows a non-limiting example of a multifunctional siNA molecule
having a first region that is complementary to a first target
nucleic acid sequence (complementary region 1) and a second region
that is complementary to a second target nucleic acid sequence
(complementary region 2), wherein the second complementary region
is situated at the 3'-end of the polynucleotide sequence in the
multifunctional siNA, and wherein the first and second
complementary regions further comprise a self complementary,
palindrome, or repeat region. The dashed portions of each
polynucleotide sequence of the multifunctional siNA construct have
complementarity with regard to corresponding portions of the siNA
duplex, but do not have complementarity to the target nucleic acid
sequences. FIG. 19B shows a non-limiting example of a
multifunctional siNA molecule having a first region that is
complementary to a frist target nucleic acid sequence
(complementary region 1) and a second region that is complementary
to a second target nucleic acid sequence (complementary region 2),
wherein the first complementary region is situated at the 5'end of
the polynucleotide sequence in the multifunctional siNA, and
wherein the first and second complementary regions further comprise
a self complementary, palindrome, or repeat region. The dashed
portions of each polynucleotide sequence of the multifunctional
siNA construct have complementarity with regard to corresponding
portions of the siNA duplex, but do not have complementarity to the
target nucleic acid sequences. In one embodiment, these
multifunctional siNA constructs are processed in vivo or in vitro
to generate multifunctional siNA constructs as shown in FIG.
18.
[0283] FIG. 20 shows a non-limiting example of how multifunctional
siNA molecules of the invention can target two separate target
nucleic acid molecules, such as separate RNA molecules encoding
differing proteins, for example a cytokine and its corresponding
receptor, differing viral strains, a virus and a cellular protein
involved in viral infection or replication, or differing proteins
involved in a common or divergent biologic pathway that is
implicated in the maintenance of progression of disease. Each
strand of the multifunctional siNA construct comprises a region
having complementarity to separate target nucleic acid molecules.
The multifunctional siNA molecule is designed such that each strand
of the siNA can be utilized by the RISC complex to initiate RNA
interferance mediated cleavage of its corresponding target. These
design parameters can include destabilization of each end of the
siNA construct (see for example Schwarz et al., 2003, Cell, 115,
199-208). Such destabilization can be accomplished for example by
using guanosine-cytidine base pairs, alternate base pairs (e.g.,
wobbles), or destabilizing chemically modified nucleotides at
terminal nucleotide positions as is known in the art.
[0284] FIG. 21 shows a non-limiting example of how multifunctional
siNA molecules of the invention can target two separate target
nucleic acid seqeunces within the same target nucleic acid
molecule, such as alternate coding regions of a RNA, coding and
non-coding regions of a RNA, or alternate splice variant regions of
a RNA. Each strand of the multifunctional siNA construct comprises
a region having complementarity to the separate regions of the
target nucleic acid molecule. The multifunctional siNA molecule is
designed such that each strand of the siNA can be utilized by the
RISC complex to initiate RNA interferance mediated cleavage of its
corresponding target region. These design parameters can include
destabilization of each end of the siNA construct (see for example
Schwarz et al., 2003, Cell, 115, 199-208). Such destabilization can
be accomplished for example by using guanosine-cytidine base pairs,
alternate base pairs (e.g., wobbles), or destabilizing chemically
modified nucleotides at terminal nucleotide positions as is known
in the art.
[0285] FIG. 22 shows a non-limiting example of reduction of VEGFR1
mRNA in A375 cells mediated by chemically-modified siNAs that
target VEGFR1 mRNA. A549 cells were transfected with 0.25 ug/well
of lipid complexed with 25 nM siNA. A screen of siNA constructs
(Stabilization "Stab" chemistries are shown in Table IV, constructs
are referred to by RPI number, see Table III) comprising Stab 4/5
chemistry (RPI 31190/31193), Stab 1/2 chemistry (RPI 31183/31186
and RPI 31184/31187), and unmodified RNA (RPI 30075/30076) were
compared to untreated cells, matched chemistry inverted control
siNA constructs, (RPI 31208/31211, RPI 31201/31204, RPI
31202/31205, and RPI 30077/30078) scrambled siNA control constructs
(Scram1 and Scram2), and cells transfected with lipid alone
(transfection control). All of the siNA constructs show significant
reduction of VEGFR1 RNA expression.
[0286] FIG. 23 shows a non-limiting example of reduction of VEGFR1
mRNA levels in HAEC cell culture using Stab 9/10 directed against
eight sites in VEGFR1 mRNA compared to matched chemistry inverted
controls siNA constructs. Controls UNT and LF2K refer to untreated
cells and cells treated with LF2K transfection reagent alone,
respectively.
[0287] FIG. 24 shows a non-limiting example of reduction of VEGFr2
mRNA in HAEC cells mediated by chemically-modified siNAs that
target VEGFr2 mRNA. HAEC cells were transfected with 0.25 ug/well
of lipid complexed with 25 nM siNA. A screen of siNA constructs
(Stabilization "Stab" chemistries are shown in Table IV, constructs
are referred to by Compound No., see Table III) in site 3854
comprising Stab 4/5 chemistry (Compound No. 30786/30790), Stab 7/8
chemistry (Compound No. 31858/31860), and Stab 9/10 chemistry
(Compound No. 31862/31864) and in site 3948 comprising Stab 4/5
chemistry (Compound No. 31856/31857), Stab 7/8 chemistry (Compound
No. 31859/31861), and Stab 9/10 chemistry (Compound No.
31863/31865) were compared to untreated cells, matched chemistry
inverted control siNA constructs in site 3854 (Compound No.
31878/31880, Compound No. 31882/31884, and Compound No.
31886/31888), and in site 3948 (Compound No. 31879/31881, Compound
No. 31883/31885, and Compound No. 31887/31889), cells transfected
with LF2K (transfection reagent), and an all RNA control (Compound
No. 31435/31439 in site 3854 and Compound No. 31437/31441 in site
3948). All of the siNA constructs show significant reduction of
VEGFr2 RNA expression.
[0288] FIG. 25 shows a non-limiting example of reduction of VEGFR2
mRNA levels in HAEC cell culture using Stab 0/0 directed against
four sites in VEGFR2 mRNA compared to irrelevant control siNA
constructs (IC1, IC2). Controls UNT and LF2K refer to untreated
cells and cells treated with LF2K transfection reagent alone,
respectively.
[0289] FIG. 26 shows non-limiting examples of reduction of VEGFR1
(Flt-1) mRNA levels in HAEC cells (15,000 cells/well) 24 hours
after treatment with siNA molecules targeting sequences having
VEGFR1 (Flt-1) and VEGFR2 (KDR) homology. HAEC cells were
transfected with 1.5 ug/well of lipid complexed with 25 nM siNA.
Activity of the siNA moleclues is shown compared to matched
chemistry inverted siNA controls, untreated cells, and cells
treated with lipid only (transfection control). siNA molecules and
controls are referred to by compound numbers (sense/antisense), see
Table III for sequences. FIG. 26A shows data for Stab 9/10 siNA
constructs. FIG. 26B shows data for Stab 7/8 siNA constructs. The
FIG. 26B study includes a construct that targets only VEGFR1
(32748/32755) and a matched chemistry inverted control thereof
(32772/32779) as additional controls. As shown in the figures, the
siNA constructs that target both VEGFR1 and VEGFR2 sequences
demonstrate potent efficacy in inhibiting VEGFR1 expression in cell
cuture experiments.
[0290] FIG. 27 shows non-limiting examples of reduction of VEGFr2
(KDR) mRNA levels in HAEC cells (15,000 cells/well) 24 hours after
treatment with siNA molecules targeting sequences having VEGFr1 and
VEGFr2 homology. HAEC cells were transfected with 1.5 ug/well of
lipid complexed with 25 nM siNA. Activity of the siNA moleclues is
shown compared to matched chemistry inverted siNA controls,
untreated cells, and cells treated with lipid only (transfection
control). siNA molecules and controls are referred to by compound
numbers (sense/antisense), see Table III for sequences. FIG. 27A
shows data for Stab 9/10 siNA constructs. FIG. 237 shows data for
Stab 7/8 siNA constructs. The FIG. 27B study includes a construct
that targets only VEGFr1 (32748/32755) and a matched chemistry
inverted control thereof (32772/32779) as additional controls. As
shown in the figures, the siNA constructs that target both VEGFr1
and VEGFr2 sequences demonstrate potent efficacy in inhibiting
VEGFr2 expression in cell cuture experiments.
[0291] FIG. 28 shows a non-limiting example of siNA mediated
inhibition of VEGF-induced angiogenesis using the rat corneal model
of angiogenesis. siNA targeting site 2340 of VEGFR1 RNA (shown as
RPI No. 29695/29699 sense strand/antisense strand) was compared to
an inverted control siNA (shown as RPI No. 29983/29984 sense
strand/antisense strand) at three different concentrations (1 ug, 3
ug, and 10 ug) and compared to a VEGF control in which no siNA was
administered. As shown in the Figure, siNA constructs targeting
VEGFR1 RNA can provide significant inhibition of angiogenesis in
the rat corneal model.
[0292] FIG. 29 shows a non-limiting example of inhibition of VEGF
induced neovascularization in the rat corneal model. VEGFR1 site
349 active siNA having "Stab 9/10" chemistry (Compound No.
31270/31273) was tested for inhibition of VEGF-induced angiogenesis
at three different concentrations (2.0 ug, 1.0 ug, and 0.1 ug dose
response) as compared to a matched chemistry inverted control siNA
construct (Compound No. 31276/31279) at each concentration and a
VEGF control in which no siNA was administered. As shown in the
figure, the active siNA construct having "Stab 9/10" chemistry
(Compound No. 31270/31273) is highly effective in inhibiting
VEGF-induced angiogenesis in the rat corneal model compared to the
matched chemistry inverted control siNA at concentrations from 0.1
ug to 2.0 ug.
[0293] FIG. 30 shows a non-limiting example of a study in which
sites adjacent to VEGFR1 site 349 were evaluated for efficacy using
two different siNA stabilization chemistries. Chemistry C=Stab 9/10
whereas Chemistry D=Stab 7/8.
[0294] FIG. 31 shows a non-limiting example of inhibition of VEGF
induced ocular angiogenesis using siNA constructs that target
homologous sequences shared by VEGFR1 and VEGFR2 via subconjuctival
administration of the siNA after VEGF disk implantation. siNA
constructs were administered intraocularly on days 1 and 7
following laser induced injury to the choroid, and choroidal
neovascularization assessed on day 14.
[0295] FIG. 32 shows a non-limiting example of inhibition of VEGF
induced neovascularization in a mouse model of coroidal
neovascularization via intraocular administration of siNA. VEGFR1
site 349 active siNA having "Stab 9/10" chemistry (Compound No.
31270/31273) was tested for inhibition of neovascularization at two
different concentrations (1.5 ug, and 0.5 ug) as compared to a
matched chemistry inverted control siNA construct (Compound No.
31276/31279) and phosphate buffered saline (PBS). siNA constructs
were administered intraocularly on days 1 and 7 following laser
induced injury to the choroid, and choroidal neovascularization
assessed on day 14. As shown in the figure, the active siNA
construct having "Stab 9/10" chemistry (Compound No. 31270/31273)
is highly effective in inhibiting neovascularization via
intraocular administration in this model.
[0296] FIG. 33 shows a non-limiting example of inhibition of VEGF
induced neovascularization in a mouse model of coroidal
neovascularization via periocular administration of siNA. VEGFR1
site 349 active siNA having "Stab 9/10" chemistry (Compound No.
31270/31273) was tested for inhibition of neovascularization at two
different concentrations (1.5 ug with a saline control, and 0.5 ug
with an inverted siNA control, Compound No. 31276/31279). Eight
mice were used in each arm of the study with one eye receiving the
active siNA and the other eye receiving the saline or inverted
control. siNA constructs and controls were adminitered daily up to
14 days, and neovascularization was assessed at day 17 following
laser induced injury to the choroid. As shown in the figure, the
active siNA construct having "Stab 9/10" chemistry (Compound No.
31270/31273) is highly effective in inhibiting neovascularization
via periocular administration in this model.
[0297] FIG. 34 shows another non-limiting example of inhibition of
VEGF induced neovascularization in a mouse model of coroidal
neovascularization via periocular administration of siNA. VEGFR1
site 349 active siNA having "Stab 9/10" chemistry (Compound No.
31270/31273) was tested for inhibition of neovascularization at two
different concentrations (1.5 ug with an inverted siNA control,
Compound No. 31276/31279 and 0.5 ug with a saline control). Nine
mice were used in the active versus inverted arm of the study with
one eye receiving the active siNA and the other eye receiving the
inverted control. Eight mice were used in the active versus saline
arm of the study with one eye receiving the active siNA and the
other eye receiving the saline control. siNA constructs and
controls were administered daily up to 14 days, and
neovascularization was assessed at day 17 following laser induced
injury to the choroid. As shown in the figure, the active siNA
construct having "Stab 9/10" chemistry (Compound No. 31270/31273)
is highly effective in inhibiting neovascularization via periocular
administration in this model.
[0298] FIG. 35 shows a non-limiting example of siNA mediated
inhibition of choroidal neovascularization (CNV) in mice injected
with active siNA (31270/31273) targeting site 349 of VEGFR1 mRNA
compared to mice injected with a matched chemistry inverted control
siNA construct (31276/31279) in a mouse model of ocular
neovascularization. Periocular injections were performed every
three days after rupture of Bruch's membrane. Eyes treated with
active siNA had significantly smaller areas of CNV than eyes
treated with inverted control siNA constructs (n=13, p=0.0002).
[0299] FIG. 36 shows a non-limiting example of siNA mediated
inhibition of VEGFR1 mRNA levels in mice injected with active siNA
(31270/31273) targeting site 349 of VEGFR1 mRNA compared to mice
injected with a matched chemistry inverted control siNA construct
(31276/31279) in a mouse model of oxygen induced retinopathy (OIR).
Periocular injections of VEGFR1 siNA (31270/31273) (5 .mu.l; 1.5
.mu.g/.mu.l) on P12, P14, and P16 significantly reduced VEGFR1 mRNA
expression compared to injections with a matched chemistry inverted
control siNA construct (31276/31279), (40% inhibition; n=9,
p=0.0121).
[0300] FIG. 37 shows a non-limiting example of siNA mediated
inhibition of VEGFR1 protein levels in mice injected with active
siNA (31270/31273) targeting site 349 of VEGFR1 mRNA compared to
mice injected with a matched chemistry inverted control siNA
construct (31276/31279) in a mouse model of oxygen induced
retinopathy (OIR). Intraocular injections of VEGFR1 siNA
(31270/31273) (5 .mu.g), significantly reduced VEGFR1 protein
levels compared to injections with a matched chemistry inverted
control siNA construct (31276/31279), (30% inhibition; n=7,
p=0.0103).
[0301] FIG. 38 shows a non-limiting example of the reduction of
primary tumor volume in a mouse 4T1-luciferase mammary carcinoma
syngeneic tumor model using active Stab 9/10 siNA targeting site
349 of VEGFR1 RNA (Compound # 31270/31273) compared to a matched
chemistry inactive inverted control siNA (Compound # 31276/31279)
and saline. As shown in the figure, the active siNA construct is
effective in reducing tumor volume in this model.
[0302] FIG. 39 shows a non-limiting example of the reduction of
soluble VEGFR1 serum levels in a mouse 4T1-luciferase mammary
carcinoma syngeneic tumor model using active Stab 9/10 siNA
targeting site 349 of VEGFR1 RNA (Compound # 31270/31273) compared
to a matched chemistry inactive inverted control siNA (Compound #
31276/31279). As shown in the figure, the active siNA construct is
effective in reducing soluble VEGFR1 serum levels in this
model.
DETAILED DESCRIPTION OF THE INVENTION
[0303] Mechanism of Action of Nucleic Acid Molecules of the
Invention
[0304] The discussion that follows discusses the proposed mechanism
of RNA interference mediated by short interfering RNA as is
presently known, and is not meant to be limiting and is not an
admission of prior art. Applicant demonstrates herein that
chemically-modified short interfering nucleic acids possess similar
or improved capacity to mediate RNAi as do siRNA molecules and are
expected to possess improved stability and activity in vivo;
therefore, this discussion is not meant to be limiting only to
siRNA and can be applied to siNA as a whole. By "improved capacity
to mediate RNAi" or "improved RNAi activity" is meant to include
RNAi activity measured in vitro and/or in vivo where the RNAi
activity is a reflection of both the ability of the siNA to mediate
RNAi and the stability of the siNAs of the invention. In this
invention, the product of these activities can be increased in
vitro and/or in vivo compared to an all RNA siRNA or a siNA
containing a plurality of ribonucleotides. In some cases, the
activity or stability of the siNA molecule can be decreased (i.e.,
less than ten-fold), but the overall activity of the siNA molecule
is enhanced in vitro and/or in vivo.
[0305] RNA interference refers to the process of sequence specific
post-transcriptional gene silencing in animals mediated by short
interfering RNAs (siRNAs) (Fire et al., 1998, Nature, 391, 806).
The corresponding process in plants is commonly referred to as
post-transcriptional gene silencing or RNA silencing and is also
referred to as quelling in fungi. The process of
post-transcriptional gene silencing is thought to be an
evolutionarily-conserved cellular defense mechanism used to prevent
the expression of foreign genes which is commonly shared by diverse
flora and phyla (Fire et al., 1999, Trends Genet., 15, 358). Such
protection from foreign gene expression may have evolved in
response to the production of double-stranded RNAs (dsRNAs) derived
from viral infection or the random integration of transposon
elements into a host genome via a cellular response that
specifically destroys homologous single-stranded RNA or viral
genomic RNA. The presence of dsRNA in cells triggers the RNAi
response though a mechanism that has yet to be fully characterized.
This mechanism appears to be different from the interferon response
that results from dsRNA-mediated activation of protein kinase PKR
and 2',5'-oligoadenylate synthetase resulting in non-specific
cleavage of mRNA by ribonuclease L.
[0306] The presence of long dsRNAs in cells stimulates the activity
of a ribonuclease III enzyme referred to as Dicer. Dicer is
involved in the processing of the dsRNA into short pieces of dsRNA
known as short interfering RNAs (siRNAs) (Berstein et al., 2001,
Nature, 409, 363). Short interfering RNAs derived from Dicer
activity are typically about 21 to about 23 nucleotides in length
and comprise about 19 base pair duplexes. Dicer has also been
implicated in the excision of 21- and 22-nucleotide small temporal
RNAs (stRNAs) from precursor RNA of conserved structure that are
implicated in translational control (Hutvagner et al., 2001,
Science, 293, 834). The RNAi response also features an endonuclease
complex containing a siRNA, commonly referred to as an RNA-induced
silencing complex (RISC), which mediates cleavage of
single-stranded RNA having sequence homologous to the siRNA.
Cleavage of the target RNA takes place in the middle of the region
complementary to the guide sequence of the siRNA duplex (Elbashir
et al., 2001, Genes Dev., 15, 188). In addition, RNA interference
can also involve small RNA (e.g., micro-RNA or mRNA) mediated gene
silencing, presumably though cellular mechanisms that regulate
chromatin structure and thereby prevent transcription of target
gene sequences (see for example Allshire, 2002, Science, 297,
1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein,
2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297,
2232-2237). As such, siNA molecules of the invention can be used to
mediate gene silencing via interaction with RNA transcripts or
alternately by interaction with particular gene sequences, wherein
such interaction results in gene silencing either at the
transcriptional level or post-transcriptional level.
[0307] RNAi has been studied in a variety of systems. Fire et al.,
1998, Nature, 391, 806, were the first to observe RNAi in C.
elegans. Wianny and Goetz, 1999, Nature Cell Biol., 2, 70, describe
RNAi mediated by dsRNA in mouse embryos. Hammond et al., 2000,
Nature, 404, 293, describe RNAi in Drosophila cells transfected
with dsRNA. Elbashir et al., 2001, Nature, 411, 494, describe RNAi
induced by introduction of duplexes of synthetic 21-nucleotide RNAs
in cultured mammalian cells including human embryonic kidney and
HeLa cells. Recent work in Drosophila embryonic lysates has
revealed certain requirements for siRNA length, structure, chemical
composition, and sequence that are essential to mediate efficient
RNAi activity. These studies have shown that 21 nucleotide siRNA
duplexes are most active when containing two 2-nucleotide
3'-terminal nucleotide overhangs. Furthermore, substitution of one
or both siRNA strands with 2'-deoxy or 2'-O-methyl nucleotides
abolishes RNAi activity, whereas substitution of 3'-terminal siRNA
nucleotides with deoxy nucleotides was shown to be tolerated.
Mismatch sequences in the center of the siRNA duplex were also
shown to abolish RNAi activity. In addition, these studies also
indicate that the position of the cleavage site in the target RNA
is defined by the 5'-end of the siRNA guide sequence rather than
the 3'-end (Elbashir et al., 2001, EMBO J., 20, 6877). Other
studies have indicated that a 5'-phosphate on the
target-complementary strand of a siRNA duplex is required for siRNA
activity and that ATP is utilized to maintain the 5'-phosphate
moiety on the siRNA (Nykanen et al., 2001, Cell, 107, 309);
however, siRNA molecules lacking a 5'-phosphate are active when
introduced exogenously, suggesting that 5'-phosphorylation of siRNA
constructs may occur in vivo.
[0308] Synthesis of Nucleic Acid Molecules
[0309] Synthesis of nucleic acids greater than 100 nucleotides in
length is difficult using automated methods, and the therapeutic
cost of such molecules is prohibitive. In this invention, small
nucleic acid motifs ("small" refers to nucleic acid motifs no more
than 100 nucleotides in length, preferably no more than 80
nucleotides in length, and most preferably no more than 50
nucleotides in length; e.g., individual siNA oligonucleotide
sequences or siNA sequences synthesized in tandem) are preferably
used for exogenous delivery. The simple structure of these
molecules increases the ability of the nucleic acid to invade
targeted regions of protein and/or RNA structure. Exemplary
molecules of the instant invention are chemically synthesized, and
others can similarly be synthesized.
[0310] Oligonucleotides (e.g., certain modified oligonucleotides or
portions of oligonucleotides lacking ribonucleotides) are
synthesized using protocols known in the art, for example as
described in Caruthers et al., 1992, Methods in Enzymology 211,
3-19, Thompson et al., International PCT Publication No. WO
99/54459, Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684,
Wincott et al., 1997, Methods Mol. Bio., 74, 59, Brennan et al.,
1998, Biotechnol Bioeng., 61, 33-45, and Brennan, U.S. Pat. No.
6,001,311. All of these references are incorporated herein by
reference. The synthesis of oligonucleotides makes use of common
nucleic acid protecting and coupling groups, such as
dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end.
In a non-limiting example, small scale syntheses are conducted on a
394 Applied Biosystems, Inc. synthesizer using a 0.2 .mu.mol scale
protocol with a 2.5 min coupling step for 2'-O-methylated
nucleotides and a 45 second coupling step for 2'-deoxy nucleotides
or 2'-deoxy-2'-fluoro nucleotides. Table V outlines the amounts and
the contact times of the reagents used in the synthesis cycle.
Alternatively, syntheses at the 0.2 .mu.mol scale can be performed
on a 96-well plate synthesizer, such as the instrument produced by
Protogene (Palo Alto, Calif.) with minimal modification to the
cycle. A 33-fold excess (60 .mu.L of 0.11 M=6.6 mmol) of
2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl
tetrazole (60 .mu.L of 0.25 M=15 mmol) can be used in each coupling
cycle of 2'-O-methyl residues relative to polymer-bound
5'-hydroxyl. A 22-fold excess (40 .mu.L of 0.11 M=4.4 .mu.mol) of
deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40
.mu.L of 0.25 M=10 .mu.mol) can be used in each coupling cycle of
deoxy residues relative to polymer-bound 5'-hydroxyl. Average
coupling yields on the 394 Applied Biosystems, Inc. synthesizer,
determined by calorimetric quantitation of the trityl fractions,
are typically 97.5-99%. Other oligonucleotide synthesis reagents
for the 394 Applied Biosystems, Inc. synthesizer include the
following: detritylation solution is 3% TCA in methylene chloride
(ABI); capping is performed with 16% N-methyl imidazole in THF
(ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and
oxidation solution is 16.9 mM I.sub.2, 49 mM pyridine, 9% water in
THF (PerSeptive Biosystems, Inc.). Burdick & Jackson Synthesis
Grade acetonitrile is used directly from the reagent bottle.
S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from
the solid obtained from American International Chemical, Inc.
Alternately, for the introduction of phosphorothioate linkages,
Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in
acetonitrile) is used.
[0311] Deprotection of the DNA-based oligonucleotides is performed
as follows: the polymer-bound trityl-on oligoribonucleotide is
transferred to a 4 mL glass screw top vial and suspended in a
solution of 40% aqueous methylamine (1 mL) at 65.degree. C. for 10
minutes. After cooling to -20.degree. C., the supernatant is
removed from the polymer support. The support is washed three times
with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is
then added to the first supernatant. The combined supernatants,
containing the oligoribonucleotide, are dried to a white
powder.
[0312] The method of synthesis used for RNA including certain siNA
molecules of the invention follows the procedure as described in
Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringe et al.,
1990, Nucleic Acids Res., 18, 5433; and Wincott et al., 1995,
Nucleic Acids Res. 23, 2677-2684 Wincott et al., 1997, Methods Mol.
Bio., 74, 59, and makes use of common nucleic acid protecting and
coupling groups, such as dimethoxytrityl at the 5'-end, and
phosphoramidites at the 3'-end. In a non-limiting example, small
scale syntheses are conducted on a 394 Applied Biosystems, Inc.
synthesizer using a 0.2 .mu.mol scale protocol with a 7.5 min
coupling step for alkylsilyl protected nucleotides and a 2.5 min
coupling step for 2'-O-methylated nucleotides. Table V outlines the
amounts and the contact times of the reagents used in the synthesis
cycle. Alternatively, syntheses at the 0.2 .mu.mol scale can be
done on a 96-well plate synthesizer, such as the instrument
produced by Protogene (Palo Alto, Calif.) with minimal modification
to the cycle. A 33-fold excess (60 .mu.L of 0.11 M=6.6 .mu.mol) of
2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl
tetrazole (60 .mu.L of 0.25 M=15 .mu.mol) can be used in each
coupling cycle of 2'-O-methyl residues relative to polymer-bound
5'-hydroxyl. A 66-fold excess (120 .mu.L of 0.11 M=13.2 mmol) of
alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess
of S-ethyl tetrazole (120 .mu.L of 0.25 M=30 .mu.mol) can be used
in each coupling cycle of ribo residues relative to polymer-bound
5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems,
Inc. synthesizer, determined by colorimetric quantitation of the
trityl fractions, are typically 97.5-99%. Other oligonucleotide
synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer
include the following: detritylation solution is 3% TCA in
methylene chloride (ABI); capping is performed with 16% N-methyl
imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in
THF (ABI); oxidation solution is 16.9 mM 12, 49 mM pyridine, 9%
water in THF (PerSeptive Biosystems, Inc.). Burdick & Jackson
Synthesis Grade acetonitrile is used directly from the reagent
bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made
up from the solid obtained from American International Chemical,
Inc. Alternately, for the introduction of phosphorothioate
linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one
1,1-dioxide0.05 M in acetonitrile) is used.
[0313] Deprotection of the RNA is performed using either a two-pot
or one-pot protocol. For the two-pot protocol, the polymer-bound
trityl-on oligoribonucleotide is transferred to a 4 mL glass screw
top vial and suspended in a solution of 40% aq. methylamine (1 mL)
at 65.degree. C. for 10 min. After cooling to -20.degree. C., the
supernatant is removed from the polymer support. The support is
washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and
the supernatant is then added to the first supernatant. The
combined supernatants, containing the oligoribonucleotide, are
dried to a white powder. The base deprotected oligoribonucleotide
is resuspended in anhydrous TEA/HF/NMP solution (300 .mu.L of a
solution of 1.5 mL N-methylpyrrolidinone, 750 .mu.L TEA and 1 mL
TEA.3HF to provide a 1.4 M HF concentration) and heated to
65.degree. C. After 1.5 h, the oligomer is quenched with 1.5 M
NH.sub.4HCO.sub.3.
[0314] Alternatively, for the one-pot protocol, the polymer-bound
trityl-on oligoribonucleotide is transferred to a 4 mL glass screw
top vial and suspended in a solution of 33% ethanolic
methylamine/DMSO: 1/1 (0.8 mL) at 65.degree. C. for 15 minutes. The
vial is brought to room temperature TEA.3HF (0.1 mL) is added and
the vial is heated at 65.degree. C. for 15 minutes. The sample is
cooled at -20.degree. C. and then quenched with 1.5 M
NH.sub.4HCO.sub.3.
[0315] For purification of the trityl-on oligomers, the quenched
NH.sub.4HCO.sub.3 solution is loaded onto a C-18 containing
cartridge that had been prewashed with acetonitrile followed by 50
mM TEAA. After washing the loaded cartridge with water, the RNA is
detritylated with 0.5% TFA for 13 minutes. The cartridge is then
washed again with water, salt exchanged with 1 M NaCl and washed
with water again. The oligonucleotide is then eluted with 30%
acetonitrile.
[0316] The average stepwise coupling yields are typically >98%
(Wincott et al., 1995 Nucleic Acids Res. 23, 2677-2684). Those of
ordinary skill in the art will recognize that the scale of
synthesis can be adapted to be larger or smaller than the example
described above including but not limited to 96-well format.
[0317] Alternatively, the nucleic acid molecules of the present
invention can be synthesized separately and joined together
post-synthetically, for example, by ligation (Moore et al., 1992,
Science 256, 9923; Draper et al., International PCT publication No.
WO 93/23569; Shabarova et al., 1991, Nucleic Acids Research 19,
4247; Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951;
Bellon et al., 1997, Bioconjugate Chem. 8, 204), or by
hybridization following synthesis and/or deprotection.
[0318] The siNA molecules of the invention can also be synthesized
via a tandem synthesis methodology as described in Example 1
herein, wherein both siNA strands are synthesized as a single
contiguous oligonucleotide fragment or strand separated by a
cleavable linker which is subsequently cleaved to provide separate
siNA fragments or strands that hybridize and permit purification of
the siNA duplex. The linker can be a polynucleotide linker or a
non-nucleotide linker. The tandem synthesis of siNA as described
herein can be readily adapted to both multiwell/multiplate
synthesis platforms such as 96 well or similarly larger multi-well
platforms. The tandem synthesis of siNA as described herein can
also be readily adapted to large scale synthesis platforms
employing batch reactors, synthesis columns and the like.
[0319] A siNA molecule can also be assembled from two distinct
nucleic acid strands or fragments wherein one fragment includes the
sense region and the second fragment includes the antisense region
of the RNA molecule.
[0320] The nucleic acid molecules of the present invention can be
modified extensively to enhance stability by modification with
nuclease resistant groups, for example, 2'-amino, 2'-C-allyl,
2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren,
1992, TIBS 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31,
163). siNA constructs can be purified by gel electrophoresis using
general methods or can be purified by high pressure liquid
chromatography (HPLC; see Wincott et al., supra, the totality of
which is hereby incorporated herein by reference) and re-suspended
in water.
[0321] In another aspect of the invention, siNA molecules of the
invention are expressed from transcription units inserted into DNA
or RNA vectors. The recombinant vectors can be DNA plasmids or
viral vectors. siNA expressing viral vectors can be constructed
based on, but not limited to, adeno-associated virus, retrovirus,
adenovirus, or alphavirus. The recombinant vectors capable of
expressing the siNA molecules can be delivered as described herein,
and persist in target cells. Alternatively, viral vectors can be
used that provide for transient expression of siNA molecules.
[0322] Optimizing Activity of the Nucleic Acid Molecule of the
Invention.
[0323] Chemically synthesizing nucleic acid molecules with
modifications (base, sugar and/or phosphate) can prevent their
degradation by serum ribonucleases, which can increase their
potency (see e.g., Eckstein et al., International Publication No.
WO 92/07065; Perrault et al., 1990 Nature 344, 565; Pieken et al.,
1991, Science 253, 314; Usman and Cedergren, 1992, Trends in
Biochem. Sci. 17, 334; Usman et al., International Publication No.
WO 93/15187; and Rossi et al., International Publication No. WO
91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold et al., U.S. Pat.
No. 6,300,074; and Burgin et al., supra; all of which are
incorporated by reference herein). All of the above references
describe various chemical modifications that can be made to the
base, phosphate and/or sugar moieties of the nucleic acid molecules
described herein. Modifications that enhance their efficacy in
cells, and removal of bases from nucleic acid molecules to shorten
oligonucleotide synthesis times and reduce chemical requirements
are desired.
[0324] There are several examples in the art describing sugar, base
and phosphate modifications that can be introduced into nucleic
acid molecules with significant enhancement in their nuclease
stability and efficacy. For example, oligonucleotides are modified
to enhance stability and/or enhance biological activity by
modification with nuclease resistant groups, for example, 2'-amino,
2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide
base modifications (for a review see Usman and Cedergren, 1992,
TIBS. 17, 34; Usman et al., 1994, Nucleic Acids Symp. Ser. 31, 163;
Burgin et al., 1996, Biochemistry, 35, 14090). Sugar modification
of nucleic acid molecules have been extensively described in the
art (see Eckstein et al., International Publication PCT No. WO
92/07065; Perrault et al. Nature, 1990, 344, 565-568; Pieken et al.
Science, 1991, 253, 314-317; Usman and Cedergren, Trends in
Biochem. Sci., 1992, 17, 334-339; Usman et al. International
Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711
and Beigelman et al., 1995, J. Biol. Chem., 270, 25702; Beigelman
et al., International PCT publication No. WO 97/26270; Beigelman et
al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No.
5,627,053; Woolf et al., International PCT Publication No. WO
98/13526; Thompson et al., U.S. Ser. No. 60/082,404 which was filed
on Apr. 20, 1998; Karpeisky et al., 1998, Tetrahedron Lett., 39,
1131; Eamshaw and Gait, 1998, Biopolymers (Nucleic Acid Sciences),
48, 39-55; Verma and Eckstein, 1998, Annu. Rev. Biochem., 67,
99-134; and Burlina et al., 1997, Bioorg. Med. Chem., 5, 1999-2010;
all of the references are hereby incorporated in their totality by
reference herein). Such publications describe general methods and
strategies to determine the location of incorporation of sugar,
base and/or phosphate modifications and the like into nucleic acid
molecules without modulating catalysis, and are incorporated by
reference herein. In view of such teachings, similar modifications
can be used as described herein to modify the siNA nucleic acid
molecules of the instant invention so long as the ability of siNA
to promote RNAi is cells is not significantly inhibited.
[0325] While chemical modification of oligonucleotide
internucleotide linkages with phosphorothioate, phosphorodithioate,
and/or 5'-methylphosphonate linkages improves stability, excessive
modifications can cause some toxicity or decreased activity.
Therefore, when designing nucleic acid molecules, the amount of
these internucleotide linkages should be minimized. The reduction
in the concentration of these linkages should lower toxicity,
resulting in increased efficacy and higher specificity of these
molecules.
[0326] Short interfering nucleic acid (siNA) molecules having
chemical modifications that maintain or enhance activity are
provided. Such a nucleic acid is also generally more resistant to
nucleases than an unmodified nucleic acid. Accordingly, the in
vitro and/or in vivo activity should not be significantly lowered.
In cases in which modulation is the goal, therapeutic nucleic acid
molecules delivered exogenously should optimally be stable within
cells until translation of the target RNA has been modulated long
enough to reduce the levels of the undesirable protein. This period
of time varies between hours to days depending upon the disease
state. Improvements in the chemical synthesis of RNA and DNA
(Wincott et al., 1995, Nucleic Acids Res. 23, 2677; Caruthers et
al., 1992, Methods in Enzymology 211, 3-19 (incorporated by
reference herein)) have expanded the ability to modify nucleic acid
molecules by introducing nucleotide modifications to enhance their
nuclease stability, as described above.
[0327] In one embodiment, nucleic acid molecules of the invention
include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
more) G-clamp nucleotides. A G-clamp nucleotide is a modified
cytosine analog wherein the modifications confer the ability to
hydrogen bond both Watson-Crick and Hoogsteen faces of a
complementary guanine within a duplex, see for example Lin and
Matteucci, 1998, J. Am. Chem. Soc., 120, 8531-8532. A single
G-clamp analog substitution within an oligonucleotide can result in
substantially enhanced helical thermal stability and mismatch
discrimination when hybridized to complementary oligonucleotides.
The inclusion of such nucleotides in nucleic acid molecules of the
invention results in both enhanced affinity and specificity to
nucleic acid targets, complementary sequences, or template strands.
In another embodiment, nucleic acid molecules of the invention
include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or
more) LNA "locked nucleic acid" nucleotides such as a 2',4'-C
methylene bicyclo nucleotide (see for example Wengel et al.,
International PCT Publication No. WO 00/66604 and WO 99/14226).
[0328] In another embodiment, the invention features conjugates
and/or complexes of siNA molecules of the invention. Such
conjugates and/or complexes can be used to facilitate delivery of
siNA molecules into a biological system, such as a cell. The
conjugates and complexes provided by the instant invention can
impart therapeutic activity by transferring therapeutic compounds
across cellular membranes, altering the pharmacokinetics, and/or
modulating the localization of nucleic acid molecules of the
invention. The present invention encompasses the design and
synthesis of novel conjugates and complexes for the delivery of
molecules, including, but not limited to, small molecules, lipids,
cholesterol, phospholipids, nucleosides, nucleotides, nucleic
acids, antibodies, toxins, negatively charged polymers and other
polymers, for example proteins, peptides, hormones, carbohydrates,
polyethylene glycols, or polyamines, across cellular membranes. In
general, the transporters described are designed to be used either
individually or as part of a multi-component system, with or
without degradable linkers. These compounds are expected to improve
delivery and/or localization of nucleic acid molecules of the
invention into a number of cell types originating from different
tissues, in the presence or absence of serum (see Sullenger and
Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules
described herein can be attached to biologically active molecules
via linkers that are biodegradable, such as biodegradable nucleic
acid linker molecules.
[0329] The term "biodegradable linker" as used herein, refers to a
nucleic acid or non-nucleic acid linker molecule that is designed
as a biodegradable linker to connect one molecule to another
molecule, for example, a biologically active molecule to a siNA
molecule of the invention or the sense and antisense strands of a
siNA molecule of the invention. The biodegradable linker is
designed such that its stability can be modulated for a particular
purpose, such as delivery to a particular tissue or cell type. The
stability of a nucleic acid-based biodegradable linker molecule can
be modulated by using various chemistries, for example combinations
of ribonucleotides, deoxyribonucleotides, and chemically-modified
nucleotides, such as 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino,
2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified
nucleotides. The biodegradable nucleic acid linker molecule can be
a dimer, trimer, tetramer or longer nucleic acid molecule, for
example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or
can comprise a single nucleotide with a phosphorus-based linkage,
for example, a phosphoramidate or phosphodiester linkage. The
biodegradable nucleic acid linker molecule can also comprise
nucleic acid backbone, nucleic acid sugar, or nucleic acid base
modifications.
[0330] The term "biodegradable" as used herein, refers to
degradation in a biological system, for example enzymatic
degradation or chemical degradation.
[0331] The term "biologically active molecule" as used herein,
refers to compounds or molecules that are capable of eliciting or
modifying a biological response in a system. Non-limiting examples
of biologically active siNA molecules either alone or in
combination with other molecules contemplated by the instant
invention include therapeutically active molecules such as
antibodies, cholesterol, hormones, antivirals, peptides, proteins,
chemotherapeutics, small molecules, vitamins, co-factors,
nucleosides, nucleotides, oligonucleotides, enzymatic nucleic
acids, antisense nucleic acids, triplex forming oligonucleotides,
2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and
analogs thereof. Biologically active molecules of the invention
also include molecules capable of modulating the pharmacokinetics
and/or pharmacodynamics of other biologically active molecules, for
example, lipids and polymers such as polyamines, polyamides,
polyethylene glycol and other polyethers.
[0332] The term "phospholipid" as used herein, refers to a
hydrophobic molecule comprising at least one phosphorus group. For
example, a phospholipid can comprise a phosphorus-containing group
and saturated or unsaturated alkyl group, optionally substituted
with OH, COOH, oxo, amine, or substituted or unsubstituted aryl
groups.
[0333] Therapeutic nucleic acid molecules (e.g., siNA molecules)
delivered exogenously optimally are stable within cells until
reverse transcription of the RNA has been modulated long enough to
reduce the levels of the RNA transcript. The nucleic acid molecules
are resistant to nucleases in order to function as effective
intracellular therapeutic agents. Improvements in the chemical
synthesis of nucleic acid molecules described in the instant
invention and in the art have expanded the ability to modify
nucleic acid molecules by introducing nucleotide modifications to
enhance their nuclease stability as described above.
[0334] In yet another embodiment, siNA molecules having chemical
modifications that maintain or enhance enzymatic activity of
proteins involved in RNAi are provided. Such nucleic acids are also
generally more resistant to nucleases than unmodified nucleic
acids. Thus, in vitro and/or in vivo the activity should not be
significantly lowered.
[0335] Use of the nucleic acid-based molecules of the invention
will lead to better treatment of the disease progression by
affording the possibility of combination therapies (e.g., multiple
siNA molecules targeted to different genes; nucleic acid molecules
coupled with known small molecule modulators; or intermittent
treatment with combinations of molecules, including different
motifs and/or other chemical or biological molecules). The
treatment of subjects with siNA molecules can also include
combinations of different types of nucleic acid molecules, such as
enzymatic nucleic acid molecules (ribozymes), allozymes, antisense,
2,5-A oligoadenylate, decoys, and aptamers.
[0336] In another aspect a siNA molecule of the invention comprises
one or more 5' and/or a 3'-cap structure, for example on only the
sense siNA strand, the antisense siNA strand, or both siNA
strands.
[0337] By "cap structure" is meant chemical modifications, which
have been incorporated at either terminus of the oligonucleotide
(see, for example, Adamic et al., U.S. Pat. No. 5,998,203,
incorporated by reference herein). These terminal modifications
protect the nucleic acid molecule from exonuclease degradation, and
may help in delivery and/or localization within a cell. The cap may
be present at the 5'-terminus (5'-cap) or at the 3'-terminal
(3'-cap) or may be present on both termini. In non-limiting
examples, the 5'-cap includes, but is not limited to, glyceryl,
inverted deoxy abasic residue (moiety); 4',5'-methylene nucleotide;
1-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide;
carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide;
L-nucleotides; alpha-nucleotides; modified base nucleotide;
phosphorodithioate linkage; threo-pentofuranosyl nucleotide;
acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl
nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted
nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted
nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol
phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl
phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate;
or bridging or non-bridging methylphosphonate moiety.
[0338] Non-limiting examples of the 3'-cap include, but are not
limited to, glyceryl, inverted deoxy abasic residue (moiety),
4',5'-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide;
4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl
phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate;
6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl
phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide;
alpha-nucleotide; modified base nucleotide; phosphorodithioate;
threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide;
3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide,
5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety;
5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate;
5'-amino; bridging and/or non-bridging 5'-phosphoramidate,
phosphorothioate and/or phosphorodithioate, bridging or non
bridging methylphosphonate and 5'-mercapto moieties (for more
details see Beaucage and Iyer, 1993, Tetrahedron 49, 1925;
incorporated by reference herein).
[0339] By the term "non-nucleotide" is meant any group or compound
which can be incorporated into a nucleic acid chain in the place of
one or more nucleotide units, including either sugar and/or
phosphate substitutions, and allows the remaining bases to exhibit
their enzymatic activity. The group or compound is abasic in that
it does not contain a commonly recognized nucleotide base, such as
adenosine, guanine, cytosine, uracil or thymine and therefore lacks
a base at the 1'-position.
[0340] An "alkyl" group refers to a saturated aliphatic
hydrocarbon, including straight-chain, branched-chain, and cyclic
alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More
preferably, it is a lower alkyl of from 1 to 7 carbons, more
preferably 1 to 4 carbons. The alkyl group can be substituted or
unsubstituted. When substituted the substituted group(s) is
preferably, hydroxyl, cyano, alkoxy, .dbd.O, .dbd.S, NO.sub.2 or
N(CH.sub.3).sub.2, amino, or SH. The term also includes alkenyl
groups that are unsaturated hydrocarbon groups containing at least
one carbon-carbon double bond, including straight-chain,
branched-chain, and cyclic groups. Preferably, the alkenyl group
has 1 to 12 carbons. More preferably, it is a lower alkenyl of from
1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group
may be substituted or unsubstituted. When substituted the
substituted group(s) is preferably, hydroxyl, cyano, alkoxy,
.dbd.O, .dbd.S, NO.sub.2, halogen, N(CH.sub.3).sub.2, amino, or SH.
The term "alkyl" also includes alkynyl groups that have an
unsaturated hydrocarbon group containing at least one carbon-carbon
triple bond, including straight-chain, branched-chain, and cyclic
groups. Preferably, the alkynyl group has 1 to 12 carbons. More
preferably, it is a lower alkynyl of from 1 to 7 carbons, more
preferably 1 to 4 carbons. The alkynyl group may be substituted or
unsubstituted. When substituted the substituted group(s) is
preferably, hydroxyl, cyano, alkoxy, .dbd.O, .dbd.S, NO.sub.2 or
N(CH.sub.3).sub.2, amino or SH.
[0341] Such alkyl groups can also include aryl, alkylaryl,
carbocyclic aryl, heterocyclic aryl, amide and ester groups. An
"aryl" group refers to an aromatic group that has at least one ring
having a conjugated pi electron system and includes carbocyclic
aryl, heterocyclic aryl and biaryl groups, all of which may be
optionally substituted. The preferred substituent(s) of aryl groups
are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl,
alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to
an alkyl group (as described above) covalently joined to an aryl
group (as described above). Carbocyclic aryl groups are groups
wherein the ring atoms on the aromatic ring are all carbon atoms.
The carbon atoms are optionally substituted. Heterocyclic aryl
groups are groups having from 1 to 3 heteroatoms as ring atoms in
the aromatic ring and the remainder of the ring atoms are carbon
atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen,
and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl
pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all
optionally substituted. An "amide" refers to an --C(O)--NH--R,
where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester"
refers to an --C(O)--OR', where R is either alkyl, aryl, alkylaryl
or hydrogen.
[0342] By "nucleotide" as used herein is as recognized in the art
to include natural bases (standard), and modified bases well known
in the art. Such bases are generally located at the 1' position of
a nucleotide sugar moiety. Nucleotides generally comprise a base,
sugar and a phosphate group. The nucleotides can be unmodified or
modified at the sugar, phosphate and/or base moiety, (also referred
to interchangeably as nucleotide analogs, modified nucleotides,
non-natural nucleotides, non-standard nucleotides and other; see,
for example, Usman and McSwiggen, supra; Eckstein et al.,
International PCT Publication No. WO 92/07065; Usman et al.,
International PCT Publication No. WO 93/15187; Uhlman & Peyman,
supra, all are hereby incorporated by reference herein). There are
several examples of modified nucleic acid bases known in the art as
summarized by Limbach et al., 1994, Nucleic Acids Res. 22, 2183.
Some of the non-limiting examples of base modifications that can be
introduced into nucleic acid molecules include, inosine, purine,
pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4,
6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl,
aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine),
5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g.,
5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g.
6-methyluridine), propyne, and others (Burgin et al., 1996,
Biochemistry, 35, 14090; Uhlman & Peyman, supra). By "modified
bases" in this aspect is meant nucleotide bases other than adenine,
guanine, cytosine and uracil at 1' position or their
equivalents.
[0343] In one embodiment, the invention features modified siNA
molecules, with phosphate backbone modifications comprising one or
more phosphorothioate, phosphorodithioate, methylphosphonate,
phosphotriester, morpholino, amidate carbamate, carboxymethyl,
acetamidate, polyamide, sulfonate, sulfonamide, sulfamate,
formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a
review of oligonucleotide backbone modifications, see Hunziker and
Leumann, 1995, Nucleic Acid Analogues: Synthesis and Properties, in
Modern Synthetic Methods, VCH, 331-417, and Mesmaeker et al., 1994,
Novel Backbone Replacements for Oligonucleotides, in Carbohydrate
Modifications in Antisense Research, ACS, 24-39.
[0344] By "abasic" is meant sugar moieties lacking a base or having
other chemical groups in place of a base at the 1' position, see
for example Adamic et al., U.S. Pat. No. 5,998,203.
[0345] By "unmodified nucleoside" is meant one of the bases
adenine, cytosine, guanine, thymine, or uracil joined to the 1'
carbon of .beta.-D-ribo-furanose.
[0346] By "modified nucleoside" is meant any nucleotide base which
contains a modification in the chemical structure of an unmodified
nucleotide base, sugar and/or phosphate. Non-limiting examples of
modified nucleotides are shown by Formulae I-VII and/or other
modifications described herein.
[0347] In connection with 2'-modified nucleotides as described for
the present invention, by "amino" is meant 2'-NH.sub.2 or
2'-O--NH.sub.2, which can be modified or unmodified. Such modified
groups are described, for example, in Eckstein et al., U.S. Pat.
No. 5,672,695 and Matulic-Adamic et al., U.S. Pat. No. 6,248,878,
which are both incorporated by reference in their entireties.
[0348] Various modifications to nucleic acid siNA structure can be
made to enhance the utility of these molecules. Such modifications
will enhance shelf-life, half-life in vitro, stability, and ease of
introduction of such oligonucleotides to the target site, e.g., to
enhance penetration of cellular membranes, and confer the ability
to recognize and bind to targeted cells.
[0349] Administration of Nucleic Acid Molecules
[0350] A siNA molecule of the invention can be adapted for use to
treat, for example, variety of disease and conditions described
herein, such as proliferative diseases and conditions and/or cancer
including breast cancer, cancers of the head and neck including
various lymphomas such as mantle cell lymphoma, non-Hodgkins
lymphoma, adenoma, squamous cell carcinoma, laryngeal carcinoma,
cancers of the retina, cancers of the esophagus, multiple myeloma,
ovarian cancer, uterine cancer, melanoma, colorectal cancer, lung
cancer, bladder cancer, prostate cancer, glioblastoma, lung cancer
(including non-small cell lung carcinoma), pancreatic cancer,
cervical cancer, head and neck cancer, skin cancers, nasopharyngeal
carcinoma, liposarcoma, epithelial carcinoma, renal cell carcinoma,
gallbladder adeno carcinoma, parotid adenocarcinoma, endometrial
sarcoma, multidrug resistant cancers; and proliferative diseases
and conditions, such as neovascularization associated with tumor
angiogenesis, macular degeneration (e.g., wet/dry AMD), corneal
neovascularization, diabetic retinopathy, neovascular glaucoma,
myopic degeneration and other proliferative diseases and conditions
such as restenosis and polycystic kidney disease, and any other
diseases or conditions that are related to or will respond to the
levels of VEGF and/or VEGFr in a cell or tissue, alone or in
combination with other therapies. For example, a siNA molecule can
comprise a delivery vehicle, including liposomes, for
administration to a subject, carriers and diluents and their salts,
and/or can be present in pharmaceutically acceptable formulations.
Methods for the delivery of nucleic acid molecules are described in
Akhtar et al., 1992, Trends Cell Bio., 2, 139; Delivery Strategies
for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995,
Maurer et al., 1999, Mol. Membr. Biol., 16, 129-140; Hofland and
Huang, 1999, Handb. Exp. Pharmacol., 137, 165-192; and Lee et al.,
2000, ACS Symp. Ser., 752, 184-192, all of which are incorporated
herein by reference. Beigelman et al., U.S. Pat. No. 6,395,713 and
Sullivan et al., PCT WO 94/02595 further describe the general
methods for delivery of nucleic acid molecules. These protocols can
be utilized for the delivery of virtually any nucleic acid
molecule. Nucleic acid molecules can be administered to cells by a
variety of methods known to those of skill in the art, including,
but not restricted to, encapsulation in liposomes, by
iontophoresis, or by incorporation into other vehicles, such as
biodegradable polymers, hydrogels, cyclodextrins (see for example
Gonzalez et al., 1999, Bioconjugate Chem., 10, 1068-1074; Wang et
al., International PCT publication Nos. WO 03/47518 and WO
03/46185), poly(lactic-co-glycolic)acid (PLGA) and PLCA
microspheres (see for example U.S. Pat. No. 6,447,796 and US Patent
Application Publication No. U.S. 2002130430), biodegradable
nanocapsules, and bioadhesive microspheres, or by proteinaceous
vectors (O'Hare and Normand, International PCT Publication No. WO
00/53722). In another embodiment, the nucleic acid molecules of the
invention can also be formulated or complexed with
polyethyleneimine and derivatives thereof, such as
polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine
(PEI-PEG-GAL) or
polyethyleneimine-polyethyleneglycol-tri-N-acetylgalacto- samine
(PEI-PEG-triGAL) derivatives. Alternatively, the nucleic
acid/vehicle combination is locally delivered by direct injection
or by use of an infusion pump.
[0351] In one embodiment, a siNA molecule of the invention is
designed or formulated to specifically target endothelial cells or
tumor cells. For example, various formulations and conjugates can
be utilized to specifically target endothelial cells or tumor
cells, including PEI-PEG-folate, PEI-PEG-RGD, PEI-PEG-biotin,
PEI-PEG-cholesterol, and other conjugates known in the art that
enable specific targeting to endothelial cells and/or tumor
cells.
[0352] In one embodiment, a compound, molecule, or composition for
the treatment of ocular conditions (e.g., macular degeneration,
diabetic retinopathy etc.) is administered to a subject
intraocularly or by intraocular means. In another embodiment, a
compound, molecule, or composition for the treatment of ocular
conditions (e.g., macular degeneration, diabetic retinopathy etc.)
is administered to a subject periocularly or by periocular means
(see for example Ahlheim et al., International PCT publication No.
WO 03/24420). In one embodiment, a siNA molecule and/or formulation
or composition thereof is administered to a subject intraocularly
or by intraocular means. In another embodiment, a siNA molecule
and/or formualtion or composition thereof is administered to a
subject periocularly or by periocular means. Periocular
administration generally provides a less invasive approach to
administering siNA molecules and formualtion or composition thereof
to a subject (see for example Ahlheim et al., International PCT
publication No. WO 03/24420). The use of periocular administraction
also minimizes the risk of retinal detachment, allows for more
frequent dosing or administraction, provides a clinically relevant
route of administraction for macular degeneration and other optic
conditions, and also provides the possiblilty of using resevoirs
(e.g., implants, pumps or other devices) for drug delivery.
[0353] In one embodiment, the nucleic acid molecules or the
invention are administered to the CNS. Experiments have
demonstrated the efficient in vivo uptake of nucleic acids by
neurons. As an example of local administration of nucleic acids to
nerve cells, Sommer et al., 1998, Antisense Nuc. Acid Drug Dev., 8,
75, describe a study in which a 15mer phosphorothioate antisense
nucleic acid molecule to c-fos is administered to rats via
microinjection into the brain. Antisense molecules labeled with
tetramethylrhodamine-isothiocyanate (TRITC) or fluorescein
isothiocyanate (FITC) were taken up by exclusively by neurons
thirty minutes post-injection. A diffuse cytoplasmic staining and
nuclear staining was observed in these cells. As an example of
systemic administration of nucleic acid to nerve cells, Epa et al.,
2000, Antisense Nuc. Acid Drug Dev., 10, 469, describe an in vivo
mouse study in which beta-cyclodextrin-adamantane-oligonucleotide
conjugates were used to target the p75 neurotrophin receptor in
neuronally differentiated PC12 cells. Following a two week course
of IP administration, pronounced uptake of p75 neurotrophin
receptor antisense was observed in dorsal root ganglion (DRG)
cells. In addition, a marked and consistent down-regulation of p75
was observed in DRG neurons. Additional approaches to the targeting
of nucleic acid to neurons are described in Broaddus et al., 1998,
J. Neurosurg., 88(4), 734; Karle et al., 1997, Eur. J. Pharmocol.,
340(2/3), 153; Bannai et al., 1998, Brain Research, 784(1,2), 304;
Rajakumar et al., 1997, Synapse, 26(3), 199; Wu-pong et al., 1999,
BioPharm, 12(1), 32; Bannai et al., 1998, Brain Res. Protoc., 3(1),
83; Simantov et al., 1996, Neuroscience, 74(1), 39. Nucleic acid
molecules of the invention are therefore amenable to delivery to
and uptake by cells that express VEGF and/or VEGFr for modulation
of VEGF and/or VEGFr gene expression. The delivery of nucleic acid
molecules of the invention, targeting VEGF and/or VEGFr is provided
by a variety of different strategies. Traditional approaches to CNS
delivery that can be used include, but are not limited to,
intrathecal and intracerebroventricular administration,
implantation of catheters and pumps, direct injection or perfusion
at the site of injury or lesion, injection into the brain arterial
system, or by chemical or osmotic opening of the blood-brain
barrier. Other approaches can include the use of various transport
and carrier systems, for example though the use of conjugates and
biodegradable polymers. Furthermore, gene therapy approaches, for
example as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and
Davidson, WO 04/013280, can be used to express nucleic acid
molecules in the CNS.
[0354] In one embodiment, the nucleic acid molecules or the
invention are administered via pulmonary delivery, such as by
inhalation of an aerosol or spray dried formulation administered by
an inhalation device or nebulizer, providing rapid local uptake of
the nucleic acid molecules into relevant pulmonary tissues. Solid
particulate compositions containing respirable dry particles of
micronized nucleic acid compositions can be prepared by grinding
dried or lyophilized nucleic acid compositions, and then passing
the micronized composition through, for example, a 400 mesh screen
to break up or separate out large agglomerates. A solid particulate
composition comprising the nucleic acid compositions of the
invention can optionally contain a dispersant which serves to
facilitate the formation of an aerosol as well as other therapeutic
compounds. A suitable dispersant is lactose, which can be blended
with the nucleic acid compound in any suitable ratio, such as a 1
to 1 ratio by weight. Aerosols of liquid particles comprising a
nucleic acid composition of the invention can be produced by any
suitable means, such as with a nebulizer (see for example U.S. Pat.
No. 4,501,729). Nebulizers are commercially available devices which
transform solutions or suspensions of an active ingredient into a
therapeutic aerosol mist either by means of acceleration of a
compressed gas, typically air or oxygen, through a narrow venturi
orifice or by means of ultrasonic agitation. Suitable formulations
for use in nebulizers comprise the active ingredient in a liquid
carrier in an amount of up to 40% w/w preferably less than 20% w/w
of the formulation. The carrier is typically water or a dilute
aqueous alcoholic solution, preferably made isotonic with body
fluids by the addition of, for example, sodium chloride or other
suitable salts. Optional additives include preservatives if the
formulation is not prepared sterile, for example, methyl
hydroxybenzoate, anti-oxidants, flavorings, volatile oils,
buffering agents and emulsifiers and other formulation surfactants.
The aerosols of solid particles comprising the active composition
and surfactant can likewise be produced with any solid particulate
aerosol generator. Aerosol generators for administering solid
particulate therapeutics to a subject produce particles which are
respirable, as explained above, and generate a volume of aerosol
containing a predetermined metered dose of a therapeutic
composition at a rate suitable for human administration. One
illustrative type of solid particulate aerosol generator is an
insufflator. Suitable formulations for administration by
insufflation include finely comminuted powders which can be
delivered by means of an insufflator. In the insufflator, the
powder, e.g., a metered dose thereof effective to carry out the
treatments described herein, is contained in capsules or
cartridges, typically made of gelatin or plastic, which are either
pierced or opened in situ and the powder delivered by air drawn
through the device upon inhalation or by means of a
manually-operated pump. The powder employed in the insufflator
consists either solely of the active ingredient or of a powder
blend comprising the active ingredient, a suitable powder diluent,
such as lactose, and an optional surfactant. The active ingredient
typically comprises from 0.1 to 100 w/w of the formulation. A
second type of illustrative aerosol generator comprises a metered
dose inhaler. Metered dose inhalers are pressurized aerosol
dispensers, typically containing a suspension or solution
formulation of the active ingredient in a liquified propellant.
During use these devices discharge the formulation through a valve
adapted to deliver a metered volume to produce a fine particle
spray containing the active ingredient. Suitable propellants
include certain chlorofluorocarbon compounds, for example,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane and mixtures thereof. The formulation can
additionally contain one or more co-solvents, for example, ethanol,
emulsifiers and other formulation surfactants, such as oleic acid
or sorbitan trioleate, anti-oxidants and suitable flavoring agents.
Other methods for pulmonary delivery are described in, for example
US Patent Application No. 20040037780, and U.S. Pat. Nos.
6,592,904; 6,582,728; 6,565,885.
[0355] In one embodiment, a siNA molecule of the invention is
complexed with membrane disruptive agents such as those described
in U.S. Patent Appliaction Publication No. 20010007666,
incorporated by reference herein in its entirety including the
drawings. In another embodiment, the membrane disruptive agent or
agents and the siNA molecule are also complexed with a cationic
lipid or helper lipid molecule, such as those lipids described in
U.S. Pat. No. 6,235,310, incorporated by reference herein in its
entirety including the drawings.
[0356] Thus, the invention features a pharmaceutical composition
comprising one or more nucleic acid(s) of the invention in an
acceptable carrier, such as a stabilizer, buffer, and the like. The
polynucleotides of the invention can be administered (e.g., RNA,
DNA or protein) and introduced into a subject by any standard
means, with or without stabilizers, buffers, and the like, to form
a pharmaceutical composition. When it is desired to use a liposome
delivery mechanism, standard protocols for formation of liposomes
can be followed. The compositions of the present invention can also
be formulated and used as tablets, capsules or elixirs for oral
administration, suppositories for rectal administration, sterile
solutions, suspensions for injectable administration, and the other
compositions known in the art.
[0357] The present invention also includes pharmaceutically
acceptable formulations of the compounds described. These
formulations include salts of the above compounds, e.g., acid
addition salts, for example, salts of hydrochloric, hydrobromic,
acetic acid, and benzene sulfonic acid.
[0358] A pharmacological composition or formulation refers to a
composition or formulation in a form suitable for administration,
e.g., systemic administration, into a cell or subject, including
for example a human. Suitable forms, in part, depend upon the use
or the route of entry, for example oral, transdermal, or by
injection. Such forms should not prevent the composition or
formulation from reaching a target cell (i.e., a cell to which the
negatively charged nucleic acid is desirable for delivery). For
example, pharmacological compositions injected into the blood
stream should be soluble. Other factors are known in the art, and
include considerations such as toxicity and forms that prevent the
composition or formulation from exerting its effect.
[0359] By "systemic administration" is meant in vivo systemic
absorption or accumulation of drugs in the blood stream followed by
distribution throughout the entire body. Administration routes that
lead to systemic absorption include, without limitation:
intravenous, subcutaneous, intraperitoneal, inhalation, oral,
intrapulmonary and intramuscular. Each of these administration
routes exposes the siNA molecules of the invention to an accessible
diseased tissue. The rate of entry of a drug into the circulation
has been shown to be a function of molecular weight or size. The
use of a liposome or other drug carrier comprising the compounds of
the instant invention can potentially localize the drug, for
example, in certain tissue types, such as the tissues of the
reticular endothelial system (RES). A liposome formulation that can
facilitate the association of drug with the surface of cells, such
as, lymphocytes and macrophages is also useful. This approach can
provide enhanced delivery of the drug to target cells by taking
advantage of the specificity of macrophage and lymphocyte immune
recognition of abnormal cells, such as cells producing excess VEGF
and/or VEGFr genes.
[0360] By "pharmaceutically acceptable formulation" is meant, a
composition or formulation that allows for the effective
distribution of the nucleic acid molecules of the instant invention
in the physical location most suitable for their desired activity.
Non-limiting examples of agents suitable for formulation with the
nucleic acid molecules of the instant invention include:
P-glycoprotein inhibitors (such as Pluronic P85),; biodegradable
polymers, such as poly (DL-lactide-coglycolide) microspheres for
sustained release delivery (Emerich, D F et al, 1999, Cell
Transplant, 8, 47-58); and loaded nanoparticles, such as those made
of polybutylcyanoacrylate. Other non-limiting examples of delivery
strategies for the nucleic acid molecules of the instant invention
include material described in Boado et al., 1998, J. Pharm. Sci.,
87, 1308-1315; Tyler et al., 1999, FEBS Lett., 421, 280-284;
Pardridge et al., 1995, PNAS USA., 92, 5592-5596; Boado, 1995, Adv.
Drug Delivery Rev., 15, 73-107; Aldrian-Herrada et al., 1998,
Nucleic Acids Res., 26, 4910-4916; and Tyler et al., 1999, PNAS
USA., 96, 7053-7058.
[0361] The invention also features the use of the composition
comprising surface-modified liposomes containing poly (ethylene
glycol) lipids (PEG-modified, or long-circulating liposomes or
stealth liposomes). These formulations offer a method for
increasing the accumulation of drugs in target tissues. This class
of drug carriers resists opsonization and elimination by the
mononuclear phagocytic system (MPS or RES), thereby enabling longer
blood circulation times and enhanced tissue exposure for the
encapsulated drug (Lasic et al. Chem. Rev. 1995, 95, 2601-2627;
Ishiwata et al., Chem. Pharm. Bull. 1995, 43, 1005-1011). Such
liposomes have been shown to accumulate selectively in tumors,
presumably by extravasation and capture in the neovascularized
target tissues (Lasic et al., Science 1995, 267, 1275-1276; Oku et
al., 1995, Biochim. Biophys. Acta, 1238, 86-90). The
long-circulating liposomes enhance the pharmacokinetics and
pharmacodynamics of DNA and RNA, particularly compared to
conventional cationic liposomes which are known to accumulate in
tissues of the MPS (Liu et al., J. Biol. Chem. 1995, 42,
24864-24870; Choi et al., International PCT Publication No. WO
96/10391; Ansell et al., International PCT Publication No. WO
96/10390; Holland et al., International PCT Publication No. WO
96/10392). Long-circulating liposomes are also likely to protect
drugs from nuclease degradation to a greater extent compared to
cationic liposomes, based on their ability to avoid accumulation in
metabolically aggressive MPS tissues such as the liver and
spleen.
[0362] The present invention also includes compositions prepared
for storage or administration that include a pharmaceutically
effective amount of the desired compounds in a pharmaceutically
acceptable carrier or diluent. Acceptable carriers or diluents for
therapeutic use are well known in the pharmaceutical art, and are
described, for example, in Remington's Pharmaceutical Sciences,
Mack Publishing Co. (A. R. Gennaro edit. 1985), hereby incorporated
by reference herein. For example, preservatives, stabilizers, dyes
and flavoring agents can be provided. These include sodium
benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In
addition, antioxidants and suspending agents can be used.
[0363] A pharmaceutically effective dose is that dose required to
prevent, inhibit the occurrence, or treat (alleviate a symptom to
some extent, preferably all of the symptoms) of a disease state.
The pharmaceutically effective dose depends on the type of disease,
the composition used, the route of administration, the type of
mammal being treated, the physical characteristics of the specific
mammal under consideration, concurrent medication, and other
factors that those skilled in the medical arts will recognize.
Generally, an amount between 0.1 mg/kg and 100 mg/kg body
weight/day of active ingredients is administered dependent upon
potency of the negatively charged polymer.
[0364] The nucleic acid molecules of the invention and formulations
thereof can be administered orally, topically, parenterally, by
inhalation or spray, or rectally in dosage unit formulations
containing conventional non-toxic pharmaceutically acceptable
carriers, adjuvants and/or vehicles. The term parenteral as used
herein includes percutaneous, subcutaneous, intravascular (e.g.,
intravenous), intramuscular, or intrathecal injection or infusion
techniques and the like. In addition, there is provided a
pharmaceutical formulation comprising a nucleic acid molecule of
the invention and a pharmaceutically acceptable carrier. One or
more nucleic acid molecules of the invention can be present in
association with one or more non-toxic pharmaceutically acceptable
carriers and/or diluents and/or adjuvants, and if desired other
active ingredients. The pharmaceutical compositions containing
nucleic acid molecules of the invention can be in a form suitable
for oral use, for example, as tablets, troches, lozenges, aqueous
or oily suspensions, dispersible powders or granules, emulsion,
hard or soft capsules, or syrups or elixirs.
[0365] Compositions intended for oral use can be prepared according
to any method known to the art for the manufacture of
pharmaceutical compositions and such compositions can contain one
or more such sweetening agents, flavoring agents, coloring agents
or preservative agents in order to provide pharmaceutically elegant
and palatable preparations. Tablets contain the active ingredient
in admixture with non-toxic pharmaceutically acceptable excipients
that are suitable for the manufacture of tablets. These excipients
can be, for example, inert diluents; such as calcium carbonate,
sodium carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, corn starch, or
alginic acid; binding agents, for example starch, gelatin or
acacia; and lubricating agents, for example magnesium stearate,
stearic acid or talc. The tablets can be uncoated or they can be
coated by known techniques. In some cases such coatings can be
prepared by known techniques to delay disintegration and absorption
in the gastrointestinal tract and thereby provide a sustained
action over a longer period. For example, a time delay material
such as glyceryl monosterate or glyceryl distearate can be
employed.
[0366] Formulations for oral use can also be presented as hard
gelatin capsules wherein the active ingredient is mixed with an
inert solid diluent, for example, calcium carbonate, calcium
phosphate or kaolin, or as soft gelatin capsules wherein the active
ingredient is mixed with water or an oil medium, for example peanut
oil, liquid paraffin or olive oil.
[0367] Aqueous suspensions contain the active materials in a
mixture with excipients suitable for the manufacture of aqueous
suspensions. Such excipients are suspending agents, for example
sodium carboxymethylcellulose, methylcellulose,
hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone,
gum tragacanth and gum acacia; dispersing or wetting agents can be
a naturally-occurring phosphatide, for example, lecithin, or
condensation products of an alkylene oxide with fatty acids, for
example polyoxyethylene stearate, or condensation products of
ethylene oxide with long chain aliphatic alcohols, for example
heptadecaethyleneoxycetanol, or condensation products of ethylene
oxide with partial esters derived from fatty acids and a hexitol
such as polyoxyethylene sorbitol monooleate, or condensation
products of ethylene oxide with partial esters derived from fatty
acids and hexitol anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions can also contain one or more
preservatives, for example ethyl, or n-propyl p-hydroxybenzoate,
one or more coloring agents, one or more flavoring agents, and one
or more sweetening agents, such as sucrose or saccharin.
[0368] Oily suspensions can be formulated by suspending the active
ingredients in a vegetable oil, for example arachis oil, olive oil,
sesame oil or coconut oil, or in a mineral oil such as liquid
paraffin. The oily suspensions can contain a thickening agent, for
example beeswax, hard paraffin or cetyl alcohol. Sweetening agents
and flavoring agents can be added to provide palatable oral
preparations. These compositions can be preserved by the addition
of an anti-oxidant such as ascorbic acid.
[0369] Dispersible powders and granules suitable for preparation of
an aqueous suspension by the addition of water provide the active
ingredient in admixture with a dispersing or wetting agent,
suspending agent and one or more preservatives. Suitable dispersing
or wetting agents or suspending agents are exemplified by those
already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, can also be present.
[0370] Pharmaceutical compositions of the invention can also be in
the form of oil-in-water emulsions. The oily phase can be a
vegetable oil or a mineral oil or mixtures of these. Suitable
emulsifying agents can be naturally-occurring gums, for example gum
acacia or gum tragacanth, naturally-occurring phosphatides, for
example soy bean, lecithin, and esters or partial esters derived
from fatty acids and hexitol, anhydrides, for example sorbitan
monooleate, and condensation products of the said partial esters
with ethylene oxide, for example polyoxyethylene sorbitan
monooleate. The emulsions can also contain sweetening and flavoring
agents.
[0371] Syrups and elixirs can be formulated with sweetening agents,
for example glycerol, propylene glycol, sorbitol, glucose or
sucrose. Such formulations can also contain a demulcent, a
preservative and flavoring and coloring agents. The pharmaceutical
compositions can be in the form of a sterile injectable aqueous or
oleaginous suspension. This suspension can be formulated according
to the known art using those suitable dispersing or wetting agents
and suspending agents that have been mentioned above. The sterile
injectable preparation can also be a sterile injectable solution or
suspension in a non-toxic parentally acceptable diluent or solvent,
for example as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that can be employed are water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose, any bland fixed oil can be
employed including synthetic mono-or diglycerides. In addition,
fatty acids such as oleic acid find use in the preparation of
injectables.
[0372] The nucleic acid molecules of the invention can also be
administered in the form of suppositories, e.g., for rectal
administration of the drug. These compositions can be prepared by
mixing the drug with a suitable non-irritating excipient that is
solid at ordinary temperatures but liquid at the rectal temperature
and will therefore melt in the rectum to release the drug. Such
materials include cocoa butter and polyethylene glycols.
[0373] Nucleic acid molecules of the invention can be administered
parenterally in a sterile medium. The drug, depending on the
vehicle and concentration used, can either be suspended or
dissolved in the vehicle. Advantageously, adjuvants such as local
anesthetics, preservatives and buffering agents can be dissolved in
the vehicle.
[0374] Dosage levels of the order of from about 0.1 mg to about 140
mg per kilogram of body weight per day are useful in the treatment
of the above-indicated conditions (about 0.5 mg to about 7 g per
subject per day). The amount of active ingredient that can be
combined with the carrier materials to produce a single dosage form
varies depending upon the host treated and the particular mode of
administration. Dosage unit forms generally contain between from
about 1 mg to about 500 mg of an active ingredient.
[0375] It is understood that the specific dose level for any
particular subject depends upon a variety of factors including the
activity of the specific compound employed, the age, body weight,
general health, sex, diet, time of administration, route of
administration, and rate of excretion, drug combination and the
severity of the particular disease undergoing therapy.
[0376] For administration to non-human animals, the composition can
also be added to the animal feed or drinking water. It can be
convenient to formulate the animal feed and drinking water
compositions so that the animal takes in a therapeutically
appropriate quantity of the composition along with its diet. It can
also be convenient to present the composition as a premix for
addition to the feed or drinking water.
[0377] The nucleic acid molecules of the present invention can also
be administered to a subject in combination with other therapeutic
compounds to increase the overall therapeutic effect. The use of
multiple compounds to treat an indication can increase the
beneficial effects while reducing the presence of side effects.
[0378] In one embodiment, the invention comprises compositions
suitable for administering nucleic acid molecules of the invention
to specific cell types. For example, the asialoglycoprotein
receptor (ASGPr) (Wu and Wu, 1987, J. Biol. Chem. 262, 4429-4432)
is unique to hepatocytes and binds branched galactose-terminal
glycoproteins, such as asialoorosomucoid (ASOR). In another
example, the folate receptor is overexpressed in many cancer cells.
Binding of such glycoproteins, synthetic glycoconjugates, or
folates to the receptor takes place with an affinity that strongly
depends on the degree of branching of the oligosaccharide chain,
for example, triatennary structures are bound with greater affinity
than biatenarry or monoatennary chains (Baenziger and Fiete, 1980,
Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem., 257,
939-945). Lee and Lee, 1987, Glycoconjugate J., 4, 317-328,
obtained this high specificity through the use of
N-acetyl-D-galactosamine as the carbohydrate moiety, which has
higher affinity for the receptor, compared to galactose. This
"clustering effect" has also been described for the binding and
uptake of mannosyl-terminating glycoproteins or glycoconjugates
(Ponpipom et al., 1981, J. Med. Chem., 24, 1388-1395). The use of
galactose, galactosamine, or folate based conjugates to transport
exogenous compounds across cell membranes can provide a targeted
delivery approach to, for example, the treatment of liver disease,
cancers of the liver, or other cancers. The use of bioconjugates
can also provide a reduction in the required dose of therapeutic
compounds required for treatment. Furthermore, therapeutic
bioavialability, pharmacodynamics, and pharmacokinetic parameters
can be modulated through the use of nucleic acid bioconjugates of
the invention. Non-limiting examples of such bioconjugates are
described in Vargeese et al., U.S. Ser. No. 10/201,394, filed Aug.
13, 2001; and Matulic-Adamic et al., U.S. Ser. No. 10/151,116,
filed May 17, 2002. In one embodiment, nucleic acid molecules of
the invention are complexed with or covalently attached to
nanoparticles, such as Hepatitis B virus S, M, or L evelope
proteins (see for example Yamado et al., 2003, Nature
Biotechnology, 21, 885). In one embodiment, nucleic acid molecules
of the invention are delivered with specificity for human tumor
cells, specifically non-apoptotic human tumor cells including for
example T-cells, hepatocytes, breast carcinoma cells, ovarian
carcinoma cells, melanoma cells, intestinal epithelial cells,
prostate cells, testicular cells, non-small cell lung cancers,
small cell lung cancers, etc.
[0379] Alternatively, certain siNA molecules of the instant
invention can be expressed within cells from eukaryotic promoters
(e.g., Izant and Weintraub, 1985, Science, 229, 345; McGarry and
Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399; Scanlon et
al., 1991, Proc. Natl. Acad. Sci. USA, 88, 10591-5; Kashani-Sabet
et al., 1992, Antisense Res. Dev., 2, 3-15; Dropulic et al., 1992,
J. Virol., 66, 1432-41; Weerasinghe et al., 1991, J. Virol., 65,
5531-4; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89,
10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Sarver
et al., 1990 Science, 247, 1222-1225; Thompson et al., 1995,
Nucleic Acids Res., 23, 2259; Good et al., 1997, Gene Therapy, 4,
45. Those skilled in the art realize that any nucleic acid can be
expressed in eukaryotic cells from the appropriate DNA/RNA vector.
The activity of such nucleic acids can be augmented by their
release from the primary transcript by a enzymatic nucleic acid
(Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO
94/02595; Ohkawa et al., 1992, Nucleic Acids Symp. Ser., 27, 15-6;
Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura et
al., 1993, Nucleic Acids Res., 21, 3249-55; Chowrira et al., 1994,
J. Biol. Chem., 269, 25856.
[0380] In another aspect of the invention, RNA molecules of the
present invention can be expressed from transcription units (see
for example Couture et al., 1996, TIG., 12, 510) inserted into DNA
or RNA vectors. The recombinant vectors can be DNA plasmids or
viral vectors. siNA expressing viral vectors can be constructed
based on, but not limited to, adeno-associated virus, retrovirus,
adenovirus, or alphavirus. In another embodiment, pol III based
constructs are used to express nucleic acid molecules of the
invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and
6,146,886). The recombinant vectors capable of expressing the siNA
molecules can be delivered as described above, and persist in
target cells. Alternatively, viral vectors can be used that provide
for transient expression of nucleic acid molecules. Such vectors
can be repeatedly administered as necessary. Once expressed, the
siNA molecule interacts with the target mRNA and generates an RNAi
response. Delivery of siNA molecule expressing vectors can be
systemic, such as by intravenous or intra-muscular administration,
by administration to target cells ex-planted from a subject
followed by reintroduction into the subject, or by any other means
that would allow for introduction into the desired target cell (for
a review see Couture et al., 1996, TIG., 12, 510).
[0381] In one aspect the invention features an expression vector
comprising a nucleic acid sequence encoding at least one siNA
molecule of the instant invention. The expression vector can encode
one or both strands of a siNA duplex, or a single
self-complementary strand that self hybridizes into a siNA duplex.
The nucleic acid sequences encoding the siNA molecules of the
instant invention can be operably linked in a manner that allows
expression of the siNA molecule (see for example Paul et al., 2002,
Nature Biotechnology, 19, 505; Miyagishi and Taira, 2002, Nature
Biotechnology, 19, 497; Lee et al., 2002, Nature Biotechnology, 19,
500; and Novina et al., 2002, Nature Medicine, advance online
publication doi:10.1038/nm725).
[0382] In another aspect, the invention features an expression
vector comprising: a) a transcription initiation region (e.g.,
eukaryotic pol I, II or III initiation region); b) a transcription
termination region (e.g., eukaryotic pol I, II or III termination
region); and c) a nucleic acid sequence encoding at least one of
the siNA molecules of the instant invention, wherein said sequence
is operably linked to said initiation region and said termination
region in a manner that allows expression and/or delivery of the
siNA molecule. The vector can optionally include an open reading
frame (ORF) for a protein operably linked on the 5' side or the
3'-side of the sequence encoding the siNA of the invention; and/or
an intron (intervening sequences).
[0383] Transcription of the siNA molecule sequences can be driven
from a promoter for eukaryotic RNA polymerase I (pol I), RNA
polymerase II (pol II), or RNA polymerase III (pol III).
Transcripts from pol II or pol III promoters are expressed at high
levels in all cells; the levels of a given pol II promoter in a
given cell type depends on the nature of the gene regulatory
sequences (enhancers, silencers, etc.) present nearby. Prokaryotic
RNA polymerase promoters are also used, providing that the
prokaryotic RNA polymerase enzyme is expressed in the appropriate
cells (Elroy-Stein and Moss, 1990, Proc. Natl. Acad. Sci. USA, 87,
6743-7; Gao and Huang 1993, Nucleic Acids Res., 21, 2867-72; Lieber
et al., 1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990, Mol.
Cell. Biol., 10, 4529-37). Several investigators have demonstrated
that nucleic acid molecules expressed from such promoters can
function in mammalian cells (e.g. Kashani-Sabet et al., 1992,
Antisense Res. Dev., 2, 3-15; Ojwang et al., 1992, Proc. Natl.
Acad. Sci. USA, 89, 10802-6; Chen et al., 1992, Nucleic Acids Res.,
20, 4581-9; Yu et al., 1993, Proc. Natl. Acad. Sci. USA, 90,
6340-4; L'Huillier et al., 1992, EMBO J, 11, 4411-8; Lisziewicz et
al., 1993, Proc. Natl. Acad. Sci. U.S. A, 90, 8000-4; Thompson et
al., 1995, Nucleic Acids Res., 23, 2259; Sullenger & Cech,
1993, Science, 262, 1566). More specifically, transcription units
such as the ones derived from genes encoding U6 small nuclear
(snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in
generating high concentrations of desired RNA molecules such as
siNA in cells (Thompson et al., supra; Couture and Stinchcomb,
1996, supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830;
Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, Gene
Ther., 4, 45; Beigelman et al., International PCT Publication No.
WO 96/18736. The above siNA transcription units can be incorporated
into a variety of vectors for introduction into mammalian cells,
including but not restricted to, plasmid DNA vectors, viral DNA
vectors (such as adenovirus or adeno-associated virus vectors), or
viral RNA vectors (such as retroviral or alphavirus vectors) (for a
review see Couture and Stinchcomb, 1996, supra).
[0384] In another aspect the invention features an expression
vector comprising a nucleic acid sequence encoding at least one of
the siNA molecules of the invention in a manner that allows
expression of that siNA molecule. The expression vector comprises
in one embodiment; a) a transcription initiation region; b) a
transcription termination region; and c) a nucleic acid sequence
encoding at least one strand of the siNA molecule, wherein the
sequence is operably linked to the initiation region and the
termination region in a manner that allows expression and/or
delivery of the siNA molecule.
[0385] In another embodiment the expression vector comprises: a) a
transcription initiation region; b) a transcription termination
region; c) an open reading frame; and d) a nucleic acid sequence
encoding at least one strand of a siNA molecule, wherein the
sequence is operably linked to the 3'-end of the open reading frame
and wherein the sequence is operably linked to the initiation
region, the open reading frame and the termination region in a
manner that allows expression and/or delivery of the siNA molecule.
In yet another embodiment, the expression vector comprises: a) a
transcription initiation region; b) a transcription termination
region; c) an intron; and d) a nucleic acid sequence encoding at
least one siNA molecule, wherein the sequence is operably linked to
the initiation region, the intron and the termination region in a
manner which allows expression and/or delivery of the nucleic acid
molecule.
[0386] In another embodiment, the expression vector comprises: a) a
transcription initiation region; b) a transcription termination
region; c) an intron; d) an open reading frame; and e) a nucleic
acid sequence encoding at least one strand of a siNA molecule,
wherein the sequence is operably linked to the 3'-end of the open
reading frame and wherein the sequence is operably linked to the
initiation region, the intron, the open reading frame and the
termination region in a manner which allows expression and/or
delivery of the siNA molecule.
[0387] VEGF/VEGFr Biology and Biochemistry
[0388] The following discussion is adapted from R&D Systems,
Cytokine Mini Reviews, Vascular Endothelial Growth Factor (VEGF),
Copyright .COPYRGT.2002 R&D Systems. Angiogenesis is a process
of new blood vessel development from pre-existing vasculature. It
plays an essential role in embryonic development, normal growth of
tissues, wound healing, the female reproductive cycle (i.e.,
ovulation, menstruation and placental development), as well as a
major role in many diseases. Particular interest has focused on
cancer, since tumors cannot grow beyond a few millimeters in size
without developing a new blood supply. Angiogenesis is also
necessary for the spread and growth of tumor cell metastases.
[0389] One of the most important growth and survival factors for
endothelium is vascular endothelial growth factor (VEGF). VEGF
induces angiogenesis and endothelial cell proliferation and plays
an important role in regulating vasculogenesis. VEGF is a
heparin-binding glycoprotein that is secreted as a homodimer of 45
kDa. Most types of cells, but usually not endothelial cells
themselves, secrete VEGF. Since the initially discovered VEGF,
VEGF-A, increases vascular permeability, it was known as vascular
permeability factor. In addition, VEGF causes vasodilatation,
partly through stimulation of nitric oxide synthase in endothelial
cells. VEGF can also stimulate cell migration and inhibit
apoptosis.
[0390] There are several splice variants of VEGF-A. The major ones
include: 121, 165, 189 and 206 amino acids (aa), each one
comprising a specific exon addition. VEGF165 is the most
predominant protein, but transcripts of VEGF 121 may be more
abundant. VEGF206 is rarely expressed and has been detected only in
fetal liver. Recently, other splice variants of 145 and 183 aa have
also been described. The 165, 189 and 206 aa splice variants have
heparin-binding domains, which help anchor them in extracellular
matrix and are involved in binding to heparin sulfate and
presentation to VEGF receptors. Such presentation is a key factor
for VEGF potency (i.e., the heparin-binding forms are more active).
Several other members of the VEGF family have been cloned including
VEGF-B, -C, and -D. Placenta growth factor (PlGF) is also closely
related to VEGF-A. VEGF-A, -B, -C, -D, and PlGF are all distantly
related to platelet-derived growth factors-A and -B. Less is known
about the function and regulation of VEGF-B, -C, and -D, but they
do not seem to be regulated by the major pathways that regulate
VEGF-A.
[0391] VEGF-A transcription is potentiated in response to hypoxia
and by activated oncogenes. The transcription factors, hypoxia
inducible factor-1a (hif-1a) and -2a, are degraded by proteosomes
in normoxia and stabilized in hypoxia. This pathway is dependent on
the Von Hippel-Lindau gene product. Hif-1a and hif-2 a
heterodimerize with the aryl hydrocarbon nuclear translocator in
the nucleus and bind the VEGF promoter/enhancer. This is a key
pathway expressed in most types of cells. Hypoxia inducibility, in
particular, characterizes VEGF-A versus other members of the VEGF
family and other angiogenic factors. VEGF transcription in normoxia
is activated by many oncogenes, including H-ras and several
transmembrane tyrosine kinases, such as the epidermal growth factor
receptor and erbB2. These pathways together account for a marked
upregulation of VEGF-A in tumors compared to normal tissues and are
often of prognostic importance.
[0392] There are three receptors in the VEGF receptor family. They
have the common properties of multiple IgG-like extracellular
domains and tyrosine kinase activity. The enzyme domains of VEGF
receptor 1 (VEGFR1, also known as Flt-1), VEGFR2 (also known as KDR
or Flk-1), and VEGFr3 (also known as Flt-4) are divided by an
inserted sequence. Endothelial cells also express additional VEGF
receptors, Neuropilin-1 and Neuropilin-2. VEGF-A binds to VEGFR1
and VEGFR2 and to Neuropilin-1 and Neuropilin-2. PlGF and VEGF-B
bind VEGFR1 and Neuropilin-1. VEGF-C and -D bind VEGFr3 and
VEGFR2.
[0393] The VEGF-C/VEGFr3 pathway is important for lymphatic
proliferation. VEGFr3 is specifically expressed on lymphatic
endothelium. A soluble form of Flt-1 can be detected in peripheral
blood and is a high affinity ligand for VEGF. Soluble Flt-1 can be
used to antagonize VEGF function. VEGFR1 and VEGFR2 are upregulated
in tumor and proliferating endothelium, partly by hypoxia and also
in response to VEGF-A itself. VEGFR1 and VEGFR2 can interact with
multiple downstream signaling pathways via proteins such as PLC-g,
Ras, Shc, Nck, PKC and P13-kinase. VEGFR1 is of higher affinity
than VEGFR2 and mediates motility and vascular permeability. VEGFR2
is necessary for proliferation.
[0394] VEGF can be detected in both plasma and serum samples of
patients, with much higher levels in serum. Platelets release VEGF
upon aggregation and may be a major source of VEGF delivery to
tumors. Several studies have shown that association of high serum
levels of VEGF with poor prognosis in cancer patients may be
correlated with an elevated platelet count. Many tumors release
cytokines that can stimulate the production of megakaryocytes in
the marrow and elevate the platelet count. This can result in an
indirect increase of VEGF delivery to tumors.
[0395] VEGF is implicated in several other pathological conditions
associated with enhanced angiogenesis. For example, VEGF plays a
role in both psoriasis and rheumatoid arthritis. Diabetic
retinopathy is associated with high intraocular levels of VEGF.
Inhibition of VEGF function may result in infertility by blockade
of corpus luteum function. Direct demonstration of the importance
of VEGF in tumor growth has been achieved using dominant negative
VEGF receptors to block in vivo proliferation, as well as blocking
antibodies to VEGF39 or to VEGFR2.
[0396] The use of small interfering nucleic acid molecules
targeting VEGF and corresponding receptors and ligands therefore
provides a class of novel therapeutic agents that can be used in
the diagnosis of and the treatment of cancer, proliferative
diseases, or any other disease or condition that responds to
modulation of VEGF and/or VEGFr genes.
EXAMPLES
[0397] The following are non-limiting examples showing the
selection, isolation, synthesis and activity of nucleic acids of
the instant invention.
Example 1
Tandem Synthesis of siNA Constructs
[0398] Exemplary siNA molecules of the invention are synthesized in
tandem using a cleavable linker, for example, a succinyl-based
linker. Tandem synthesis as described herein is followed by a
one-step purification process that provides RNAi molecules in high
yield. This approach is highly amenable to siNA synthesis in
support of high throughput RNAi screening, and can be readily
adapted to multi-column or multi-well synthesis platforms.
[0399] After completing a tandem synthesis of a siNA oligo and its
complement in which the 5'-terminal dimethoxytrityl (5'-O-DMT)
group remains intact (trityl on synthesis), the oligonucleotides
are deprotected as described above. Following deprotection, the
siNA sequence strands are allowed to spontaneously hybridize. This
hybridization yields a duplex in which one strand has retained the
5'-O-DMT group while the complementary strand comprises a terminal
5'-hydroxyl. The newly formed duplex behaves as a single molecule
during routine solid-phase extraction purification (Trityl-On
purification) even though only one molecule has a dimethoxytrityl
group. Because the strands form a stable duplex, this
dimethoxytrityl group (or an equivalent group, such as other trityl
groups or other hydrophobic moieties) is all that is required to
purify the pair of oligos, for example, by using a C18
cartridge.
[0400] Standard phosphoramidite synthesis chemistry is used up to
the point of introducing a tandem linker, such as an inverted deoxy
abasic succinate or glyceryl succinate linker (see FIG. 1) or an
equivalent cleavable linker. A non-limiting example of linker
coupling conditions that can be used includes a hindered base such
as diisopropylethylamine (DIPA) and/or DMAP in the presence of an
activator reagent such as
Bromotripyrrolidinophosphoniumhexaflurorophosphate (PyBrOP). After
the linker is coupled, standard synthesis chemistry is utilized to
complete synthesis of the second sequence leaving the terminal the
5'-O-DMT intact. Following synthesis, the resulting oligonucleotide
is deprotected according to the procedures described herein and
quenched with a suitable buffer, for example with 50 mM NaOAc or
1.5M NH.sub.4H.sub.2CO.sub.3.
[0401] Purification of the siNA duplex can be readily accomplished
using solid phase extraction, for example using a Waters C18 SepPak
1 g cartridge conditioned with 1 column volume (CV) of
acetonitrile, 2 CV H2O, and 2 CV 50 mM NaOAc. The sample is loaded
and then washed with 1 CV H2O or 50 mM NaOAc. Failure sequences are
eluted with 1 CV 14% ACN (Aqueous with 50 mM NaOAc and 50 mM NaCl).
The column is then washed, for example with 1 CV H2O followed by
on-column detritylation, for example by passing 1 CV of 1% aqueous
trifluoroacetic acid (TFA) over the column, then adding a second CV
of 1% aqueous TFA to the column and allowing to stand for
approximately 10 minutes. The remaining TFA solution is removed and
the column washed with H2O followed by 1 CV 1 M NaCl and additional
H.sub.2O. The siNA duplex product is then eluted, for example,
using 1 CV 20% aqueous CAN.
[0402] FIG. 2 provides an example of MALDI-TOF mass spectrometry
analysis of a purified siNA construct in which each peak
corresponds to the calculated mass of an individual siNA strand of
the siNA duplex. The same purified siNA provides three peaks when
analyzed by capillary gel electrophoresis (CGE), one peak
presumably corresponding to the duplex siNA, and two peaks
presumably corresponding to the separate siNA sequence strands. Ion
exchange HPLC analysis of the same siNA contract only shows a
single peak. Testing of the purified siNA construct using a
luciferase reporter assay described below demonstrated the same
RNAi activity compared to siNA constructs generated from separately
synthesized oligonucleotide sequence strands.
Example 2
Identification of Potential siNA Target Sites in any RNA
Sequence
[0403] The sequence of an RNA target of interest, such as a viral
or human mRNA transcript, is screened for target sites, for example
by using a computer folding algorithm. In a non-limiting example,
the sequence of a gene or RNA gene transcript derived from a
database, such as Genbank, is used to generate siNA targets having
complementarity to the target. Such sequences can be obtained from
a database, or can be determined experimentally as known in the
art. Target sites that are known, for example, those target sites
determined to be effective target sites based on studies with other
nucleic acid molecules, for example ribozymes or antisense, or
those targets known to be associated with a disease or condition
such as those sites containing mutations or deletions, can be used
to design siNA molecules targeting those sites. Various parameters
can be used to determine which sites are the most suitable target
sites within the target RNA sequence. These parameters include but
are not limited to secondary or tertiary RNA structure, the
nucleotide base composition of the target sequence, the degree of
homology between various regions of the target sequence, or the
relative position of the target sequence within the RNA transcript.
Based on these determinations, any number of target sites within
the RNA transcript can be chosen to screen siNA molecules for
efficacy, for example by using in vitro RNA cleavage assays, cell
culture, or animal models. In a non-limiting example, anywhere from
1 to 1000 target sites are chosen within the transcript based on
the size of the siNA construct to be used. High throughput
screening assays can be developed for screening siNA molecules
using methods known in the art, such as with multi-well or
multi-plate assays to determine efficient reduction in target gene
expression.
Example 3
Selection of siNA Molecule Target Sites in a RNA
[0404] The following non-limiting steps can be used to carry out
the selection of siNAs targeting a given gene sequence or
transcript.
[0405] 1. The target sequence is parsed in silico into a list of
all fragments or subsequences of a particular length, for example
23 nucleotide fragments, contained within the target sequence. This
step is typically carried out using a custom Perl script, but
commercial sequence analysis programs such as Oligo, MacVector, or
the GCG Wisconsin Package can be employed as well.
[0406] 2. In some instances the siNAs correspond to more than one
target sequence; such would be the case for example in targeting
different transcripts of the same gene, targeting different
transcripts of more than one gene, or for targeting both the human
gene and an animal homolog. In this case, a subsequence list of a
particular length is generated for each of the targets, and then
the lists are compared to find matching sequences in each list. The
subsequences are then ranked according to the number of target
sequences that contain the given subsequence; the goal is to find
subsequences that are present in most or all of the target
sequences. Alternately, the ranking can identify subsequences that
are unique to a target sequence, such as a mutant target sequence.
Such an approach would enable the use of siNA to target
specifically the mutant sequence and not effect the expression of
the normal sequence.
[0407] 3. In some instances the siNA subsequences are absent in one
or more sequences while present in the desired target sequence;
such would be the case if the siNA targets a gene with a paralogous
family member that is to remain untargeted. As in case 2 above, a
subsequence list of a particular length is generated for each of
the targets, and then the lists are compared to find sequences that
are present in the target gene but are absent in the untargeted
paralog.
[0408] 4. The ranked siNA subsequences can be further analyzed and
ranked according to GC content. A preference can be given to sites
containing 30-70% GC, with a further preference to sites containing
40-60% GC.
[0409] 5. The ranked siNA subsequences can be further analyzed and
ranked according to self-folding and internal hairpins. Weaker
internal folds are preferred; strong hairpin structures are to be
avoided.
[0410] 6. The ranked siNA subsequences can be further analyzed and
ranked according to whether they have runs of GGG or CCC in the
sequence. GGG (or even more Gs) in either strand can make
oligonucleotide synthesis problematic and can potentially interfere
with RNAi activity, so it is avoided whenever better sequences are
available. CCC is searched in the target strand because that will
place GGG in the antisense strand.
[0411] 7. The ranked siNA subsequences can be further analyzed and
ranked according to whether they have the dinucleotide UU (uridine
dinucleotide) on the 3'-end of the sequence, and/or AA on the
5'-end of the sequence (to yield 3' UU on the antisense sequence).
These sequences allow one to design siNA molecules with terminal TT
thymidine dinucleotides.
[0412] 8. Four or five target sites are chosen from the ranked list
of subsequences as described above. For example, in subsequences
having 23 nucleotides, the right 21 nucleotides of each chosen
23-mer subsequence are then designed and synthesized for the upper
(sense) strand of the siNA duplex, while the reverse complement of
the left 21 nucleotides of each chosen 23-mer subsequence are then
designed and synthesized for the lower (antisense) strand of the
siNA duplex (see Tables II and III). If terminal TT residues are
desired for the sequence (as described in paragraph 7), then the
two 3' terminal nucleotides of both the sense and antisense strands
are replaced by TT prior to synthesizing the oligos.
[0413] 9. The siNA molecules are screened in an in vitro, cell
culture or animal model system to identify the most active siNA
molecule or the most preferred target site within the target RNA
sequence.
[0414] 10. Other design considerations can be used when selecting
target nucleic acid sequences, see for example Reynolds et al.,
2004, Nature Biotechnology Advanced Online Publication, 1 Feb.
2004, doi:10.1038/nbt936 and Ui-Tei et al., 2004, Nucleic Acids
Research, 32, doi:10.1093/nar/gkh247.
[0415] In an alternate approach, a pool of siNA constructs specific
to a VEGF and/or VEGFr target sequence is used to screen for target
sites in cells expressing VEGF and/or VEGFr RNA, such as HUVEC,
HMVEC, or A375 cells. The general strategy used in this approach is
shown in FIG. 9. A non-limiting example of such is a pool
comprising sequences having any of SEQ ID NOS 1-2549. Cells
expressing VEGF and/or VEGFr (e.g., HUVEC, HMVEC, or A375 cells)
are transfected with the pool of siNA constructs and cells that
demonstrate a phenotype associated with VEGF and/or VEGFr
inhibition are sorted. The pool of siNA constructs can be expressed
from transcription cassettes inserted into appropriate vectors (see
for example FIG. 7 and FIG. 8). The siNA from cells demonstrating a
positive phenotypic change (e.g., decreased proliferation,
decreased VEGF and/or VEGFr mRNA levels or decreased VEGF and/or
VEGFr protein expression), are sequenced to determine the most
suitable target site(s) within the target VEGF and/or VEGFr RNA
sequence.
Example 4
VEGF and/or VEGFr Targeted siNA Design
[0416] siNA target sites were chosen by analyzing sequences of the
VEGF and/or VEGFr RNA target and optionally prioritizing the target
sites on the basis of folding (structure of any given sequence
analyzed to determine siNA accessibility to the target), by using a
library of siNA molecules as described in Example 3, or alternately
by using an in vitro siNA system as described in Example 6 herein.
siNA molecules were designed that could bind each target and are
optionally individually analyzed by computer folding to assess
whether the siNA molecule can interact with the target sequence.
Varying the length of the siNA molecules can be chosen to optimize
activity. Generally, a sufficient number of complementary
nucleotide bases are chosen to bind to, or otherwise interact with,
the target RNA, but the degree of complementarity can be modulated
to accommodate siNA duplexes or varying length or base composition.
By using such methodologies, siNA molecules can be designed to
target sites within any known RNA sequence, for example those RNA
sequences corresponding to the any gene transcript.
[0417] Chemically modified siNA constructs are designed to provide
nuclease stability for systemic administration in vivo and/or
improved pharmacokinetic, localization, and delivery properties
while preserving the ability to mediate RNAi activity. Chemical
modifications as described herein are introduced synthetically
using synthetic methods described herein and those generally known
in the art. The synthetic siNA constructs are then assayed for
nuclease stability in serum and/or cellular/tissue extracts (e.g.
liver extracts). The synthetic siNA constructs are also tested in
parallel for RNAi activity using an appropriate assay, such as a
luciferase reporter assay as described herein or another suitable
assay that can quantity RNAi activity. Synthetic siNA constructs
that possess both nuclease stability and RNAi activity can be
further modified and re-evaluated in stability and activity assays.
The chemical modifications of the stabilized active siNA constructs
can then be applied to any siNA sequence targeting any chosen RNA
and used, for example, in target screening assays to pick lead siNA
compounds for therapeutic development (see for example FIG.
11).
Example 5
Chemical Synthesis and Purification of siNA
[0418] siNA molecules can be designed to interact with various
sites in the RNA message, for example, target sequences within the
RNA sequences described herein. The sequence of one strand of the
siNA molecule(s) is complementary to the target site sequences
described above. The siNA molecules can be chemically synthesized
using methods described herein. Inactive siNA molecules that are
used as control sequences can be synthesized by scrambling the
sequence of the siNA molecules such that it is not complementary to
the target sequence. Generally, siNA constructs can by synthesized
using solid phase oligonucleotide synthesis methods as described
herein (see for example Usman et al., U.S. Pat. Nos. 5,804,683;
5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117;
6,469,158; Scaringe et al., U.S. Pat. Nos. 6,111,086; 6,008,400;
6,111,086 all incorporated by reference herein in their
entirety).
[0419] In a non-limiting example, RNA oligonucleotides are
synthesized in a stepwise fashion using the phosphoramidite
chemistry as is known in the art. Standard phosphoramidite
chemistry involves the use of nucleosides comprising any of
5'-O-dimethoxytrityl, 2'-O-tert-butyldimethylsilyl,
3'-O-2-Cyanoethyl N,N-diisopropylphos-phoroamidite groups, and
exocyclic amine protecting groups (e.g. N6-benzoyl adenosine, N4
acetyl cytidine, and N2-isobutyryl guanosine). Alternately,
2'-O-Silyl Ethers can be used in conjunction with acid-labile
2'-O-orthoester protecting groups in the synthesis of RNA as
described by Scaringe supra. Differing 2' chemistries can require
different protecting groups, for example 2'-deoxy-2'-amino
nucleosides can utilize N-phthaloyl protection as described by
Usman et al., U.S. Pat. No. 5,631,360, incorporated by reference
herein in its entirety).
[0420] During solid phase synthesis, each nucleotide is added
sequentially (3'- to 5'-direction) to the solid support-bound
oligonucleotide. The first nucleoside at the 3'-end of the chain is
covalently attached to a solid support (e.g., controlled pore glass
or polystyrene) using various linkers. The nucleotide precursor, a
ribonucleoside phosphoramidite, and activator are combined
resulting in the coupling of the second nucleoside phosphoramidite
onto the 5'-end of the first nucleoside. The support is then washed
and any unreacted 5'-hydroxyl groups are capped with a capping
reagent such as acetic anhydride to yield inactive 5'-acetyl
moieties. The trivalent phosphorus linkage is then oxidized to a
more stable phosphate linkage. At the end of the nucleotide
addition cycle, the 5'-O-protecting group is cleaved under suitable
conditions (e.g., acidic conditions for trityl-based groups and
Fluoride for silyl-based groups). The cycle is repeated for each
subsequent nucleotide.
[0421] Modification of synthesis conditions can be used to optimize
coupling efficiency, for example by using differing coupling times,
differing reagent/phosphoramidite concentrations, differing contact
times, differing solid supports and solid support linker
chemistries depending on the particular chemical composition of the
siNA to be synthesized. Deprotection and purification of the siNA
can be performed as is generally described in Deprotection and
purification of the siNA can be performed as is generally described
in Usman et al., U.S. Pat. No. 5,831,071, U.S. Pat. No. 6,353,098,
U.S. Pat. No. 6,437,117, and Bellon et al., U.S. Pat. No.
6,054,576, U.S. Pat. No. 6,162,909, U.S. Pat. No. 6,303,773, or
Scaringe supra, incorporated by reference herein in their
entireties. Additionally, deprotection conditions can be modified
to provide the best possible yield and purity of siNA constructs.
For example, applicant has observed that oligonucleotides
comprising 2'-deoxy-2'-fluoro nucleotides can degrade under
inappropriate deprotection conditions. Such oligonucleotides are
deprotected using aqueous methylamine at about 35.degree. C. for 30
minutes. If the 2'-deoxy-2'-fluoro containing oligonucleotide also
comprises ribonucleotides, after deprotection with aqueous
methylamine at about 35.degree. C. for 30 minutes, TEA-HF is added
and the reaction maintained at about 65.degree. C. for an
additional 15 minutes.
Example 6
RNAi In Vitro Assay to Assess siNA Activity
[0422] An in vitro assay that recapitulates RNAi in a cell-free
system is used to evaluate siNA constructs targeting VEGF and/or
VEGFr RNA targets. The assay comprises the system described by
Tuschl et al., 1999, Genes and Development, 13, 3191-3197 and
Zamore et al., 2000, Cell, 101, 25-33 adapted for use with VEGF
and/or VEGFr target RNA. A Drosophila extract derived from
syncytial blastoderm is used to reconstitute RNAi activity in
vitro. Target RNA is generated via in vitro transcription from an
appropriate VEGF and/or VEGFr expressing plasmid using T7 RNA
polymerase or via chemical synthesis as described herein. Sense and
antisense siNA strands (for example 20 uM each) are annealed by
incubation in buffer (such as 100 mM potassium acetate, 30 mM
HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 minute at
90.degree. C. followed by 1 hour at 37.degree. C., then diluted in
lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH
at pH 7.4, 2 mM magnesium acetate). Annealing can be monitored by
gel electrophoresis on an agarose gel in TBE buffer and stained
with ethidium bromide. The Drosophila lysate is prepared using zero
to two-hour-old embryos from Oregon R flies collected on yeasted
molasses agar that are dechorionated and lysed. The lysate is
centrifuged and the supernatant isolated. The assay comprises a
reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM
final concentration), and 10% [vol/vol] lysis buffer containing
siNA (10 nM final concentration). The reaction mixture also
contains 10 mM creatine phosphate, 10 ug.ml creatine phosphokinase,
100 um GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL
RNasin (Promega), and 100 uM of each amino acid. The final
concentration of potassium acetate is adjusted to 100 mM. The
reactions are pre-assembled on ice and preincubated at 25.degree.
C. for 10 minutes before adding RNA, then incubated at 25.degree.
C. for an additional 60 minutes. Reactions are quenched with 4
volumes of 1.25.times.Passive Lysis Buffer (Promega). Target RNA
cleavage is assayed by RT-PCR analysis or other methods known in
the art and are compared to control reactions in which siNA is
omitted from the reaction.
[0423] Alternately, internally-labeled target RNA for the assay is
prepared by in vitro transcription in the presence of
[alpha-.sup.32P] CTP, passed over a G 50 Sephadex column by spin
chromatography and used as target RNA without further purification.
Optionally, target RNA is 5'-.sup.32P-end labeled using T4
polynucleotide kinase enzyme. Assays are performed as described
above and target RNA and the specific RNA cleavage products
generated by RNAi are visualized on an autoradiograph of a gel. The
percentage of cleavage is determined by Phosphor Imager.RTM.
quantitation of bands representing intact control RNA or RNA from
control reactions without siNA and the cleavage products generated
by the assay.
[0424] In one embodiment, this assay is used to determine target
sites the VEGF and/or VEGFr RNA target for siNA mediated RNAi
cleavage, wherein a plurality of siNA constructs are screened for
RNAi mediated cleavage of the VEGF and/or VEGFr RNA target, for
example, by analyzing the assay reaction by electrophoresis of
labeled target RNA, or by northern blotting, as well as by other
methodology well known in the art.
Example 7
Nucleic Acid Inhibition of VEGF and/or VEGFr Target RNA In Vivo
[0425] siNA molecules targeted to the human VEGF and/or VEGFr RNA
are designed and synthesized as described above. These nucleic acid
molecules can be tested for cleavage activity in vivo, for example,
using the following procedure. The target sequences and the
nucleotide location within the VEGF and/or VEGFr RNA are given in
Table II and III.
[0426] Two formats are used to test the efficacy of siNAs targeting
VEGF and/or VEGFr. First, the reagents are tested in cell culture
using, for example, HUVEC, HMVEC, or A375 cells to determine the
extent of RNA and protein inhibition. siNA reagents (e.g.; see
Tables II and III) are selected against the VEGF and/or VEGFr
target as described herein. RNA inhibition is measured after
delivery of these reagents by a suitable transfection agent to, for
example, HUVEC, HMVEC, or A375 cells. Relative amounts of target
RNA are measured versus actin using real-time PCR monitoring of
amplification (eg., ABI 7700 Taqman.RTM.). A comparison is made to
a mixture of oligonucleotide sequences made to unrelated targets or
to a randomized siNA control with the same overall length and
chemistry, but randomly substituted at each position. Primary and
secondary lead reagents are chosen for the target and optimization
performed. After an optimal transfection agent concentration is
chosen, a RNA time-course of inhibition is performed with the lead
siNA molecule. In addition, a cell-plating format can be used to
determine RNA inhibition.
[0427] Delivery of siNA to Cells
[0428] Cells (e.g., HUVEC, HMVEC, or A375 cells) are seeded, for
example, at 1.times.10.sup.5 cells per well of a six-well dish in
EGM-2 (BioWhittaker) the day before transfection. siNA (final
concentration, for example 20 nM) and cationic lipid (e.g., final
concentration 2 .mu.g/ml) are complexed in EGM basal media
(Biowhittaker) at 37.degree. C. for 30 minutes in polystyrene
tubes. Following vortexing, the complexed siNA is added to each
well and incubated for the times indicated. For initial
optimization experiments, cells are seeded, for example, at
1.times.10.sup.3 in 96 well plates and siNA complex added as
described. Efficiency of delivery of siNA to cells is determined
using a fluorescent siNA complexed with lipid. Cells in 6-well
dishes are incubated with siNA for 24 hours, rinsed with PBS and
fixed in 2% paraformaldehyde for 15 minutes at room temperature.
Uptake of siNA is visualized using a fluorescent microscope.
[0429] Tagman and Lightcycler Quantification of mRNA
[0430] Total RNA is prepared from cells following siNA delivery,
for example, using Qiagen RNA purification kits for 6-well or
Rneasy extraction kits for 96-well assays. For Taqman analysis,
dual-labeled probes are synthesized with the reporter dye, FAM or
JOE, covalently linked at the 5'-end and the quencher dye TAMRA
conjugated to the 3'-end. One-step RT-PCR amplifications are
performed on, for example, an ABI PRISM 7700 Sequence Detector
using 50 .mu.l reactions consisting of 10 .mu.l total RNA, 100 nM
forward primer, 900 nM reverse primer, 100 nM probe, 1.times.TaqMan
PCR reaction buffer (PE-Applied Biosystems), 5.5 mM MgCl.sub.2, 300
.mu.M each dATP, dCTP, dGTP, and dTTP, 10U RNase Inhibitor
(Promega), 1.25U AmpliTaq Gold (PE-Applied Biosystems) and 10U
M-MLV Reverse Transcriptase (Promega). The thermal cycling
conditions can consist of 30 minutes at 48.degree. C., 10 minutes
at 95.degree. C., followed by 40 cycles of 15 seconds at 95.degree.
C. and 1 minute at 60.degree. C. Quantitation of mRNA levels is
determined relative to standards generated from serially diluted
total cellular RNA (300, 100, 33, 11 ng/rxn) and normalizing to
.beta.-actin or GAPDH mRNA in parallel TaqMan reactions. For each
gene of interest an upper and lower primer and a fluorescently
labeled probe are designed. Real time incorporation of SYBR Green I
dye into a specific PCR product can be measured in glass capillary
tubes using a lightcyler. A standard curve is generated for each
primer pair using control cRNA. Values are represented as relative
expression to GAPDH in each sample.
[0431] Western Blotting
[0432] Nuclear extracts can be prepared using a standard micro
preparation technique (see for example Andrews and Faller, 1991,
Nucleic Acids Research, 19, 2499). Protein extracts from
supernatants are prepared, for example using TCA precipitation. An
equal volume of 20% TCA is added to the cell supernatant, incubated
on ice for 1 hour and pelleted by centrifugation for 5 minutes.
Pellets are washed in acetone, dried and resuspended in water.
Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear
extracts) or 4-12% Tris-Glycine (supernatant extracts)
polyacrylamide gel and transferred onto nitro-cellulose membranes.
Non-specific binding can be blocked by incubation, for example,
with 5% non-fat milk for 1 hour followed by primary antibody for 16
hour at 4.degree. C. Following washes, the secondary antibody is
applied, for example (1:10,000 dilution) for 1 hour at room
temperature and the signal detected with SuperSignal reagent
(Pierce).
Example 8
Animal Models Useful to Evaluate the Down-Regulation of VEGF and/or
VEGFr Gene Expression
[0433] There are several animal models in which the
anti-angiogenesis effect of nucleic acids of the present invention,
such as siRNA, directed against VEGF, VEGFR1, VEGFR2 and/or VEGFr3
mRNAs can be tested. Typically a corneal model has been used to
study angiogenesis in rat and rabbit since recruitment of vessels
can easily be followed in this normally avascular tissue (Pandey et
al., 1995 Science 268: 567-569). In these models, a small Teflon or
Hydron disk pretreated with an angiogenesis factor (e.g. bFGF or
VEGF) is inserted into a pocket surgically created in the cornea.
Angiogenesis is monitored 3 to 5 days later. siRNA directed against
VEGF, VEGFR1, VEGFR2 and/or VEGFr3 mRNAs are delivered in the disk
as well, or dropwise to the eye over the time course of the
experiment. In another eye model, hypoxia has been shown to cause
both increased expression of VEGF and neovascularization in the
retina (Pierce et al., 1995 Proc. Natl. Acad. Sci. USA. 92:
905-909; Shweiki et al., 1992 J. Clin. Invest. 91: 2235-2243).
[0434] In human glioblastomas, it has been shown that VEGF is at
least partially responsible for tumor angiogenesis (Plate et al.,
1992 Nature 359, 845). Animal models have been developed in which
glioblastoma cells are implanted subcutaneously into nude mice and
the progress of tumor growth and angiogenesism is studied (Kim et
al., 1993 supra; Millauer et al., 1994 supra).
[0435] Another animal model that addresses neovascularization
involves Matrigel, an extract of basement membrane that becomes a
solid gel when injected subcutaneously (Passaniti et al., 1992 Lab.
Invest. 67: 519-528). When the Matrigel is supplemented with
angiogenesis factors such as VEGF, vessels grow into the Matrigel
over a period of 3 to 5 days and angiogenesis can be assessed.
Again, nucleic acids directed against VEGFr mRNAs are delivered in
the Matrigel.
[0436] Several animal models exist for screening of anti-angiogenic
agents. These include corneal vessel formation following corneal
injury (Burger et al., 1985 Cornea 4: 35-41; Lepri, et al., 1994 J
Ocular Pharmacol. 10: 273-280; Ormerod et al., 1990 Am. J. Pathol.
137: 1243-1252) or intracorneal growth factor implant (Grant et
al., 1993 Diabetologia 36: 282-291; Pandey et al. 1995 supra;
Zieche et al., 1992 Lab. Invest. 67: 711-715), vessel growth into
Matrigel matrix containing growth factors (Passaniti et al., 1992
supra), female reproductive organ neovascularization following
hormonal manipulation (Shweiki et al., 1993 Clin. Invest. 91:
2235-2243), several models involving inhibition of tumor growth in
highly vascularized solid tumors (O'Reilly et al., 1994 Cell 79:
315-328; Senger et al., 1993 Cancer and Metas. Rev. 12: 303-324;
Takahasi et al., 1994 Cancer Res. 54: 4233-4237; Kim et al., 1993
supra), and transient hypoxia-induced neovascularization in the
mouse retina (Pierce et al., 1995 Proc. Natl. Acad. Sci. USA. 92:
905-909). Other model systems to study tumor angiogenesis are
reviewed by Folkman, 1985 Adv. Cancer. Res. 43, 175.
[0437] Ocular Models of Angiogenesis
[0438] The cornea model, described in Pandey et al. supra, is the
most common and well characterized model for screening
anti-angiogenic agent efficacy. This model involves an avascular
tissue into which vessels are recruited by a stimulating agent
(growth factor, thermal or alkalai burn, endotoxin). The corneal
model utilizes the intrastromal corneal implantation of a Teflon
pellet soaked in a VEGF-Hydron solution to recruit blood vessels
toward the pellet, which can be quantitated using standard
microscopic and image analysis techniques. To evaluate their
anti-angiogenic efficacy, nucleic acids are applied topically to
the eye or bound within Hydron on the Teflon pellet itself. This
avascular cornea as well as the Matrigel (see below) provide for
low background assays. While the corneal model has been performed
extensively in the rabbit, studies in the rat have also been
conducted.
[0439] The mouse model (Passaniti et al., supra) is a non-tissue
model that utilizes Matrigel, an extract of basement membrane
(Kleinman et al., 1986) or Millipore.RTM. filter disk, which can be
impregnated with growth factors and anti-angiogenic agents in a
liquid form prior to injection. Upon subcutaneous administration at
body temperature, the Matrigel or Millipore.RTM. filter disk forms
a solid implant. VEGF embedded in the Matrigel or Millipore.RTM.
filter disk is used to recruit vessels within the matrix of the
Matrigel or Millipore.RTM. filter disk which can be processed
histologically for endothelial cell specific vWF (factor VIII
antigen) immunohistochemistry, Trichrome-Masson stain, or
hemoglobin content. Like the cornea, the Matrigel or Millipore.RTM.
filter disk is avascular; however, it is not tissue. In the
Matrigel or Millipore.RTM. filter disk model, nucleic acids are
administered within the matrix of the Matrigel or Millipore.RTM.
filter disk to test their anti-angiogenic efficacy. Thus, delivery
issues in this model, as with delivery of nucleic acids by
Hydron-coated Teflon pellets in the rat cornea model, may be less
problematic due to the homogeneous presence of the nucleic acid
within the respective matrix.
[0440] Additionally, siNA molecules of the invention targeting VEGF
and/or VEGFr (e.g. VEGFR1, VEGFR2, and/or VEGFR3) can be assesed
for activity transgenic mice to determine whether modulation of
VEGF and/or VEGFr can inhibit optic neovasculariation. Animal
models of choroidal neovascularization are described in, for
exmaple, Mori et al., 2001, Journal of Cellular Physiology, 188,
253; Mori et al., 2001, American Journal of Pathology, 159, 313;
Ohno-Matsui et al., 2002, American Journal of Pathology, 160, 711;
and Kwak et al., 2000, Investigative Ophthalmology & Visual
Science, 41, 3158. VEGF plays a central role in causing retinal
neovascularization. Increased expression of VEGFR2 in retinal
photoreceptors of transgenic mice stimulates neovascularization
within the retina, and a blockade of VEGFR2 signaling has been
shown to inhibit retinal choroidal neovascularization (CNV) (Mori
et al., 2001, J. Cell. Physiol., 188, 253).
[0441] CNV is laser induced in, for example, adult C57BL/6 mice.
The mice are also given an intravitreous, periocular or a
subretinal injection of VEGF and/or VEGFr (e.g., VEGFR2) siNA in
each eye. Intravitreous injections are made using a Harvard pump
microinjection apparatus and pulled glass micropipets. Then a
micropipette is passed through the sclera just behind the limbus
into the vitreous cavity. The subretinal injections are made using
a condensing lens system on a dissecting microscope. The pipet tip
is then passed through the sclera posterior to the limbus and
positioned above the retina. Five days after the injection of the
vector the mice are anesthetized with ketamine hydrochloride (100
mg/kg body weight), 1% tropicamide is also used to dilate the
pupil, and a diode laser photocoagulation is used to rupture
Bruch's membrane at three locations in each eye. A slit lamp
delivery system and a hand-held cover slide are used for laser
photocoagulation. Burns are made in the 9, 12, and 3 o'clock
positions 2-3 disc diameters from the optic nerve (Mori et al.,
supra).
[0442] The mice typically develop subretinal neovasculariation due
to the expression of VEGF in photoreceptors beginning at prenatal
day 7. At prenatal day 21, the mice are anesthetized and perfused
with 1 ml of phosphate-buffered saline containing 50 mg/ml of
fluorescein-labeled dextran. Then the eyes are removed and placed
for 1 hour in a 10% phosphate-buffered formalin. The retinas are
removed and examined by fluorescence microscopy (Mori et al.,
supra).
[0443] Fourteen days after the laser induced rupture of Bruch's
membrane, the eyes that received intravitreous and subretinal
injection of siNA are evaluated for smaller appearing areas of CNV,
while control eyes are evaluated for large areas of CNV. The eyes
that receive intravitreous injections or a subretinal injection of
siNA are also evaluated for fewer areas of neovasculariation on the
outer surface of the retina and potenial abortive sprouts from deep
retinal capillaries that do not reach the retinal surface compared
to eyes that did not receive an injection of siNA.
[0444] Tumor Models of Angiogenesis
[0445] Use of Murine Models
[0446] For a typical systemic study involving 10 mice (20 g each)
per dose group, 5 doses (1, 3, 10, 30 and 100 mg/kg daily over 14
days continuous administration), approximately 400 mg of siRNA,
formulated in saline is used. A similar study in young adult rats
(200 g) requires over 4 g. Parallel pharmacokinetic studies involve
the use of similar quantities of siRNA further justifying the use
of murine models.
[0447] Lewis Lung Carcinoma and B-16 Melanoma Murine Models
[0448] Identifying a common animal model for systemic efficacy
testing of nucleic acids is an efficient way of screening siNA for
systemic efficacy.
[0449] The Lewis lung carcinoma and B-16 murine melanoma models are
well accepted models of primary and metastatic cancer and are used
for initial screening of anti-cancer agents. These murine models
are not dependent upon the use of immunodeficient mice, are
relatively inexpensive, and minimize housing concerns. Both the
Lewis lung and B-16 melanoma models involve subcutaneous
implantation of approximately 10.sup.6 tumor cells from
metastatically aggressive tumor cell lines (Lewis lung lines 3LL or
D122, LLc-LN7; B-16-BL6 melanoma) in C57BL/6J mice. Alternatively,
the Lewis lung model can be produced by the surgical implantation
of tumor spheres (approximately 0.8 mm in diameter). Metastasis
also can be modeled by injecting the tumor cells directly
intravenously. In the Lewis lung model, microscopic metastases can
be observed approximately 14 days following implantation with
quantifiable macroscopic metastatic tumors developing within 21-25
days. The B-16 melanoma exhibits a similar time course with tumor
neovascularization beginning 4 days following implantation. Since
both primary and metastatic tumors exist in these models after
21-25 days in the same animal, multiple measurements can be taken
as indices of efficacy. Primary tumor volume and growth latency as
well as the number of micro- and macroscopic metastatic lung foci
or number of animals exhibiting metastases can be quantitated. The
percent increase in lifespan can also be measured. Thus, these
models provide suitable primary efficacy assays for screening
systemically administered siRNA nucleic acids and siRNA nucleic
acid formulations.
[0450] In the Lewis lung and B-16 melanoma models, systemic
pharmacotherapy with a wide variety of agents usually begins 1-7
days following tumor implantation/inoculation with either
continuous or multiple administration regimens. Concurrent
pharmacokinetic studies can be performed to determine whether
sufficient tissue levels of siRNA can be achieved for
pharmacodynamic effect to be expected. Furthermore, primary tumors
and secondary lung metastases can be removed and subjected to a
variety of in vitro studies (i.e. target RNA reduction).
[0451] In addition, animal models are useful in screening
compounds, eg. siNA molecules, for efficacy in treating renal
failure, such as a result of autosomal dominant polycystic kidney
disease (ADPKD). The Han:SPRD rat model, mice with a targeted
mutation in the Pkd2 gene and congenital polycystic kidney (cpk)
mice, closely resemble human ADPKD and provide animal models to
evaluate the therapeutic effect of siRNA constructs that have the
potential to interfere with one or more of the pathogenic elements
of ADPKD mediated renal failure, such as angiogenesis. Angiogenesis
may be necessary in the progression of ADPKD for growth of cyst
cells as well as increased vascular permeability promoting fluid
secretion into cysts. Proliferation of cystic epithelium is also a
feature of ADPKD because cyst cells in culture produce soluble
vascular endothelial growth factor (VEGF). VEGFR1 has also been
detected in epithelial cells of cystic tubules but not in
endothelial cells in the vasculature of cystic kidneys or normal
kidneys. VEGFR2 expression is increased in endothelial cells of
cyst vessels and in endothelial cells during renal
ischemia-reperfusion. It is proposed that inhibition of VEGF
receptors with anti-VEGFR1 and anti-VEGFR2 siRNA molecules would
attenuate cyst formation, renal failure and mortality in ADPKD.
Anti-VEGFR2 siRNA molecules would therefore be designed to inhibit
angiogenesis involved in cyst formation. As VEGFR1 is present in
cystic epithelium and not in vascular endothelium of cysts, it is
proposed that anti-VEGFR1 siRNA molecules would attenuate cystic
epithelial cell proliferation and apoptosis which would in turn
lead to less cyst formation. Further, it is proposed that VEGF
produced by cystic epithelial cells is one of the stimuli for
angiogenesis as well as epithelial cell proliferation and
apoptosis. The use of Han:SPRD rats (see for eaxmple
Kaspareit-Rittinghausen et al., 1991, Am. J. Pathol. 139, 693-696),
mice with a targeted mutation in the Pkd2 gene (Pkd2-/- mice, see
for example Wu et al., 2000, Nat. Genet. 24, 75-78) and cpk mice
(see for example Woo et al., 1994, Nature, 368, 750-753) all
provide animal models to study the efficacy of siRNA molecles of
the invention against VEGFR1 and VEGFR2 mediated renal failure.
[0452] VEGF, VEGFR1 VGFR2 and/or VEGFr3 protein levels can be
measured clinically or experimentally by FACS analysis. VEGF,
VEGFR1 VGFR2 and/or VEGFr3 encoded mRNA levels are assessed by
Northern analysis, RNase-protection, primer extension analysis
and/or quantitative RT-PCR. siRNA nucleic acids that block VEGF,
VEGFR1 VGFR2 and/or VEGFr3 protein encoding mRNAs and therefore
result in decreased levels of VEGF, VEGFR1 VGFR2 and/or VEGFr3
activity by more than 20% in vitro can be identified.
Example 9
RNAi Mediated Inhibition of VEGFr Expression in Cell Culture
[0453] Inhibition of VEGFR1 RNA Expression Using siNA Targeting
VEGFR1 RNA
[0454] siNA constructs (Table III) are tested for efficacy in
reducing VEGF and/or VEGFr RNA expression in, for example, HUVEC,
HMVEC, or A375 cells. Cells are plated approximately 24 hours
before transfection in 96-well plates at 5,000-7,500 cells/well,
100 .mu.l/well, such that at the time of transfection cells are
70-90% confluent. For transfection, annealed siNAs are mixed with
the transfection reagent (Lipofectamine 2000, Invitrogen) in a
volume of 50 .mu.l/well and incubated for 20 min. at room
temperature. The siNA transfection mixtures are added to cells to
give a final siNA concentration of 25 nM in a volume of 150 .mu.l.
Each siNA transfection mixture is added to 3 wells for triplicate
siNA treatments. Cells are incubated at 37.degree. for 24h in the
continued presence of the siNA transfection mixture. At 24h, RNA is
prepared from each well of treated cells. The supernatants with the
transfection mixtures are first removed and discarded, then the
cells are lysed and RNA prepared from each well. Target gene
expression following treatment is evaluated by RT-PCR for the
target gene and for a control gene (36B4, an RNA polymerase
subunit) for normalization. The triplicate data is averaged and the
standard deviations determined for each treatment. Normalized data
are graphed and the percent reduction of target mRNA by active
siNAs in comparison to their respective inverted control siNAs is
determined.
[0455] FIG. 22 shows a non-limiting example of reduction of VEGFR1
mRNA in A375 cells mediated by chemically-modified siNAs that
target VEGFR1 mRNA. A549 cells were transfected with 0.25 ug/well
of lipid complexed with 25 nM siNA. A screen of siNA constructs
(Stabilization "Stab" chemistries are shown in Table IV, constructs
are referred to by RPI number, see Table III) comprising Stab 4/5
chemistry (Sirna/RPI 31190/31193), Stab 1/2 chemistry (Sirna/RPI
31183/31186 and Sirna/RPI 31184/31187), and unmodified RNA
(Sima/RPI 30075/30076) were compared to untreated cells, matched
chemistry inverted control siNA constructs (Sirna/RPI 31208/31211,
Sirna/RPI 31201/31204, Sirna/RPI 31202/31205, and Sirna/RPI
30077/30078), scrambled siNA control constructs (Scram1 and
Scram2), and cells transfected with lipid alone (transfection
control). As shown in the figure, all of the siNA constructs
significantly reduce VEGFR1 RNA expression. Additional
stabilization chemistries as described in Table IV are similarly
assayed for activity. These siNA constructs are compared to
appropriate matched chemistry inverted controls. In addition, the
siNA constructs are also compared to untreated cells, cells
transfected with lipid and scrambled siNA constructs, and cells
transfected with lipid alone (transfection control).
[0456] FIG. 23 shows a non-limiting example of reduction of VEGFR1
mRNA levels in HAEC cell culture using Stab 9/10 directed against
eight sites in VEGFR1 mRNA compared to matched chemistry inverted
controls siNA constructs. Controls UNT and LF2K refer to untreated
cells and cells treated with LF2K transfection reagent alone,
respectively.
[0457] Inhibition of VEGFR2 RNA Expression Using siNA Targeting
VEGFR2 RNA
[0458] siNA constructs (Table III) are tested for efficacy in
reducing VEGF and/or VEGFr RNA expression in, for example, HUVEC,
HMVEC, or A375 cells. Cells are plated approximately 24 hours
before transfection in 96-well plates at 5,000-7,500 cells/well,
100 .mu.l/well, such that at the time of transfection cells are
70-90% confluent. For transfection, annealed siNAs are mixed with
the transfection reagent (Lipofectamine 2000, Invitrogen) in a
volume of 50 .mu.l/well and incubated for 20 min. at room
temperature. The siNA transfection mixtures are added to cells to
give a final siNA concentration of 25 nM in a volume of 150 .mu.l.
Each siNA transfection mixture is added to 3 wells for triplicate
siNA treatments. Cells are incubated at 37.degree. for 24h in the
continued presence of the siNA transfection mixture. At 24h, RNA is
prepared from each well of treated cells. The supernatants with the
transfection mixtures are first removed and discarded, then the
cells are lysed and RNA prepared from each well. Target gene
expression following treatment is evaluated by RT-PCR for the
target gene and for a control gene (36B4, an RNA polymerase
subunit) for normalization. The triplicate data is averaged and the
standard deviations determined for each treatment. Normalized data
are graphed and the percent reduction of target mRNA by active
siNAs in comparison to their respective inverted control siNAs is
determined.
[0459] FIG. 24 shows a non-limiting example of reduction of VEGFR2
mRNA in HAEC cells mediated by chemically-modified siNAs that
target VEGFR2 mRNA. HAEC cells were transfected with 0.25 ug/well
of lipid complexed with 25 nM siNA. A screen of siNA constructs
(Stabilization "Stab" chemistries are shown in Table IV, constructs
are referred to by Compound No., see Table III) in site 3854
comprising Stab 4/5 chemistry (Compound No. 30786/30790), Stab 7/8
chemistry (Compound No. 31858/31860), and Stab 9/10 chemistry
(Compound No. 31862/31864) and in site 3948 comprising Stab 4/5
chemistry (Compound No. 31856/31857), Stab 7/8 chemistry (Compound
No. 31859/31861), and Stab 9/10 chemistry (Compound No.
31863/31865) were compared to untreated cells, matched chemistry
inverted control siNA constructs in site 3854 (Compound No.
31878/31880, Compound No. 31882/31884, and Compound No.
31886/31888) and in site 3948 (Compound No. 31879/31881, Compound
No. 31883/31885, and Compound No. 31887/31889), and cells
transfected with LF2K (transfection reagent), and an all RNA
control (Compound No. 31435/31439 in site 3854 and Compound No.
31437/31441 in site 3948). As shown in the figure, all of the siNA
constructs significantly reduce VEGFR2 RNA expression. Additional
stabilization chemistries as described in Table IV are similarly
assayed for activity. These siNA constructs are compared to
appropriate matched chemistry inverted controls. In addition, the
siNA constructs are also compared to untreated cells, cells
transfected with lipid and scrambled siNA constructs, and cells
transfected with lipid alone (transfection control).
[0460] FIG. 25 shows a non-limiting example of reduction of VEGFR2
mRNA levels in HAEC cell culture using Stab 0/0 directed against
four sites in VEGFR2 mRNA compared to irrelevant control siNA
constructs (IC1, IC2). Controls UNT and LF2K refer to untreated
cells and cells treated with LF2K transfection reagent alone,
respectively.
[0461] Inhibition of VEGFR1 and VEGFR2 RNA Expression Using siNA
Targeting VEGFR1 and VEGFR2 Homologous RNA Sequences
[0462] VEGFR1 and VEGFR2 RNA levels were assessed in HAEC cells 24
hours after treatment with siNA molecules targeting sequences
having VEGFR1 and VEGFR2 homology. HAEC cells were transfected with
1.5 ug/well of lipid complexed with 25 nM siNA. Activity of the
siNA moleclues is shown compared to matched chemistry inverted siNA
controls, untreated cells, and cells treated with lipid only
(transfection control). siNA molecules and controls are referred to
by compound numbers (sense/antisense), see Table III for sequences.
As shown in FIGS. 26A and B, siNA constructs that target both
VEGFR1 and VEGFR2 sequences demonstrate potent efficacy in
inhibiting VEGFR1 expression in cell cuture experiments. As shown
in FIGS. 27A and B, siNA constructs that target both VEGFR1 and
VEGFR2 sequences demonstrate potent efficacy in inhibiting VEGFR2
expression in cell cuture experiments.
Example 10
siNA-Mediated Inhibition of Angiogenesis In Vivo
[0463] Evaluation of siNA Molecules in the Rat Cornea Model of VEGF
Induced Angiogenesis
[0464] The purpose of this study was to assess the anti-angiogenic
activity of siNA targeted against VEGFR1, using the rat cornea
model of VEGF induced angiogenesis. The siNA molecules referred to
in FIG. 28 have matched inverted controls which are inactive since
they are not able to interact with the RNA target. The siNA
molecules and VEGF were co-delivered using the filter disk method.
Nitrocellulose filter disks (Millipore.RTM.) of 0.057 diameter were
immersed in appropriate solutions and were surgically implanted in
rat cornea as described by Pandey et al., supra.
[0465] The stimulus for angiogenesis in this study was the
treatment of the filter disk with 30 .mu.M VEGF, which is implanted
within the cornea's stroma. This dose yields reproducible
neovascularization stemming from the pericorneal vascular plexus
growing toward the disk in a dose-response study 5 days following
implant. Filter disks treated only with the vehicle for VEGF show
no angiogenic response. The siNA were co-adminstered with VEGF on a
disk in three different siNA concentrations. One concern with the
simultaneous administration is that the siNA would not be able to
inhibit angiogenesis since VEGF receptors can be stimulated.
However, Applicant has observed that in low VEGF doses, the
neovascular response reverts to normal suggesting that the VEGF
stimulus is essential for maintaining the angiogenic response.
Blocking the production of VEGF receptors using simultaneous
administration of anti-VEGF-R mRNA siNA could attenuate the normal
neovascularization induced by the filter disk treated with
VEGF.
[0466] Materials and Methods:
[0467] Test Compounds and Controls
[0468] R&D Systems VEGF, carrier free at 75 .mu.M in 82 mM
Tris-Cl, pH 6.9
[0469] Active siNA constructs and inverted controls (Table III)
[0470] Animals
[0471] Harlan Sprague-Dawley Rats, Approximately 225-250 g
[0472] 45 males, 5 animals per group.
[0473] Husbandry
[0474] Animals are housed in groups of two. Feed, water,
temperature and humidity are determined according to Pharmacology
Testing Facility performance standards (SOP's) which are in
accordance with the 1996 Guide for the Care and Use of Laboratory
Animals (NRC). Animals are acclimated to the facility for at least
7 days prior to experimentation. During this time, animals are
observed for overall health and sentinels are bled for baseline
serology.
[0475] Experimental Groups
[0476] Each solution (VEGF and siNAs) was prepared as a
1.times.solution for final concentrations shown in the experimental
groups described in Table III.
[0477] siNA Annealing Conditions
[0478] siNA sense and antisense strands are annealed for 1 minute
in H.sub.2O at 1.67 mg/mL/strand followed by a 1 hour incubation at
37.degree. C. producing 3.34 mg/mL of duplexed siNA. For the 20
.mu.g/eye treatment, 6 .mu.s of the 3.34 mg/mL duplex is injected
into the eye (see below). The 3.34 mg/mL duplex siNA can then be
serially diluted for dose response assays.
[0479] Preparation of VEGF Filter Disk
[0480] For corneal implantation, 0.57 mm diameter nitrocellulose
disks, prepared from 0.45 .mu.m pore diameter nitrocellulose filter
membranes (Millipore Corporation), were soaked for 30 min in 1
.mu.L of 75 .mu.M VEGF in 82 mM Tris HCl (pH 6.9) in covered petri
dishes on ice. Filter disks soaked only with the vehicle for VEGF
(83 mM Tris-Cl pH 6.9) elicit no angiogenic response.
[0481] Corneal Surgery
[0482] The rat corneal model used in this study was a modified from
Koch et al. Supra and Pandey et al., supra. Briefly, corneas were
irrigated with 0.5% povidone iodine solution followed by normal
saline and two drops of 2% lidocaine. Under a dissecting microscope
(Leica MZ-6), a stromal pocket was created and a presoaked filter
disk (see above) was inserted into the pocket such that its edge
was 1 mm from the corneal limbus.
[0483] Intraconjunctival Injection of Test Solutions
[0484] Immediately after disk insertion, the tip of a 40-50 .mu.m
OD injector (constructed in our laboratory) was inserted within the
conjunctival tissue 1 mm away from the edge of the corneal limbus
that was directly adjacent to the VEGF-soaked filter disk. Six
hundred nanoliters of test solution (siNA, inverted control or
sterile water vehicle) were dispensed at a rate of 1.2 .mu.L/min
using a syringe pump (Kd Scientific). The injector was then
removed, serially rinsed in 70% ethanol and sterile water and
immersed in sterile water between each injection. Once the test
solution was injected, closure of the eyelid was maintained using
microaneurism clips until the animal began to recover gross motor
activity. Following treatment, animals were warmed on a heating pad
at 37.degree. C.
[0485] Quantitation of Angiogenic Response
[0486] Five days after disk implantation, animals were euthanized
following administration of 0.4 mg/kg atropine and corneas were
digitally imaged. The neovascular surface area (NSA, expressed in
pixels) was measured postmortem from blood-filled corneal vessels
using computerized morphometry (Image Pro Plus, Media Cybernetics,
v2.0). The individual mean NSA was determined in triplicate from
three regions of identical size in the area of maximal
neovascularization between the filter disk and the limbus. The
number of pixels corresponding to the blood-filled corneal vessels
in these regions was summated to produce an index of NSA. A group
mean NSA was then calculated. Data from each treatment group were
normalized to VEGF/siNA vehicle-treated control NSA and finally
expressed as percent inhibition of VEGF-induced angiogenesis.
[0487] Statistics
[0488] After determining the normality of treatment group means,
group mean percent inhibition of VEGF-induced angiogenesis was
subjected to a one-way analysis of variance. This was followed by
two post-hoc tests for significance including Dunnett's (comparison
to VEGF control) and Tukey-Kramer (all other group mean
comparisons) at alpha=0.05. Statistical analyses were performed
using JMP v.3.1.6 (SAS Institute).
[0489] Results of the study are graphically represented in FIGS. 28
and 29. As shown in FIG. 28, VEGFR1 site 4229 active siNA
(Sirna/RPI 29695/29699) at three concentrations was effective at
inhibiting angiogenesis compared to the inverted siNA control
(Sirna/RPI 29983/29984) and the VEGF control. A chemically modified
version of the VEGFR1 site 4229 active siNA comprising a sense
strand having 2'-deoxy-2'-fluoro pyrimidines and ribo purines with
5' and 3' terminal inverted deoxyabasic residues and an antisense
strand having having 2'-deoxy-2'-fluoro pyrimidines and ribo
purines with a terminal 3'-phosphorothioate internucleotide linkage
(Sirna/RPI 30196/30416), showed similar inhibition. Furthermore,
VEGFR1 site 349 active siNA having "Stab 9/10" chemistry (Compound
No. 31270/31273) was tested for inhibition of VEGF-induced
angiogenesis at three different concentrations (2.0 ug, 1.0 ug, and
0.1 ug dose response) as compared to a matched chemistry inverted
control siNA construct (Compound No. 31276/31279) at each
concentration and a VEGF control in which no siNA was administered.
As shown in FIG. 29, the active siNA construct having "Stab 9/10"
chemistry (Compound No. 31270/31273) is highly effective in
inhibiting VEGF-induced angiogenesis in the rat corneal model
compared to the matched chemistry inverted control siNA at
concentrations from 0.1 ug to 2.0 ug. These results demonstrate
that siNA molecules having different chemically modified
compositions, such as the modifications described herein, are
capable of significantly inhibiting angiogenesis in vivo. Results
of a follow study in which sites adjacent to VEGFR1 site 349 were
evaluated for efficacy using two different siNA stabilization
chemistries is shown in FIG. 30.
[0490] Evaluation of siNA Molecules Targeting Homologous VEGFR1 and
VEGFR2 Sequences in the Rat Cornea Model of VEGF Induced
Angiogenesis
[0491] The above model was utilized to evaluate the efficacy of
siNA molecules targeting homologous VEGFR1 and VEGFR2 sequences in
inibiting VEGF induced ocular angiogenesis. Test compounds and
controls are referred to in Table VII, sequences are shown in Table
II. The siNAs or other test articles were administered by
subconjunctival injection after VEGF disk implantation. The siNAs
were preannealed prior to administration. Subconjuctival injections
were performed using polyimide coated fused silica glass catheter
tubing (OD=148 .mu.m, ID=74 .mu.m). This tubing was inserted into a
borosilicate glass micropipette that was pulled to a fine point of
approximately 40-50 microns OD using a Flaming/Brown Micropipette
Puller (Model P-87, Sutter Instrument Co.). The micropipette was
inserted into the pericorneal conjunctiva in the vicinity of the
implanted filter disc and a volume of 1.2 .mu.L was delivered over
15 seconds using a Hamilton Gastight syringe (25 .mu.L) and a
syringe pump. The rat eye was prepared by trimming the whiskers
around the eye and washing the eye with providone iodine following
topical lidocaine anesthesia. The silver nitrate sticks were
touched to the surface of the cornea to induce a wound healing
response and concurrent neovascularization. On day five, animals
were anesthetized using ketamine/xylazine/acepromazine and vessel
growth scores obtained. Animals were euthanized by CO.sub.2
inhalation and digital images of each eye were obtained for
quantitation of vessel growth using Image Pro Plus. Quantitated
neovascular surface area was analyzed by ANOVA followed by two
post-hoc tests including Dunnet's and Tukey-Kramer tests for
significance at the 95% confidence level. Results are shown in FIG.
31 as percent inhibition of VEGF induced angiogenesis compared to
VEGF control. As shown in the figure, several siNA constructs that
target both VEGFR1 and VEGFR2 via homologous sequences (e.g.,
compound Nos. 33725/33731, 33737/33743, 33742/33748, and
33729/33735) provide inhibition of VEGF-induced angiogenesis in
this model. These compounds appear to provide equal or greater
inhibition than a siNA construct (Compound No. 31270/31273)
targeting VEGFR1 only.
[0492] Evaluation of siNA Molecules in the Mouse Coroidal Model of
Neovascularization.
[0493] Intraocular Administration of siNA
[0494] Female C57BL/6 mice (4-5 weeks old) were anesthetized with a
0.2 ml of a mixture of ketamine/xylazine (8:1), and the pupils were
dilated with a single drop of 1% tropicamide. Then a 532 nm diode
laser photocoagulation (75 .mu.m spot size, 0.1-second duration,
120 mW) was used to generate three laser spots in each eye
surrounding the optic nerve by using a hand-held coverslip as a
contact lens. A bubble formed at the laser spot indicating a
rupture of the Bruch's membrane. Next, the laser spots were
evaluated for the presence of CNV on day 17 after laser
treatment.
[0495] After laser induction of multiple CNV lesions in mice, the
siNA was administered by intraocular injections under a dissecting
microscope. Intravitreous injections were performed with a Harvard
pump microinjection apparatus and pulled glass micropipets. Each
micropipet was calibrated to deliver 1 .mu.L of vehicle containing
0.5 ug or 1.5 ug of siNA, inverted control siNA, or saline. The
mice were anesthetized, pupils were dilated, and, the sharpened tip
of the micropipet was passed through the sclera, just behind the
limbus into the vitreous cavity, and the foot switch was depressed.
The injection was repeated at day 7 after laser
photocoagulation.
[0496] At the time of death, mice were anesthetized
(ketamine/xylazine mixture, 8:1) and perfused through the heart
with 1 ml PBS containing 50 mg/ml fluorescein-labeled dextran
(FITC-Dextran, 2 million average molecular weight, Sigma). The eyes
were removed and fixed for overnight in 1% phosphate-buffered 4%
Formalin. The cornea and the lens were removed and the neurosensory
retina was carefully dissected from the eyecup. Five radial cuts
were made from the edge of the eyecup to the equator; the
sclera-choroid-retinal pigment epithelium (RPE) complex was
flat-mounted, with the sclera facing down, on a glass slide in
Aquamount. Flat mounts were examined with a Nikon fluorescence
microscope. A laser spot with green vessels was scored
CNV-positive, and a laser spot lacking green vessels was scored
CNV-negative. Flatmounts were examined by fluorescence microscopy
(Axioskop; Carl Zeiss, Thornwood, N.Y.), and images were digitized
with a three-color charge-coupled device (CCD) video camera and a
frame grabber. Image-analysis software (Image-Pro Plus; Media
Cybernetics, Silver Spring, Md.) was used to measure the total area
of hyperfluorescence associated with each burn, corresponding to
the total fibrovascular scar. The areas within each eye were
averaged to give one experimental value per eye for plotting the
areas.
[0497] Measurement of VEGFR1 expression was also determined using
RT-PCR and/or real-time PCR. Retinal RNA was isolated by a Rnaeasy
kit, and reverse transcription was performed with approximately 0.5
.mu.g total RNA, reverse transcriptase (SuperScript II), and 5.0
.mu.M oligo-d(T) primer. PCR amplification was performed using
primers specific for VEGFR-1 (5'-AAGATGCCAGCCGAAGGAGA-3', SEQ ID
NO: 2550) and (5'-GGCTCGGCACCTATAGACA-3', SEQ ID NO: 2551).
Titrations were determined to ensure that PCR reactions were
performed in the linear range of amplification. Mouse S16 ribosomal
protein primers (5'-CACTGCAAACGGGGAAATGG-3', SEQ ID NO: 2552 and
5'-TGAGATGGACTGTCGGATGG-- 3', SEQ ID NO: 2553) were used to provide
an internal control for the amount of template in the PCR
reactions.
[0498] VEGFR1 site 349 active siNA having "Stab 9/10" chemistry
(Compound No. 31270/31273, Table III) was tested for inhibition of
VEGF-induced neovascularization at two different concentrations
(1.5 ug, and 0.5 ug dose response) as compared to a matched
chemistry 1.5 ug inverted control siNA construct (Compound No.
31276/31279, Table III) and a saline control. As shown in FIG. 32,
the active siNA construct having "Stab 9/10" chemistry is highly
effective in inhibiting VEGFR1 induced neovascularization (57%
inhibition) in the C57BL/6 mice intraocular delivery model compared
to the matched chemistry inverted control siNA. The active siNA
construct was also highly effective in inhibiting VEGFR1 induced
neovascularization (66% inhibition) compared to the saline control.
Additionally, RT-PCR analysis of VEGFR1 site 349 siNA having "Stab
9/10" chemistry (Compound No. 31270/31273, Table III) showed
significant reduction in the level of VEGFR1 mRNA compared to the
inverted siNA construct (Compound No. 31276/31279, Table III) and
saline. Furthermore, ELISA analysis of VEGFR1 protein using the
active siNA and inverted control siNA above showed significant
reduction in the level of VEGFR1 protein expression using the
active siNA compared to the inactive siNA construct. These results
demonstrate that siNA molecules having different chemically
modified compositions, such as the modifications described herein,
are capable of significantly inhibiting neovascularization as shown
in this model of intraocular administration.
[0499] Periocular Administration of siNA
[0500] Female C57BL/6 mice (4-5 weeks old) were anesthetized with a
0.2 ml of a mixture of ketamine/xylazine (8:1), and the pupils were
dilated with a single drop of 1% tropicamide. Then a 532 nm diode
laser photocoagulation (75 .mu.m spot size, 0.1-s duration, 120 mW)
was used to generate three laser spots in each eye surrounding the
optic nerve by using a hand-held coverslip as a contact lens. A
bubble formed at the laser spot indicating a rupture of the Bruch's
membrane. Next, the laser spots were evaluated for the presence of
CNV on day 17 after laser treatment.
[0501] After laser induction of multiple CNV lesions in mice, the
siNA was administered via periocular injections under a dissecting
microscope. Periocular injections were performed with a Harvard
pump microinjection apparatus and pulled glass micropipets. Each
micropipet was calibrated to deliver 5 .mu.L of vehicle containing
test siNA at concentrations of 0.5 ug or 1.5 ug of siNA. The mice
were anesthetized, pupils were dilated, and, the sharpened tip of
the micropipet was passed, and the foot switch was depressed.
Periocular injections were given daily starting at day 1 through
day 14 after laser photocoagulation. Alternately, periocular
injections are given every 3 days after rupture of Bruch's
membrane.
[0502] At the time of death, mice were anesthetized
(ketamine/xylazine mixture, 8:1) and perfused through the heart
with 1 mL PBS containing 50 mg/mL fluorescein-labeled dextran
(FITC-Dextran, 2 million average molecular weight, Sigma). The eyes
were removed and fixed overnight in 1% phosphate-buffered 4%
Formalin. The cornea and the lens were removed and the neurosensory
retina was carefully dissected from the eyecup. Five radial cuts
were made from the edge of the eyecup to the equator; the
sclera-choroid-retinal pigment epithelium (RPE) complex was
flat-mounted, with the sclera facing down, on a glass slide in
Aquamount. Flat mounts were examined with a Nikon fluorescence
microscope. A laser spot with green vessels was scored
CNV-positive, and a laser spot lacking green vessels was scored
CNV-negative. Flatmounts were examined by fluorescence microscopy
(Axioskop; Carl Zeiss, Thornwood, N.Y.) and images were digitized
with a three-color charge-coupled device (CCD) video camera and a
frame grabber. Image-analysis software (Image-Pro Plus; Media
Cybernetics, Silver Spring, Md.) was used to measure the total area
of hyperfluorescence associated with each burn, corresponding to
the total fibrovascular scar. The areas within each eye were
averaged to give one experimental value per eye.
[0503] VEGFR1 site 349 active siNA having "Stab 9/10" chemistry
(Compound No. 31270/31273, Table III) was tested for inhibition of
VEGF-induced neovascularization at two different concentrations
(1.5 ug, and 0.5 ug dose response) as compared to a matched
chemistry saline control and 0.5 ug inverted control siRNA
construct (Compound No. 31276/31279, Table III). As shown in FIG.
33, the active siNA construct having "Stab 9/10" chemistry
(Compound No. 31270/31273) is effective in inhibiting VEGFR1
induced neovascularization (20% inhibition) in the C57BL/6 mice
periocular delivery model compared to the matched chemistry
inverted control siNA. The active siNA construct was also highly
effective in inhibiting VEGFR1 induced neovascularization (54%
inhibition) compared to the saline control. In an additional assay
shown in FIG. 34, VEGFR1 site 349 active siNA having "Stab 9/10"
chemistry (Compound No. 31270/31273) at two concentrations was
effective at inhibiting neovascularization in CNV lesions compared
to the inverted siNA control and the saline control. As shown in
FIG. 34, the active siNA construct having "Stab 9/10" chemistry
(Compound No. 31270/31273) is effective in inhibiting VEGFR1
induced neovascularization (43% inhibition) in the C57BL/6 mice
periocular delivery model compared to the matched chemistry
inverted control siNA. The active siNA construct was also effective
in inhibiting VEGFR1 induced neovascularization (45% inhibition)
compared to the saline control with periocular injection treatment
given every 3 days after rupture of Bruch's membrane (see FIG. 35).
These results demonstrate that siNA molecules having different
chemically modified compositions, such as the modifications
described herein, are capable of significantly inhibiting
neovascularization as shown in this model of periocular
administration.
[0504] Evaluation of siNA Molecules in the Mouse Retinopathy of
Prematurity Model
[0505] The following protocol was used to evaluate siNA molecules
targeting VEGF receptor mRNA in an oxygen-induced ischemic
retinopathy/retinopathy of prematurity model. Pups from female
C57BL/6 mice were placed into a 75% oxygen (ROP) environment at P7
(seven days after birth). Mothers were changed quickly at P10. Mice
were removed from 75% oxygen chamber at P12. Pups were injected on
P12, three hours after being removed from the 75% oxygen
environment. siNA was delivered via an intravitreal or periocular
injection under a dissecting microscope. A Harvard pump
microinjection apparatus and pulled glass micropipette were used
for injection. Each micropipette was calibrated to deliver 1 .mu.L
of vehicle containing test siRNA. The mice were anesthetized, the
pupils were dilated, and the sharpened tip of the micropipette was
passed through the limbus and the foot of the microinjection
apparatus was depressed. Mice were sacrificed by cervical
dislocation for RNA and protein extraction on P15, three days after
being removed from the high oxygen environment. The retinas were
removed and placed in appropriate lysis buffer (see below for
protein and RNA analysis methods).
[0506] Protein Analysis: Protein lysis buffer contained 50 .mu.L 1M
Tris-HCl (pH 7.4), 50 .mu.L 10% SDS (Sodium Dodecyl Sulfate), 5
.mu.L 100 nM PHSF (Phenylmethaneculfonyl) and 5 mL serilized,
de-ionized water. 200 .mu.L of lysis buffer was added to fresh
tissue, and homogenized by pipeting. Tissue was sonicated at
4.degree. C. for 25 minutes, and spun at 13K for 5 minutes at
4.degree. C. The pellet was discarded, and supernate transferred to
fresh tube. BioRad assay was used to measure protein concentration
using BSA as a standard. Samples were stored at -80.degree. C.
ELISAs were carried out using VEGFR1 and R2 kits from R&D
Systems (Quantikine.RTM. Immunoassay). The protocols provided in
the manuals were followed exactly.
[0507] RNA analysis: RNA was extracted using Quiagen, RNeasy mini
kit and following protocol for extraction from animal cells. RNA
samples were treated with DNA-free.TM. by Ambion following company
protocol. First Strand cDNA was then synthesized for real time PCR
using Invitrogen, Superscript 1st Strand System for RT-PCR, and
following protocol. Real-time PCR was then preformed in a Roche
Lightcycler using Fast Start DNA Master SYBR Green I. Cyclophilin A
was used as a control, and purified PCR products were used as
standards.
[0508] Analysis of neovascularization: Mice were sacrificed on P17
by cervical dislocation. Eyes were removed and fresh frozen in
October and stored at -80.degree. C. Eyes were then sectioned and
immunohistochemically stained for lectin. 10 .mu.m frozen sections
of eyes were histochemically stained with biotinylated Griffonia
simplicifolia lectin B4 (GSA; Vector Laboratories, Burlingame,
Calif.), which selectively binds to endothelial cells. Slides were
dried and fixed with 4% PFA for 20 minutes, then incubated in
methanol/H2O2 for 10 minutes at room temperature. After washing
with 0.05 M Tris-buffered saline, pH 7.6 (TBS), the slides were
blocked with 10% swine serum for 30 minutes. Slides were first
stained with biotinylated GSA for 2 hours at room temperature,
followed by a thorough wash with 0.05 M TBS. The slides were
further stained with avidin coupled to alkaline phosphatase (Vector
Laboratories) for 45 minutes at room temperature. Slides were
incubated with a red stain (Histomark Red; Kirkegaard and Perry,
Gaithersburg, Md.) to give a red reaction product. A computer and
image-analysis software (Image-Pro Plus software; Media
Cybernetics, Silver Spring, Md.) was used to quantify GSA-stained
cells on the surface of the retina, and their area was measured.
The mean of the 15 measurements from each eye was used as a single
experimental value.
[0509] Results of a representative study are shown in FIGS. 36 and
37. As shown in FIG. 36, in mice with oxygen induced retinopathy
(OIR), periocular injections of VEGFR1 siNA (31270/31273) (5 .mu.l;
1.5 .mu.g/.mu.l) on P12, P14, and P16 significantly reduced VEGFR1
mRNA expression compared to injections with a matched chemistry
inverted control siNA construct (31276/31279), (40% inhibition;
n=9, p=0.0121). As shown in FIG. 37, in mice with oxygen induced
retinopathy (OIR), intraocular injections of VEGFR1 siNA
(31270/31273) (5 .mu.g), significantly reduced VEGFR1 protein
levels compared to injections with a matched chemistry inverted
control siNA construct (31276/31279), (30% inhibition; n=7,
p=0.0103).
[0510] Evaluation of siNA Molecules in the Mouse 4T1-Luciferase
Mammary Carcinoma Syngeneic Tumor Model
[0511] The current study was designed to determine if systemically
administered siRNA directed against VEGFR-1 inhibits the growth of
subcutaneous tumors. Test compounds included active Stab 9/10 siNA
targeting site 349 of VEGFR-1 RNA (Compound # 31270/31273), a
matched chemistry inactive inverted control siNA (Compound #
31276/31279) and saline. Animal subjects were female Balb/c mice
approximately 20-25 g (5-7 weeks old). The number of subjects
tested was 40 mice; treatment groups are described in Table VI.
Mice were housed in groups of four. The feed, water, temperature
and humidity conditions followed Pharmacology Testing Facility
performance standards (SOP's) which are in accordance with the 1996
Guide for the Care and Use of Laboratory Animals (NRC). Animals
were acclimated to the facility for at least 3 days prior to
experimentation. During this time, animals were observed for
overall health and sentinels were bled for baseline serology.
4T1-luc mammary carcinoma tumor cells were maintained in cell
culture until injection into animals used in the study. On day 0 of
the study, animals were anesthetized with ketamine/xylazine and
1.0.times.10.sup.6 cells in an injection volume of 100 .mu.l were
subcutaneously inoculated in the right flank. Primary tumor volume
was measured using microcalipers. Length and width measurements
were obtained from each tumor 3.times./week (M,W,F) beginning 3
days after inoculation up through and including 21 days after
inoculation. Tumor volumes were calculated from the length/width
measurements according to the equation: Tumor volume=(a)
(b).sup.2/2 where a=the long axis of the tumor and b=the shorter
axis of the tumor. Tumors were allowed to grow for a period of 3
days prior to dosing. Dosing consisted of a daily intravenous tail
vein injection of the test compounds for 18 days. On day 21,
animals were euthanized 24 hours following the last dose of test
compound, or when the animals began to exhibit signs of moribundity
(such as weight loss, lethargia, lack of grooming etc.) using
CO.sub.2 inhalation and lungs were subsequently removed. Lung
metastases were counted under a Leitz dissecting microscope at
25.times. magnification. Tumors were removed and flash frozen in
LN.sub.2 for analysis of immunohistochemical endpoints or mRNA
levels. Results are shown in FIG. 38. As shown in the Figure, the
active siNA construct inhibited tumor growth by 50% compared to the
inactive control siNA construct.
[0512] In addition, levels of soluble VEGFR1 in plasma were
assessed in mice treated with the active and inverted control siNA
constucts. FIG. 39 shows the reduction of soluble VEGFR1 serum
levels in the mouse 4T1-luciferase mammary carcinoma syngeneic
tumor model using active Stab 9/10 siNA targeting site 349 of
VEGFR1 RNA (Compound # 31270/31273) compared to a matched chemistry
inactive inverted control siNA (Compound # 31276/31279). As shown
in FIG. 39, the active siNA construct is effective in reducing
soluble VEGFR1 serum levels in this model.
Example 11
Indications
[0513] The present body of knowledge in VEGF and/or VEGFr research
indicates the need for methods to assay VEGF and/or VEGFr activity
and for compounds that can regulate VEGF and/or VEGFr expression
for research, diagnostic, and therapeutic use. As described herein,
the nucleic acid molecules of the present invention can be used in
assays to diagnose disease state related of VEGF and/or VEGFr
levels. In addition, the nucleic acid molecules can be used to
treat disease state related to VEGF and/or VEGFr levels.
[0514] Particular conditions and disease states that can be
associated with VEGF and/or VEGFr expression modulation include,
but are not limited to:
[0515] 1) Tumor angiogenesis: Angiogenesis has been shown to be
necessary for tumors to grow into pathological size (Folkman, 1971,
PNAS 76, 5217-5221; Wellstein & Czubayko, 1996, Breast Cancer
Res and Treatment 38, 109-119). In addition, it allows tumor cells
to travel through the circulatory system during metastasis.
Increased levels of gene expression of a number of angiogenic
factors such as vascular endothelial growth factor (VEGF) have been
reported in vascularized and edema-associated brain tumors (Berkman
et al., 1993 J. Clini. Invest. 91, 153). A more direct demostration
of the role of VEGF in tumor angiogenesis was demonstrated by Jim
Kim et al., 1993 Nature 362,841 wherein, monoclonal antibodies
against VEGF were successfully used to inhibit the growth of
rhabdomyosarcoma, glioblastoma multiforme cells in nude mice.
Similarly, expression of a dominant negative mutated form of the
flt-1 VEGF receptor inhibits vascularization induced by human
glioblastoma cells in nude mice (Millauer et al., 1994, Nature 367,
576). Specific tumor/cancer types that can be targeted using the
nucleic acid molecules of the invention include but are not limited
to the tumor/cancer types described herein.
[0516] 2) Ocular diseases: Neovascularization has been shown to
cause or exacerbate ocular diseases including, but not limited to,
macular degeneration, neovascular glaucoma, diabetic retinopathy,
myopic degeneration, and trachoma (Norrby, 1997, APMIS 105,
417-437). Aiello et al., 1994 New Engl. J. Med. 331, 1480, showed
that the ocular fluid of a majority of patients suffering from
diabetic retinopathy and other retinal disorders contains a high
concentration of VEGF. Miller et al., 1994 Am. J. Pathol. 145, 574,
reported elevated levels of VEGF mRNA in patients suffering from
retinal ischemia. These observations support a direct role for VEGF
in ocular diseases. Other factors, including those that stimulate
VEGF synthesis, may also contribute to these indications.
[0517] 3) Dermatological Disorders: Many indications have been
identified which may beangiogenesis dependent, including but not
limited to, psoriasis, verruca vulgaris, angiofibroma of tuberous
sclerosis, pot-wine stains, Sturge Weber syndrome,
Kippel-Trenaunay-Weber syndrome, and Osler-Weber-Rendu syndrome
(Norrby, supra). Intradermal injection of the angiogenic factor
b-FGF demonstrated angiogenesis in nude mice (Weckbecker et al.,
1992, Angiogenesis. Key principles-Science-Technology- -Medicine,
ed R. Steiner). Detmar et al., 1994 J. Exp. Med. 180, 1141 reported
that VEGF and its receptors were over-expressed in psoriatic skin
and psoriatic dermal microvessels, suggesting that VEGF plays a
significant role in psoriasis.
[0518] 4) Rheumatoid arthritis: Immunohistochemistry and in situ
hybridization studies on tissues from the joints of patients
suffering from rheumatoid arthritis show an increased level of VEGF
and its receptors (Fava et al., 1994 J. Exp. Med. 180, 341).
Additionally, Koch et al., 1994 J. Immunol. 152, 4149, found that
VEGF-specific antibodies were able to significantly reduce the
mitogenic activity of synovial tissues from patients suffering from
rheumatoid arthritis. These observations support a direct role for
VEGF in rheumatoid arthritis. Other angiogenic factors including
those of the present invention may also be involved in
arthritis.
[0519] 5) Endometriosis: Various studies indicate that VEGF is
directly implicated in endometriosis. In one study, VEGF
concentrations measured by ELISA in peritoneal fluid were found to
be significantly higher in women with endometriosis than in women
without endometriosis (24.1.+-.15 ng/ml vs 13.3.+-.7.2 ng/ml in
normals). In patients with endometriosis, higher concentrations of
VEGF were detected in the proliferative phase of the menstrual
cycle (33.+-.13 ng/ml) compared to the secretory phase (10.7.+-.5
ng/ml). The cyclic variation was not noted in fluid from normal
patients (McLaren et al., 1996, Human Reprod. 11, 220-223). In
another study, women with moderate to severe endometriosis had
significantly higher concentrations of peritoneal fluid VEGF than
women without endometriosis. There was a positive correlation
between the severity of endometriosis and the concentration of VEGF
in peritoneal fluid. In human endometrial biopsies, VEGF expression
increased relative to the early proliferative phase approximately
1.6-, 2-, and 3.6-fold in midproliferative, late proliferative, and
secretory endometrium (Shifren et al., 1996, J. Clin. Endocrinol.
Metab. 81, 3112-3118). In a third study, VEGF-positive staining of
human ectopic endometrium was shown to be localized to macrophages
(double immunofluorescent staining with CD14 marker). Peritoneal
fluid macrophages demonstrated VEGF staining in women with and
without endometriosis. However, increased activation of macrophages
(acid phosphatatse activity) was demonstrated in fluid from women
with endometriosis compared with controls. Peritoneal fluid
macrophage conditioned media from patients with endometriosis
resulted in significantly increased cell proliferation ([.sup.3H]
thymidine incorporation) in HUVEC cells compared to controls. The
percentage of peritoneal fluid macrophages with VEGFR2 mRNA was
higher during the secretory phase, and significantly higher in
fluid from women with endometriosis (80.+-.15%) compared with
controls (32.+-.20%). Flt-mRNA was detected in peritoneal fluid
macrophages from women with and without endometriosis, but there
was no difference between the groups or any evidence of cyclic
dependence (McLaren et al., 1996, J. Clin. Invest. 98, 482-489). In
the early proliferative phase of the menstrual cycle, VEGF has been
found to be expressed in secretory columnar epithelium
(estrogen-responsive) lining both the oviducts and the uterus in
female mice. During the secretory phase, VEGF expression was shown
to have shifted to the underlying stroma composing the functional
endometrium. In addition to examining the endometium,
neovascularization of ovarian follicles and the corpus luteum, as
well as angiogenesis in embryonic implantation sites have been
analyzed. For these processes, VEGF was expressed in spatial and
temporal proximity to forming vasculature (Shweiki et al., 1993, J.
Clin. Invest. 91, 2235-2243).
[0520] 6) Kidney disease: Autosomal dominant polycystic kidney
disease (ADPKD) is the most common life threatening hereditary
disease in the USA. It affects about 1:400 to 1:1000 people and
approximately 50% of people with ADPKD develop renal failure. ADPKD
accounts for about 5-10% of end-stage renal failure in the USA,
requiring dialysis and renal transplantation. Angiogenesis is
implicated in the progression of ADPKD for growth of cyst cells, as
well as increased vascular permeability promoting fluid secretion
into cysts. Proliferation of cystic epithelium is a feature of
ADPKD because cyst cells in culture produce soluble vascular
endothelial growth factor (VEGF). VEGFR1 has been detected in
epithelial cells of cystic tubules but not in endothelial cells in
the vasculature of cystic kidneys or normal kidneys. VEGFR2
expression is increased in endothelial cells of cyst vessels and in
endothelial cells during renal ischemia-reperfusion.
[0521] The use of radiation treatments and chemotherapeutics, such
as Gemcytabine and cyclophosphamide, are non-limiting examples of
chemotherapeutic agents that can be combined with or used in
conjunction with the nucleic acid molecules (e.g. siNA molecules)
of the instant invention. Those skilled in the art will recognize
that other anti-cancer compounds and therapies can similarly be
readily combined with the nucleic acid molecules of the instant
invention (e.g. siNA molecules) and are hence within the scope of
the instant invention. Such compounds and therapies are well known
in the art (see for example Cancer: Principles and Pranctice of
Oncology, Volumes 1 and 2, eds Devita, V. T., Hellman, S., and
Rosenberg, S. A., J. B. Lippincott Company, Philadelphia, USA;
incorporated herein by reference) and include, without limitation,
folates, antifolates, pyrimidine analogs, fluoropyrimidines, purine
analogs, adenosine analogs, topoisomerase I inhibitors,
anthrapyrazoles, retinoids, antibiotics, anthacyclins, platinum
analogs, alkylating agents, nitrosoureas, plant derived compounds
such as vinca alkaloids, epipodophyllotoxins, tyrosine kinase
inhibitors, taxols, radiation therapy, surgery, nutritional
supplements, gene therapy, radiotherapy, for example 3D-CRT,
immunotoxin therapy, for example ricin, and monoclonal antibodies.
Specific examples of chemotherapeutic compounds that can be
combined with or used in conjuction with the nucleic acid molecules
of the invention include, but are not limited to, Paclitaxel;
Docetaxel; Methotrexate; Doxorubin; Edatrexate; Vinorelbine;
Tomaxifen; Leucovorin; 5-fluoro uridine (5-FU); lonotecan;
Cisplatin; Carboplatin; Amsacrine; Cytarabine; Bleomycin; Mitomycin
C; Dactinomycin; Mithramycin; Hexamethylmelamine; Dacarbazine;
L-asperginase; Nitrogen mustard; Melphalan, Chlorambucil; Busulfan;
Ifosfamide; 4-hydroperoxycyclophospham- ide; Thiotepa; Irinotecan
(CAMPTOSAR.RTM., CPT-11, Camptothecin-11, Campto) Tamoxifen;
Herceptin; IMC C225; ABX-EGF; and combinations thereof. The above
list of compounds are non-limiting examples of compounds and/or
methods that can be combined with or used in conjunction with the
nucleic acid molecules (e.g. siNA) of the instant invention. Those
skilled in the art will recognize that other drug compounds and
therapies can similarly be readily combined with the nucleic acid
molecules of the instant invention (e.g., siNA molecules) are hence
within the scope of the instant invention.
Example 12
Diagnostic Uses
[0522] The siNA molecules of the invention can be used in a variety
of diagnostic applications, such as in the identification of
molecular targets (e.g., RNA) in a variety of applications, for
example, in clinical, industrial, environmental, agricultural
and/or research settings. Such diagnostic use of siNA molecules
involves utilizing reconstituted RNAi systems, for example, using
cellular lysates or partially purified cellular lysates. siNA
molecules of this invention can be used as diagnostic tools to
examine genetic drift and mutations within diseased cells or to
detect the presence of endogenous or exogenous, for example viral,
RNA in a cell. The close relationship between siNA activity and the
structure of the target RNA allows the detection of mutations in
any region of the molecule, which alters the base-pairing and
three-dimensional structure of the target RNA. By using multiple
siNA molecules described in this invention, one can map nucleotide
changes, which are important to RNA structure and function in
vitro, as well as in cells and tissues. Cleavage of target RNAs
with siNA molecules can be used to inhibit gene expression and
define the role of specified gene products in the progression of
disease or infection. In this manner, other genetic targets can be
defined as important mediators of the disease. These experiments
will lead to better treatment of the disease progression by
affording the possibility of combination therapies (e.g., multiple
siNA molecules targeted to different genes, siNA molecules coupled
with known small molecule inhibitors, or intermittent treatment
with combinations siNA molecules and/or other chemical or
biological molecules). Other in vitro uses of siNA molecules of
this invention are well known in the art, and include detection of
the presence of mRNAs associated with a disease, infection, or
related condition. Such RNA is detected by determining the presence
of a cleavage product after treatment with a siNA using standard
methodologies, for example, fluorescence resonance emission
transfer (FRET).
[0523] In a specific example, siNA molecules that cleave only
wild-type or mutant forms of the target RNA are used for the assay.
The first siNA molecules (i.e., those that cleave only wild-type
forms of target RNA) are used to identify wild-type RNA present in
the sample and the second siNA molecules (i.e., those that cleave
only mutant forms of target RNA) are used to identify mutant RNA in
the sample. As reaction controls, synthetic substrates of both
wild-type and mutant RNA are cleaved by both siNA molecules to
demonstrate the relative siNA efficiencies in the reactions and the
absence of cleavage of the "non-targeted" RNA species. The cleavage
products from the synthetic substrates also serve to generate size
markers for the analysis of wild-type and mutant RNAs in the sample
population. Thus, each analysis requires two siNA molecules, two
substrates and one unknown sample, which is combined into six
reactions. The presence of cleavage products is determined using an
RNase protection assay so that full-length and cleavage fragments
of each RNA can be analyzed in one lane of a polyacrylamide gel. It
is not absolutely required to quantify the results to gain insight
into the expression of mutant RNAs and putative risk of the desired
phenotypic changes in target cells. The expression of mRNA whose
protein product is implicated in the development of the phenotype
(i.e., disease related or infection related) is adequate to
establish risk. If probes of comparable specific activity are used
for both transcripts, then a qualitative comparison of RNA levels
is adequate and decreases the cost of the initial diagnosis. Higher
mutant form to wild-type ratios are correlated with higher risk
whether RNA levels are compared qualitatively or
quantitatively.
[0524] All patents and publications mentioned in the specification
are indicative of the levels of skill of those skilled in the art
to which the invention pertains. All references cited in this
disclosure are incorporated by reference to the same extent as if
each reference had been incorporated by reference in its entirety
individually.
[0525] One skilled in the art would readily appreciate that the
present invention is well adapted to carry out the objects and
obtain the ends and advantages mentioned, as well as those inherent
therein. The methods and compositions described herein as presently
representative of preferred embodiments are exemplary and are not
intended as limitations on the scope of the invention. Changes
therein and other uses will occur to those skilled in the art,
which are encompassed within the spirit of the invention, are
defined by the scope of the claims.
[0526] It will be readily apparent to one skilled in the art that
varying substitutions and modifications can be made to the
invention disclosed herein without departing from the scope and
spirit of the invention. Thus, such additional embodiments are
within the scope of the present invention and the following claims.
The present invention teaches one skilled in the art to test
various combinations and/or substitutions of chemical modifications
described herein toward generating nucleic acid constructs with
improved activity for mediating RNAi activity. Such improved
activity can comprise improved stability, improved bioavailability,
and/or improved activation of cellular responses mediating RNAi.
Therefore, the specific embodiments described herein are not
limiting and one skilled in the art can readily appreciate that
specific combinations of the modifications described herein can be
tested without undue experimentation toward identifying siNA
molecules with improved RNAi activity.
[0527] The invention illustratively described herein suitably can
be practiced in the absence of any element or elements, limitation
or limitations that are not specifically disclosed herein. Thus,
for example, in each instance herein any of the terms "comprising",
"consisting essentially of", and "consisting of" may be replaced
with either of the other two terms. The terms and expressions which
have been employed are used as terms of description and not of
limitation, and there is no intention that in the use of such terms
and expressions of excluding any equivalents of the features shown
and described or portions thereof, but it is recognized that
various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that although the
present invention has been specifically disclosed by preferred
embodiments, optional features, modification and variation of the
concepts herein disclosed may be resorted to by those skilled in
the art, and that such modifications and variations are considered
to be within the scope of this invention as defined by the
description and the appended claims.
[0528] In addition, where features or aspects of the invention are
described in terms of Markush groups or other grouping of
alternatives, those skilled in the art will recognize that the
invention is also thereby described in terms of any individual
member or subgroup of members of the Markush group or other
group.
1TABLE I VEGF and VEGFr Accession Numbers NM_005429 Homo sapiens
vascular endothelial growth factor C (VEGFC), mRNA
gi.vertline.19924300.vertline.ref.-
vertline.NM_005429.2.vertline.[19924300] NM_003376 Homo sapiens
vascular endothelial growth factor (VEGF), mRNA
gi.vertline.19923239.vertline.ref.vertline.NM_003376.2.vertline.[19923239-
] AF095785 Homo sapiens vascular endothelial growth factor (VEGF)
gene, promoter region and partial cds
gi.vertline.4154290.vertline.gb.vertline.AF095785.1.vertline.[4154290]
NM_003377 Homo sapiens vascular endothelial growth factor B
(VEGFB), mRNA gi.vertline.20070172.vertline.ref.vertline.-
NM_003377.2.vertline.[20070172] AF486837 Homo sapiens vascular
endothelial growth factor isoform VEGF165 (VEGF) mRNA, complete cds
gi.vertline.19909064.vertline.gb.vertline.AF48-
6837.1.vertline.[19909064] AF468110 Homo sapiens vascular
endothelial growth factor B isoform (VEGFB) gene, complete cds,
alternatively spliced gi.vertline.18766397.vertline.gb.vert-
line.AF468110.1.vertline.[18766397] AF437895 Homo sapiens vascular
endothelial growth factor (VEGF) gene, partial cds
gi.vertline.16660685.vertline.gb.vertline.AF437895.1.vertline.AF437895[-
16660685] AY047581 Homo sapiens vascular endothelial growth factor
(VEGF) mRNA, complete cds
gi.vertline.15422108.vertline.gb.vertline.AY047581.1.vertline.[15422108]
AF063657 Homo sapiens vascular endothelial growth factor receptor
(FLT1) mRNA, complete cds
gi.vertline.3132830.vertline.gb.vertline.AF063657.1.vertline.AF063657[313-
2830] AF092127 Homo sapiens vascular endothelial growth factor
(VEGF) gene, partial sequence
gi.vertline.4139168.vertline.gb.vertline.AF092127.1.vertline.AF092127[413-
9168] AF092126 Homo sapiens vascular endothelial growth factor
(VEGF) gene, 5' UTR gi.vertline.4139167.vertline.g-
b.vertline.AF092126.1.vertline.AF092126[4139167] AF092125 Homo
sapiens vascular endothelial growth factor (VEGF) gene, partial cds
gi.vertline.4139165.vertline.gb.vertline.AF092125.1.v-
ertline.AF092125[4139165] E15157 Human VEGF mRNA
gi.vertline.5709840.vertline.dbj.vertline.E15157.1.vertline..vertline.pat-
.vertline.JP.vertline.1998052285.vertline.2[5709840] E15156 Human
VEGF mRNA gi.vertline.5709839.vertline.dbj.vertline.E15156-
.1.vertline..vertline.pat.vertline.JP.vertline.1998052285.vertline.1[57098-
39] E14233 Human mRNA for vascular endothelial growth factor
(VEGF), complete cds gi.vertline.5708916.vertline.-
dbj.vertline.E14233.1.vertline..vertline.pat.vertline.JP.vertline.19972867-
95.vertline.1[5708916] AF024710 Homo sapiens vascular endothelial
growth factor (VEGF) mRNA, 3'UTR
gi.vertline.2565322.vertline.gb.vertline.AF024710.1.vertline.AF024710[256-
5322] AJ010438 Homo sapiens mRNA for vascular endothelial growth
factor, splicing variant VEGF183
gi.vertline.3647280.vertline.emb.vertline.AJ010438.1.vertline.HSA010438[3-
647280] AF098331 Homo sapiens vascular endothelial growth factor
(VEGF) gene, promoter, partial sequence
gi.vertline.4235431.vertline.gb.vertline.AF098331.1.vertline.AF098331[423-
5431] AF022375 Homo sapiens vascular endothelial growth factor
mRNA, complete cds gi.vertline.3719220.vertline.gb-
.vertline.AF022375.1.vertline.AF022375[3719220] AH006909 vascular
endothelial growth factor {alternative splicing} [human, Genomic,
414 nt 5 segments] gi.vertline.1680143.vertline.-
gb.vertline.AH006909.1.vertline..vertline.bbm.vertline.191843[1680143]
U01134 Human soluble vascular endothelial cell growth factor
receptor (sflt) mRNA, complete cds
gi.vertline.451321.vertline.gb.vertline.U01134.1.vertline.U01134[451321]
E14000 Human mRNA for FLT gi.vertline.3252767.ver-
tline.dbj.vertline.E14000.1.vertline..vertline.pat.vertline.JP.vertline.19-
97255700.vertline.1[3252767] E13332 cDNA encoding vascular
endodermal cell growth factor VEGF
gi.vertline.3252137.vertline.dbj.vertline.E13332.1.vertline..vertline.pat-
.vertline.JP.vertline.1997173075.vertline.1[3252137] E13256 Human
mRNA for FLT, complete cds gi.vertline.3252061.vertline.db-
j.vertline.E13256.1.vertline..vertline.pat.vertline.JP.vertline.1997154588-
.vertline.1[3252061] AF063658 Homo sapiens vascular endothelial
growth factor receptor 2 (KDR) mRNA, complete cds
gi.vertline.3132832.vertline.gb.vertline.AF063658.1.vertline.-
AF063658[3132832] AJ000185 Homo sapiens mRNA for vascular
endothelial growth factor-D gi.vertline.2879833.vertline.-
emb.vertline.AJ000185.1.vertline.HSAJ185[2879833] D89630 Homo
sapiens mRNA for VEGF-D, complete cds
gi.vertline.2780339.vertline.dbj.vertline.D89630.1.vertline.[2780339]
AF035121 Homo sapiens KDR/flk-1 protein mRNA, complete cds
gi.vertline.2655411.vertline.gb.vertline.AF035121.1.vertline.AF03512-
1[2655411] AF020393 Homo sapiens vascular endothelial growth factor
C gene, partial cds and 5' upstream region
gi.vertline.2582366.vertline.gb.vertline.AF020393.1.vertline.AF02-
0393[2582366] Y08736 H. sapiens vegf gene, 3'UTR
gi.vertline.1619596.vertline.emb.vertline.Y08736.1.vertline.HSVEGF3UT[161-
9596] X62568 H. sapiens vegf gene for vascular endothelial growth
factor gi.vertline.37658.vertline.emb.vertline.X62-
568.1.vertline.HSVEGF[37658] X94216 H. sapiens mRNA for VEGF-C
protein gi.vertline.1177488.vertline.emb.vertline.X94216.1-
.vertline.HSVEGFC[1177488] NM_002020 Homo sapiens fms-related
tyrosine kinase 4 (FLT4), mRNA
gi.vertline.4503752.vertline.ref.vertline.NM_002020.1.vertline.[4503752]
NM_002253 Homo sapiens kinase insert domain receptor (a type III
receptor tyrosine kinase) (KDR), mRNA
gi.vertline.11321596.vertline.ref.vertline.NM_002253.1.vertline.[11321596-
]
[0529]
2TABLE II VEGFr siNA and Target Sequences Seq Seq Seq Pos Target
Sequence ID UPos Upper seq ID LPos Lower seq ID VEGFR1
gi.vertline.4503748.vertline.ref.vertl- ine.NM_002019.1 1
GCGGACACUCCUCUCGGCU 1 1 GCGGACACUCCUCUCGGCU 1 23
AGCCGAGAGGAGUGUCCGC 428 19 UCCUCCCCGGCAGCGGCGG 2 19
UCCUCCCCGGCAGCGGCGG 2 41 CCGCCGCUGCCGGGGAGGA 429 37
GCGGCUCGGAGCGGGCUCC 3 37 GCGGCUCGGAGCGGGCUCC 3 59
GGAGCCCGCUCCGAGCCGC 430 55 CGGGGCUCGGGUGCAGCGG 4 55
CGGGGCUCGGGUGCAGCGG 4 77 CCGCUGCACCCGAGCCCCG 431 73
GCCAGCGGGCCUGGCGGCG 5 73 GCCAGCGGGCCUGGCGGCG 5 95
CGCCGCCAGGCCCGCUGGC 432 91 GAGGAUUACCCGGGGAAGU 6 91
GAGGAUUACCCGGGGAAGU 6 113 ACUUCCCCGGGUAAUCCUC 433 109
UGGUUGUCUCCUGGCUGGA 7 109 UGGUUGUCUCCUGGCUGGA 7 131
UCCAGCCAGGAGACAACCA 434 127 AGCCGCGAGACGGGCGCUC 8 127
AGCCGCGAGACGGGCGCUC 8 149 GAGCGCCCGUCUCGCGGCU 435 145
CAGGGCGCGGGGCCGGCGG 9 145 CAGGGCGCGGGGCCGGCGG 9 167
CCGCCGGCCCCGCGCCCUG 436 163 GCGGCGAACGAGAGGACGG 10 163
GCGGCGAACGAGAGGACGG 10 185 CCGUCCUCUCGUUCGCCGC 437 181
GACUCUGGCGGCCGGGUCG 11 181 GACUCUGGCGGCCGGGUCG 11 203
CGACCCGGCCGCCAGAGUC 438 199 GUUGGCCGGGGGAGCGCGG 12 199
GUUGGCCGGGGGAGCGCGG 12 221 CCGCGCUCCCCCGGCCAAC 439 217
GGCACCGGGCGAGCAGGCC 13 217 GGCACCGGGCGAGCAGGCC 13 239
GGCCUGCUCGCCCGGUGCC 440 235 CGCGUCGCGCUCACCAUGG 14 235
CGCGUCGCGCUCACCAUGG 14 257 CCAUGGUGAGCGCGACGCG 441 253
GUCAGCUACUGGGACACCG 15 253 GUCAGCUACUGGGACACCG 15 275
CGGUGUCCCAGUAGCUGAC 442 271 GGGGUCCUGCUGUGCGCGC 16 271
GGGGUCCUGCUGUGCGCGC 16 293 GCGCGCACAGCAGGACCCC 443 289
CUGCUCAGCUGUCUGCUUC 17 289 CUGCUCAGCUGUCUGCUUC 17 311
GAAGCAGACAGCUGAGCAG 444 307 CUCACAGGAUCUAGUUCAG 18 307
CUCACAGGAUCUAGUUCAG 18 329 CUGAACUAGAUCCUGUGAG 445 325
GGUUCAAAAUUAAAAGAUC 19 325 GGUUCAAAAUUAAAAGAUC 19 347
GAUCUUUUAAUUUUGAACC 446 343 CCUGAACUGAGUUUAAAAG 20 343
CCUGAACUGAGUUUAAAAG 20 365 CUUUUAAACUCAGUUCAGG 447 361
GGCACCCAGCACAUCAUGC 21 361 GGCACCCAGCACAUCAUGC 21 383
GCAUGAUGUGCUGGGUGCC 448 379 CAAGCAGGCCAGACACUGC 22 379
CAAGCAGGCCAGACACUGC 22 401 GCAGUGUCUGGCCUGCUUG 449 397
CAUCUCCAAUGCAGGGGGG 23 397 CAUCUCCAAUGCAGGGGGG 23 419
CCCCCCUGCAUUGGAGAUG 450 415 GAAGCAGCCCAUkAAUGGU 24 415
GAAGCAGCCCAUAAAUGGU 24 437 ACCAUUUAUGGGCUGCUUC 451 433
UCUUUGCCUGAAAUGGUGA 25 433 UCUUUGCCUGAAAUGGUGA 25 455
UCACCAUUUCAGGCAAAGA 452 451 AGUAAGGAAAGCGAAAGGC 26 451
AGUAAGGAAAGCGAAAGGC 26 473 GCCUUUCGCUUUCCUUACU 453 469
CUGAGCAUAACUAAAUCUG 27 469 CUGAGCAUAACUAAAUCUG 27 491
CAGAUUUAGUUAUGCUCAG 454 487 GCCUGUGGAAGAAAUGGCA 28 487
GCCUGUGGAAGAAAUGGCA 28 509 UGCCAUUUCUUCCACAGGC 455 505
AAACAAUUCUGCAGUACUU 29 505 AAACAAUUCUGCAGUACUU 29 527
AAGUACUGCAGAAUUGUUU 456 523 UUAACCUUGAACACAGCUC 30 523
UUAACCUUGAACACAGCUC 30 545 GAGCUGUGUUCAAGGUUAA 457 541
CAAGCAAACCACACUGGCU 31 541 CAAGCAAACCACACUGGCU 31 563
AGCCAGUGUGGUUUGCUUG 458 559 UUCUACAGCUGCAAAUAUC 32 559
UUCUACAGCUGCAAAUAUC 32 581 GAUAUUUGCAGCUGUAGAA 459 577
CUAGCUGUACCUACUUCAA 33 577 CUAGCUGUACCUACUUCAA 33 599
UUGAAGUAGGUACAGCUAG 460 595 AAGAAGAAGGAAACAGAAU 34 595
AAGAAGAAGGAAAGAGAAU 34 617 AUUCUGUUUCCUUCUUCUU 461 613
UCUGCAAUCUAUAUAUUUA 35 613 UCUGCAAUCUAUAUAUUUA 35 635
UAAAUAUAUAGAUUGCAGA 462 631 AUUAGUGAUACAGGUAGAC 36 631
AUUAGUGAUACAGGUAGAC 36 653 GUCUACCUGUAUCACUAAU 463 649
CCUUUCGUAGAGAUGUACA 37 649 CCUUUCGUAGAGAUGUACA 37 671
UGUACAUCUCUACGAAAGG 464 667 AGUGAAAUCCCCGAAAUUA 38 667
AGUGAAAUCCCCGAAAUUA 38 689 UAAUUUCGGGGAUUUCACU 465 685
AUACACAUGACUGAAGGAA 39 685 AUACACAUGACUGAAGGAA 39 707
UUCCUUCAGUCAUGUGUAU 466 703 AGGGAGCUCGUCAUUCCCU 40 703
AGGGAGCUCGUCAUUCCCU 40 725 AGGGAAUGACGAGCUCCCU 467 721
UGCCGGGUUACGUCACCUA 41 721 UGCCGGGUUACGUCACCUA 41 743
UAGGUGACGUAACCCGGCA 468 739 AACAUCACUGUUACUUUAA 42 739
AACAUCACUGUUACUUUAA 42 761 UUAAAGUAACAGUGAUGUU 469 757
AAAAAGUUUCCACUUGACA 43 757 AAAAAGUUUCCACUUGACA 43 779
UGUCAAGUGGAAACUUUUU 470 775 ACUUUGAUCCCUGAUGGAA 44 775
ACUUUGAUCCCUGAUGGAA 44 797 UUCCAUCAGGGAUCAAAGU 471 793
AAACGCAUAAUCUGGGACA 45 793 AAACGCAUAAUCUGGGACA 45 815
UGUCCCAGAUUAUGCGUUU 472 811 AGUAGAAAGGGCUUCAUCA 46 811
AGUAGAAAGGGCUUCAUCA 46 833 UGAUGAAGCCCUUUCUACU 473 829
AUAUCAAAUGCAACGUACA 47 829 AUAUCAAAUGCAACGUACA 47 851
UGUACGUUGCAUUUGAUAU 474 847 AAAGAAAUAGGGCUUCUGA 48 847
AAAGAAAUAGGGCUUCUGA 48 869 UCAGPAGCCCUAUUUCUUU 475 865
ACCUGUGAAGCAACAGUCA 49 865 ACCUGUGAAGCAACAGUCA 49 887
UGACUGUUGCUUCACAGGU 476 883 AAUGGGCAUUUGUAUAAGA 50 883
AAUGGGCAUUUGUAUAAGA 50 905 UCUUAUACAAAUGCCCAUU 477 901
ACAAACUAUCUCACACAUC 51 901 ACAAACUAUCUCACACAUC 51 923
GAUGUGUGAGAUAGUUUGU 478 919 CGACAAACCAAUACAAUCA 52 919
CGACAAACCAAUACAAUCA 52 941 UGAUUGUAUUGGUUUGUCG 479 937
AUAGAUGUCCAAAUAAGCA 53 937 AUAGAUGUCCAAAUAAGCA 53 959
UGCUUAUUUGGACAUCUAU 480 955 ACACCACGCCCAGUCAAAU 54 955
ACACCACGCCCAGUCAAAU 54 977 AUUUGACUGGGCGUGGUGU 481 973
UUACUUAGAGGCCAUACUC 55 973 UUACUUAGAGGCCAUACUC 55 995
GAGUAUGGCCUCUAAGUAA 482 991 CUUGUCCUCAAUUGUACUG 56 991
CUUGUCCUCAAUUGUACUG 56 1013 CAGUACAAUUGAGGACAAG 483 1009
GCUACCACUCCCUUGAACA 57 1009 GCUACCACUCCCUUGAACA 57 1031
UGUUCAAGGGAGUGGUAGC 484 1027 ACGAGAGUUCAAAUGACCU 58 1027
ACGAGAGUUCAAAUGACCU 58 1049 AGGUCAUUUGAACUCUCGU 485 1045
UGGAGUUACCCUGAUGAAA 59 1045 UGGAGUUACCCUGAUGAAA 59 1067
UUUCAUCAGGGUAACUCCA 486 1063 AAAAAUAAGAGAGCUUCCG 60 1063
AAAAAUAAGAGAGCUUCCG 60 1085 CGGAAGCUCUCUUAUUUUU 487 1081
GUAAGGCGACGAAUUGACC 61 1081 GUAAGGCGACGAAUUGACC 61 1103
GGUCAAUUCGUCGCCUUAC 488 1099 CAAAGCAAUUCCCAUGCCA 62 1099
CAAAGCAAUUCCCAUGCCA 62 1121 UGGCAUGGGAAUUGCUUUG 489 1117
AACAUAUUCUACAGUGUUC 63 1117 AACAUAUUCUACAGUGUUC 63 1139
GAACACUGUAGAAUAUGUU 490 1135 CUUACUAUUGACAAAAUGC 64 1135
CUUACUAUUGACAAAAUGC 64 1157 GCAUUUUGUCAAUAGUAAG 491 1153
CAGAACAAAGACAAAGGAC 65 1153 CAGAACAAAGACAAAGGAC 65 1175
GUCCUUUGUCUUUGUUCUG 492 1171 CUUUAUACUUGUCGUGUAA 66 1171
CUUUAUACUUGUCGUGUAA 66 1193 UUACACGACAAGUAUAAAG 493 1189
AGGAGUGGACCAUCAUUCA 67 1189 AGGAGUGGACCAUCAUUCA 67 1211
UGAAUGAUGGUCCACUCCU 494 1207 AAAUCUGUUAACACCUCAG 68 1207
AAAUCUGUUAACACCUCAG 68 1229 CUGAGGUGUUAACAGAUUU 495 1225
GUGCAUAUAUAUGAUkAAG 69 1225 GUGCAUAUAUAUGAUAAAG 69 1247
CUUUAUCAUAUAUAUGCAC 496 1243 GCAUUCAUCACUGUGAAAC 70 1243
GCAUUCAUCACUGUGAAAC 70 1265 GUUUCACAGUGAUGAAUGC 497 1261
CAUCGAAAACAGCAGGUGC 71 1261 CAUCGAAAACAGCAGGUGC 71 1283
GCACCUGCUGUUUUCGAUG 498 1279 CUUGAAACCGUAGCUGGCA 72 1279
CUUGAAACCGUAGCUGGCA 72 1301 UGCCAGCUACGGUUUCAAG 499 1297
AAGCGGUCUUACCGGCUCU 73 1297 AAGCGGUCUUACCGGCUCU 73 1319
AGAGCCGGUAAGACCGCUU 500 1315 UCUAUGAAAGUGAAGGCAU 74 1315
UCUAUGAAAGUGAAGGCAU 74 1337 AUGCCUUCACUUUCAUAGA 501 1333
UUUCCCUCGCCGGAAGUUG 75 1333 UUUCCCUCGCCGGAAGUUG 75 1355
CAACUUCCGGCGAGGGAAA 502 1351 GUAUGGUUAAAAGAUGGGU 76 1351
GUAUGGUUAAAAGAUGGGU 76 1373 ACCCAUCUUUUAACCAUAC 503 1369
UUACCUGCGACUGAGAAAU 77 1369 UUACCUGCGACUGAGAAAU 77 1391
AUUUCUCAGUCGCAGGUAA 504 1387 UCUGCUCGCUAUUUGACUC 78 1387
UCUGCUCGCUAUUUGACUC 78 1409 GAGUCAAAUAGCGAGCAGA 505 1405
CGUGGCUACUCGUUAAUUA 79 1405 CGUGGCUACUCGUUAAUUA 79 1427
UAAUUAACGAGUAGCCACG 506 1423 AUCAAGGACGUAACUGAAG 80 1423
AUCAAGGACGUAACUGAAG 80 1445 CUUCAGUUACGUCCUUGAU 507 1441
GAGGAUGCAGGGAAUUAUA 81 1441 GAGGAUGCAGGGAAUUAUA 81 1463
UAUAAUUCCCUGCAUCCUC 508 1459 ACAAUCUUGCUGAGCAUAA 82 1459
ACAAUCUUGCUGAGCAUAA 82 1481 UUAUGCUCAGCAAGAUUGU 509 1477
AAACAGUCAAAUGUGUUUA 83 1477 AAACAGUCAAAUGUGUUUA 83 1499
UAAACACAUUUGACUGUUU 510 1495 AAAAACCUCACUGCCACUC 84 1495
AAAAACCUCACUGCCACUC 84 1517 GAGUGGCAGUGAGGUUUUU 511 1513
CUAAUUGUCAAUGUGAAAC 85 1513 CUAAUUGUCAAUGUGAAAC 85 1535
GUUUCACAUUGACAAUUAG 512 1531 CCCCAGAUUUACGAAAAGG 86 1531
CCCCAGAUUUACGAAAAGG 86 1553 CCUUUUCGUAAAUCUGGGG 513 1549
GCCGUGUCAUCGUUUCCAG 87 1549 GCCGUGUCAUCGUUUCCAG 87 1571
CUGGAAACGAUGACACGGC 514 1567 GACCCGGCUCUCUACCCAC 88 1567
GACCCGGCUCUCUACCCAC 88 1589 GUGGGUAGAGAGCCGGGUC 515 1585
CUGGGCAGCAGACAAAUCC 89 1585 CUGGGCAGCAGACAAAUCC 89 1607
GGAUUUGUCUGCUGCCCAG 516 1603 CUGACUUGUACCGCAUAUG 90 1603
CUGACUUGUACCGCAUAUG 90 1625 CAUAUGCGGUACAAGUCAG 517 1621
GGUAUCCCUCAACCUACAA 91 1621 GGUAUCCCUCAACCUACAA 91 1643
UUGUAGGUUGAGGGAUACC 518 1639 AUCAAGUGGUUCUGGCACC 92 1639
AUCAAGUGGUUCUGGCACC 92 1661 GGUGCCAGAACCACUUGAU 519 1657
CCCUGUAACCAUAAUCAUU 93 1657 CCCUGUAACCAUAAUCAUU 93 1679
AAUGAUUAUGGUUACAGGG 520 1675 UCCGAAGCAAGGUGUGACU 94 1675
UCCGAAGCAAGGUGUGACU 94 1697 AGUCACACCUUGCUUCGGA 521 1693
UUUUGUUCCAAUAAUGAAG 95 1693 UUUUGUUCCAAUAAUGAAG 95 1715
CUUCAUUAUUGGAACAAAA 522 1711 GAGUCCUUUAUCCUGGAUG 96 1711
GAGUCCUUUAUCCUGGAUG 96 1733 CAUCCAGGAUAAAGGACUC 523 1729
GCUGACAGCAACAUGGGAA 97 1729 GCUGACAGCAACAUGGGAA 97 1751
UUCCCAUGUUGCUGUCAGC 524 1747 AACAGAAUUGAGAGCAUCA 98 1747
AACAGAAUUGAGAGCAUCA 98 1769 UGAUGCUCUCAAUUCUGUU 525 1765
ACUCAGCGCAUGGCAAUAA 99 1765 ACUCAGCGCAUGGCAAUAA 99 1787
UUAUUGCCAUGCGCUGAGU 526 1783 AUAGAAGGAAAGAAUAAGA 100 1783
AUAGAAGGAAAGAAUAAGA 100 1805 UCUUAUUCUUUCCUUCUAU 527 1801
AUGGCUAGCACCUUGGUUG 101 1801 AUGGCUAGCACCUUGGUUG 101 1823
CAACCAAGGUGCUAGCCAU 528 1819 GUGGCUGACUCUAGAAUUU 102 1819
GUGGCUGACUCUAGAAUUU 102 1841 AAAUUCUAGAGUCAGCCAC 529 1837
UCUGGAAUCUACAUUUGCA 103 1837 UCUGGAAUCUACAUUUGCA 103 1859
UGCAAAUGUAGAUUCCAGA 530 1855 AUAGCUUCCAAUAAAGUUG 104 1855
AUAGCUUCCAAUAAAGUUG 104 1877 CAACUUUAUUGGAAGCUAU 531 1873
GGGACUGUGGGAAGAAACA 105 1873 GGGACUGUGGGAAGAAACA 105 1895
UGUUUCUUCCCACAGUCCC 532 1891 AUAAGCUUUUAUAUCACAG 106 1891
AUAAGCUUUUAUAUCACAG 106 1913 CUGUGAUAUAAAAGCUUAU 533 1909
GAUGUGCCAAAUGGGUUUC 107 1909 GAUGUGCCAAAUGGGUUUC 107 1931
GAAACCCAUUUGGCACAUC 534 1927 CAUGUUAACUUGGAAAAAA 108 1927
CAUGUUAACUUGGAAAAAA 108 1949 UUUUUUCCAAGUUAACAUG 535 1945
AUGCCGACGGAAGGAGAGG 109 1945 AUGCCGACGGAAGGAGAGG 109 1967
CCUCUCCUUCCGUCGGCAU 536 1963 GACCUGAAACUGUCUUGCA 110 1963
GACCUGAAACUGUCUUGCA 110 1985 UGCAAGACAGUUUCAGGUC 537 1981
ACAGUUAACAAGUUCUUAU 111 1981 ACAGUUAACAAGUUCUUAU 111 2003
AUAAGAACUUGUUAACUGU 538 1999 UACAGAGACGUUACUUGGA 112 1999
UACAGAGACGUUACUUGGA 112 2021 UCCAAGUAACGUCUCUGUA 539 2017
AUUUUACUGCGGACAGUUA 113 2017 AUUUUACUGCGGACAGUUA 113 2039
UAACUGUCCGCAGUAAAAU 540 2035 AAUAACAGAACAAUGCACU 114 2035
AAUAACAGAACAAUGCACU 114 2057 AGUGCAUUGUUCUGUUAUU 541 2053
UACAGUAUUAGCAAGCAAA 115 2053 UACAGUAUUAGCAAGCAAA 115 2075
UUUGCUUGCUAAUACUGUA 542 2071 AAAAUGGCCAUCACUAAGG 116 2071
AAAAUGGCCAUCACUAAGG 116 2093 CCUUAGUGAUGGCCAUUUU 543 2089
GAGCACUCCAUCACUCUUA 117 2089 GAGCACUCCAUCACUCUUA 117 2111
UAAGAGUGAUGGAGUGCUC 544 2107 AAUCUUACCAUCAUGAAUG 118 2107
AAUCUUACCAUCAUGAAUG 118 2129 CAUUCAUGAUGGUAAGAUU 545 2125
GUUUCCCUGCAAGAUUCAG 119 2125 GUUUCCCUGCAAGAUUCAG 119 2147
CUGAAUCUUGCAGGGAAAC 546 2143 GGCACCUAUGCCUGCAGAG 120 2143
GGCACCUAUGCCUGCAGAG 120 2165 CUCUGCAGGCAUAGGUGCC 547 2161
GCCAGGAAUGUAUACACAG 121 2161 GCCAGGAAUGUAUACACAG 121 2183
CUGUGUAUACAUUCCUGGC 548 2179 GGGGAAGAAAUCCUCCAGA 122 2179
GGGGAAGAAAUCCUCCAGA 122 2201 UCUGGAGGAUUUCUUCCCC 549 2197
AAGAAAGAAAUUACAAUCA 123 2197 AAGAAAGAAAUUACAAUCA 123 2219
UGAUUGUAAUUUCUUUCUU 550 2215 AGAGAUCAGGAAGCACCAU 124 2215
AGAGAUCAGGAAGCACCAU 124 2237 AUGGUGCUUCCUGAUCUCU 551 2233
UACCUCCUGCGAAACCUCA 125 2233 UACCUCCUGCGAAACCUCA 125 2255
UGAGGUUUCGCAGGAGGUA 552 2251 AGUGAUCACACAGUGGCCA 126 2251
AGUGAUCACACAGUGGCCA 126 2273 UGGCCACUGUGUGAUCACU 553 2269
AUCAGCAGUUCCACCACUU 127 2269 AUCAGCAGUUCCACCACUU 127 2291
AAGUGGUGGAACUGCUGAU 554 2287 UUAGACUGUCAUGCUAAUG 128 2287
UUAGACUGUCAUGCUAAUG 128 2309 CAUUAGCAUGACAGUCUAA 555 2305
GGUGUCCCCGAGCCUCAGA 129 2305 GGUGUCCCCGAGCCUCAGA 129 2327
UCUGAGGCUCGGGGACACC 556 2323 AUCACUUGGUUUAAAAACA 130 2323
AUCACUUGGUUUAAAAACA 130 2345 UGUUUUUAAACCAAGUGAU 557 2341
AACCACAAAAUACAACAAG 131 2341 AACCACAAAAUACAACAAG 131 2363
CUUGUUGUAUUUUGUGGUU 558 2359 GAGCCUGGAAUUAUUUUAG 132 2359
GAGCCUGGAAUUAUUUUAG 132 2381 CUAAAAUAAUUCCAGGCUC 559 2377
GGACCAGGPAGCAGCACGC 133 2377 GGACCAGGAAGCAGCACGC 133 2399
GCGUGCUGCUUCCUGGUCC 560 2395 CUGUUUAUUGAAAGAGUCA 134 2395
CUGUUUAUUGAAAGAGUCA 134 2417 UGACUCUUUCAAUAAACAG 561 2413
ACAGAAGAGGAUGAAGGUG 135 2413 ACAGAAGAGGAUGAAGGUG 135 2435
CACCUUCAUCCUCUUCUGU 562 2431 GUCUAUCACUGCAAAGCCA 136 2431
GUCUAUCACUGCAAAGCCA 136 2453 UGGCUUUGCAGUGAUAGAC 563 2449
ACCAACCAGAAGGGCUCUG 137 2449 ACCAACCAGAAGGGCUCUG 137 2471
CAGAGCCCUUCUGGUUGGU 564 2467 GUGGAAAGUUCAGCAUACC 138 2467
GUGGAAAGUUCAGCAUACC 138 2489 GGUAUGCUGAACUUUCCAC 565 2485
CUCACUGUUCAAGGAACCU 139 2485 CUCACUGUUCAAGGAACCU 139 2507
AGGUUCCUUGAACAGUGAG 566 2503 UCGGACAAGUCUAAUCUGG 140 2503
UCGGACAAGUCUAAUCUGG 140 2525 CCAGAUUAGACUUGUCCGA 567 2521
GAGCUGAUCACUCUAACAU 141 2521 GAGCUGAUCACUCUAACAU 141 2543
AUGUUAGAGUGAUCAGCUC 568 2539 UGCACCUGUGUGGCUGCGA 142 2539
UGCACCUGUGUGGCUGCGA 142 2561 UCGCAGCCACACAGGUGCA 569 2557
ACUCUCUUCUGGCUCCUAU 143 2557 ACUCUCUUCUGGCUCCUAU 143 2579
AUAGGAGCCAGAAGAGAGU 570 2575 UUAACCCUCCUUAUCCGAA 144 2575
UUAACCCUCCUUAUCCGAA 144 2597 UUCGGAUAAGGAGGGUUAA 571 2593
AAAAUGAAAAGGUCUUCUU 145 2593 AAAAUGAAAAGGUCUUCUU 145 2615
AAGAAGACCUUUUCAUUUU 572 2611 UCUGAAAUAAAGACUGACU 146 2611
UCUGAAAUAAAGACUGACU 146 2633 AGUCAGUCUUUAUUUCAGA 573 2629
UACCUAUCAAUUAUAAUGG 147 2629 UACCUAUCAAUUAUAAUGG 147 2651
CCAUUAUAAUUGAUAGGUA 574 2647 GACCCAGAUGAAGUUCCUU 148 2647
GACCCAGAUGAAGUUCCUU 148 2669 AAGGAACUUCAUCUGGGUC 575 2665
UUGGAUGAGCAGUGUGAGC 149 2665 UUGGAUGAGCAGUGUGAGC 149 2687
GCUCACACUGCUCAUCCAA 576 2683 CGGCUCCCUUAUGAUGCCA 150 2683
CGGCUCCCUUAUGAUGCCA 150 2705 UGGCAUCAUAAGGGAGCCG 577 2701
AGCAAGUGGGAGUUUGCCC 151 2701 AGCAAGUGGGAGUUUGCCC 151 2723
GGGCAAACUCCCACUUGCU 578 2719 CGGGAGAGACUUAAACUGG 152 2719
CGGGAGAGACUUAAACUGG 152 2741 CCAGUUUAAGUCUCUCCCG 579 2737
GGCAAAUCACUUGGAAGAG 153 2737 GGCAAAUCACUUGGAAGAG 153 2759
CUCUUCCAAGUGAUUUGCC 580 2755 GGGGCUUUUGGAAAAGUGG 154 2755
GGGGCUUUUGGAAAAGUGG 154 2777 CCACUUUUCCAAAAGCCCC 581 2773
GUUCAAGCAUCAGCAUUUG 155 2773 GUUCAAGCAUCAGCAUUUG 155 2795
CAAAUGCUGAUGCUUGAAC 582 2791 GGCAUUAAGAAAUCACCUA 156 2791
GGCAUUAAGAAAUCACCUA 156 2813 UAGGUGAUUUCUUAAUGCC 583 2809
ACGUGCCGGACUGUGGCUG 157 2809 ACGUGCCGGACUGUGGCUG 157 2831
CAGCCACAGUCCGGCACGU 584 2827 GUGAAAAUGCUGAAAGAGG 158 2827
GUGAAAAUGCUGAAAGAGG 158 2849 CCUCUUUCAGCAUUUUCAC 585 2845
GGGGCCACGGCCAGCGAGU 159 2845 GGGGCCACGGCCAGCGAGU 159 2867
ACUCGCUGGCCGUGGCCCC 586 2863 UACAAAGCUCUGAUGACUG 160 2863
UACAAAGCUCUGAUGACUG 160 2885 CAGUCAUCAGAGCUUUGUA 587 2881
GAGCUAAAAAUCUUGACCC 161 2881 GAGCUAAAAAUCUUGACCC 161 2903
GGGUCAAGAUUUUUAGCUC 588 2899 CACAUUGGCCACCAUCUGA 162 2899
CACAUUGGCCACCAUCUGA 162 2921 UCAGAUGGUGGCCAAUGUG 589 2917
AACGUGGUUAACCUGCUGG 163 2917 AACGUGGUUAACCUGCUGG 163 2939
CCAGCAGGUUAACCACGUU 590 2935 GGAGCCUGCACCAAGCAAG 164 2935
GGAGCCUGCACCAAGCAAG 164 2957 CUUGCUUGGUGCAGGCUCC 591 2953
GGAGGGCCUCUGAUGGUGA 165 2953 GGAGGGCCUCUGAUGGUGA 165 2975
UCACCAUCAGAGGCCCUCC 592 2971 AUUGUUGAAUACUGCAAAU 166 2971
AUUGUUGAAUACUGCAAAU 166 2993 AUUUGCAGUAUUCAACAAU 593 2989
UAUGGAAAUCUCUCCAACU 167 2989 UAUGGAAAUCUCUCCAACU 167 3011
AGUUGGAGAGAUUUCCAUA 594 3007 UACCUCAAGAGCAAACGUG 168 3007
UACCUCAAGAGCAAACGUG 168 3029 CACGUUUGCUCUUGAGGUA 595 3025
GACUUAUUUUUUCUCAACA 169 3025 GACUUAUUUUUUCUCAACA 169 3047
UGUUGAGAAAAAAUAAGUC 596 3043 AAGGAUGCAGCACUACACA 170 3043
AAGGAUGCAGCACUACACA 170 3065 UGUGUAGUGCUGCAUCCUU 597 3061
AUGGAGCCUAAGAAAGAAA 171 3061 AUGGAGCCUAAGAAAGAAA 171 3083
UUUCUUUCUUAGGCUCCAU 598 3079 AAAAUGGAGCCAGGCCUGG 172 3079
AAAAUGGAGCCAGGCCUGG 172 3101 CCAGGCCUGGCUCCAUUUU 599 3097
GAACAAGGCAAGAAACCAA 173 3097 GAACAAGGCAAGAAACCAA 173 3119
UUGGUUUCUUGCCUUGUUC 600 3115 AGACUAGAUAGCGUCACCA 174 3115
AGACUAGAUAGCGUCACCA 174 3137 UGGUGACGCUAUCUAGUCU 601 3133
AGCAGCGAAAGCUUUGCGA 175 3133 AGCAGCGAAAGCUUUGCGA 175 3155
UCGCAAAGCUUUCGCUGCU 602 3151 AGCUCCGGCUUUCAGGAAG 176 3151
AGCUCCGGCUUUCAGGAAG 176 3173 CUUCCUGAAAGCCGGAGCU 603 3169
GAUAAAAGUCUGAGUGAUG 177 3169 GAUAAAAGUCUGAGUGAUG 177 3191
CAUCACUCAGACUUUUAUC 604 3187 GUUGAGGAAGAGGAGGAUU 178 3187
GUUGAGGAAGAGGAGGAUU 178 3209 AAUCCUCCUCUUCCUCAAC 605 3205
UCUGACGGUUUCUACAAGG 179 3205 UCUGACGGUUUCUACAAGG 179 3227
CCUUGUAGAAACCGUCAGA 606 3223 GAGCCCAUCACUAUGGAAG 180 3223
GAGCCCAUCACUAUGGAAG 180 3245 CUUCCAUAGUGAUGGGCUC 607 3241
GAUCUGAUUUCUUACAGUU 181 3241 GAUCUGAUUUCUUACAGUU 181 3263
AACUGUAAGAAAUCAGAUC 608 3259 UUUCAAGUGGCCAGAGGCA 182 3259
UUUCAAGUGGCCAGAGGCA 182 3281 UGCCUCUGGCCACUUGAAA 609 3277
AUGGAGUUCCUGUCUUCCA 183 3277 AUGGAGUUCCUGUCUUCCA 183 3299
UGGAAGACAGGAACUCCAU 610 3295 AGAAAGUGCAUUCAUCGGG 184 3295
AGAAAGUGCAUUCAUCGGG 184 3317 CCCGAUGAAUGCACUUUCU 611 3313
GACCUGGCAGCGAGAAACA 185 3313 GACCUGGCAGCGAGAAACA 185 3335
UGUUUCUCGCUGCCAGGUC 612 3331 AUUCUUUUAUCUGAGAACA 186 3331
AUUCUUUUAUCUGAGAACA 186 3353 UGUUCUCAGAUAAAAGAAU 613 3349
AACGUGGUGAAGAUUUGUG 187 3349 AACGUGGUGAAGAUUUGUG 187 3371
CACAAAUCUUCACCACGUU 614 3367 GAUUUUGGCCUUGCCCGGG 188 3367
GAUUUUGGCCUUGCCCGGG 188 3389 CCCGGGCAAGGCCAAAAUC 615 3385
GAUAUUUAUAAGAACCCCG 189 3385 GAUAUUUAUAAGAACCCCG 189 3407
CGGGGUUCUUAUAAAUAUC 616 3403 GAUUAUGUGAGAAAAGGAG 190 3403
GAUUAUGUGAGAAAAGGAG 190 3425 CUCCUUUUCUCACAUAAUC 617 3421
GAUACUCGACUUCCUCUGA 191 3421 GAUACUCGACUUCCUCUGA 191 3443
UCAGAGGAAGUCGAGUAUC 618 3439 AAAUGGAUGGCUCCCGAAU 192 3439
AAAUGGAUGGCUCCCGAAU 192 3461 AUUCGGGAGCCAUCCAUUU 619 3457
UCUAUCUUUGACAAAAUCU 193 3457 UCUAUCUUUGACAAAAUCU 193 3479
AGAUUUUGUCAAAGAUAGA 620 3475 UACAGCACCAAGAGCGACG 194 3475
UACAGCACCAAGAGCGACG 194 3497 CGUCGCUCUUGGUGCUGUA 621 3493
GUGUGGUCUUACGGAGUAU 195 3493 GUGUGGUCUUACGGAGUAU 195 3515
AUACUCCGUAAGACCACAC 622 3511 UUGCUGUGGGAAAUCUUCU 196 3511
UUGCUGUGGGAAAUCUUCU 196 3533 AGAAGAUUUCCCACAGCAA 623 3529
UCCUUAGGUGGGUCUCCAU 197 3529 UCCUUAGGUGGGUCUCCAU 197 3551
AUGGAGACCCACCUAAGGA 624 3547 UACCCAGGAGUACAAAUGG 198 3547
UACCCAGGAGUACAAAUGG 198 3569 CCAUUUGUACUCCUGGGUA 625 3565
GAUGAGGACUUUUGCAGUC 199 3565 GAUGAGGACUUUUGCAGUC 199 3587
GACUGCAAAAGUCCUCAUC 626 3583 CGCCUGAGGGAAGGCAUGA 200 3583
CGCCUGAGGGAAGGCAUGA 200 3605 UCAUGCCUUCCCUCAGGCG 627 3601
AGGAUGAGAGCUCCUGAGU 201 3601 AGGAUGAGAGCUCCUGAGU 201 3623
ACUCAGGAGCUCUCAUCCU 628 3619 UACUCUACUCCUGAAAUCU 202 3619
UACUCUACUCCUGAAAUCU 202 3641 AGAUUUCAGGAGUAGAGUA 629 3637
UAUCAGAUCAUGCUGGACU 203 3637 UAUCAGAUCAUGCUGGACU 203 3659
AGUCCAGCAUGAUCUGAUA 630 3655 UGCUGGCACAGAGACCCAA 204 3655
UGCUGGCACAGAGACCCAA 204 3677 UUGGGUCUCUGUGCCAGCA 631 3673
AAAGAAAGGCCAAGAUUUG 205 3673 AAAGAAAGGCCAAGAUUUG 205 3695
CAAAUCUUGGCCUUUCUUU 632 3691 GCAGAACUUGUGGAAAAAC 206 3691
GCAGAACUUGUGGAAAAAC 206 3713 GUUUUUCCACAAGUUCUGC 633 3709
CUAGGUGAUUUGCUUCAAG 207 3709 CUAGGUGAUUUGCUUCAAG 207 3731
CUUGAAGCAAAUCACCUAG 634 3727 GCAAAUGUACAACAGGAUG 208 3727
GCAAAUGUACAACAGGAUG 208 3749 CAUCCUGUUGUACAUUUGC 635 3745
GGUAAAGACUACAUCCCAA 209 3745 GGUAAAGACUACAUCCCAA 209 3767
UUGGGAUGUAGUCUUUACC 636 3763 AUCAAUGCCAUACUGACAG 210 3763
AUCAAUGCCAUACUGACAG 210 3785 CUGUCAGUAUGGCAUUGAU 637 3781
GGAAAUAGUGGGUUUACAU 211 3781 GGAAAUAGUGGGUUUACAU 211 3803
AUGUAAACCCACUAUUUCC 638 3799 UACUCAACUCCUGCCUUCU 212 3799
UACUCAACUCCUGCCUUCU 212 3821 AGAAGGCAGGAGUUGAGUA 639 3817
UCUGAGGACUUCUUCAAGG 213 3817 UCUGAGGACUUCUUCAAGG 213 3839
CCUUGAAGkAGUCCUCAGA 640 3835 GAAAGUAUUUCAGCUCCGA 214 3835
GAAAGUAUUUCAGCUCCGA 214 3857 UCGGAGCUGAAAUACUUUC 641 3853
AAGUUUAAUUCAGGAAGCU 215 3853 AAGUUUAAUUCAGGAAGCU 215 3875
AGCUUCCUGAAUUAAACUU 642 3871 UCUGAUGAUGUCAGAUAUG 216 3871
UCUGAUGAUGUCAGAUAUG 216 3893 CAUAUCUGACAUCAUCAGA 643 3889
GUAAAUGCUUUCAAGUUCA 217 3889 GUAAAUGCUUUCAAGUUCA 217 3911
UGAACUUGAAAGCAUUUAC 644 3907 AUGAGCCUGGAAAGAAUCA 218 3907
AUGAGCCUGGAAAGAAUCA 218 3929 UGAUUCUUUCCAGGCUCAU 645 3925
AAAACCUUUGAAGAACUUU 219 3925 AAAACCUUUGAAGAACUUU 219 3947
AAAGUUCUUCAAAGGUUUU 646 3943 UUACCGAAUGCCACCUCCA 220 3943
UUACCGAAUGCCACCUCCA 220 3965 UGGAGGUGGCAUUCGGUAA 647 3961
AUGUUUGAUGACUACCAGG 221 3961 AUGUUUGAUGACUACCAGG 221 3983
CCUGGUAGUCAUCAAACAU 648 3979 GGCGACAGCAGCACUCUGU 222 3979
GGCGACAGCAGCACUCUGU 222 4001 ACAGAGUGCUGCUGUCGCC 649 3997
UUGGCCUCUCCCAUGCUGA 223 3997 UUGGCCUCUCCCAUGCUGA 223 4019
UCAGCAUGGGAGAGGCCAA 650 4015 AAGCGCUUCACCUGGACUG 224 4015
AAGCGCUUCACCUGGACUG 224 4037 CAGUCCAGGUGAAGCGCUU 651 4033
GACAGCAAACCCAAGGCCU 225 4033 GACAGCAAACCCAAGGCCU 225 4055
AGGCCUUGGGUUUGCUGUC 652 4051 UCGCUCAAGAUUGACUUGA 226 4051
UCGCUCAAGAUUGACUUGA 226 4073 UCAAGUCAAUCUUGAGCGA 653 4069
AGAGUAACCAGUAAAAGUA 227 4069 AGAGUAACCAGUAAAAGUA 227 4091
UACUUUUACUGGUUACUCU 654 4087 AAGGAGUCGGGGCUGUCUG 228 4087
AAGGAGUCGGGGCUGUCUG 228 4109 CAGACAGCCCCGACUCCUU 655 4105
GAUGUCAGCAGGCCCAGUU 229 4105 GAUGUCAGCAGGCCCAGUU 229 4127
AACUGGGCCUGCUGACAUC 656 4123 UUCUGCCAUUCCAGCUGUG 230 4123
UUCUGCCAUUCCAGCUGUG 230 4145 CACAGCUGGAAUGGCAGAA 657 4141
GGGCACGUCAGCGAAGGCA 231 4141 GGGCACGUCAGCGAAGGCA 231 4163
UGCCUUCGCUGACGUGCCC 658 4159 AAGCGCAGGUUCACCUACG 232 4159
AAGCGCAGGUUCACCUACG 232 4181 CGUAGGUGAACCUGCGCUU 659 4177
GACCACGCUGAGCUGGAAA 233 4177 GACCACGCUGAGCUGGAAA 233 4199
UUUCCAGCUCAGCGUGGUC 660 4195 AGGAAAAUCGCGUGCUGCU 234 4195
AGGAAAAUCGCGUGCUGCU 234 4217 AGCAGCACGCGAUUUUCCU 661 4213
UCCCCGCCCCCAGACUACA 235 4213 UCCCCGCCCCCAGACUACA 235 4235
UGUAGUCUGGGGGCGGGGA 662 4231 AACUCGGUGGUCCUGUACU 236 4231
AACUCGGUGGUCCUGUACU 236 4253 AGUACAGGACCACCGAGUU 663 4249
UCCACCCCACCCAUCUAGA 237 4249 UCCACCCCACCCAUCUAGA 237 4271
UCUAGAUGGGUGGGGUGGA 664 4267 AGUUUGACACGAAGCCUUA 238 4267
AGUUUGACACGAAGCCUUA 238 4289 UAAGGCUUCGUGUCAAACU 665 4285
AUUUCUAGAAGCACAUGUG 239 4285 AUUUCUAGAAGCACAUGUG 239 4307
CACAUGUGCUUCUAGAAAU 666 4303 GUAUUUAUACCCCCAGGAA 240 4303
GUAUUUAUACCCCCAGGAA 240 4325 UUCCUGGGGGUAUAAAUAC 667 4321
AACUAGCUUUUGCCAGUAU 241 4321 AACUAGCUUUUGCCAGUAU 241 4343
AUACUGGCAAAAGCUAGUU 668 4339 UUAUGCAUAUAUAAGUUUA 242 4339
UUAUGCAUAUAUAAGUUUA 242 4361 UAAACUUAUAUAUGCAUAA 669 4357
ACACCUUUAUCUUUCCAUG 243 4357 ACACCUUUAUCUUUCCAUG 243 4379
CAUGGAAAGAUAAAGGUGU 670 4375 GGGAGCCAGCUGCUUUUUG 244 4375
GGGAGCCAGCUGCUUUUUG 244 4397 CAAAAAGCAGCUGGCUCCC 671 4393
GUGAUUUUUUUAAUAGUGC 245 4393 GUGAUUUUUUUAAUAGUGC 245 4415
GCACUAUUAAAAAAAUCAC 672 4411 CUUUUUUUUUUUGACUAAC 246 4411
CUUUUUUUUUUUGACUAAC 246 4433 GUUAGUCAAAAAAAAAAAG 673 4429
CAAGAAUGUAACUCCAGAU 247 4429 CAAGAAUGUAACUCCAGAU 247 4451
AUCUGGAGUUACAUUCUUG 674 4447 UAGAGAAAUAGUGACAAGU 248 4447
UAGAGAAAUAGUGACAAGU 248 4469 ACUUGUCACUAUUUCUCUA 675 4465
UGAAGAACACUACUGCUAA 249 4465 UGAAGAACACUACUGCUAA 249 4487
UUAGCAGUAGUGUUCUUCA 676 4483 AAUCCUCAUGUUACUCAGU 250 4483
AAUCCUCAUGUUACUCAGU 250 4505 ACUGAGUAACAUGAGGAUU 677 4501
UGUUAGAGAAAUCCUUCCU 251 4501 UGUUAGAGAAAUCCUUCCU 251 4523
AGGAAGGAUUUCUCUAACA 678 4519 UAAACCCAAUGACUUCCCU 252 4519
UAAACCCAAUGACUUCCCU 252 4541 AGGGAAGUCAUUGGGUUUA 679 4537
UGCUCCAACCCCCGCCACC 253 4537 UGCUCCAACCCCCGCCACC 253 4559
GGUGGCGGGGGUUGGAGCA 680 4555 CUCAGGGCACGCAGGACCA 254 4555
CUCAGGGCACGCAGGACCA 254 4577 UGGUCCUGCGUGCCCUGAG 681 4573
AGUUUGAUUGAGGAGCUGC 255 4573 AGUUUGAUUGAGGAGCUGC 255 4595
GCAGCUCCUCAAUCAAACU 682 4591 CACUGAUCACCCAAUGCAU 256 4591
CACUGAUCACCCAAUGCAU 256 4613 AUGCAUUGGGUGAUCAGUG 683 4609
UCACGUACCCCACUGGGCC 257 4609 UCACGUACCCCACUGGGCC 257 4631
GGCCCAGUGGGGUACGUGA 684 4627 CAGCCCUGCAGCCCAAAAC 258 4627
CAGCCCUGCAGCCCAAAAC 258 4649 GUUUUGGGCUGCAGGGCUG 685 4645
CCCAGGGCAACAAGCCCGU 259 4645 CCCAGGGCAACAAGCCCGU 259 4667
ACGGGCUUGUUGCCCUGGG 686 4663 UUAGCCCCAGGGGAUCACU 260 4663
UUAGCCCCAGGGGAUCACU 260 4685 AGUGAUCCCCUGGGGCUAA 687 4681
UGGCUGGCCUGAGCAACAU 261 4681 UGGCUGGCCUGAGCAACAU 261 4703
AUGUUGCUCAGGCCAGCCA 688 4699 UCUCGGGAGUCCUCUAGCA 262 4699
UCUCGGGAGUCCUCUAGCA 262 4721 UGCUAGAGGACUCCCGAGA 689 4717
AGGCCUAAGACAUGUGAGG 263 4717 AGGCCUAAGACAUGUGAGG 263 4739
CCUCACAUGUCUUAGGCCU 690 4735 GAGGAAAAGGAAAAAAAGC 264 4735
GAGGAAAAGGAAAAAAAGC 264 4757 GCUUUUUUUCCUUUUCCUC 691 4753
CAAAAAGCAAGGGAGAAAA 265 4753 CAAAAAGCAAGGGAGAAAA 265 4775
UUUUCUCCCUUGCUUUUUG 692 4771 AGAGAAACCGGGAGAAGGC 266 4771
AGAGAAACCGGGAGAAGGC 266 4793 GCCUUCUCCCGGUUUCUCU 693 4789
CAUGAGAAAGAAUUUGAGA 267 4789 CAUGAGAAAGAAUUUGAGA 267 4811
UCUCAAAUUCUUUCUCAUG 694 4807 ACGCACCAUGUGGGCACGG 268 4807
ACGCACCAUGUGGGCACGG 268 4829 CCGUGCCCACAUGGUGCGU 695 4825
GAGGGGGACGGGGCUCAGC 269 4825 GAGGGGGACGGGGCUCAGC 269 4847
GCUGAGCCCCGUCCCCCUC 696 4843 CAAUGCCAUUUCAGUGGCU 270 4843
CAAUGCCAUUUCAGUGGCU 270 4865 AGCCACUGAAAUGGCAUUG 697 4861
UUCCCAGCUCUGACCCUUC 271 4861 UUCCCAGCUCUGACCCUUC 271 4883
GAAGGGUCAGAGCUGGGAA 698 4879 CUACAUUUGAGGGCCCAGC 272 4879
CUACAUUUGAGGGCCCAGC 272 4901 GCUGGGCCCUCAAAUGUAG 699 4897
CCAGGAGCAGAUGGACAGC 273 4897 CCAGGAGCAGAUGGACAGC 273 4919
GCUGUCCAUCUGCUCCUGG 700 4915 CGAUGAGGGGACAUUUUCU 274 4915
CGAUGAGGGGACAUUUUCU 274 4937 AGAAAAUGUCCCCUCAUCG 701 4933
UGGAUUCUGGGAGGCAAGA 275 4933 UGGAUUCUGGGAGGCAAGA 275 4955
UCUUGCCUCCCAGAAUCCA 702 4951 AAAAGGACAAAUAUCUUUU 276 4951
AAAAGGACAAAUAUCUUUU 276 4973 AAAAGAUAUUUGUCCUUUU 703 4969
UUUGGAACUAAAGCAAAUU 277 4969 UUUGGAACUAAAGCAAAUU 277 4991
AAUUUGCUUUAGUUCCAAA 704 4987 UUUAGACCUUUACCUAUGG 278 4987
UUUAGACCUUUACCUAUGG 278 5009 CCAUAGGUAAAGGUCUAAA 705 5005
GAAGUGGUUCUAUGUCCAU 279 5005 GAAGUGGUUCUAUGUCCAU 279 5027
AUGGACAUAGAACCACUUC 706 5023 UUCUCAUUCGUGGCAUGUU 280 5023
UUCUCAUUCGUGGCAUGUU 280 5045 AACAUGCCACGAAUGAGAA 707 5041
UUUGAUUUGUAGCACUGAG 281 5041 UUUGAUUUGUAGCACUGAG 281 5063
CUCAGUGCUACAAAUCAAA 708 5059 GGGUGGCACUCAACUCUGA 282 5059
GGGUGGCACUCAACUCUGA 282 5081 UCAGAGUUGAGUGCCACCC 709 5077
AGCCCAUACUUUUGGCUCC 283 5077 AGCCCAUACUUUUGGCUCC 283 5099
GGAGCCAAAAGUAUGGGCU 710 5095 CUCUAGUAAGAUGCACUGA 284 5095
CUCUAGUAAGAUGCACUGA 284 5117 UCAGUGCAUCUUACUAGAG 711 5113
AAAACUUAGCCAGAGUUAG 285 5113 AAAACUUAGCCAGAGUUAG 285 5135
CUAACUCUGGCUAAGUUUU 712 5131 GGUUGUCUCCAGGCCAUGA 286 5131
GGUUGUCUCCAGGCCAUGA 286 5153 UCAUGGCCUGGAGACAACC 713 5149
AUGGCCUUACACUGAAAAU 287 5149 AUGGCCUUACACUGAAAAU 287 5171
AUUUUCAGUGUAAGGCCAU 714 5167 UGUCACAUUCUAUUUUGGG 288 5167
UGUCACAUUCUAUUUUGGG 288 5189 CCCAAAAUAGAAUGUGACA 715 5185
GUAUUAAUAUAUAGUCCAG 289 5185 GUAUUAAUAUAUAGUCCAG 289 5207
CUGGACUAUAUAUUAAUAC 716 5203 GACACUUAACUCAAUUUCU 290 5203
GACACUUAACUCAAUUUCU 290 5225 AGAAAUUGAGUUAAGUGUC 717 5221
UUGGUAUUAUUCUGUUUUG 291 5221 UUGGUAUUAUUCUGUUUUG 291 5243
CAAAACAGAAUAAUACCAA 718 5239 GCACAGUUAGUUGUGAAAG 292 5239
GCACAGUUAGUUGUGAAAG 292 5261 CUUUCACAACUAACUGUGC 719 5257
GAAAGCUGAGAAGAAUGAA 293 5257 GAAAGCUGAGAAGAAUGAA 293 5279
UUCAUUCUUCUCAGCUUUC 720 5275 AAAUGCAGUCCUGAGGAGA 294 5275
AAAUGCAGUCCUGAGGAGA 294 5297 UCUCCUCAGGACUGCAUUU 721 5293
AGUUUUCUCCAUAUCAAAA 295 5293 AGUUUUCUCCAUAUCAAAA 295 5315
UUUUGAUAUGGAGAAAACU 722 5311 ACGAGGGCUGAUGGAGGAA 296 5311
ACGAGGGCUGAUGGAGGAA 296 5333 UUCCUCCAUCAGCCCUCGU 723 5329
AAAAGGUCAAUAAGGUCAA 297 5329 AAAAGGUCAAUAAGGUCAA 297 5351
UUGACCUUAUUGACCUUUU 724 5347 AGGGAAGACCCCGUCUCUA 298 5347
AGGGAAGACCCCGUCUCUA 298 5369 UAGAGACGGGGUCUUCCCU 725 5365
AUACCAACCAAACCAAUUC 299 5365 AUACCAACCAAACCAAUUC 299 5387
GAAUUGGUUUGGUUGGUAU 726 5383 CACCAACACAGUUGGGACC 300 5383
CACCAACACAGUUGGGACC 300 5405 GGUCCCAACUGUGUUGGUG 727 5401
CCAAAACACAGGAAGUCAG 301 5401 CCAAAACACAGGAAGUCAG 301 5423
CUGACUUCCUGUGUUUUGG 728 5419 GUCACGUUUCCUUUUCAUU 302 5419
GUCACGUUUCCUUUUCAUU 302 5441 AAUGAAAAGGAAACGUGAC 729 5437
UUAAUGGGGAUUCCACUAU 303 5437 UUAAUGGGGAUUCCACUAU 303 5459
AUAGUGGAAUCCCCAUUAA 730 5455 UCUCACACUAAUCUGAAAG 304 5455
UCUCACACUAAUCUGAAAG 304 5477 CUUUCAGAUUAGUGUGAGA 731 5473
GGAUGUGGAAGAGCAUUAG 305 5473 GGAUGUGGAAGAGCAUUAG 305 5495
CUAAUGCUCUUCCACAUCC 732 5491 GCUGGCGCAUAUUAAGCAC 306 5491
GCUGGCGCAUAUUAAGCAC 306 5513 GUGCUUAAUAUGCGCCAGC 733 5509
CUUUAAGCUCCUUGAGUAA 307 5509 CUUUAAGCUCCUUGAGUAA 307 5531
UUACUCAAGGAGCUUAAAG 734 5527 AAAAGGUGGUAUGUAAUUU 308 5527
AAAAGGUGGUAUGUAAUUU 308 5549 AAAUUACAUACCACCUUUU 735 5545
UAUGCAAGGUAUUUCUCCA 309 5545 UAUGCAAGGUAUUUCUCCA 309 5567
UGGAGAAAUACCUUGCAUA 736 5563 AGUUGGGACUCAGGAUAUU 310 5563
AGUUGGGACUCAGGAUAUU 310 5585 AAUAUCCUGAGUCCCAACU 737 5581
UAGUUAAUGAGCCAUCACU 311 5581 UAGUUAAUGAGCCAUCACU 311 5603
AGUGAUGGCUCAUUAACUA 738 5599 UAGAAGAAPAGCCCAUUUU 312 5599
UAGAAGAAAAGCCCAUUUU 312 5621 AAAAUGGGCUUUUCUUCUA 739 5617
UCAACUGCUUUGAAACUUG 313 5617 UCAACUGCUUUGAAACUUG 313 5639
CAAGUUUCAAAGCAGUUGA 740 5635 GCCUGGGGUCUGAGCAUGA 314 5635
GCCUGGGGUCUGAGCAUGA 314 5657 UCAUGCUCAGACCCCAGGC 741 5653
AUGGGAAUAGGGAGACAGG 315 5653 AUGGGAAUAGGGAGACAGG 315 5675
CCUGUCUCCCUAUUCCCAU 742 5671 GGUAGGAAAGGGCGCCUAC 316 5671
GGUAGGAAAGGGCGCCUAC 316 5693 GUAGGCGCCCUUUCCUACC 743 5689
CUCUUCAGGGUCUAAAGAU 317 5689 CUCUUCAGGGUCUAAAGAU 317 5711
AUCUUUAGACCCUGAAGAG 744 5707 UCAAGUGGGCCUUGGAUCG 318 5707
UCAAGUGGGCCUUGGAUCG 318 5729 CGAUCCAAGGCCCACUUGA 745 5725
GCUAAGCUGGCUCUGUUUG 319 5725 GCUAAGCUGGCUCUGUUUG 319 5747
CAAACAGAGCCAGCUUAGC 746 5743 GAUGCUAUUUAUGCAAGUU 320 5743
GAUGCUAUUUAUGCAAGUU 320 5765 AACUUGCAUAAAUAGCAUC 747 5761
UAGGGUCUAUGUAUUUAGG 321 5761 UAGGGUCUAUGUAUUUAGG 321 5783
CCUAAAUACAUAGACCCUA 748 5779 GAUGCGCCUACUCUUCAGG 322 5779
GAUGCGCCUACUCUUCAGG 322 5801 CCUGAAGAGUAGGCGCAUC 749 5797
GGUCUAAAGAUCAAGUGGG 323 5797 GGUCUAAAGAUCAAGUGGG 323 5819
CCCACUUGAUCUUUAGACC 750 5815 GCCUUGGAUCGCUAAGCUG 324 5815
GCCUUGGAUCGCUAAGCUG 324 5837 CAGCUUAGCGAUCCAAGGC 751 5833
GGCUCUGUUUGAUGCUAUU 325 5833 GGCUCUGUUUGAUGCUAUU 325 5855
AAUAGCAUCAAACAGAGCC 752 5851 UUAUGCAAGUUAGGGUCUA 326 5851
UUAUGCAAGUUAGGGUCUA 326 5873 UAGACCCUAACUUGCAUAA 753 5869
AUGUAUUUAGGAUGUCUGC 327 5869 AUGUAUUUAGGAUGUCUGC 327 5891
GCAGACAUCCUAAAUACAU 754 5887 CACCUUCUGCAGCCAGuCA 328 5887
CACCUUCUGCAGCCAGUCA 328 5909 UGACUGGCUGCAGAAGGUG 755 5905
AGAAGCUGGAGAGGCAACA 329 5905 AGAAGCUGGAGAGGCAACA 329 5927
UGUUGCCUCUCCAGCUUCU 756 5923 AGUGGAUUGCUGCUUCUUG 330 5923
AGUGGAUUGCUGCUUCUUG 330 5945 CAAGAAGCAGCAAUCCACU 757 5941
GGGGAGAAGAGUAUGCUUC 331 5941 GGGGAGAAGAGUAUGCUUC 331 5963
GAAGCAUACUCUUCUCCCC 758 5959 CCUUUUAUCCAUGUAAUUU 332 5959
CCUUUUAUCCAUGUAAUUU 332 5981 AAAUUACAUGGAUAAAAGG 759 5977
UAACUGUAGAACCUGAGCU 333 5977 UAACUGUAGAACCUGAGCU 333 5999
AGCUCAGGUUCUACAGUUA 760 5995 UCUAAGUAACCGAAGAAUG 334 5995
UCUAAGUAACCGAAGAAUG 334 6017 CAUUCUUCGGUUACUUAGA 761 6013
GUAUGCCUCUGUUCUUAUG 335 6013 GUAUGCCUCUGUUCUUAUG 335 6035
CAUAAGAACAGAGGCAUAC 762 6031 GUGCCACAUCCUUGUUUAA 336 6031
GUGCCACAUCCUUGUUUAA 336 6053 UUAAACAAGGAUGUGGCAC 763 6049
AAGGCUCUCUGUAUGAAGA 337 6049 AAGGCUCUCUGUAUGAAGA 337 6071
UCUUCAUACAGAGAGCCUU 764 6067 AGAUGGGACCGUCAUCAGC 338 6067
AGAUGGGACCGUCAUCAGC 338 6089 GCUGAUGACGGUCCCAUCU 765 6085
CACAUUCCCUAGUGAGCCU 339 6085 CACAUUCCCUAGUGAGCCU 339 6107
AGGCUCACUAGGGAAUGUG 766 6103 UACUGGCUCCUGGCAGCGG 340 6103
UACUGGCUCCUGGCAGCGG 340 6125 CCGCUGCCAGGAGCCAGUA 767 6121
GCUUUUGUGGAAGACUCAC 341 6121 GCUUUUGUGGAAGACUCAC 341 6143
GUGAGUCUUCCACAAAAGC 768 6139 CUAGCCAGAAGAGAGGAGU 342 6139
CUAGCCAGAAGAGAGGAGU 342 6161 ACUCCUCUCUUCUGGCUAG 769 6157
UGGGACAGUCCUCUCCACC 343 6157 UGGGACAGUCCUCUCCACC 343 6179
GGUGGAGAGGACUGUCCCA 770 6175 CAAGAUCUAAAUCCAAACA 344 6175
CAAGAUCUAAAUCCAAACA 344 6197 UGUUUGGAUUUAGAUCUUG 771 6193
AAAAGCAGGCUAGAGCCAG 345 6193 AAAAGCAGGCUAGAGCCAG 345 6215
CUGGCUCUAGCCUGCUUUU 772 6211 GAAGAGAGGACAAAUCUUU 346 6211
GAAGAGAGGACAAAUCUUU 346 6233 AAAGAUUUGUCCUCUCUUC 773 6229
UGUUGUUCCUCUUCUUUAC 347 6229 UGUUGUUCCUCUUCUUUAC 347 6251
GUAAAGAAGAGGAACAACA 774 6247 CACAUACGCAAACCACCUG 348 6247
CACAUACGCAAACCACCUG 348 6269 CAGGUGGUUUGCGUAUGUG 775 6265
GUGACAGCUGGCAAUUUUA 349 6265 GUGACAGCUGGCAAUUUUA 349 6287
UAAAAUUGCCAGCUGUCAC 776 6283 AUAAAUCAGGUAACUGGAA 350 6283
AUAAAUCAGGUAACUGGAA 350 6305 UUCCAGUUACCUGAUUUAU 777 6301
AGGAGGUUAAACUCAGAAA 351 6301 AGGAGGUUAAACUCAGAAA 351 6323
UUUCUGAGUUUAACCUCCU 778 6319 AAAAGAAGACCUCAGUCAA 352 6319
AAAAGAAGACCUCAGUCAA 352 6341 UUGACUGAGGUCUUCUUUU 779 6337
AUUCUCUACUUUUUUUUUU 353 6337 AUUCUCUACUUUUUUUUUU 353 6359
AAAAAAAAAAGUAGAGAAU 780 6355 UUUUUUUCCAAAUCAGAUA 354 6355
UUUUUUUCCAAAUCAGAUA 354 6377 UAUCUGAUUUGGAAAAAAA 781 6373
AAUAGCCCAGCAAAUAGUG 355 6373 AAUAGCCCAGCAAAUAGUG 355 6395
CACUAUUUGCUGGGCUAUU 782 6391 GAUAACAAAUAAAACCUUA 356 6391
GAUAACAAAUAAAACCUUA 356 6413 UAAGGUUUUAUUUGUUAUC 783 6409
AGCUGUUCAUGUCUUGAUU 357 6409 AGCUGUUCAUGUCUUGAUU 357 6431
AAUCAAGACAUGAACAGCU 784 6427 UUCAAUAAUUAAUUCUUAA 358 6427
UUCAAUAAUUAAUUCUUAA 358 6449 UUAAGAAUUAAUUAUUGAA 785 6445
AUCAUUAAGAGACCAUAAU 359 6445 AUCAUUAAGAGACCAUAAU 359 6467
AUUAUGGUCUCUUAAUGAU 786 6463 UAAAUACUCCUUUUCAAGA 360 6463
UAAAUACUCCUUUUCAAGA 360 6485 UCUUGAAAAGGAGUAUUUA 787 6481
AGAAAAGCAAAACCAUUAG 361 6481 AGAAAAGCAAAACCAUUAG 361 6503
CUAAUGGUUUUGCUUUUCU 788 6499 GAAUUGUUACUCAGCUCCU 362 6499
GAAUUGUUACUCAGCUCCU 362 6521 AGGAGCUGAGUAACAAUUC 789 6517
UUCAAACUCAGGUUUGUAG 363 6517 UUCAAACUCAGGUUUGUAG 363 6539
CUACAAACCUGAGUUUGAA 790 6535 GCAUACAUGAGUCCAUCCA 364 6535
GCAUACAUGAGUCCAUCCA 364 6557 UGGAUGGACUCAUGUAUGC 791 6553
AUCAGUCAAAGAAUGGUUC 365 6553 AUCAGUCAAAGAAUGGUUC 365 6575
GAACCAUUCUUUGACUGAU 792 6571 CCAUCUGGAGUCUUAAUGU 366 6571
CCAUCUGGAGUCUUAAUGU 366 6593 ACAUUAAGACUCCAGAUGG 793 6589
UAGAAAGAAAAAUGGAGAC 367 6589 UAGAAAGAAAAAUGGAGAC 367 6611
GUCUCCAUUUUUCUUUCUA 794 6607 CUUGUAAUAAUGAGCUAGU 368 6607
CUUGUAAUAAUGAGCUAGU 368 6629 ACUAGCUCAUUAUUACAAG 795 6625
UUACAAAGUGCUUGUUCAU 369 6625 UUACAAAGUGCUUGUUCAU 369 6647
AUGAACAAGCACUUUGUAA 796 6643 UUAAAAUAGCACUGAAAAU 370 6643
UUAAAAUAGCACUGAAAAU 370 6665 AUUUUCAGUGCUAUUUUAA 797 6661
UUGAAACAUGAAUUAACUG 371 6661 UUGAAACAUGAAUUAACUG 371 6683
CAGUUAAUUCAUGUUUCAA 798 6679 GAUAAUAUUCCAAUCAUUU 372 6679
GAUAAUAUUCCAAUCAUUU 372 6701 AAAUGAUUGGAAUAUUAUC 799 6697
UGCCAUUUAUGACAAAAAU 373 6697 UGCCAUUUAUGACAAAAAU 373 6719
AUUUUUGUCAUAAAUGGCA 800 6715 UGGUUGGCACUAACAAAGA 374 6715
UGGUUGGCACUAACAAAGA 374 6737 UCUUUGUUAGUGCCAACCA 801 6733
AACGAGCACUUCCUUUCAG 375 6733 AACGAGCACUUCCUUUCAG 375 6755
CUGAAAGGAAGUGCUCGUU 802 6751 GAGUUUCUGAGAUAAUGUA 376 6751
GAGUUUCUGAGAUAAUGUA 376 6773 UACAUUAUCUCAGAAACUC 803 6769
ACGUGGAACAGUCUGGGUG 377 6769 ACGUGGAACAGUCUGGGUG 377 6791
CACCCAGACUGUUCCACGU 804 6787 GGAAUGGGGCUGAAACCAU 378 6787
GGAAUGGGGCUGAAACCAU 378 6809 AUGGUUUCAGCCCCAUUCC 805 6805
UGUGCAAGUCUGUGUCUUG 379 6805 UGUGCAAGUCUGUGUCUUG 379 6827
CAAGACACAGACUUGCACA 806 6823 GUCAGUCCAAGAAGUGACA 380 6823
GUCAGUCCAAGAAGUGACA 380 6845 UGUCACUUCUUGGACUGAC 807 6841
ACCGAGAUGUUAAUUUUAG 381 6841 ACCGAGAUGUUAAUUUUAG 381 6863
CUAAAAUUAACAUCUCGGU 808 6859 GGGACCCGUGCCUUGUUUC 382 6859
GGGACCCGUGCCUUGUUUC 382 6881 GAAACAAGGCACGGGUCCC 809 6877
CCUAGCCCACAAGAAUGCA 383 6877 CCUAGCCCACAAGAAUGCA 383 6899
UGCAUUCUUGUGGGCUAGG 810 6895 AAACAUCAAACAGAUACUC 384 6895
AAACAUCAAACAGAUACUC 384 6917 GAGUAUCUGUUUGAUGUUU 811 6913
CGCUAGCCUCAUUUAAAUU 385 6913 CGCUAGCCUCAUUUAAAUU 385 6935
AAUUUAAAUGAGGCUAGCG 812 6931 UGAUUAAAGGAGGAGUGCA 386 6931
UGAUUAAAGGAGGAGUGCA 386 6953 UGCACUCCUCCUUUAAUCA 813 6949
AUCUUUGGCCGACAGUGGU 387 6949 AUCUUUGGCCGACAGUGGU 387 6971
ACCACUGUCGGCCAAAGAU 814 6967 UGUAACUGUGUGUGUGUGU 388 6967
UGUAACUGUGUGUGUGUGU 388 6989 ACACACACACACAGUUACA 815 6985
UGUGUGUGUGUGUGUGUGU 389 6985 UGUGUGUGUGUGUGUGUGU 389 7007
ACACACACACACACACACA 816 7003 UGUGUGUGUGUGGGUGUGG 390 7003
UGUGUGUGUGUGGGUGUGG 390 7025 CCACACCCACACACACACA 817 7021
GGUGUAUGUGUGUUUUGUG 391 7021 GGUGUAUGUGUGUUUUGUG 391 7043
CACAAAACACACAUACACC 818 7039 GCAUAACUAUUUAAGGAAA 392 7039
GCAUAACUAUUUAAGGAAA 392 7061 UUUCCUUAAAUAGUUAUGC 819 7057
ACUGGAAUUUUAAAGUUAC 393 7057 ACUGGAAUUUUAAAGUUAC 393 7079
GUAACUUUAAAAUUCCAGU 820 7075 CUUUUAUACAAACCAAGAA 394 7075
CUUUUAUACAAACCAAGAA 394 7097 UUCUUGGUUUGUAUAAAAG 821 7093
AUAUAUGCUACAGAUAUAA 395 7093 AUAUAUGCUACAGAUAUAA 395 7115
UUAUAUCUGUAGCAUAUAU 522 7111 AGACAGACAUGGUUUGGUC 396 7111
AGACAGACAUGGUUUGGUC 396 7133 GACCAAACCAUGUCUGUCU 823 7129
CCUAUAUUUCUAGUCAUGA 397 7129 CCUAUAUUUCUAGUCAUGA 397 7151
UCAUGACUAGAAAUAUAGG 824 7147 AUGAAUGUAUUUUGUAUAC 398 7147
AUGAAUGUAUUUUGUAUAC 398 7169 GUAUACAAAAUACAUUCAU 825 7165
CCAUCUUCAUAUAAUAUAC 399 7165 CCAUCUUCAUAUAAUAUAC 399 7187
GUAUAUUAUAUGAAGAUGG 826 7183 CUUAAAAAUAUUUCUUAAU 400 7183
CUUAAAAAUAUUUCUUAAU 400 7205 AUUAAGAAAUAUUUUUAAG 827 7201
UUGGGAUUUGUAAUCGUAC 401 7201 UUGGGAUUUGUAAUCGUAC 401 7223
GUACGAUUACAAAUCCCAA 828 7219 CCAACUUAAUUGAUAAACU 402 7219
CCAACUUAAUUGAUAAACU 402 7241 AGUUUAUCAAUUAAGUUGG 829 7237
UUGGCAACUGCUUUUAUGU 403 7237 UUGGCAACUGCUUUUAUGU 403 7259
ACAUAAAAGCAGUUGCCAA 830 7255 UUCUGUCUCCUUCCAUAAA 404 7255
UUCUGUCUCCUUCCAUAAA 404 7277 UUUAUGGAAGGAGACAGAA 831 7273
AUUUUUCAAAAUACUAAUU 405 7273 AUUUUUCAAAAUACUAAUU 405 7295
AAUUAGUAUUUUGAAAAAU 832 7291 UCAACAAAGAAAAAGCUCU 406 7291
UCAACAAAGAAAAAGCUCU 406 7313 AGAGCUUUUUCUUUGUUGA 833 7309
UUUUUUUUCCUAAAAUAAA 407 7309 UUUUUUUUCCUAAAAUAAA 407 7331
UUUAUUUUAGGAAAAAAAA 834 7327 ACUCAAAUUUAUCCUUGUU 408 7327
ACUCAAAUUUAUCCUUGUU 408 7349 AACAAGGAUAAAUUUGAGU 835 7345
UUAGAGCAGAGAAAAAUUA 409 7345 UUAGAGCAGAGAAAAAUUA 409 7367
UAAUUUUUCUCUGCUCUAA 836 7363 AAGAAAAACUUUGAAAUGG 410 7363
AAGAAAAACUUUGAAAUGG 410 7385 CCAUUUCAAAGUUUUUCUU 837 7381
GUCUCAAAAAAUUGCUAAA 411 7381 GUCUCAAAAAAUUGCUAAA 411 7403
UUUAGCAAUUUUUUGAGAC 838 7399 AUAUUUUCAAUGGAAAACU 412 7399
AUAUUUUCAAUGGAAAACU 412 7421 AGUUUUCCAUUGAAAAUAU 839 7417
UAAAUGUUAGUUUAGCUGA 413 7417 UAAAUGUUAGUUUAGCUGA 413 7439
UCAGCUAAACUAACAUUUA 840 7435 AUUGUAUGGGGUUUUCGAA 414 7435
AUUGUAUGGGGUUUUCGAA 414 7457 UUCGAAAACCCCAUACAAU 841 7453
ACCUUUCACUUUUUGUUUG 415 7453 ACCUUUCACUUUUUGUUUG 415 7475
CAAACAAAAAGUGAAAGGU 842 7471 GUUUUACCUAUUUCACAAC 416 7471
GUUUUACCUAUUUCACAAC 416 7493 GUUGUGAAAUAGGUAAAAC 843 7489
CUGUGUAAAUUGCCAAUAA 417 7489 CUGUGUAAAUUGCCAAUAA 417 7511
UUAUUGGCAAUUUACACAG 844 7507 AUUCCUGUCCAUGAAAAUG 418 7507
AUUCCUGUCCAUGAAAAUG 418 7529 CAUUUUCAUGGACAGGAAU 845 7525
GCAAAUUAUCCAGUGUAGA 419 7525 GCAAAUUAUCCAGUGUAGA 419 7547
UCUACACUGGAUAAUUUGC 846 7543 AUAUAUUUGACCAUCACCC 420 7543
AUAUAUUUGACCAUCACCC 420 7565 GGGUGAUGGUCAAAUAUAU 847 7561
CUAUGGAUAUUGGCUAGUU 421 7561 CUAUGGAUAUUGGCUAGUU 421 7583
AACUAGCCAAUAUCCAUAG 848 7579 UUUGCCUUUAUUAAGCAAA 422 7579
UUUGCCUUUAUUAAGCAAA 422 7601 UUUGCUUAAUAAAGGCAAA 849 7597
AUUCAUUUCAGCCUGAAUG 423 7597 AUUCAUUUCAGCCUGAAUG 423 7619
CAUUCAGGCUGAAAUGAAU 850 7615 GUCUGCCUAUAUAUUCUCU 424 7615
GUCUGCCUAUAUAUUCUCU 424 7637 AGAGAAUAUAUAGGCAGAC 851 7633
UGCUCUUUGUAUUCUCCUU 425 7633 UGCUCUUUGUAUUCUCCUU 425 7655
AAGGAGAAUACAAAGAGCA 852 7651 UUGAACCCGUUAAAACAUC 426 7651
UUGAACCCGUUAAAACAUC 426 7673 GAUGUUUUAACGGGUUCAA 853 7662
AAAACAUCCUGUGGCACUC 427 7662 AAAACAUCCUGUGGCACUC 427 7684
GAGUGCCACAGGAUGUUUU 854 VEGFR2 gi.vertline.11321596.vertl-
ine.ref.vertline.NM_002253.1 1 ACUGAGUCCCGGGACCCCG 855 1
ACUGAGUCCCGGGACCCCG 855 23 CGGGGUCCCGGGACUCAGU 1179 19
GGGAGAGCGGUCAGUGUGU 856 19 GGGAGAGCGGUCAGUGUGU 856 41
ACACACUGACCGCUCUCCC 1180 37 UGGUCGCUGCGUUUCCUCU 857 37
UGGUCGCUGCGUUUCCUCU 857 59 AGAGGAAACGCAGCGACCA 1181 55
UGCCUGCGCCGGGCAUCAC 858 55 UGCCUGCGCCGGGCAUCAC 858 77
GUGAUGCCCGGCGCAGGCA 1182 73 CUUGCGCGCCGCAGAAAGU 859 73
CUUGCGCGCCGCAGAAAGU 859 95 ACUUUCUGCGGCGCGCAAG 1183 91
UCCGUCUGGCAGCCUGGAU 860 91 UCCGUCUGGCAGCCUGGAu 860 113
AUCCAGGCUGCCAGACGGA 1184 109 UAUCCUCUCCUACCGGCAC 861 109
UAUCCUCUCCUACCGGCAC 861 131 GUGCCGGUAGGAGAGGAUA 1185 127
CCCGCAGACGCCCCUGCAG 862 127 CCCGCAGACGCCCCUGCAG 862 149
CUGCAGGGGCGUCUGCGGG 1186 145 GCCGCCGGUCGGCGCCCGG 863 145
GCCGCCGGUCGGCGCCCGG 863 167 CCGGGCGCCGACCGGCGGC 1187 163
GGCUCCCUAGCCCUGUGCG 864 163 GGCUCCCUAGCCCUGUGCG 864 185
CGCACAGGGCUAGGGAGCC 1188 181 GCUCAACUGUCCUGCGCUG 865 181
GCUCAACUGUCCUGCGCUG 865 203 CAGCGCAGGACAGUUGAGC 1189 199
GCGGGGUGCCGCGAGUUCC 866 199 GCGGGGUGCCGCGAGUUCC 866 221
GGAACUCGCGGCACCCCGC 1190 217 CACCUCCGCGCCUCCUUCU 867 217
CACCUCCGCGCCUCCUUCU 867 239 AGAAGGAGGCGCGGAGGUG 1191 235
UCUAGACAGGCGCUGGGAG 868 235 UCUAGACAGGCGCUGGGAG 868 257
CUCCCAGCGCCUGUCUAGA 1192 253 GAAAGAACCGGCUCCCGAG 869 253
GAAAGAACCGGCUCCCGAG 869 275 CUCGGGAGCCGGUUCUUUC 1193 271
GUUCUGGGCAUUUCGCCCG 870 271 GUUCUGGGCAUUUCGCCCG 870 293
CGGGCGAAAUGCCCAGAAC 1194 289 GGCUCGAGGUGCAGGAUGC 871 289
GGCUCGAGGUGCAGGAUGC 871 311 GCAUCCUGCACCUCGAGCC 1195 307
CAGAGCAAGGUGCUGCUGG 872 307 CAGAGCAAGGUGCUGCUGG 872 329
CCAGCAGCACCUUGCUCUG 1196 325 GCCGUCGCCCUGUGGCUCU 873 325
GCCGUCGCCCUGUGGCUCU 873 347 AGAGCCACAGGGCGACGGC 1197 343
UGCGUGGAGACCCGGGCCG 874 343 UGCGUGGAGACCCGGGCCG 874 365
CGGCCCGGGUCUCCACGCA 1198 361 GCCUCUGUGGGUUUGCCUA 875 361
GCCUCUGUGGGUUUGCCUA 875 383 UAGGCAAACCCACAGAGGC 1199 379
AGUGUUUCUCUUGAUCUGC 876 379 AGUGUUUCUCUUGAUCUGC 876 401
GCAGAUCAAGAGAAACACU 1200 397 CCCAGGCUCAGCAUACAAA 877 397
CCCAGGCUCAGCAUACAAA 877 419 UUUGUAUGCUGAGCCUGGG 1201 415
AAAGACAUACUUACAAUUA 878 415 AAAGACAUACUUACAAUUA 878 437
UAAUUGUAAGUAUGUCUUU 1202 433 AAGGCUAAUACAACUCUUC 879 433
AAGGCUAAUACAACUCUUC 879 455 GAAGAGUUGUAUUAGCCUU 1203 451
CAAAUUACUUGCAGGGGAC 880 451 CAAAUUACUUGCAGGGGAC 880 473
GUCCCCUGCAAGUAAUUUG 1204 469 CAGAGGGACUUGGACUGGC 881 469
CAGAGGGACUUGGACUGGC 881 491 GCCAGUCCAAGUCCCUCUG 1205 487
CUUUGGCCCAAUAAUCAGA 882 487 CUUUGGCCCAAUAAUCAGA 882 509
UCUGAUUAUUGGGCCAAAG 1206 505 AGUGGCAGUGAGCAAAGGG 883 505
AGUGGCAGUGAGCAAAGGG 883 527 CCCUUUGCUCACUGCCACU 1207 523
GUGGAGGUGACUGAGUGCA 884 523 GUGGAGGUGACUGAGUGCA 884 545
UGCACUCAGUCACCUCCAC 1208 541 AGCGAUGGCCUCUUCUGUA 885 541
AGCGAUGGCCUCUUCUGUA 885 563 UACAGAAGAGGCCAUCGCU 1209 559
AAGACACUCACAAUUCCAA 886 559 AAGACACUCACAAUUCCAA 886 581
UUGGAAUUGUGAGUGUCUU 1210 577 AAAGUGAUCGGAAAUGACA 887 577
AAAGUGAUCGGAAAUGACA 887 599 UGUCAUUUCCGAUCACUUU 1211 595
ACUGGAGCCUACAAGUGCU 888 595 ACUGGAGCCUACAAGUGCU 888 617
AGCACUUGUAGGCUCCAGU 1212 613 UUCUACCGGGAAACUGACU 889 613
UUCUACCGGGAAACUGACU 889 635 AGUCAGUUUCCCGGUAGAA 1213 631
UUGGCCUCGGUCAUUUAUG 890 631 UUGGCCUCGGUCAUUUAUG 890 653
CAUAAAUGACCGAGGCCAA 1214 649 GUCUAUGUUCAAGAUUACA 891 649
GUCUAUGUUCAAGAUUACA 891 671 UGUAAUCUUGAACAUAGAC 1215 667
AGAUCUCCAUUUAUUGCUU 892 667 AGAUCUCCAUUUAUUGCUU 892 689
AAGCAAUAAAUGGAGAUCU 1216 685 UCUGUUAGUGACCAACAUG 893 685
UCUGUUAGUGACCAACAUG 893 707 CAUGUUGGUCACUAACAGA 1217 703
GGAGUCGUGUACAUUACUG 894 703 GGAGUCGUGUACAUUACUG 894 725
CAGUAAUGUACACGACUCC 1218 721 GAGAACAAAAACAAAACUG 895 721
GAGAACAAAAACAAAACUG 895 743 CAGUUUUGUUUUUGUUCUC 1219 739
GUGGUGAUUCCAUGUCUCG 896 739 GUGGUGAUUCCAUGUCUCG 896 761
CGAGACAUGGAAUCACCAC 1220 757 GGGUCCAUUUCAAAUCUCA 897 757
GGGUCCAUUUCAAAUCUCA 897 779 UGAGAUUUGAAAUGGACCC 1221 775
AACGUGUCACUUUGUGCAA 898 775 AACGUGUCACUUUGUGCAA 898 797
UUGCACAAAGUGACACGUU 1222 793 AGAUACCCAGAAAAGAGAU 899 793
AGAUACCCAGAAAAGAGAU 899 815 AUCUCUUUUCUGGGUAUCU 1223 811
UUUGUUCCUGAUGGUAACA 900 811 UUUGUUCCUGAUGGUAACA 900 833
UGUUACCAUCAGGAACAAA 1224 829 AGAAUUUCCUGGGACAGCA 901 829
AGAAUUUCCUGGGACAGCA 901 851 UGCUGUCCCAGGAAAUUCU 1225 847
AAGAAGGGCUUUACUAUUC 902 847 AAGAAGGGCUUUACUAUUC 902 869
GAAUAGUAAAGCCCUUCUU 1226 865 CCCAGCUACAUGAUCAGCU 903 865
CCCAGCUACAUGAUCAGCU 903 887 AGCUGAUCAUGUAGCUGGG 1227 883
UAUGCUGGCAUGGUCUUCU 904 883 UAUGCUGGCAUGGUCUUCU 904 905
AGAAGACCAUGCCAGCAUA 1228 901 UGUGAAGCAAAAAUUAAUG 905 901
UGUGAAGCAAAAAUUAAUG 905 923 CAUUAAUUUUUGCUUCACA 1229 919
GAUGAAAGUUACCAGUCUA 906 919 GAUGAAAGUUACCAGUCUA 906 941
UAGACUGGUAACUUUCAUC 1230 937 AUUAUGUACAUAGUUGUCG 907 937
AUUAUGUACAUAGUUGUCG 907 959 CGACAACUAUGUACAUAAU 1231 955
GUUGUAGGGUAUAGGAUUU 908 955 GUUGUAGGGUAUAGGAUUU 908 977
AAAUCCUAUACCCUACAAC 1232 973 UAUGAUGUGGUUCUGAGUC 909 973
UAUGAUGUGGUUCUGAGUC 909 995 GACUCAGAACCACAUCAUA 1233 991
CCGUCUCAUGGAAUUGAAC 910 991 CCGUCUCAUGGAAUUGAAC 910 1013
GUUCAAUUCCAUGAGACGG 1234 1009 CUAUCUGUUGGAGAAAAGC 911 1009
CUAUCUGUUGGAGAAAAGC 911 1031 GCUUUUCUCCAACAGAUAG 1235 1027
CUUGUCUUAAAUUGUACAG 912 1027 CUUGUCUUAAAUUGUACAG 912 1049
CUGUACAAUUUAAGACAAG 1236 1045 GCAAGAACUGAACUAAAUG 913 1045
GCAAGPACUGAACUAAAUG 913 1067 CAUUUAGUUCAGUUCUUGC 1237 1063
GUGGGGAUUGACUUCAACU 914 1063 GUGGGGAUUGACUUCAACU 914 1085
AGUUGAAGUCAAUCCCCAC 1238 1081 UGGGAAUACCCUUCUUCGA 915 1081
UGGGAAUACCCUUCUUCGA 915 1103 UCGAAGAAGGGUAUUCCCA 1239 1099
AAGCAUCAGCAUAAGAAAC 916 1099 AAGCAUCAGCAUAAGAAAC 916 1121
GUUUCUUAUGCUGAUGCUU 1240 1117 CUUGUAAACCGAGACCUAA 917 1117
CUUGUAAACCGAGACCUAA 917 1139 UUAGGUCUCGGUUUACAAG 1241 1135
AAAACCCAGUCUGGGAGUG 918 1135 AAAACCCAGUCUGGGAGUG 918 1157
CACUCCCAGACUGGGUUUU 1242 1153 GAGAUGAAGAAAUUUUUGA 919 1153
GAGAUGAAGAAAUUUUUGA 919 1175 UCAAAAAUUUCUUCAUCUC 1243 1171
AGCACCUUAACUAUAGAUG 920 1171 AGCACCUUAACUAUAGAUG 920 1193
CAUCUAUAGUUAAGGUGCU 1244 1189 GGUGUAACCCGGAGUGACC 921 1189
GGUGUAACCCGGAGUGACC 921 1211 GGUCACUCCGGGUUACACC 1245 1207
CAAGGAUUGUACACCUGUG 922 1207 CAAGGAUUGUACACCUGUG 922 1229
CACAGGUGUACAAUCCUUG 1246 1225 GCAGCAUCCAGUGGGCUGA 923 1225
GCAGCAUCCAGUGGGCUGA 923 1247 UCAGCCCACUGGAUGCUGC 1247 1243
AUGACCAAGAAGAACAGCA 924 1243 AUGACCAAGAAGAACAGCA 924 1265
UGCUGUUCUUCUUGGUCAU 1248 1261 ACAUUUGUCAGGGUCCAUG 925 1261
ACAUUUGUCAGGGUCCAUG 925 1283 CAUGGACCCUGACAAAUGU 1249 1279
GAAAAACCUUUUGUUGCUU 926 1279 GAAAAACCUUUUGUUGCUU 926 1301
AAGCAACAAAAGGUUUUUC 1250 1297 UUUGGAAGUGGCAUGGAAU 927 1297
UUUGGAAGUGGCAUGGAAU 927 1319 AUUCCAUGCCACUUCCAAA 1251 1315
UCUCUGGUGGAAGCCACGG 928 1315 UCUCUGGUGGAAGCCACGG 928 1337
CCGUGGCUUCCACCAGAGA 1252 1333 GUGGGGGAGCGUGUCAGAA 929 1333
GUGGGGGAGCGUGUCAGAA 929 1355 UUCUGACACGCUCCCCCAC 1253 1351
AUCCCUGCGAAGUACCUUG 930 1351 AUCCCUGCGAAGUACCUUG 930 1373
CAAGGUACUUCGCAGGGAU 1254 1369 GGUUACCCACCCCCAGAAA 931 1369
GGUUACCCACCCCCAGAAA 931 1391
UUUCUGGGGGUGGGUAACC 1255 1387 AUAAAAUGGUAUAAAAAUG 932 1387
AUAAAAUGGUAUAAAAAUG 932 1409 CAUUUUUAUACCAUUUUAU 1256 1405
GGAAUACCCCUuGAGUCCA 933 1405 GGAAUACCCCUUGAGUCCA 933 1427
UGGACUCAAGGGGUAUUCC 1257 1423 AAUCACACAAUUAAAGCGG 934 1423
AAUCACACAAUUAAAGCGG 934 1445 CCGCUUUAAUUGUGUGAUU 1258 1441
GGGCAUGUACUGACGAUUA 935 1441 GGGCAUGUACUGACGAUUA 935 1463
UAAUCGUCAGUACAUGCCC 1259 1459 AUGGAAGUGAGUGAAAGAG 936 1459
AUGGAAGUGAGUGAAAGAG 936 1481 CUCUUUCACUCACUUCCAU 1260 1477
GACACAGGAAAUUACACUG 937 1477 GACACAGGAAAUUACACUG 937 1499
CAGUGUAAUUUCCUGUGUC 1261 1495 GUCAUCCUUACCAAUCCCA 938 1495
GUCAUCCUUACCAAUCCCA 938 1517 UGGGAUUGGUAAGGAUGAC 1262 1513
AUUUCAAAGGAGAAGCAGA 939 1513 AUUUCAAAGGAGAAGCAGA 939 1535
UCUGCUUCUCCUUUGAAAU 1263 1531 AGCCAUGUGGUCUCUCUGG 940 1531
AGCCAUGUGGUCUCUCUGG 940 1553 CCAGAGAGACCACAUGGCU 1264 1549
GUUGUGUAUGUCCCACCCC 941 1549 GUUGUGUAUGUCCCACCCC 941 1571
GGGGUGGGACAUACACAAC 1265 1567 CAGAUUGGUGAGAAAUCUC 942 1567
CAGAUUGGUGAGAAAUCUC 942 1589 GAGAUUUCUCACCAAUCUG 1266 1585
CUAAUCUCUCCUGUGGAUU 943 1585 CUAAUCUCUCCUGUGGAUU 943 1607
AAUCCACAGGAGAGAUUAG 1267 1603 UCCUACCAGUACGGCACCA 944 1603
UCCUACCAGUACGGCACCA 944 1625 UGGUGCCGUACUGGUAGGA 1268 1621
ACUCAAACGCUGACAUGUA 945 1621 ACUCAAACGCUGACAUGUA 945 1643
UACAUGUCAGCGUUUGAGU 1269 1639 ACGGUCUAUGCCAUUCCUC 946 1639
ACGGUCUAUGCCAUUCCUC 946 1661 GAGGAAUGGCAUAGACCGU 1270 1657
CCCCCGCAUCACAUCCACU 947 1657 CCCCCGCAUCACAUCCACU 947 1679
AGUGGAUGUGAUGCGGGGG 1271 1675 UGGUAUUGGCAGUUGGAGG 948 1675
UGGUAUUGGCAGUUGGAGG 948 1697 CCUCCAACUGCCAAUACCA 1272 1693
GAAGAGUGCGCCAACGAGC 949 1693 GAAGAGUGCGCCAACGAGC 949 1715
GCUCGUUGGCGCACUCUUC 1273 1711 CCCAGCCAAGCUGUCUCAG 950 1711
CCCAGCCAAGCUGUCUCAG 950 1733 CUGAGACAGCUUGGCUGGG 1274 1729
GUGACAAACCCAUACCCUU 951 1729 GUGACAAACCCAUACCCUU 951 1751
AAGGGUAUGGGUUUGUCAC 1275 1747 UGUGAAGAAUGGAGAAGUG 952 1747
UGUGAAGAAUGGAGAAGUG 952 1769 CACUUCUCCAUUCUUCACA 1276 1765
GUGGAGGACUUCCAGGGAG 953 1765 GUGGAGGACUUCCAGGGAG 953 1787
CUCCCUGGAAGUCCUCCAC 1277 1783 GGAAAUAAAAUUGAAGUUA 954 1783
GGAAAUAAAAUUGAAGUUA 954 1805 UAACUUCAAUUUUAUUUCC 1278 1801
AAUAAAAAUCAAUUUGCUC 955 1801 AAUAAAAAUCAAUUUGCUC 955 1823
GAGCAAAUUGAUUUUUAUU 1279 1819 CUAAUUGAAGGAAAAAACA 956 1819
CUAAUUGAAGGAAAAAACA 956 1841 UGUUUUUUCCUUCAAUUAG 1280 1837
AAAACUGUAAGUACCCUUG 957 1837 AAAACUGUAAGUACCCUUG 957 1859
CAAGGGUACUUACAGUUUU 1281 1855 GUUAUCCAAGCGGCAAAUG 958 1855
GUUAUCCAAGCGGCAAAUG 958 1877 CAUUUGCCGCUUGGAUAAC 1282 1873
GUGUCAGCUUUGUACAAAU 959 1873 GUGUCAGCUUUGUACAAAU 959 1895
AUUUGUACAAAGCUGACAC 1283 1891 UGUGAAGCGGUCAACAAAG 960 1891
UGUGAAGCGGUCAACAAAG 960 1913 CUUUGUUGACCGCUUCACA 1284 1909
GUCGGGAGAGGAGAGAGGG 961 1909 GUCGGGAGAGGAGAGAGGG 961 1931
CCCUCUCUCCUCUCCCGAC 1285 1927 GUGAUCUCCUUCCACGUGA 962 1927
GUGAUCUCCUUCCACGUGA 962 1949 UCACGUGGAAGGAGAUCAC 1286 1945
ACCAGGGGUCCUGAAAUUA 963 1945 ACCAGGGGUCCUGAAAUUA 963 1967
UAAUUUCAGGACCCCUGGU 1287 1963 ACUUUGCAACCUGACAUGC 964 1963
ACUUUGCAACCUGACAUGC 964 1985 GCAUGUCAGGUUGCAAAGU 1288 1981
CAGCCCACUGAGCAGGAGA 965 1981 CAGCCCACUGAGCAGGAGA 965 2003
UCUCCUGCUCAGUGGGCUG 1289 1999 AGCGUGUCUUUGUGGUGCA 966 1999
AGCGUGUCUUUGUGGUGCA 966 2021 UGCACCACPAAGACACGCU 1290 2017
ACUGCAGACAGAUCUACGU 967 2017 ACUGCAGACAGAUCUACGU 967 2039
ACGUAGAUCUGUCUGCAGU 1291 2035 UUUGAGAACCUCACAUGGU 968 2035
UUUGAGAACCUCACAUGGU 968 2057 ACCAUGUGAGGUUCUCAAA 1292 2053
UACAAGCUUGGCCCACAGC 969 2053 UACAAGCUUGGCCCACAGC 969 2075
GCUGUGGGCCAAGCUUGUA 1293 2071 CCUCUGCCAAUCCAUGUGG 970 2071
CCUCUGCCAAUCCAUGUGG 970 2093 CCACAUGGAUUGGCAGAGG 1294 2089
GGAGAGUUGCCCACACCUG 971 2089 GGAGAGUUGCCCACACCUG 971 2111
CAGGUGUGGGCAACUCUCC 1295 2107 GUUUGCAAGAACUUGGAUA 972 2107
GUUUGCAAGAACUUGGAUA 972 2129 UAUCCAAGUUCUUGCAAAC 1296 2125
ACUCUUUGGAAAUUGAAUG 973 2125 ACUCUUUGGAAAUUGAAUG 973 2147
CAUUCAAUUUCCAAAGAGU 1297 2143 GCCACCAUGUUCUCUAAUA 974 2143
GCCACCAUGUUCUCUAAUA 974 2165 UAUUAGAGAACAUGGUGGC 1298 2161
AGCACAAAUGACAUUUUGA 975 2161 AGCACAAAUGACAUUUUGA 975 2183
UCAAAAUGUCAUUUGUGCU 1299 2179 AUCAUGGAGCUUAAGAAUG 976 2179
AUCAUGGAGCUUAAGAAUG 976 2201 CAUUCUUAAGCUCCAUGAU 1300 2197
GCAUCCUUGCAGGACCAAG 977 2197 GCAUCCUUGCAGGACCAAG 977 2219
CUUGGUCCUGCAAGGAUGC 1301 2215 GGAGACUAUGUCUGCCUUG 978 2215
GGAGACUAUGUCUGCCUUG 978 2237 CAAGGCAGACAUAGUCUCC 1302 2233
GCUCAAGACAGGAAGACCA 979 2233 GCUCAAGACAGGAAGACCA 979 2255
UGGUCUUCCUGUCUUGAGC 1303 2251 AAGAAAAGACAUUGCGUGG 980 2251
AAGAAAAGACAUUGCGUGG 980 2273 CCACGCAAUGUCUUUUCUU 1304 2269
GUCAGGCAGCUCACAGUCC 981 2269 GUCAGGCAGCUCACAGUCC 981 2291
GGACUGUGAGCUGCCUGAC 1305 2287 CUAGAGCGUGUGGCACCCA 982 2287
CUAGAGCGUGUGGCACCCA 982 2309 UGGGUGCCACACGCUCUAG 1306 2305
ACGAUCACAGGAAACCUGG 983 2305 ACGAUCACAGGAAACCUGG 983 2327
CCAGGUUUCCUGUGAUCGU 1307 2323 GAGAAUCAGACGACAAGUA 984 2323
GAGAAUCAGACGACAAGUA 984 2345 UACUUGUCGUCUGAUUCUC 1308 2341
AUUGGGGAAAGCAUCGAAG 985 2341 AUUGGGGAAAGCAUCGAAG 985 2363
CUUCGAUGCUUUCCCCAAU 1309 2359 GUCUCAUGCACGGCAUCUG 986 2359
GUCUCAUGCACGGCAUCUG 986 2381 CAGAUGCCGUGCAUGAGAC 1310 2377
GGGAAUCCCCCUCCACAGA 987 2377 GGGAAUCCCCCUCCACAGA 987 2399
UCUGUGGAGGGGGAUUCCC 1311 2395 AUCAUGUGGUUUAAAGAUA 988 2395
AUCAUGUGGUUUAAAGAUA 988 2417 UAUCUUUAAACCACAUGAU 1312 2413
AAUGAGACCCUUGUAGAAG 989 2413 AAUGAGACCCUUGUAGAAG 989 2435
CUUCUACAAGGGUCUCAUU 1313 2431 GACUCAGGCAUUGUAUUGA 990 2431
GACUCAGGCAUUGUAUUGA 990 2453 UCAAUACAAUGCCUGAGUC 1314 2449
AAGGAUGGGAACCGGAACC 991 2449 AAGGAUGGGAACCGGAACC 991 2471
GGUUCCGGUUCCCAUCCUU 1315 2467 CUCACUAUCCGCAGAGUGA 992 2467
CUCACUAUCCGCAGAGUGA 992 2489 UCACUCUGCGGAUAGUGAG 1316 2485
AGGAAGGAGGACGAAGGCC 993 2485 AGGAAGGAGGACGAAGGCC 993 2507
GGCCUUCGUCCUCCUUCCU 1317 2503 CUCUACACCUGCCAGGCAU 994 2503
CUCUACACCUGCCAGGCAU 994 2525 AUGCCUGGCAGGUGUAGAG 1318 2521
UGCAGUGUUCUUGGCUGUG 995 2521 UGCAGUGUUCUUGGCUGUG 995 2543
CACAGCCAAGAACACUGCA 1319 2539 GCAAAAGUGGAGGCAUUUU 996 2539
GCAAAAGUGGAGGCAUUUU 996 2561 AAAAUGCCUCCACUUUUGC 1320 2557
UUCAUAAUAGAAGGUGCCC 997 2557 UUCAUAAUAGAAGGUGCCC 997 2579
GGGCACCUUCUAUUAUGAA 1321 2575 CAGGAAAAGACGAACUUGG 998 2575
CAGGAAAAGACGAACUUGG 998 2597 CCAAGUUCGUCUUUUCCUG 1322 2593
GAAAUCAUUAUUCUAGUAG 999 2593 GAAAUCAUUAUUCUAGUAG 999 2615
CUACUAGAAUAAUGAUUUC 1323 2611 GGCACGGCGGUGAUUGCCA 1000 2611
GGCACGGCGGUGAUUGCCA 1000 2633 UGGCAAUCACCGCCGUGCC 1324 2629
AUGUUCUUCUGGCUACUUC 1001 2629 AUGUUCUUCUGGCUACUUC 1001 2651
GAAGUAGCCAGAAGAACAU 1325 2647 CUUGUCAUCAUCCUACGGA 1002 2647
CUUGUCAUCAUCCUACGGA 1002 2669 UCCGUAGGAUGAUGACAAG 1326 2665
ACCGUUAAGCGGGCCAAUG 1003 2665 ACCGUUAAGCGGGCCAAUG 1003 2687
CAUUGGCCCGCUUAACGGU 1327 2683 GGAGGGGAACUGAAGACAG 1004 2683
GGAGGGGAACUGAAGACAG 1004 2705 CUGUCUUCAGUUCCCCUCC 1328 2701
GGCUACUUGUCCAUCGUCA 1005 2701 GGCUACUUGUCCAUCGUCA 1005 2723
UGACGAUGGACAAGUAGCC 1329 2719 AUGGAUCCAGAUGAACUCC 1006 2719
AUGGAUCCAGAUGAACUCC 1006 2741 GGAGUUCAUCUGGAUCCAU 1330 2737
CCAUUGGAUGAACAUUGUG 1007 2737 CCAUUGGAUGAACAUUGUG 1007 2759
CACAAUGUUCAUCCAAUGG 1331 2755 GAACGACUGCCUUAUGAUG 1008 2755
GAACGACUGCCUUAUGAUG 1008 2777 CAUCAUAAGGCAGUCGUUC 1332 2773
GCCAGCAAAUGGGAAUUCC 1009 2773 GCCAGCAAAUGGGAAUUCC 1009 2795
GGAAUUCCCAUUUGCUGGC 1333 2791 CCCAGAGACCGGCUGAAGC 1010 2791
CCCAGAGACCGGCUGAAGC 1010 2813 GCUUCAGCCGGUCUCUGGG 1334 2809
CUAGGUAAGCCUCUUGGCC 1011 2809 CUAGGUAAGCCUCUUGGCC 1011 2831
GGCCAAGAGGCUUACCUAG 1335 2827 CGUGGUGCCUUUGGCCAAG 1012 2827
CGUGGUGCCUUUGGCCAAG 1012 2849 CUUGGCCAAAGGCACCACG 1336 2845
GUGAUUGAAGCAGAUGCCU 1013 2845 GUGAUUGAAGCAGAUGCCU 1013 2867
AGGCAUCUGCUUCAAUCAC 1337 2863 UUUGGAAUUGACAAGACAG 1014 2863
UUUGGAAUUGACAAGACAG 1014 2885 CUGUCUUGUCAAUUCCAAA 1338 2881
GCAACUUGCAGGACAGUAG 1015 2881 GCAACUUGCAGGACAGUAG 1015 2903
CUACUGUCCUGCAAGUUGC 1339 2899 GCAGUCAAAAUGUUGAAAG 1016 2899
GCAGUCAAAAUGUUGAAAG 1016 2921 CUUUCAACAUUUUGACUGC 1340 2917
GAAGGAGCAACACACAGUG 1017 2917 GAAGGAGCAACACACAGUG 1017 2939
CACUGUGUGUUGCUCCUUC 1341 2935 GAGCAUCGAGCUCUCAUGU 1018 2935
GAGCAUCGAGCUCUCAUGU 1018 2957 ACAUGAGAGCUCGAUGCUC 1342 2953
UCUGAACUCAAGAUCCUCA 1019 2953 UCUGAACUCAAGAUCCUCA 1019 2975
UGAGGAUCUUGAGUUCAGA 1343 2971 AUUCAUAUUGGUCACCAUC 1020 2971
AUUCAUAUUGGUCACCAUC 1020 2993 GAUGGUGACCAAUAUGAAU 1344 2989
CUCAAUGUGGUCAACCUUC 1021 2989 CUCAAUGUGGUCAACCUUC 1021 3011
GAAGGUUGACCACAUUGAG 1345 3007 CUAGGUGCCUGUACCAAGC 1022 3007
CUAGGUGCCUGUACCAAGC 1022 3029 GCUUGGUACAGGCACCUAG 1346 3025
CCAGGAGGGCCACUCAUGG 1023 3025 CCAGGAGGGCCACUCAUGG 1023 3047
CCAUGAGUGGCCCUCCUGG 1347 3043 GUGAUUGUGGAAUUCUGCA 1024 3043
GUGAUUGUGGAAUUCUGCA 1024 3065 UGCAGAAUUCCACAAUCAC 1348 3061
AAAUUUGGAAACCUGUCCA 1025 3061 AAAUUUGGAAACCUGUCCA 1025 3083
UGGACAGGUUUCCAAAUUU 1349 3079 ACUUACCUGAGGAGCAAGA 1026 3079
ACUUACCUGAGGAGCAAGA 1026 3101 UCUUGCUCCUCAGGUAAGU 1350 3097
AGAAAUGAAUUUGUCCCCU 1027 3097 AGAAAUGAAUUUGUCCCCU 1027 3119
AGGGGACAAAUUCAUUUCU 1351 3115 UACAAGACCAAAGGGGCAC 1028 3115
UACAAGACCAAAGGGGCAC 1028 3137 GUGCCCCUUUGGUCUUGUA 1352 3133
CGAUUCCGUCAAGGGAAAG 1029 3133 CGAUUCCGUCAAGGGAAAG 1029 3155
CUUUCCCUUGACGGAAUCG 1353 3151 GACUACGUUGGAGCAAUCC 1030 3151
GACUACGUUGGAGCAAUCC 1030 3173 GGAUUGCUCCAACGUAGUC 1354 3169
CCUGUGGAUCUGAAACGGC 1031 3169 CCUGUGGAUCUGAAACGGC 1031 3191
GCCGUUUCAGAUCCACAGG 1355 3187 CGCUUGGACAGCAUCACCA 1032 3187
CGCUUGGACAGCAUCACCA 1032 3209 UGGUGAUGCUGUCCAAGCG 1356 3205
AGUAGCCAGAGCUCAGCCA 1033 3205 AGUAGCCAGAGCUCAGCCA 1033 3227
UGGCUGAGCUCUGGCUACU 1357 3223 AGCUCUGGAUUUGUGGAGG 1034 3223
AGCUCUGGAUUUGUGGAGG 1034 3245 CCUCCACAAAUCCAGAGCU 1358 3241
GAGAAGUCCCUCAGUGAUG 1035 3241 GAGAAGUCCCUCAGUGAUG 1035 3263
CAUCACUGAGGGACUUCUC 1359 3259 GUAGAAGAAGAGGAAGCUC 1036 3259
GUAGAAGAAGAGGAAGCUC 1036 3281 GAGCUUCCUCUUCUUCUAC 1360 3277
CCUGAAGAUCUGUAUAAGG 1037 3277 CCUGAAGAUCUGUAUAAGG 1037 3299
CCUUAUACAGAUCUUCAGG 1361 3295 GACUUCCUGACCUUGGAGC 1038 3295
GACUUCCUGACCUUGGAGC 1038 3317 GCUCCAAGGUCAGGAAGUC 1362 3313
CAUCUCAUCUGUUACAGCU 1039 3313 CAUCUCAUCUGUUACAGCU 1039 3335
AGCUGUAACAGAUGAGAUG 1363 3331 UUCCAAGUGGCUAAGGGCA 1040 3331
UUCCAAGUGGCUAAGGGCA 1040 3353 UGCCCUUAGCCACUUGGAA 1364 3349
AUGGAGUUCUUGGCAUCGC 1041 3349 AUGGAGUUCUUGGCAUCGC 1041 3371
GCGAUGCCAAGAACUCCAU 1365 3367 CGAAAGUGUAUCCACAGGG 1042 3367
CGAAAGUGUAUCCACAGGG 1042 3389 CCCUGUGGAUACACUUUCG 1366 3385
GACCUGGCGGCACGAAAUA 1043 3385 GACCUGGCGGCACGAAAUA 1043 3407
UAUUUCGUGCCGCCAGGUC 1367 3403 AUCCUCUUAUCGGAGAAGA 1044 3403
AUCCUCUUAUCGGAGAAGA 1044 3425 UCUUCUCCGAUAAGAGGAU 1368 3421
AACGUGGUUAAAAUCUGUG 1045 3421 AACGUGGUUAAAAUCUGUG 1045 3443
CACAGAUUUUAACCACGUU 1369 3439 GACUUUGGCUUGGCCCGGG 1046 3439
GACUUUGGCUUGGCCCGGG 1046 3461 CCCGGGCCAAGCCAAAGUC 1370 3457
GAUAUUUAUAAAGAUCCAG 1047 3457 GAUAUUUAUAAAGAUCCAG 1047 3479
CUGGAUCUUUAUAAAUAUC 1371 3475 GAUUAUGUCAGAAAAGGAG 1048 3475
GAUUAUGUCAGAAAAGGAG 1048 3497 CUCCUUUUCUGACAUAAUC 1372 3493
GAUGCUCGCCUCCCUUUGA 1049 3493 GAUGCUCGCCUCCCUUUGA 1049 3515
UCAAAGGGAGGCGAGCAUC 1373 3511 AAAUGGAUGGCCCCAGAAA 1050 3511
AAAUGGAUGGCCCCAGAAA 1050 3533 UUUCUGGGGCCAUCCAUUU 1374 3529
ACAAUUUUUGACAGAGUGU 1051 3529 ACAAUUUUUGACAGAGUGU 1051 3551
ACACUCUGUCAAAAAUUGU 1375 3547 UACACAAUCCAGAGUGACG 1052 3547
UACACAAUCCAGAGUGACG 1052 3569 CGUCACUCUGGAUUGUGUA 1376 3565
GUCUGGUCUUUUGGUGUUU 1053 3565 GUCUGGUCUUUUGGUGUUU 1053 3587
AAACACCAAAAGACCAGAC 1377 3583 UUGCUGUGGGAAAUAUUUU 1054 3583
UUGCUGUGGGAAAUAUUUU 1054 3605 AAAAUAUUUCCCACAGCAA 1378 3601
UCCUUAGGUGCUUCUCCAU 1055 3601 UCCUUAGGUGCUUCUCCAU 1055 3623
AUGGAGAAGCACCUAAGGA 1379 3619 UAUCCUGGGGUAAAGAUUG 1056 3619
UAUCCUGGGGUAAAGAUUG 1056 3641 CAAUCUUUACCCCAGGAUA 1380 3637
GAUGAAGAAUUUUGUAGGC 1057 3637 GAUGAAGAAUUUUGUAGGC 1057 3659
GCCUACAAAAUUCUUCAUC 1381 3655 CGAUUGAAAGAAGGAACUA 1058 3655
CGAUUGAAAGAAGGAACUA 1058 3677 UAGUUCCUUCUUUCAAUCG 1382 3673
AGAAUGAGGGCCCCUGAUU 1059 3673 AGAAUGAGGGCCCCUGAUU 1059 3695
AAUCAGGGGCCCUCAUUCU 1383 3691 UAUACUACACCAGAAAUGU 1060 3691
UAUACUACACCAGAAAUGU 1060 3713 ACAUUUCUGGUGUAGUAUA 1384 3709
UACCAGACCAUGCUGGACU 1061 3709 UACCAGACCAUGCUGGACU 1061 3731
AGUCCAGCAUGGUCUGGUA 1385 3727 UGCUGGCACGGGGAGCCCA 1062 3727
UGCUGGCACGGGGAGCCCA 1062 3749 UGGGCUCCCCGUGCCAGCA 1386 3745
AGUCAGAGACCCACGUUUU 1063 3745 AGUCAGAGACCCACGUUUU 1063 3767
AAAACGUGGGUCUCUGACU 1387 3763 UCAGAGUUGGUGGAACAUU 1064 3763
UCAGAGUUGGUGGAACAUU 1064 3785 AAUGUUCCACCAACUCUGA 1388 3781
UUGGGAAAUCUCUUGCAAG 1065 3781 UUGGGAAAUCUCUUGCAAG 1065 3803
CUUGCAAGAGAUUUCCCAA 1389 3799 GCUAAUGCUCAGCAGGAUG 1066 3799
GCUAAUGCUCAGCAGGAUG 1066 3821 CAUCCUGCUGAGCAUUAGC 1390 3817
GGCAAAGACUACAUUGUUC 1067 3817 GGCAAAGACUACAUUGUUC 1067 3839
GAACAAUGUAGUCUUUGCC 1391 3835 CUUCCGAUAUCAGAGACUU 1068 3835
CUUCCGAUAUCAGAGACUU 1068 3857 AAGUCUCUGAUAUCGGAAG 1392 3853
UUGAGCAUGGAAGAGGAUU 1069 3853 UUGAGCAUGGAAGAGGAUU 1069 3875
AAUCCUCUUCCAUGCUCAA 1393 3871 UCUGGACUCUCUCUGCCUA 1070 3871
UCUGGACUCUCUCUGCCUA 1070 3893 UAGGCAGAGAGAGUCCAGA 1394 3889
ACCUCACCUGUUUCCUGUA 1071 3889 ACCUCACCUGUUUCCUGUA 1071 3911
UACAGGAAACAGGUGAGGU 1395 3907 AUGGAGGAGGAGGAAGUAU 1072 3907
AUGGAGGAGGAGGAAGUAU 1072 3929 AUACUUCCUCCUCCUCCAU 1396 3925
UGUGACCCCAAAUUCCAUU 1073 3925 UGUGACCCCAAAUUCCAUU 1073 3947
AAUGGAAUUUGGGGUCACA 1397 3943 UAUGACAACACAGCAGGAA 1074 3943
UAUGACAACACAGCAGGAA 1074 3965 UUCCUGCUGUGUUGUCAUA 1398 3961
AUCAGUCAGUAUCUGCAGA 1075 3961 AUCAGUCAGUAUCUGCAGA 1075 3983
UCUGCAGAUACUGACUGAU 1399 3979 AACAGUAAGCGAAAGAGCC 1076 3979
AACAGUAAGCGAAAGAGCC 1076 4001 GGCUCUUUCGCUUACUGUU 1400 3997
CGGCCUGUGAGUGUAAAAA 1077 3997 CGGCCUGUGAGUGUAAAAA 1077 4019
UUUUUACACUCACAGGCCG 1401 4015 ACAUUUGAAGAUAUCCCGU 1078 4015
ACAUUUGAAGAUAUCCCGU 1078 4037 ACGGGAUAUCUUCAAAUGU 1402 4033
UUAGAAGAACCAGAAGUAA 1079 4033 UUAGAAGAACCAGAAGUAA 1079 4055
UUACUUCUGGUUCUUCUAA 1403 4051 AAAGUAAUCCCAGAUGACA 1080 4051
AAAGUAAUCCCAGAUGACA 1080 4073 UGUCAUCUGGGAUUACUUU 1404 4069
AACCAGACGGACAGUGGUA 1081 4069 AACCAGACGGACAGUGGUA 1081 4091
UACCACUGUCCGUCUGGUU 1405 4087 AUGGUUCUUGCCUCAGAAG 1082 4087
AUGGUUCUUGCCUCAGAAG 1082 4109 CUUCUGAGGCAAGAACCAU 1406 4105
GAGCUGAAAACUUUGGAAG 1083 4105 GAGCUGAAAACUUUGGAAG 1083 4127
CUUCCAAAGUUUUCAGCUC 1407 4123 GACAGAACCAAAUUAUCUC 1084 4123
GACAGAACCAAAUUAUCUC 1084 4145 GAGAUAAUUUGGUUCUGUC 1408 4141
CCAUCUUUUGGUGGAAUGG 1085 4141 CCAUCUUUUGGUGGAAUGG 1085 4163
CCAUUCCACCAAAAGAUGG 1409 4159 GUGCCCAGCAAAAGCAGGG 1086 4159
GUGCCCAGCAAAAGCAGGG 1086 4181 CCCUGCUUUUGCUGGGCAC 1410 4177
GAGUCUGUGGCAUCUGAAG 1087 4177 GAGUCUGUGGCAUCUGAAG 1087 4199
CUUCAGAUGCCACAGACUC 1411 4195 GGCUCAAACCAGACAAGCG 1088 4195
GGCUCAAACCAGACAAGCG 1088 4217 CGCUUGUCUGGUUUGAGCC 1412 4213
GGCUACCAGUCCGGAUAUC 1089 4213 GGCUACCAGUCCGGAUAUC 1089 4235
GAUAUCCGGACUGGUAGCC 1413 4231 CACUCCGAUGACACAGACA 1090 4231
CACUCCGAUGACACAGACA 1090 4253 UGUCUGUGUCAUCGGAGUG 1414 4249
ACCACCGUGUACUCCAGUG 1091 4249 ACCACCGUGUACUCCAGUG 1091 4271
CACUGGAGUACACGGUGGU 1415 4267 GAGGAAGCAGAACUUUUAA 1092 4267
GAGGAAGCAGAACUUUUAA 1092 4289 UUAAAAGUUCUGCUUCCUC 1416 4285
AAGCUGAUAGAGAUUGGAG 1093 4285 AAGCUGAUAGAGAUUGGAG 1093 4307
CUCCAAUCUCUAUCAGCUU 1417 4303 GUGCAAACCGGUAGCACAG 1094 4303
GUGCAAACCGGUAGCACAG 1094 4325 CUGUGCUACCGGUUUGCAC 1418 4321
GCCCAGAUUCUCCAGCCUG 1095 4321 GCCCAGAUUCUCCAGCCUG 1095 4343
CAGGCUGGAGAAUCUGGGC 1419 4339 GACUCGGGGACCACACUGA 1096 4339
GACUCGGGGACCACACUGA 1096 4361 UCAGUGUGGUCCCCGAGUC 1420 4357
AGCUCUCCUCCUGUUUAAA 1097 4357 AGCUCUCCUCCUGUUUAAA 1097 4379
UUUAAACAGGAGGAGAGCU 1421 4375 AAGGAAGCAUCCACACCCC 1098 4375
AAGGAAGCAUCCACACCCC 1098 4397 GGGGUGUGGAUGCUUCCUU 1422
4393 CAACUCCCGGACAUCACAU 1099 4393 CAACUCCCGGACAUCACAU 1099 4415
AUGUGAUGUCCGGGAGUUG 1423 4411 UGAGAGGUCUGCUCAGAUU 1100 4411
UGAGAGGUCUGCUCAGAUU 1100 4433 AAUCUGAGCAGACCUCUCA 1424 4429
UUUGAAGUGUUGUUCUUUC 1101 4429 UUUGAAGUGUUGUUCUUUC 1101 4451
GAAAGAACAACACUUCAAA 1425 4447 CCACCAGCAGGAAGUAGCC 1102 4447
CCACCAGCAGGAAGUAGCC 1102 4469 GGCUACUUCCUGCUGGUGG 1426 4465
CGCAUUUGAUUUUCAUUUC 1103 4465 CGCAUUUGAUUUUCAUUUC 1103 4487
GAAAUGAAAAUCAAAUGCG 1427 4483 CGACAACAGAAAAAGGACC 1104 4483
CGACAACAGAAAAAGGACC 1104 4505 GGUCCUUUUUCUGUUGUCG 1428 4501
CUCGGACUGCAGGGAGCCA 1105 4501 CUCGGACUGCAGGGAGCCA 1105 4523
UGGCUCCCUGCAGUCCGAG 1429 4519 AGUCUUCUAGGCAUAUCCU 1106 4519
AGUCUUCUAGGCAUAUCCU 1106 4541 AGGAUAUGCCUAGAAGACU 1430 4537
UGGAAGAGGCUUGUGACCC 1107 4537 UGGAAGAGGCUUGUGACCC 1107 4559
GGGUCACAAGCCUCUUCCA 1431 4555 CAAGAAUGUGUCUGUGUCU 1108 4555
CAAGAAUGUGUCUGUGUCU 1108 4577 AGACACAGACACAUUCUUG 1432 4573
UUCUCCCAGUGUUGACCUG 1109 4573 UUCUCCCAGUGUUGACCUG 1109 4595
CAGGUCAACACUGGGAGAA 1433 4591 GAUCCUCUUUUUUCAUUCA 1110 4591
GAUCCUCUUUUUUCAUUCA 1110 4613 UGAAUGAAAAAAGAGGAUC 1434 4609
AUUUAAAAAGCAUUAUCAU 1111 4609 AUUUAAAAAGCAUUAUCAU 1111 4631
AUGAUAAUGCUUUUUAAAU 1435 4627 UGCCCCUGCUGCGGGUCUC 1112 4627
UGCCCCUGCUGCGGGUCUC 1112 4649 GAGACCCGCAGCAGGGGCA 1436 4645
CACCAUGGGUUUAGAACAA 1113 4645 CACCAUGGGUUUAGAACAA 1113 4667
UUGUUCUAAACCCAUGGUG 1437 4663 AAGAGCUUCAAGCAAUGGC 1114 4663
AAGAGCUUCAAGCAAUGGC 1114 4685 GCCAUUGCUUGAAGCUCUU 1438 4681
CCCCAUCCUCAAAGAAGUA 1115 4681 CCCCAUCCUCAAAGAAGUA 1115 4703
UACUUCUUUGAGGAUGGGG 1439 4699 AGCAGUACCUGGGGAGCUG 1116 4699
AGCAGUACCUGGGGAGCUG 1116 4721 CAGCUCCCCAGGUACUGCU 1440 4717
GACACUUCUGUAAAACUAG 1117 4717 GACACUUCUGUAAAACUAG 1117 4739
CUAGUUUUACAGAAGUGUC 1441 4735 GAAGAUAAACCAGGCAACG 1118 4735
GAAGAUAAACCAGGCAACG 1118 4757 CGUUGCCUGGUUUAUCUUC 1442 4753
GUAAGUGUUCGAGGUGUUG 1119 4753 GUAAGUGUUCGAGGUGUUG 1119 4775
CAACACCUCGAACACUUAC 1443 4771 GAAGAUGGGAAGGAUUUGC 1120 4771
GAAGAUGGGAAGGAUUUGC 1120 4793 GCAAAUCCUUCCCAUCUUC 1444 4789
CAGGGCUGAGUCUAUCCAA 1121 4789 CAGGGCUGAGUCUAUCCAA 1121 4811
UUGGAUAGACUCAGCCCUG 1445 4807 AGAGGCUUUGUUUAGGACG 1122 4807
AGAGGCUUUGUUUAGGACG 1122 4829 CGUCCUAAACAAAGCCUCU 1446 4825
GUGGGUCCCAAGCCAAGCC 1123 4825 GUGGGUCCCAAGCCAAGCC 1123 4847
GGCUUGGCUUGGGACCCAC 1447 4843 CUUAAGUGUGGAAUUCGGA 1124 4843
CUUAAGUGUGGAAUUCGGA 1124 4865 UCCGAAUUCCACACUUAAG 1448 4861
AUUGAUAGAAAGGAAGACU 1125 4861 AUUGAUAGAAAGGAAGACU 1125 4883
AGUCUUCCUUUCUAUCAAU 1449 4879 UAACGUUACCUUGCUUUGG 1126 4879
UAACGUUACCUUGCUUUGG 1126 4901 CCAAAGCAAGGUAACGUUA 1450 4897
GAGAGUACUGGAGCCUGCA 1127 4897 GAGAGUACUGGAGCCUGCA 1127 4919
UGCAGGCUCCAGUACUCUC 1451 4915 AAAUGCAUUGUGUUUGCUC 1128 4915
AAAUGCAUUGUGUUUGCUC 1128 4937 GAGCAAACACAAUGCAUUU 1452 4933
CUGGUGGAGGUGGGCAUGG 1129 4933 CUGGUGGAGGUGGGCAUGG 1129 4955
CCAUGCCCACCUCCACCAG 1453 4951 GGGUCUGUUCUGAAAUGUA 1130 4951
GGGUCUGUUCUGAAAUGUA 1130 4973 UACAUUUCAGAACAGACCC 1454 4969
AAAGGGUUCAGACGGGGUU 1131 4969 AAAGGGUUCAGACGGGGUU 1131 4991
AACCCCGUCUGAACCCUUU 1455 4987 UUCUGGUUUUAGAAGGUUG 1132 4987
UUCUGGUUUUAGAAGGUUG 1132 5009 CAACCUUCUAAAACCAGAA 1456 5005
GCGUGUUCUUCGAGUUGGG 1133 5005 GCGUGUUCUUCGAGUUGGG 1133 5027
CCCAACUCGAAGAACACGC 1457 5023 GCUAAAGUAGAGUUCGUUG 1134 5023
GCUAAAGUAGAGUUCGUUG 1134 5045 CAACGAACUCUACUUUAGC 1458 5041
GUGCUGUUUCUGACUCCUA 1135 5041 GUGCUGUUUCUGACUCCUA 1135 5063
UAGGAGUCAGAAACAGCAC 1459 5059 AAUGAGAGUUCCUUCCAGA 1136 5059
AAUGAGAGUUCCUUCCAGA 1136 5081 UCUGGAAGGAACUCUCAUU 1460 5077
ACCGUUAGCUGUCUCCUUG 1137 5077 ACCGUUAGCUGUCUCCUUG 1137 5099
CAAGGAGACAGCUAACGGU 1461 5095 GCCAAGCCCCAGGAAGAAA 1138 5095
GCCAAGCCCCAGGAAGAAA 1138 5117 UUUCUUCCUGGGGCUUGGC 1462 5113
AAUGAUGCAGCUCUGGCUC 1139 5113 AAUGAUGCAGCUCUGGCUC 1139 5135
GAGCCAGAGCUGCAUCAUU 1463 5131 CCUUGUCUCCCAGGCUGAU 1140 5131
CCUUGUCUCCCAGGCUGAU 1140 5153 AUCAGCCUGGGAGACAAGG 1464 5149
UCCUUUAUUCAGAAUACCA 1141 5149 UCCUUUAUUCAGAAUACCA 1141 5171
UGGUAUUCUGAAUAAAGGA 1465 5167 ACAAAGAAAGGACAUUCAG 1142 5167
ACAAAGAAAGGACAUUCAG 1142 5189 CUGAAUGUCCUUUCUUUGU 1466 5185
GCUCAAGGCUCCCUGCCGU 1143 5185 GCUCAAGGCUCCCUGCCGU 1143 5207
ACGGCAGGGAGCCUUGAGC 1467 5203 UGUUGAAGAGUUCUGACUG 1144 5203
UGUUGAAGAGUUCUGACUG 1144 5225 CAGUCAGAACUCUUCAACA 1468 5221
GCACAAACCAGCUUCUGGU 1145 5221 GCACAAACCAGCUUCUGGU 1145 5243
ACCAGAAGCUGGUUUGUGC 1469 5239 UUUCUUCUGGAAUGAAUAC 1146 5239
UUUCUUCUGGAAUGAAUAC 1146 5261 GUAUUCAUUCCAGAAGAAA 1470 5257
CCCUCAUAUCUGUCCUGAU 1147 5257 CCCUCAUAUCUGUCCUGAU 1147 5279
AUCAGGACAGAUAUGAGGG 1471 5275 UGUGAUAUGUCUGAGACUG 1148 5275
UGUGAUAUGUCUGAGACUG 1148 5297 CAGUCUCAGACAUAUCACA 1472 5293
GAAUGCGGGAGGUUCAAUG 1149 5293 GAAUGCGGGAGGUUCAAUG 1149 5315
CAUUGAACCUCCCGCAUUC 1473 5311 GUGAAGCUGUGUGUGGUGU 1150 5311
GUGAAGCUGUGUGUGGUGU 1150 5333 ACACCACACACAGCUUCAC 1474 5329
UCAAAGUUUCAGGAAGGAU 1151 5329 UCAAAGUUUCAGGAAGGAU 1151 5351
AUCCUUCCUGAAACUUUGA 1475 5347 UUUUACCCUUUUGUUCUUC 1152 5347
UUUUACCCUUUUGUUCUUC 1152 5369 GAAGAACAAAAGGGUAAAA 1476 5365
CCCCCUGUCCCCAACCCAC 1153 5365 CCCCCUGUCCCCAACCCAC 1153 5387
GUGGGUUGGGGACAGGGGG 1477 5383 CUCUCACCCCGCAACCCAU 1154 5383
CUCUCACCCCGCAACCCAU 1154 5405 AUGGGUUGCGGGGUGAGAG 1478 5401
UCAGUAUUUUAGUUAUUUG 1155 5401 UCAGUAUUUUAGUUAUUUG 1155 5423
CAAAUAACUAAAAUACUGA 1479 5419 GGCCUCUACUCCAGUAAAC 1156 5419
GGCCUCUACUCCAGUAAAC 1156 5441 GUUUACUGGAGUAGAGGCC 1480 5437
CCUGAUUGGGUUUGUUCAC 1157 5437 CCUGAUUGGGUUUGUUCAC 1157 5459
GUGAACAAACCCAAUCAGG 1481 5455 CUCUCUGAAUGAUUAUUAG 1158 5455
CUCUCUGAAUGAUUAUUAG 1158 5477 CUAAUAAUCAUUCAGAGAG 1482 5473
GCCAGACUUCAAAAUUAUU 1159 5473 GCCAGACUUCAAAAUUAUU 1159 5495
AAUAAUUUUGAAGUCUGGC 1483 5491 UUUAUAGCCCAAAUUAUAA 1160 5491
UUUAUAGCCCAAAUUAUAA 1160 5513 UUAUAAUUUGGGCUAUAAA 1484 5509
ACAUCUAUUGUAUUAUUUA 1161 5509 ACAUCUAUUGUAUUAUUUA 1161 5531
UAAAUAAUACAAUAGAUGU 1485 5527 AGACUUUUAACAUAUAGAG 1162 5527
AGACUUUUAACAUAUAGAG 1162 5549 CUCUAUAUGUUAAAAGUCU 1486 5545
GCUAUUUCUACUGAUUUUU 1163 5545 GCUAUUUCUACUGAUUUUU 1163 5567
AAAAAUCAGUAGAAAUAGC 1487 5563 UGCCCUUGUUCUGUCCUUU 1164 5563
UGCCCUUGUUCUGUCCUUU 1164 5585 AAAGGACAGAACAAGGGCA 1488 5581
UUUUUCAAAAAAGAAAAUG 1165 5581 UUUUUCAAAAAAGAAAAUG 1165 5603
CAUUUUCUUUUUUGAAAAA 1489 5599 GUGUUUUUUGUUUGGUACC 1166 5599
GUGUUUUUUGUUUGGUACC 1166 5621 GGUACCAAACAAAAAACAC 1490 5617
CAUAGUGUGAAAUGCUGGG 1167 5617 CAUAGUGUGAAAUGCUGGG 1167 5639
CCCAGCAUUUCACACUAUG 1491 5635 GAACAAUGACUAUAAGACA 1168 5635
GAACAAUGACUAUAAGACA 1168 5657 UGUCUUAUAGUCAUUGUUC 1492 5653
AUGCUAUGGCACAUAUAUU 1169 5653 AUGCUAUGGCACAUAUAUU 1169 5675
AAUAUAUGUGCCAUAGCAU 1493 5671 UUAUAGUCUGUUUAUGUAG 1170 5671
UUAUAGUCUGUUUAUGUAG 1170 5693 CUACAUAAACAGACUAUAA 1494 5689
GAAACAAAUGUAAUAUAUU 1171 5689 GAAACAAAUGUAAUAUAUU 1171 5711
AAUAUAUUACAUUUGUUUC 1495 5707 UAAAGCCUUAUAUAUAAUG 1172 5707
UAAAGCCUUAUAUAUAAUG 1172 5729 CAUUAUAUAUAAGGCUUUA 1496 5725
GAACUUUGUACUAUUCACA 1173 5725 GAACUUUGUACUAUUCACA 1173 5747
UGUGAAUAGUACAAAGUUC 1497 5743 AUUUUGUAUCAGUAUUAUG 1174 5743
AUUUUGUAUCAGUAUUAUG 1174 5765 CAUAAUACUGAUACAAAAU 1498 5761
GUAGCAUAACAAAGGUCAU 1175 5761 GUAGCAUAACAAAGGUCAU 1175 5783
AUGACCUUUGUUAUGCUAC 1499 5779 UAAUGCUUUCAGCAAUUGA 1176 5779
UAAUGCUUUCAGCAAUUGA 1176 5801 UCAAUUGCUGAAAGCAUUA 1500 5797
AUGUCAUUUUAUUAAAGAA 1177 5797 AUGUCAUUUUAUUAAAGAA 1177 5819
UUCUUUAAUAAAAUGACAU 1501 5812 AGAACAUUGAAAAACUUGA 1178 5812
AGAACAUUGAAAAACUUGA 1178 5834 UCAAGUUUUUCAAUGUUCU 1502 VEGFR3
gi.vertline.4503752.vertline.reF.vertline.NM_002020.1 1
ACCCACGCGCAGCGGCCGG 1503 1 ACCCACGCGCAGCGGCCGG 1503 23
CCGGCCGCUGCGCGUGGGU 1750 19 GAGAUGCAGCGGGGCGCCG 1504 19
GAGAUGCAGCGGGGCGCCG 1504 41 CGGCGCCCCGCUGCAUCUC 1751 37
GCGCUGUGCCUGCGACUGU 1505 37 GCGCUGUGCCUGCGACUGU 1505 59
ACAGUCGCAGGCACAGCGC 1752 55 UGGCUCUGCCUGGGACUCC 1506 55
UGGCUCUGCCUGGGACUCC 1506 77 GGAGUCCCAGGCAGAGCCA 1753 73
CUGGACGGCCUGGUGAGUG 1507 73 CUGGACGGCCUGGUGAGUG 1507 95
CACUCACCAGGCCGUCCAG 1754 91 GACUACUCCAUGACCCCCC 1508 91
GACUACUCCAUGACCCCCC 1508 113 GGGGGGUCAUGGAGUAGUC 1755 109
CCGACCUUGAACAUCACGG 1509 109 CCGACCUUGAACAUCACGG 1509 131
CCGUGAUGUUCAAGGUCGG 1756 127 GAGGAGUCACACGUCAUCG 1510 127
GAGGAGUCACACGUCAUCG 1510 149 CGAUGACGUGUGACUCCUC 1757 145
GACACCGGUGACAGCCUGU 1511 145 GACACCGGUGACAGCCUGU 1511 167
ACAGGCUGUCACCGGUGUC 1758 163 UCCAUCUCCUGCAGGGGAC 1512 163
UCCAUCUCCUGCAGGGGAC 1512 185 GUCCCCUGCAGGAGAUGGA 1759 181
CAGCACCCCCUCGAGUGGG 1513 181 CAGCACCCCCUCGAGUGGG 1513 203
CCCACUCGAGGGGGUGCUG 1760 199 GCUUGGCCAGGAGCUCAGG 1514 199
GCUUGGCCAGGAGCUCAGG 1514 221 CCUGAGCUCCUGGCCAAGC 1761 217
GAGGCGCCAGCCACCGGAG 1515 217 GAGGCGCCAGCCACCGGAG 1515 239
CUCCGGUGGCUGGCGCCUC 1762 235 GACAAGGACAGCGAGGACA 1516 235
GACAAGGACAGCGAGGACA 1516 257 UGUCCUCGCUGUCCUUGUC 1763 253
ACGGGGGUGGUGCGAGACU 1517 253 ACGGGGGUGGUGCGAGACU 1517 275
AGUCUCGCACCACCCCCGU 1764 271 UGCGAGGGCACAGACGCCA 1518 271
UGCGAGGGCACAGACGCCA 1518 293 UGGCGUCUGUGCCCUCGCA 1765 289
AGGCCCUACUGCAAGGUGU 1519 289 AGGCCCUACUGCAAGGUGU 1519 311
ACACCUUGCAGUAGGGCCU 1766 307 UUGCUGCUGCACGAGGUAC 1520 307
UUGCUGCUGCACGAGGUAC 1520 329 GUACCUCGUGCAGCAGCAA 1767 325
CAUGCCAACGACACAGGCA 1521 325 CAUGCCAACGACACAGGCA 1521 347
UGCCUGUGUCGUUGGCAUG 1768 343 AGCUACGUCUGCUACUACA 1522 343
AGCUACGUCUGCUACUACA 1522 365 UGUAGUAGCAGACGUAGCU 1769 361
AAGUACAUCAAGGCACGCA 1523 361 AAGUACAUCAAGGCACGCA 1523 383
UGCGUGCCUUGAUGUACUU 1770 379 AUCGAGGGCACCACGGCCG 1524 379
AUCGAGGGCACCACGGCCG 1524 401 CGGCCGUGGUGCCCUCGAU 1771 397
GCCAGCUCCUACGUGUUCG 1525 397 GCCAGCUCCUACGUGUUCG 1525 419
CGAACACGUAGGAGCUGGC 1772 415 GUGAGAGACUUUGAGCAGC 1526 415
GUGAGAGACUUUGAGCAGC 1526 437 GCUGCUCAAAGUCUCUCAC 1773 433
CCAUUCAUCAACAAGCCUG 1527 433 CCAUUCAUCAACAAGCCUG 1527 455
CAGGCUUGUUGAUGAAUGG 1774 451 GACACGCUCUUGGUCAACA 1528 451
GACACGCUCUUGGUCAACA 1528 473 UGUUGACCAAGAGCGUGUC 1775 469
AGGAAGGACGCCAUGUGGG 1529 469 AGGAAGGACGCCAUGUGGG 1529 491
CCCACAUGGCGUCCUUCCU 1776 487 GUGCCCUGUCUGGUGUCCA 1530 487
GUGCCCUGUCUGGUGUCCA 1530 509 UGGACACCAGACAGGGCAC 1777 505
AUCCCCGGCCUCAAUGUCA 1531 505 AUCCCCGGCCUCAAUGUCA 1531 527
UGACAUUGAGGCCGGGGAU 1778 523 ACGCUGCGCUCGCAAAGCU 1532 523
ACGCUGCGCUCGCAAAGCU 1532 545 AGCUUUGCGAGCGCAGCGU 1779 541
UCGGUGCUGUGGCCAGACG 1533 541 UCGGUGCUGUGGCCAGACG 1533 563
CGUCUGGCCACAGCACCGA 1780 559 GGGCAGGAGGUGGUGUGGG 1534 559
GGGCAGGAGGUGGUGUGGG 1534 581 CCCACACCACCUCCUGCCC 1781 577
GAUGACCGGCGGGGCAUGC 1535 577 GAUGACCGGCGGGGCAUGC 1535 599
GCAUGCCCCGCCGGUCAUC 1782 595 CUCGUGUCCACGCCACUGC 1536 595
CUCGUGUCCACGCCACUGC 1536 617 GCAGUGGCGUGGACACGAG 1783 613
CUGCACGAUGCCCUGUACC 1537 613 CUGCACGAUGCCCUGUACC 1537 635
GGUACAGGGCAUCGUGCAG 1784 631 CUGCAGUGCGAGACCACCU 1538 631
CUGCAGUGCGAGACCACCU 1538 653 AGGUGGUCUCGCACUGCAG 1785 649
UGGGGAGACCAGGACUUCC 1539 649 UGGGGAGACCAGGACUUCC 1539 671
GGAAGUCCUGGUCUCCCCA 1786 667 CUUUCCAACCCCUUCCUGG 1540 667
CUUUCCAACCCCUUCCUGG 1540 689 CCAGGAAGGGGUUGGAAAG 1787 685
GUGCACAUCACAGGCAACG 1541 685 GUGCACAUCACAGGCAACG 1541 707
CGUUGCCUGUGAUGUGCAC 1788 703 GAGCUCUAUGACAUCCAGC 1542 703
GAGCUCUAUGACAUCCAGC 1542 725 GCUGGAUGUCAUAGAGCUC 1789 721
CUGUUGCCCAGGAAGUCGC 1543 721 CUGUUGCCCAGGAAGUCGC 1543 743
GCGACUUCCUGGGCAACAG 1790 739 CUGGAGCUGCUGGUAGGGG 1544 739
CUGGAGCUGCUGGUAGGGG 1544 761 CCCCUACCAGCAGCUCCAG 1791 757
GAGAAGCUGGUCCUCAACU 1545 757 GAGAAGCUGGUCCUCAACU 1545 779
AGUUGAGGACCAGCUUCUC 1792 775 UGCACCGUGUGGGCUGAGU 1546 775
UGCACCGUGUGGGCUGAGU 1546 797 ACUCAGCCCACACGGUGCA 1793 793
UUUAACUCAGGUGUCACCU 1547 793 UUUAACUCAGGUGUCACCU 1547 815
AGGUGACACCUGAGUUAAA 1794 811 UUUGACUGGGACUACCCAG 1548 811
UUUGACUGGGACUACCCAG 1548 833 CUGGGUAGUCCCAGUCAAA 1795 829
GGGAAGCAGGCAGAGCGGG 1549 829 GGGAAGCAGGCAGAGCGGG 1549 851
CCCGCUCUGCCUGCUUCCC 1796 847 GGUAAGUGGGUGCCCGAGC 1550 847
GGUAAGUGGGUGCCCGAGC 1550 869 GCUCGGGCACCCACUUACC 1797 865
CGACGCUCCCAACAGACCC 1551 865 CGACGCUCCCAACAGACCC 1551 887
GGGUCUGUUGGGAGCGUCG 1798 883 CACACAGAACUCUCCAGCA 1552 883
CACACAGAACUCUCCAGCA 1552 905 UGCUGGAGAGUUCUGUGUG 1799 901
AUCCUGACCAUCCACAACG 1553 901 AUCCUGACCAUCCACAACG 1553 923
CGUUGUGGAUGGUCAGGAU 1800 919 GUCAGCCAGCACGACCUGG 1554 919
GUCAGCCAGCACGACCUGG 1554 941 CCAGGUCGUGCUGGCUGAC 1801 937
GGCUCGUAUGUGUGCAAGG 1555 937 GGCUCGUAUGUGUGCAAGG 1555 959
CCUUGCACACAUACGAGCC 1802 955 GCCAACAACGGCAUCCAGC 1556 955
GCCAACAACGGCAUCCAGC 1556 977 GCUGGAUGCCGUUGUUGGC 1803 973
CGAUUUCGGGAGAGCACCG 1557 973 CGAUUUCGGGAGAGCACCG 1557 995
CGGUGCUCUCCCGAAAUCG 1804 991 GAGGUCAUUGUGCAUGAAA 1558 991
GAGGUCAUUGUGCAUGAAA 1558 1013 UUUCAUGCACAAUGACCUC 1805 1009
AAUCCCUUCAUCAGCGUCG 1559 1009 AAUCCCUUCAUCAGCGUCG 1559 1031
CGACGCUGAUGAAGGGAUU 1806 1027 GAGUGGCUCAAAGGACCCA 1560 1027
GAGUGGCUCAAAGGACCCA 1560 1049 UGGGUCCUUUGAGCCACUC 1807 1045
AUCCUGGAGGCCACGGCAG 1561 1045 AUCCUGGAGGCCACGGCAG 1561 1067
CUGCCGUGGCCUCCAGGAU 1808 1063 GGAGACGAGCUGGUGAAGC 1562 1063
GGAGACGAGCUGGUGAAGC 1562 1085 GCUUCACCAGCUCGUCUCC 1809 1081
CUGCCCGUGAAGCUGGCAG 1563 1081 CUGCCCGUGAAGCUGGCAG 1563 1103
CUGCCAGCUUCACGGGCAG 1810 1099 GCGUACCCCCCGCCCGAGU 1564 1099
GCGUACCCCCCGCCCGAGU 1564 1121 ACUCGGGCGGGGGGUACGC 1811 1117
UUCCAGUGGUACAAGGAUG 1565 1117 UUCCAGUGGUACAAGGAUG 1565 1139
CAUCCUUGUACCACUGGAA 1812 1135 GGAAAGGCACUGUCCGGGC 1566 1135
GGAAAGGCACUGUCCGGGC 1566 1157 GCCCGGACAGUGCCUUUCC 1813 1153
CGCCACAGUCCACAUGCCC 1567 1153 CGCCACAGUCCACAUGCCC 1567 1175
GGGCAUGUGGACUGUGGCG 1814 1171 CUGGUGCUCAAGGAGGUGA 1568 1171
CUGGUGCUCAAGGAGGUGA 1568 1193 UCACCUCCUUGAGCACCAG 1815 1189
ACAGAGGCCAGCACAGGCA 1569 1189 ACAGAGGCCAGCACAGGCA 1569 1211
UGCCUGUGCUGGCCUCUGU 1816 1207 ACCUACACCCUCGCCCUGU 1570 1207
ACCUACACCCUCGCCCUGU 1570 1229 ACAGGGCGAGGGUGUAGGU 1817 1225
UGGAACUCCGCUGCUGGCC 1571 1225 UGGAACUCCGCUGCUGGCC 1571 1247
GGCCAGCAGCGGAGUUCCA 1818 1243 CUGAGGCGCAACAUCAGCC 1572 1243
CUGAGGCGCAACAUCAGCC 1572 1265 GGCUGAUGUUGCGCCUCAG 1819 1261
CUGGAGCUGGUGGUGAAUG 1573 1261 CUGGAGCUGGUGGUGAAUG 1573 1283
CAUUCACCACCAGCUCCAG 1820 1279 GUGCCCCCCCAGAUACAUG 1574 1279
GUGCCCCCCCAGAUACAUG 1574 1301 CAUGUAUCUGGGGGGGCAC 1821 1297
GAGAAGGAGGCCUCCUCCC 1575 1297 GAGAAGGAGGCCUCCUCCC 1575 1319
GGGAGGAGGCCUCCUUCUC 1822 1315 CCCAGCAUCUACUCGCGUC 1576 1315
CCCAGCAUCUACUCGCGUC 1576 1337 GACGCGAGUAGAUGCUGGG 1823 1333
CACAGCCGCCAGGCCCUCA 1577 1333 CACAGCCGCCAGGCCCUCA 1577 1355
UGAGGGCCUGGCGGCUGUG 1824 1351 ACCUGCACGGCCUACGGGG 1578 1351
ACCUGCACGGCCUACGGGG 1578 1373 CCCCGUAGGCCGUGCAGGU 1825 1369
GUGCCCCUGCCUCUCAGCA 1579 1369 GUGCCCCUGCCUCUCAGCA 1579 1391
UGCUGAGAGGCAGGGGCAC 1826 1387 AUCCAGUGGCACUGGCGGC 1580 1387
AUCCAGUGGCACUGGCGGC 1580 1409 GCCGCCAGUGCCACUGGAU 1827 1405
CCCUGGACACCCUGCAAGA 1581 1405 CCCUGGACACCCUGCAAGA 1581 1427
UCUUGCAGGGUGUCCAGGG 1828 1423 AUGUUUGCCCAGCGUAGUC 1582 1423
AUGUUUGCCCAGCGUAGUC 1582 1445 GACUACGCUGGGCAAACAU 1829 1441
CUCCGGCGGCGGCAGCAGC 1583 1441 CUCCGGCGGCGGCAGCAGC 1583 1463
GCUGCUGCCGCCGCCGGAG 1830 1459 CAAGACCUCAUGCCACAGU 1584 1459
CAAGACCUCAUGCCACAGU 1584 1481 ACUGUGGCAUGAGGUCUUG 1831 1477
UGCCGUGACUGGAGGGCGG 1585 1477 UGCCGUGACUGGAGGGCGG 1585 1499
CCGCCCUCCAGUCACGGCA 1832 1495 GUGACCACGCAGGAUGCCG 1586 1495
GUGACCACGCAGGAUGCCG 1586 1517 CGGCAUCCUGCGUGGUCAC 1833 1513
GUGAACCCCAUCGAGAGCC 1587 1513 GUGAACCCCAUCGAGAGCC 1587 1535
GGCUCUCGAUGGGGUUCAC 1834 1531 CUGGACACCUGGACCGAGU 1588 1531
CUGGACACCUGGACCGAGU 1588 1553 ACUCGGUCCAGGUGUCCAG 1835 1549
UUUGUGGAGGGAAAGAAUA 1589 1549 UUUGUGGAGGGAAAGAAUA 1589 1571
UAUUCUUUCCCUCCACAAA 1836 1567 AAGACUGUGAGCAAGCUGG 1590 1567
AAGACUGUGAGCAAGCUGG 1590 1589 CCAGCUUGCUCACAGUCUU 1837 1585
GUGAUCCAGAAUGCCAACG 1591 1585 GUGAUCCAGAAUGCCAACG 1591 1607
CGUUGGCAUUCUGGAUCAC 1838 1603 GUGUCUGCCAUGUACAAGU 1592 1603
GUGUCUGCCAUGUACAAGU 1592 1625 ACUUGUACAUGGCAGACAC 1839 1621
UGUGUGGUCUCCAACAAGG 1593 1621 UGUGUGGUCUCCAACAAGG 1593 1643
CCUUGUUGGAGACCACACA 1840 1639 GUGGGCCAGGAUGAGCGGC 1594 1639
GUGGGCCAGGAUGAGCGGC 1594 1661 GCCGCUCAUCCUGGCCCAC 1841 1657
CUCAUCUACUUCUAUGUGA 1595 1657 CUCAUCUACUUCUAUGUGA 1595 1679
UCACAUAGAAGUAGAUGAG 1842 1675 ACCACCAUCCCCGACGGCU 1596 1675
ACCACCAUCCCCGACGGCU 1596 1697 AGCCGUCGGGGAUGGUGGU 1843 1693
UUCACCAUCGAAUCCAAGC 1597 1693 UUCACCAUCGAAUCCAAGC 1597 1715
GCUUGGAUUCGAUGGUGAA 1844 1711 CCAUCCGAGGAGCUACUAG 1598 1711
CCAUCCGAGGAGCUACUAG 1598 1733 CUAGUAGCUCCUCGGAUGG 1845 1729
GAGGGCCAGCCGGUGCUCC 1599 1729 GAGGGCCAGCCGGUGCUCC 1599 1751
GGAGCACCGGCUGGCCCUC 1846 1747 CUGAGCUGCCAAGCCGACA 1600 1747
CUGAGCUGCCAAGCCGACA 1600 1769 UGUCGGCUUGGCAGCUCAG 1847 1765
AGCUACAAGUACGAGCAUC 1601 1765 AGCUACAAGUACGAGCAUC 1601 1787
GAUGCUCGUACUUGUAGCU 1848 1783 CUGCGCUGGUACCGCCUCA 1602 1783
CUGCGCUGGUACCGCCUCA 1602 1805 UGAGGCGGUACCAGCGCAG 1849 1801
AACCUGUCCACGCUGCACG 1603 1801 AACCUGUCCACGCUGCACG 1603 1823
CGUGCAGCGUGGACAGGUU 1850 1819 GAUGCGCACGGGAACCCGC 1604 1819
GAUGCGCACGGGAACCCGC 1604 1841 GCGGGUUCCCGUGCGCAUC 1851 1837
CUUCUGCUCGACUGCAAGA 1605 1837 CUUCUGCUCGACUGCAAGA 1605 1859
UCUUGCAGUCGAGCAGAAG 1852 1855 AACGUGCAUCUGUUCGCCA 1606 1855
AACGUGCAUCUGUUCGCCA 1606 1877 UGGCGAACAGAUGCACGUU 1853 1873
ACCCCUCUGGCCGCCAGCC 1607 1873 ACCCCUCUGGCCGCCAGCC 1607 1895
GGCUGGCGGCCAGAGGGGU 1854 1891 CUGGAGGAGGUGGCACCUG 1608 1891
CUGGAGGAGGUGGCACCUG 1608 1913 CAGGUGCCACCUCCUCCAG 1855 1909
GGGGCGCGCCACGCCACGC 1609 1909 GGGGCGCGCCACGCCACGC 1609 1931
GCGUGGCGUGGCGCGCCCC 1856 1927 CUCAGCCUGAGUAUCCCCC 1610 1927
CUCAGCCUGAGUAUCCCCC 1610 1949 GGGGGAUACUCAGGCUGAG 1857 1945
CGCGUCGCGCCCGAGCACG 1611 1945 CGCGUCGCGCCCGAGCACG 1611 1967
CGUGCUCGGGCGCGACGCG 1858 1963 GAGGGCCACUAUGUGUGCG 1612 1963
GAGGGCCACUAUGUGUGCG 1612 1985 CGCACACAUAGUGGCCCUC 1859 1981
GAAGUGCAAGACCGGCGCA 1613 1981 GAAGUGCAAGACCGGCGCA 1613 2003
UGCGCCGGUCUUGCACUUC 1860 1999 AGCCAUGACAAGCACUGCC 1614 1999
AGCCAUGACAAGCACUGCC 1614 2021 GGCAGUGCUUGUCAUGGCU 1861 2017
CACAAGAAGUACCUGUCGG 1615 2017 CACAAGAAGUACCUGUCGG 1615 2039
CCGACAGGUACUUCUUGUG 1862 2035 GUGCAGGCCCUGGAAGCCC 1616 2035
GUGCAGGCCCUGGAAGCCC 1616 2057 GGGCUUCCAGGGCCUGCAC 1863 2053
CCUCGGCUCACGCAGAACU 1617 2053 CCUCGGCUCACGCAGAACU 1617 2075
AGUUCUGCGUGAGCCGAGG 1864 2071 UUGACCGACCUCCUGGUGA 1618 2071
UUGACCGACCUCCUGGUGA 1618 2093 UCACCAGGAGGUCGGUCAA 1865 2089
AACGUGAGCGACUCGCUGG 1619 2089 AACGUGAGCGACUCGCUGG 1619 2111
CCAGCGAGUCGCUCACGUU 1866 2107 GAGAUGCAGUGCUUGGUGG 1620 2107
GAGAUGCAGUGCUUGGUGG 1620 2129 CCACCAAGCACUGCAUCUC 1867 2125
GCCGGAGCGCACGCGCCCA 1621 2125 GCCGGAGCGCACGCGCCCA 1621 2147
UGGGCGCGUGCGCUCCGGC 1868 2143 AGCAUCGUGUGGUACAAAG 1622 2143
AGCAUCGUGUGGUACAAAG 1622 2165 CUUUGUACCACACGAUGCU 1869 2161
GACGAGAGGCUGCUGGAGG 1623 2161 GACGAGAGGCUGCUGGAGG 1623 2183
CCUCCAGCAGCCUCUCGUC 1870 2179 GAAAAGUCUGGAGUCGACU 1624 2179
GAAAAGUCUGGAGUCGACU 1624 2201 AGUCGACUCCAGACUUUUC 1871 2197
UUGGCGGACUCCAACCAGA 1625 2197 UUGGCGGACUCCAACCAGA 1625 2219
UCUGGUUGGAGUCCGCCAA 1872 2215 AAGCUGAGCAUCCAGCGCG 1626 2215
AAGCUGAGCAUCCAGCGCG 1626 2237 CGCGCUGGAUGCUCAGCUU 1873 2233
GUGCGCGAGGAGGAUGCGG 1627 2233 GUGCGCGAGGAGGAUGCGG 1627 2255
CCGCAUCCUCCUCGCGCAC 1874 2251 GGACCGUAUCUGUGCAGCG 1628 2251
GGACCGUAUCUGUGCAGCG 1628 2273 CGCUGCACAGAUACGGUCC 1875 2269
GUGUGCAGACCCAAGGGCU 1629 2269 GUGUGCAGACCCAAGGGCU 1629 2291
AGCCCUUGGGUCUGCACAC 1876 2287 UGCGUCAACUCCUCCGCCA 1630 2287
UGCGUCAACUCCUCCGCCA 1630 2309 UGGCGGAGGAGUUGACGCA 1877 2305
AGCGUGGCCGUGGAAGGCU 1631 2305 AGCGUGGCCGUGGAAGGCU 1631 2327
AGCCUUCCACGGCCACGCU 1878 2323 UCCGAGGAUAAGGGCAGCA 1632 2323
UCCGAGGAUAAGGGCAGCA 1632 2345 UGCUGCCCUUAUCCUCGGA 1879 2341
AUGGAGAUCGUGAUCCUUG 1633 2341 AUGGAGAUCGUGAUCCUUG 1633 2363
CAAGGAUCACGAUCUCCAU 1880 2359 GUCGGUACCGGCGUCAUCG 1634 2359
GUCGGUACCGGCGUCAUCG 1634 2381 CGAUGACGCCGGUACCGAC 1881 2377
GCUGUCUUCUUCUGGGUCC 1635 2377 GCUGUCUUCUUCUGGGUCC 1635 2399
GGACCCAGAAGAAGACAGC 1882 2395 CUCCUCCUCCUCAUCUUCU 1636 2395
CUCCUCCUCCUCAUCUUCU 1636 2417 AGAAGAUGAGGAGGAGGAG 1883 2413
UGUAACAUGAGGAGGCCGG 1637 2413 UGUAACAUGAGGAGGCCGG 1637 2435
CCGGCCUCCUCAUGUUACA 1884 2431 GCCCACGCAGACAUCAAGA 1638 2431
GCCCACGCAGACAUCAAGA 1638 2453 UCUUGAUGUCUGCGUGGGC 1885 2449
ACGGGCUACCUGUCCAUCA 1639 2449 ACGGGCUACCUGUCCAUCA 1639 2471
UGAUGGACAGGUAGCCCGU 1886 2467 AUCAUGGACCCCGGGGAGG 1640 2467
AUCAUGGACCCCGGGGAGG 1640 2489 CCUCCCCGGGGUCCAUGAU 1887 2485
GUGCCUCUGGAGGAGCAAU 1641 2485 GUGCCUCUGGAGGAGCAAU 1641 2507
AUUGCUCCUCCAGAGGCAC 1888 2503 UGCGAAUACCUGUCCUACG 1642 2503
UGCGAAUACCUGUCCUACG 1642 2525 CGUAGGACAGGUAUUCGCA 1889 2521
GAUGCCAGCCAGUGGGAAU 1643 2521 GAUGCCAGCCAGUGGGAAU 1643 2543
AUUCCCACUGGCUGGCAUC 1890 2539 UUCCCCCGAGAGCGGCUGC 1644 2539
UUCCCCCGAGAGCGGCUGC 1644 2561 GCAGCCGCUCUCGGGGGAA 1891 2557
CACCUGGGGAGAGUGCUCG 1645 2557 CACCUGGGGAGAGUGCUCG 1645 2579
CGAGCACUCUCCCCAGGUG 1892 2575 GGCUACGGCGCCUUCGGGA 1646 2575
GGCUACGGCGCCUUCGGGA 1646 2597 UCCCGAAGGCGCCGUAGCC 1893 2593
AAGGUGGUGGAAGCCUCCG 1647 2593 AAGGUGGUGGAAGCCUCCG 1647 2615
CGGAGGCUUCCACCACCUU 1894 2611 GCUUUCGGCAUCCACAAGG 1648 2611
GCUUUCGGCAUCCACAAGG 1648 2633 CCUUGUGGAUGCCGAAAGC 1895 2629
GGCAGCAGCUGUGACACCG 1649 2629 GGCAGCAGCUGUGACACCG 1649 2651
CGGUGUCACAGCUGCUGCC 1896 2647 GUGGCCGUGAAAAUGCUGA 1650 2647
GUGGCCGUGAAAAUGCUGA 1650 2669 UCAGCAUUUUCACGGCCAC 1897 2665
AAAGAGGGCGCCACGGCCA 1651 2665 AAAGAGGGCGCCACGGCCA 1651 2687
UGGCCGUGGCGCCCUCUUU 1898 2683 AGCGAGCAGCGCGCGCUGA 1652 2683
AGCGAGCAGCGCGCGCUGA 1652 2705 UCAGCGCGCGCUGCUCGCU 1899 2701
AUGUCGGAGCUCAAGAUCC 1653 2701 AUGUCGGAGCUCAAGAUCC 1653 2723
GGAUCUUGAGCUCCGACAU 1900 2719 CUCAUUCACAUCGGCAACC 1654 2719
CUCAUUCACAUCGGCAACC 1654 2741 GGUUGCCGAUGUGAAUGAG 1901 2737
CACCUCAACGUGGUCAACC 1655 2737 CACCUCAACGUGGUCAACC 1655 2759
GGUUGACCACGUUGAGGUG 1902 2755 CUCCUCGGGGCGUGCACCA 1656 2755
CUCCUCGGGGCGUGCACCA 1656 2777 UGGUGCACGCCCCGAGGAG 1903 2773
AAGCCGCAGGGCCCCCUCA 1657 2773 AAGCCGCAGGGCCCCCUCA 1657 2795
UGAGGGGGCCCUGCGGCUU 1904 2791 AUGGUGAUCGUGGAGUUCU 1658 2791
AUGGUGAUCGUGGAGUUCU 1658 2813 AGAACUCCACGAUCACCAU 1905 2809
UGCAAGUACGGCAACCUCU 1659 2809 UGCAAGUACGGCAACCUCU 1659 2831
AGAGGUUGCCGUACUUGCA 1906 2827 UCCAACUUCCUGCGCGCCA 1660 2827
UCCAACUUCCUGCGCGCCA 1660 2849 UGGCGCGCAGGAAGUUGGA 1907 2845
AAGCGGGACGCCUUCAGCC 1661 2845 AAGCGGGACGCCUUCAGCC 1661 2867
GGCUGAAGGCGUCCCGCUU 1908 2863 CCCUGCGCGGAGAAGUCUC 1662 2863
CCCUGCGCGGAGAAGUCUC 1662 2885 GAGACUUCUCCGCGCAGGG 1909 2881
CCCGAGCAGCGCGGACGCU 1663 2881 CCCGAGCAGCGCGGACGCU 1663 2903
AGCGUCCGCGCUGCUCGGG 1910 2899 UUCCGCGCCAUGGUGGAGC 1664 2899
UUCCGCGCCAUGGUGGAGC 1664 2921 GCUCCACCAUGGCGCGGAA 1911 2917
CUCGCCAGGCUGGAUCGGA 1665 2917 CUCGCCAGGCUGGAUCGGA 1665 2939
UCCGAUCCAGCCUGGCGAG 1912 2935 AGGCGGCCGGGGAGCAGCG 1666 2935
AGGCGGCCGGGGAGCAGCG 1666 2957 CGCUGCUCCCCGGCCGCCU 1913 2953
GACAGGGUCCUCUUCGCGC 1667 2953 GACAGGGUCCUCUUCGCGC 1667 2975
GCGCGAAGAGGACCCUGUC 1914 2971 CGGUUCUCGAAGACCGAGG 1668 2971
CGGUUCUCGAAGACCGAGG 1668 2993 CCUCGGUCUUCGAGAACCG 1915 2989
GGCGGAGCGAGGCGGGCUU 1669 2989 GGCGGAGCGAGGCGGGCUU 1669 3011
AAGCCCGCCUCGCUCCGCC 1916 3007 UCUCCAGACCAAGAAGCUG 1670 3007
UCUCCAGACCAAGAAGCUG 1670 3029 CAGCUUCUUGGUCUGGAGA 1917 3025
GAGGACCUGUGGCUGAGCC 1671 3025 GAGGACCUGUGGCUGAGCC 1671 3047
GGCUCAGCCACAGGUCCUC 1918 3043 CCGCUGACCAUGGAAGAUC 1672 3043
CCGCUGACCAUGGAAGAUC 1672 3065 GAUCUUCCAUGGUCAGCGG 1919 3061
CUUGUCUGCUACAGCUUCC 1673 3061 CUUGUCUGCUACAGCUUCC 1673 3083
GGAAGCUGUAGCAGACAAG 1920 3079 CAGGUGGCCAGAGGGAUGG 1674 3079
CAGGUGGCCAGAGGGAUGG 1674 3101 CCAUCCCUCUGGCCACCUG 1921 3097
GAGUUCCUGGCUUCCCGAA 1675 3097 GAGUUCCUGGCUUCCCGAA 1675 3119
UUCGGGAAGCCAGGAACUC 1922 3115 AAGUGCAUCCACAGAGACC 1676 3115
AAGUGCAUCCACAGAGACC 1676 3137 GGUCUCUGUGGAUGCACUU 1923 3133
CUGGCUGCUCGGAACAUUC 1677 3133 CUGGCUGCUCGGAACAUUC 1677 3155
GAAUGUUCCGAGCAGCCAG 1924 3151 CUGCUGUCGGAAAGCGACG 1678 3151
CUGCUGUCGGAAAGCGACG 1678 3173 CGUCGCUUUCCGACAGCAG 1925 3169
GUGGUGAAGAUCUGUGACU 1679 3169 GUGGUGAAGAUCUGUGACU 1679 3191
AGUCACAGAUCUUCACCAC 1926 3187 UUUGGCCUUGCCCGGGACA 1680 3187
UUUGGCCUUGCCCGGGACA 1680 3209 UGUCCCGGGCAAGGCCAAA 1927 3205
AUCUACAAAGACCCCGACU 1681 3205 AUCUACAAAGACCCCGACU 1681 3227
AGUCGGGGUCUUUGUAGAU 1928 3223 UACGUCCGCAAGGGCAGUG 1682 3223
UACGUCCGCAAGGGCAGUG 1682 3245 CACUGCCCUUGCGGACGUA 1929 3241
GCCCGGCUGCCCCUGAAGU 1683 3241 GCCCGGCUGCCCCUGAAGU 1683 3263
ACUUCAGGGGCAGCCGGGC 1930 3259 UGGAUGGCCCCUGAAAGCA 1684 3259
UGGAUGGCCCCUGAAAGCA 1684 3281 UGCUUUCAGGGGCCAUCCA 1931 3277
AUCUUCGACAAGGUGUACA 1685 3277 AUCUUCGACAAGGUGUACA 1685 3299
UGUACACCUUGUCGAAGAU 1932 3295 ACCACGCAGAGUGACGUGU 1686 3295
ACCACGCAGAGUGACGUGU 1686 3317 ACACGUCACUCUGCGUGGU 1933 3313
UGGUCCUUUGGGGUGCUUC 1687 3313 UGGUCCUUUGGGGUGCUUC 1687 3335
GAAGCACCCCAAAGGACCA 1934 3331 CUCUGGGAGAUCUUCUCUC 1688 3331
CUCUGGGAGAUCUUCUCUC 1688 3353 GAGAGAAGAUCUCCCAGAG 1935 3349
CUGGGGGCCUCCCCGUACC 1689 3349 CUGGGGGCCUCCCCGUACC 1689 3371
GGUACGGGGAGGCCCCCAG 1936 3367 CCUGGGGUGCAGAUCAAUG 1690 3367
CCUGGGGUGCAGAUCAAUG 1690 3389 CAUUGAUCUGCACCCCAGG 1937 3385
GAGGAGUUCUGCCAGCGCG 1691 3385 GAGGAGUUCUGCCAGCGCG 1691 3407
CGCGCUGGCAGAACUCCUC 1938 3403 GUGAGAGACGGCACAAGGA 1692 3403
GUGAGAGACGGCACAAGGA 1692 3425 UCCUUGUGCCGUCUCUCAC 1939 3421
AUGAGGGCCCCGGAGCUGG 1693 3421 AUGAGGGCCCCGGAGCUGG 1693 3443
CCAGCUCCGGGGCCCUCAU 1940 3439 GCCACUCCCGCCAUACGCC 1694 3439
GCCACUCCCGCCAUACGCC 1694 3461 GGCGUAUGGCGGGAGUGGC 1941 3457
CACAUCAUGCUGAACUGCU 1695 3457 CACAUCAUGCUGAACUGCU 1695 3479
AGCAGUUCAGCAUGAUGUG 1942 3475 UGGUCCGGAGACCCCAAGG 1696 3475
UGGUCCGGAGACCCCAAGG 1696 3497 CCUUGGGGUCUCCGGACCA 1943 3493
GCGAGACCUGCAUUCUCGG 1697 3493 GCGAGACCUGCAUUCUCGG 1697 3515
CCGAGAAUGCAGGUCUCGC 1944 3511 GACCUGGUGGAGAUCCUGG 1698 3511
GACCUGGUGGAGAUCCUGG 1698 3533 CCAGGAUCUCCACCAGGUC 1945 3529
GGGGACCUGCUCCAGGGCA 1699 3529 GGGGACCUGCUCCAGGGCA 1699 3551
UGCCCUGGAGCAGGUCCCC 1946 3547 AGGGGCCUGCAAGAGGAAG 1700 3547
AGGGGCCUGCAAGAGGAAG 1700 3569 CUUCCUCUUGCAGGCCCCU 1947 3565
GAGGAGGUCUGCAUGGCCC 1701 3565 GAGGAGGUCUGCAUGGCCC 1701 3587
GGGCCAUGCAGACCUCCUC 1948 3583 CCGCGCAGCUCUCAGAGCU 1702 3583
CCGCGCAGCUCUCAGAGCU 1702 3605 AGCUCUGAGAGCUGCGCGG 1949 3601
UCAGAAGAGGGCAGCUUCU 1703 3601 UCAGAAGAGGGCAGCUUCU 1703 3623
AGAAGCUGCCCUCUUCUGA 1950 3619 UCGCAGGUGUCCACCAUGG 1704 3619
UCGCAGGUGUCCACCAUGG 1704 3641 CCAUGGUGGACACCUGCGA 1951 3637
GCCCUACACAUCGCCCAGG 1705 3637 GCCCUACACAUCGCCCAGG 1705 3659
CCUGGGCGAUGUGUAGGGC 1952 3655 GCUGACGCUGAGGACAGCC 1706 3655
GCUGACGCUGAGGACAGCC 1706 3677 GGCUGUCCUCAGCGUCAGC 1953 3673
CCGCCAAGCCUGCAGCGCC 1707 3673 CCGCCAAGCCUGCAGCGCC 1707 3695
GGCGCUGCAGGCUUGGCGG 1954 3691 CACAGCCUGGCCGCCAGGU 1708 3691
CACAGCCUGGCCGCCAGGU 1708 3713 ACCUGGCGGCCAGGCUGUG 1955 3709
UAUUACAACUGGGUGUCCU 1709 3709 UAUUACAACUGGGUGUCCU 1709 3731
AGGACACCCAGUUGUAAUA 1956 3727 UUUCCCGGGUGCCUGGCCA 1710 3727
UUUCCCGGGUGCCUGGCCA 1710 3749 UGGCCAGGCACCCGGGAAA 1957 3745
AGAGGGGCUGAGACCCGUG 1711 3745 AGAGGGGCUGAGACCCGUG 1711 3767
CACGGGUCUCAGCCCCUCU 1958 3763 GGUUCCUCCAGGAUGAAGA 1712 3763
GGUUCCUCCAGGAUGAAGA 1712 3785 UCUUCAUCCUGGAGGAACC 1959 3781
ACAUUUGAGGAAUUCCCCA 1713 3781 ACAUUUGAGGAAUUCCCCA 1713 3803
UGGGGAAUUCCUCAAAUGU 1960 3799 AUGACCCCAACGACCUACA 1714 3799
AUGACCCCAACGACCUACA 1714 3821 UGUAGGUCGUUGGGGUCAU 1961 3817
AAAGGCUCUGUGGACAACC 1715 3817 AAAGGCUCUGUGGACAACC 1715 3839
GGUUGUCCACAGAGCCUUU 1962 3835 CAGACAGACAGUGGGAUGG 1716 3835
CAGACAGACAGUGGGAUGG 1716 3857 CCAUCCCACUGUCUGUCUG 1963 3853
GUGCUGGCCUCGGAGGAGU 1717 3853 GUGCUGGCCUCGGAGGAGU 1717 3875
ACUCCUCCGAGGCCAGCAC 1964 3871 UUUGAGCAGAUAGAGAGCA 1718 3871
UUUGAGCAGAUAGAGAGCA 1718 3893 UGCUCUCUAUCUGCUCAAA 1965 3889
AGGCAUAGACAAGAAAGCG 1719 3889 AGGCAUAGACAAGAAAGCG 1719 3911
CGCUUUCUUGUCUAUGCCU 1966 3907 GGCUUCAGGUAGCUGAAGC 1720 3907
GGCUUCAGGUAGCUGAAGC 1720 3929 GCUUCAGCUACCUGAAGCC 1967 3925
CAGAGAGAGAGAAGGCAGC 1721 3925 CAGAGAGAGAGAAGGCAGC 1721 3947
GCUGCCUUCUCUCUCUCUG 1968 3943 CAUACGUCAGCAUUUUCUU 1722 3943
CAUACGUCAGCAUUUUCUU 1722 3965 AAGAAAAUGCUGACGUAUG 1969 3961
UCUCUGCACUUAUAAGAAA 1723 3961 UCUCUGCACUUAUAAGAAA 1723 3983
UUUCUUAUAAGUGCAGAGA 1970 3979 AGAUCAAAGACUUUAAGAC 1724 3979
AGAUCAAAGACUUUAAGAC 1724 4001 GUCUUAAAGUCUUUGAUCU 1971 3997
CUUUCGCUAUUUCUUCUAC 1725 3997 CUUUCGCUAUUUCUUCUAC 1725 4019
GUAGAAGAAAUAGCGAAAG 1972 4015 CUGCUAUCUACUACAAACU 1726 4015
CUGCUAUCUACUACAAACU 1726 4037 AGUUUGUAGUAGAUAGCAG 1973 4033
UUCAAAGAGGAACCAGGAG 1727 4033 UUCAAAGAGGAACCAGGAG 1727 4055
CUCCUGGUUCCUCUUUGAA 1974 4051 GGACAAGAGGAGCAUGAAA 1728 4051
GGACAAGAGGAGCAUGAAA 1728 4073 UUUCAUGCUCCUCUUGUCC 1975 4069
AGUGGACAAGGAGUGUGAC 1729 4069 AGUGGACAAGGAGUGUGAC 1729 4091
GUCACACUCCUUGUCCACU 1976 4087 CCACUGAAGCACCACAGGG 1730 4087
CCACUGAAGCACCACAGGG 1730 4109 CCCUGUGGUGCUUCAGUGG 1977 4105
GAGGGGUUAGGCCUCCGGA 1731 4105 GAGGGGUUAGGCCUCCGGA 1731 4127
UCCGGAGGCCUAACCCCUC 1978 4123 AUGACUGCGGGCAGGCCUG 1732 4123
AUGACUGCGGGCAGGCCUG 1732 4145 CAGGCCUGCCCGCAGUCAU 1979 4141
GGAUAAUAUCCAGCCUCCC 1733 4141 GGAUAAUAUCCAGCCUCCC 1733 4163
GGGAGGCUGGAUAUUAUCC 1980 4159 CACAAGAAGCUGGUGGAGC 1734 4159
CACAAGAAGCUGGUGGAGC 1734 4181 GCUCCACCAGCUUCUUGUG 1981 4177
CAGAGUGUUCCCUGACUCC 1735 4177 CAGAGUGUUCCCUGACUCC 1735 4199
GGAGUCAGGGAACACUCUG 1982 4195 CUCCAAGGAAAGGGAGACG 1736 4195
CUCCAAGGAAAGGGAGACG 1736 4217 CGUCUCCCUUUCCUUGGAG 1983 4213
GCCCUUUCAUGGUCUGCUG 1737 4213 GCCCUUUCAUGGUCUGCUG 1737 4235
CAGCAGACCAUGAAAGGGC 1984 4231 GAGUAACAGGUGCCUUCCC 1738 4231
GAGUAACAGGUGCCUUCCC 1738 4253 GGGAAGGCACCUGUUACUC 1985 4249
CAGACACUGGCGUUACUGC 1739 4249 CAGACACUGGCGUUACUGC 1739 4271
GCAGUAACGCCAGUGUCUG 1986 4267 CUUGACCAAAGAGCCCUCA 1740 4267
CUUGACCAAAGAGCCCUCA 1740 4289 UGAGGGCUCUUUGGUCAAG 1987 4285
AAGCGGCCCUUAUGCCAGC 1741 4285 AAGCGGCCCUUAUGCCAGC 1741 4307
GCUGGCAUAAGGGCCGCUU 1988 4303 CGUGACAGAGGGCUCACCU 1742 4303
CGUGACAGAGGGCUCACCU 1742 4325 AGGUGAGCCCUCUGUCACG 1989 4321
UCUUGCCUUCUAGGUCACU 1743 4321 UCUUGCCUUCUAGGUCACU 1743 4343
AGUGACCUAGAAGGCAAGA 1990 4339 UUCUCACAAUGUCCCUUCA 1744 4339
UUCUCACAAUGUCCCUUCA 1744 4361 UGAAGGGACAUUGUGAGAA 1991 4357
AGCACCUGACCCUGUGCCC 1745 4357 AGCACCUGACCCUGUGCCC 1745 4379
GGGCACAGGGUCAGGUGCU 1992 4375 CGCCGAUUAUUCCUUGGUA 1746 4375
CGCCGAUUAUUCCUUGGUA 1746 4397 UACCAAGGAAUAAUCGGCG 1993 4393
AAUAUGAGUAAUACAUCAA 1747 4393 AAUAUGAGUAAUACAUCAA 1747 4415
UUGAUGUAUUACUCAUAUU 1994 4411 AAGAGUAGUAUUAAAAGCU 1748 4411
AAGAGUAGUAUUAAAAGCU 1748 4433 AGCUUUUAAUACUACUCUU 1995 4429
UAAUUAAUCAUGUUUAUAA 1749 4429 UAAUUAAUCAUGUUUAUAA 1749 4451
UUAUAAACAUGAUUAAUUA 1996
[0530] The 3'-ends of the Upper sequence and the Lower sequence of
the siNA construct can include an overhang sequence, for example
about 1, 2, 3, or 4 nucleotides in length, preferably 2 nucleotides
in length, wherein the overhanging sequence of the lower sequence
is optionally complementary to a portion of the target sequence.
The overhang can comprise the general structure NN or NsN, where N
stands for any nucleotide (e.g., thymidine) and s stands for
phosphorothioate or other internucleotide linkage as described
herein (e.g. internucleotide linkage having Formula I). The upper
sequence is also referred to as the sense strand, whereas the lower
sequence is also referred to as the antisense strand. The upper and
lower sequences in the Table can further comprise a chemical
modification having Formulae I-VII or any combination thereof (see
for example chemical modifications as shown in Table V herein).
3TABLE III VEGFr Synthetic Modified siNA constructs Seq COM- Seq
Target ID POUND# Aliases Sequence ID VEGFR1 GCUGUCUGCUUCUCACAGGAUCU
1997 FLT1:298U21 siNA sense UGUCUGCUUCUCACAGGAUTT 2020
GAAGGAGAGGACCUGAAACUGUC 1998 FLT1:1956U21 siNA sense
AGGAGAGGACCUGAAACUGTT 2021 AAGGAGAGGACCUGAAACUGUCU 1999
FLT1:1957U21 siNA sense GGAGAGGACCUGMACUGUTTT 2022
GCAUUUGGCAUUAAGAAAUCACC 2000 FLT1:2787U21 siNA sense
AUUUGGCAUUAAGAAAUCATT 2023 GCUGUCUGCUUCUCACAGGAUCU 1997 FLT1:316L21
siNA (298C) antisense AUCCUGUGAGAAGCAGACATT 2024
GAAGGAGAGGACCUGAAACUGUC 1998 FLT1:1974L21 siNA (1956C) antisense
CAGUUUCAGGUCCUCUCCUTT 2025 AAGGAGAGGACCUGAAACUGUCU 1999
ELT1:1975L21 siNA (1957C) antisense ACAGUUUCAGGUCCUCUCCTT 2026
GCAUUUGGCAUUAAGAAAUCACC 2000 FLT1:2805L21 siNA (2787C) antisense
UGAUUUCUUAAUGCCAAAUTT 2027 GCUGUCUGCUUCUCACAGGAUCU 1997 FLT1:298U21
siNA stab04 sense B uGucuGcuucucAcAGGAuTT B 2028
GAAGGAGAGGACCUGAAACUGUC 1998 FLT1:1956U21 siNA stab04 sense B
AGGAGAGGAccuGAAAcuGTT B 2029 AAGGAGAGGACCUGAAACUGUCU 1999
FLT1:1957U21 siNA stab04 sense B GGAGAGGAccuGAAAcuGuTT B 2030
GCAUUUGGCAUUAAGAAAUCACC 2000 FLT1:2787U21 siNA stab04 sense B
AuuuGGcAuuAAGAAAucATT B 2031 GCUGUCUGCUUCUCACAGGAUCU 1997
FLT1:316L21 siNA (298C) stab05 AuccuGuGAGAAGcAGAcATsT 2032
antisense GAAGGAGAGGACCUGAAACUGUC 1998 FLT1:1974L21 siNA (1956C)
stab05 cAGuuucAGGuccucuccuTsT 2033 antisense
AAGGAGAGGACCUGAAACUGUCU 1999 FLT1:1975L21 siNA (1957C) stab05
AcAGuuucAGGuccucuccTsT 2034 antisense GCAUUUGGCAUUAAGAAAUCACC 2000
FLT1:2805L21 siNA (2787C) stab05 uGAuuucuuAAuGccAAAuTsT 2035
antisense GCUGUCUGCUUCUCACAGGAUCU 1997 FLT1:298U21 siNA stab07
sense B uGucuGcuucucAcAGGAuTT B 2036 GAAGGAGAGGACCUGAAACUGUC 1998
FLT1:1956U21 siNA stab07 sense B AGGAGAGGAccuGAAAcuGTT B 2037
AAGGAGAGGACCUGAAACUGUCU 1999 FLT1:1957U21 sINA stab07 sense B
GGAGAGGAccuGAAAcuGuTT B 2038 GCAUUUGGCAUUAAGAAAUCACC 2000
FLT1:2787U21 siNA stab07 sense B AuuuGGcAuuAAGAAAucATT B 2039
GCUGUCUGCUUCUCACAGGAUCU 1997 FLT1:316L21 siNA (298C) stab11
AuccuGuGAGAAGcAGAcATsT 2040 antisense GAAGGAGAGGACCUGAAACUGUC 1998
FLT1:1974L21 siNA (1956C) stab11 cAGuuucAGGuccucuccuTsT 2041
antisense AAGGAGAGGACCUGAAACUGUCU 1999 FLT1:1975L21 sINA (1957C)
stab11 AcAGuuucAGGuccucuccTsT 2042 antisense
GCAUUUGGCAUUAAGAAAUCACC 2000 FLT1:2805L21 siNA (2787C) stab11
uGAuuucuuAAuGccAAAuTsT 2043 antisense AACUGAGUUUAAAAGGCACCCAG 2009
31209 FLT1:367L21 siNA (349C) stab05 inv GAcucAAAuuuuccGuGGGTsT
2176 antisense AAGCAAGGAGGGCCUCUGAUGGU 2012 31210 FLT1:2967L21 siNA
(2949C) stab05 inv cGuuccucccGGAGAcuAcTsT 2177 antisense
AGCCUGGAAAGAAUCAAAACCUU 2011 31211 FLT1:3930L21 siNA (3912C) stab05
inv GGAccuuucuuAGuuuuGGTsT 2178 antisense AACUGAGUUUAAAAGGCACCCAG
2009 31212 FLT1:349U21 siNA stab07 inv sense B
cccAcGGAAAAuuuGAGucTT B 2179 AAGCAAGGAGGGCCUCUGAUGGU 2012 31213
FLT1:2949U21 siNA stab07 inv sense B GuAGucuccGGGAGGAAcGTT B 2180
AGCCUGGAAAGAAUCAAAACCUU 2011 31214 FLT1:3912U21 siNA stab07 inv
sense B ccAAAAcuAAGAAAGGuccTT B 2181 AACUGAGUUUAAAAGGCACCCAG 2009
31215 FLT1:367L21 siNA (349C) stab08 inv GAcucAAAuuuuccGuGGGTsT
2182 antisense AAGCAAGGAGGGCCUCUGAUGGU 2012 31216 FLT1:2967L21 siNA
(2949C) stab08 inv cGuuccucccGGAGAcuAcTsT 2183 antisense
AGCCUGGAAAGAAUCAAAACCUU 2011 31217 FLT1:3930L21 siNA (3912C) stab08
inv GGAccuuucuuAGuuuuGGTsT 2184 antisense AACUGAGUUUAAAAGGCACCCAG
2009 31270 FLT1:349U21 siNA stab09 sense B CUGAGUUUAAAAGGCACCCTT B
2185 AAGCAAGGAGGGCCUCUGAUGGU 2012 31271 FLT1:2949U21 siNA stab09
sense B GCAAGGAGGGCCUCUGAUGTT B 2186 AGCCUGGAAAGAAUCAAAACCUU 2011
31272 FLT1:3912U21 siNA stab09 sense B CCUGGAAAGAAUCAAAACCTT B 2187
AACUGAGUUUAAAAGGCACCCAG 2009 31273 FLT1:367L21 siNA (349C) stab10
GGGUGCCUUUUAAACUCAGTsT 2188 antisense AAGCAAGGAGGGCCUCUGAUGGU 2012
31274 FLT1:2967L21 siNA (2949C) stab10 CAUCAGAGGCCCUCCUUGCTsT 2189
antisense AGCCUGGAAAGAAUCAAAACCUU 2011 31275 FLT1:3930L21 siNA
(3912C) stab10 GGUUUUGAUUCUUUCCAGGTsT 2190 antisense
AACUGAGUUUAAAAGGCACCCAG 2009 31276 FLT1:349U21 siNA stab09 inv
sense B CCCACGGAAAAUUUGAGUCTT B 2191 AAGCAAGGAGGGCCUCUGAUGGU 2012
31277 FLT1:2949U21 siNA stab09 inv sense B GUAGUCUCCGGGAGGAACGTT B
2192 AGCCUGGAAAGAAUCAAAACCUU 2011 31278 FLT1:3912U21 siNA stab09
inv sense B CCAAAACUAAGAAAGGUCCTT B 2193 AACUGAGUUUAAAAGGCACCCAG
2009 31279 FLT1:367L21 siNA (349C) stab10 inv
GACUCAAAUUUUCCGUGGGTsT 2194 antisense AAGCAAGGAGGGCCUCUGAUGGU 2012
31280 FLT1:2967L21 siNA (2949C) stab10 CGUUCCUCCCGGAGACUACTsT 2195
inv antisense AGCCUGGAAAGAAUCAAAACCUU 2011 31281 FLT1:3930L21 siNA
(39120) stab10 GGACCUUUCUUAGUUUUGGTsT 2196 inv antisense
AACAACCACAAAAUACAACAAGA 2010 31424 FLT1:2358L21 siNA (2340C) stab11
uuGuuGuAuuuuGuGGuuGXsX 2197 3'-BrdU antisense
AAGCAAGGAGGGCCUCUGAUGGU 2012 31425 FLT1:2967L21 siNA (2949C) stab11
cAucAGAGGcccuccuuGcXsX 2198 3'-BrdU antisense
AACAACCACAAAAUACAACAAGA 2010 31442 FLT1:2358L21 siNA (2340C) stab11
uuGuuGuAuuuuGuGGuuGXsT 2199 3'-BrdU antisense
AAGCAAGGAGGGCCUCUGAUGGU 2012 31443 FLT1 :2967L21 siNA (2949C)
stab11 cAucAGAGGcccuccuuGcXsT 2200 3'-BrdU antisense
AACAACCACAAAAUACAACAAGA 2010 31449 FLT1:2340U21 siNA stab09 sense B
CAACCACAAAAUACAACAATT B 2201 AACAACCACAAAAUACAACAAGA 2010 31450
FLT1:2340U21 siNA inv stab09 sense B AACAACAUAAAACACCAACTT B 2202
AACAACCACAAAAUACAACAAGA 2010 31451 FLT1:2358L21 siNA (2340C) stab10
UUGUUGUAUUUUGUGGUUGTsT 2203 antisense AACAACCACAAAAUACAACAAGA 2010
31452 FLT1:2358L21 siNA (2340C) inv stab10 GUUGGUGUUUUAUGUUGUUTsT
2204 antisense AACAACCACAAAAUACAACAAGA 2010 31509 FLT1:2358L21 siNA
(2340C) stab11 uuGuuGuAuuuuGuGGuuGTsT 2217 antisense
AACUGAGUUUAAAAGGCACCCAG 2009 31794 2x cholesterol + R31194 FLT1:
(H)2 ZTa B 2218 349U21 siNA stab07 sense cuGAGuuuAAAAGGcAcccTT B
AACUGAGUUUAAAAGGCACCCAG 2009 31795 2x cholesterol + R31212 FLT1:
(H)2 ZTa B 2219 349U21 siNA stab07 inv sense cccAcGGAAAAuuuGAGucTT
B AACUGAGUUUAAAAGGCACCCAG 2009 31796 2x cholesterol + R31270 FLT1:
(H)2 ZTA B 2220 349U21 siNA stab09 sense CUGAGUUUAAAAGGCACCCTT B
AACUGAGUUUAAAAGGCACCCAG 2009 31797 2x cholesterol + R31276 FLT1:
(H)2 ZTA B 2221 349U21 siNA stab09 inv sense CCCACGGAAAAUUUGAGUCTT
B AACUGAGUUUAAAAGGCACCCAG 2009 31798 2x C18 phospholipid + R31194
FLT1: (L)2 ZTa B 2222 349U21 siNA stab07 sense
cuGAGuuuAAAAGGcAcccTT B AACUGAGUUUAAAAGGCACCCAG 2009 31799 2x C18
phospholipid + R31212 FLT1: (L)2 ZTa B 2223 349U21 siNA stab07 inv
sense cccAcGGAAAAuuuGAGucTT B AACUGAGUUUAAAAGGCACCCAG 2009 31800 2x
C18 phospholipid + R31270 FLT1: (L)2 ZTA B 2224 349U21 siNA stab09
sense CUGAGUUUAAAAGGCACCCTT B AACUGAGUUUAAAAGGCACCCAG 2009 31801 2x
C18 phospholipid + R31276 FLT1: (L)2 ZTA B 2225 349U21 siNA stab09
inv sense CCCACGGAAAAUUUGAGUCTT B CAUGCUGGACUGCUGGCAC 2244 32235
FLT1:3645U21 siNA sense CAUGCUGGACUGCUGGCACTT 2275
AUGCUGGACUGCUGGCACA 2245 32236 FLT1:3646U21 siNA sense
AUGCUGGACUGCUGGCACATT 2276 UGCUGGACUGCUGGCACAG 2246 32237
FLT1:3647U21 siNA sense UGCUGGACUGCUGGCACAGTT 2277
CAUGCUGGACUGCUGGCAC 2244 32250 FLT1:3663L21 siNA (3645C) antisense
GUGCCAGCAGUCCAGCAUGTT 2278 AUGCUGGACUGCUGGCACA 2245 32251
FLT1:3664L21 siNA (3646C) antisense UGUGCCAGCAGUCCAGCAUTT 2279
UGCUGGACUGCUGGCACAG 2246 32252 FLT1:3665L21 siNA (3647C) antisense
CUGUGCCAGCAGUCCAGCATT 2280 AACUGAGUUUAAAAGGCACCCAG 2009 32278
FLT1:349U21 siNA stab16 sense B CUGAGUUUAAAAGGCACCCTT B 2281
AACUGAGUUUAAAAGGCACCCAG 2009 32279 FLT1:349U21 siNA stab18 sense B
cuGAGuuuAAAAGGcAcccTT B 2282 AACUGAGUUUAAAAGGCACCCAG 2009 32280
FLT1:349U21 siNA inv stab16 sense B CCCACGGAAAAUUUGAGUCTT B 2283
AACUGAGUUUAAAAGGCACCCAG 2009 32281 FLT1:349U21 siNA inv stab18
sense B cccAcGGAAAAuuuGAGucTT B 2284 CUGAACUGAGUUUAAAAGGCACC 2247
32282 FLT1:346U21 siNA stab09 sense B GAACUGAGUUUAAAAGGCATT B 2285
UGAACUGAGUUUAAAAGGCACCC 2248 32283 FLT1:347U21 siNA stab09 sense B
AACUGAGUUUAAAAGGCACTT B 2286 GAACUGAGUUUAAAAGGCACCCA 2249 32284
FLT1:348U21 siNA stab09 sense B ACUGAGUUUAAAAGGCACCTT B 2287
ACUGAGUUUAAAAGGCACCCAGC 2250 32285 FLT1:350U21 siNA stab09 sense B
UGAGUUUAAAAGGCACCCATT B 2288 CUGAGUUUAAAAGGCACCCAGCA 2251 32286
FLT1:351U21 siNA stab09 sense B GAGUUUAAAAGGCACCCAGTT B 2289
UGAGUUUAAAAGGCACCCAGCAC 2252 32287 FLT1:352U21 siNA stab09 sense B
AGUUUAAAAGGCACCCAGCTT B 2290 GAGUUUAAAAGGCACCCAGCACA 2253 32288
FLT1:353U21 siNA stab09 sense B GUUUAAAAGGCACCCAGCATT B 2291
CUGAACUGAGUUUAAAAGGCACC 2247 32289 FLT1:364L21 siNA (346C) stab10
UGCCUUUUAAACUCAGUUCTsT 2292 antisense UGAACUGAGUUUAAAAGGCACCC 2248
32290 FLT1:365L21 siNA (347C) stab10 GUGCCUUUUAAACUCAGUUTsT 2293
antisense GAACUGAGUUUAAAAGGCACCCA 2249 32291 FLT1:366L21 siNA
(348C) stab10 GGUGCCUUUUAAACUCAGUTsT 2294 antisense
ACUGAGUUUAAAAGGCACCCAGC 2250 32292 FLT1:368L21 siNA (350C) stab10
UGGGUGCCUUUUAAACUCATsT 2295 antisense CUGAGUUUAAAAGGCACCCAGCA 2251
32293 FLT1:369L21 siNA (351C) stab10 CUGGGUGCCUUUUAAACUCTsT 2296
antisense UGAGUUUAAAAGGCACCCAGCAC 2252 32294 FLT1:370L21 siNA
(352C) stab10 GCUGGGUGCCUUUUAAACUTsT 2297 antisense
GAGUUUAAAAGGCACCCAGCACA 2253 32295 FLT1:371L21 siNA (353C) stab10
UGCUGGGUGCCUUUUAAACTsT 2298 antisense CUGAACUGAGUUUAAAAGGCACC 2247
32296 FLT1:346U21 siNA inv stab09 sense B ACGGAAAAUUUGAGUCAAGTT B
2299 UGAACUGAGUUUAAAAGGCACCC 2248 32297 FLT1:347U21 siNA inv stab09
sense B CACGGAAAAUUUGAGUCAATT B 2300 GAACUGAGUUUAAAAGGCACCCA 2249
32298 FLT1:348U21 siNA inv stab09 sense B CCACGGAAAAUUUGAGUCATT B
2301 ACUGAGUUUAAAAGGCACCCAGC 2250 32299 FLT1:350U21 siNA inv stab09
sense B ACCCACGGAAAAUUUGAGUTT B 2302 CUGAGUUUAAAAGGCACCCAGCA 2251
32300 FLT1:351U21 siNA inv stab09 sense B GACCCACGGAAAAUUUGAGTT B
2303 UGAGUUUAAAAGGCACCCAGCAC 2252 32301 FLT1:352U21 siNA inv stab09
sense B CGACCCACGGAAAAUUUGATT B 2304 GAGUUUAAAAGGCACCCAGCACA 2253
32302 FLT1:353U21 siNA inv stab09 sense B ACGACCCACGGAAAAUUUGTT B
2305 CUGAACUGAGUUUAAAAGGCACC 2247 32303 FLT1:364L21 siNA (346C) inv
stab10 CUUGACUCAAAUUUUCCGUTsT 2306 antisense
UGAACUGAGUUUAAAAGGCACCC 2248 32304 FLT1:365L21 siNA (347C) inv
stab10 UUGACUCAAAUUUUCCGUGTsT 2307 antisense
GAACUGAGUUUAAAAGGCACCCA 2249 32305 FLT1:366L21 siNA (348C) inv
stab10 UGACUCAAAUUUUCCGUGGTsT 2308 antisense
ACUGAGUUUAAAAGGCACCCAGC 2250 32306 FLT1:368L21 siNA (350C) inv
stab10 ACUCAAAUUUUCCGUGGGUTsT 2309 antisense
CUGAGUUUAAAAGGCACCCAGCA 2251 32307 FLT1:369L21 siNA (351C) inv
stab10 CUCAAAUUUUCCGUGGGUCTsT 2310 antisense
UGAGUUUAAAAGGCACCCAGCAC 2252 32308 FLT1:370L21 siNA (352C) inv
stab10 UCAAAUUUU0CGUGGGU0GTsT 2311 antisense
GAGUUUAAAAGGCACCCAGCACA 2253 32309 FLT1:371L21 siNA (353C) inv
stab10 CAAAUUUUCCGUGGGUCGUTsT 2312 antisense
AACUGAGUUUAAAAGGCACCCAG 2009 32338 FLT1:367L21 siNA (349C) stab10
GGGUGCCUUUUAAACUCAGXsT 2313 3'-BrdU antisense
AACUGAGUUUAAAAGGCACCCAG 2009 32718 FLT1:367L21 siNA (349C) v1 5'p
pGGGUGCCUUUUAAACUC 2314 antisense GAGUUUAAAAG B
AACUGAGUUUAAAAGGCACCCAG 2009 32719 FLT1:367L21 siNA (349C) v2 5'p
pGGGUGCCUUUUAAACUCAG 2315 antisense GAGUUUAAAAG B
AAGCAAGGAGGGCCUCUGAUGGU 2012 32720 FLT1:2967L21 siNA (2949C) v1 5'p
pCAUCAGAGGCCCUCCUUGC 2316 antisense AAGGAGGGCCUCU B
AAGCAAGGAGGGCCUCUGAUGGU 2012 32721 FLT1:2967L21 siNA (2949C) v2 5'p
pCAUCAGAGGCCCUCCUU 2317 antisense AAGGAGGGCCUCUG B
AAGCAAGGAGGGCCUCUGAUGGU 2012 32722 FLT1:2967L21 siNA (2949C) v3 5'p
pCAUCAGAGGCCCUCCU 2318 antisense AGGAGGGCCUCUG B
CUGAACUGAGUUUAAAAGGCACC 2247 32748 FLT1:346U21 siNA stab07 sense B
GAAcuGAGuuuAAAAGGcATT B 2319 UGAACUGAGUUUAAAAGGCACCC 2248 32749
FLT1:347U21 siNA stab07 sense B AAcuGAGuuuAAAAGGcAcTT B 2320
GAACUGAGUUUAAAAGGCACCCA 2249 32750 FLT1:348U21 siNA stab07 sense B
AcuGAGuuuAAAAGGcAccTT B 2321 ACUGAGUUUAAAAGGCACCCAGC 2250 32751
FLT1:350U21 siNA stab07 sense B uGAGuuuAAAAGGcAcccATT B 2322
CUGAGUUUAAAAGGCACCCAGCA 2251 32752 FLT1:351U21 siNA stab07 sense B
GAGuuuAAAAGGcAcccAGTT B 2323 UGAGUUUAAAAGGCACCCAGCAC 2252 32753
FLT1:352U21 siNA stab07 sense B AGuuuAAAAGGcAcccAGcTT B 2324
GAGUUUAAAAGGCACCCAGCACA 2253 32754 FLT1:353U21 siNA stab07 sense B
GuuuAAAAGGcAcccAGcATT B 2325 CUGAACUGAGUUUAAAAGGCACC 2247 32755
FLT1:364L21 siNA (346C) stab08 uGccuuuuAAAcucAGuucTsT 2326
antisense UGAACUGAGUUUAAAAGGCACCC 2248 32756 FLT1:365L21 siNA
(347C) stab08 GuGccuuuuAAAcucAGuuTsT 2327 antisense
GAACUGAGUUUAAAAGGCACCCA 2249 32757 FLT1:366L21 siNA (348C) stab08
GGuGccuuuuAAAcucAGuTsT 2328 antisense ACUGAGUUUAAAAGGCACCCAGC 2250
32758 FLT1:368L21 siNA (350C) stab08 uGGGuGccuuuuAAAcucATsT 2329
antisense CUGAGUUUAAAAGGCACCCAGCA 2251 32759 FLT1:369L21 siNA
(351C) stab08 cuGGGuGccuuuuAAAcucTsT 2330 antisense
UGAGUUUAAAAGGCACCCAGCAC 2252 32760 FLT1:370L21 siNA (352C) stab08
GcuGGGuGccuuuuAAAcuTsT 2331 antisense GAGUUUAAAAGGCACCCAGCACA 2253
32761 FLT1:371L21 siNA (353C) stab08 uGcuGGGuGccuuuuAAAcTsT 2332
antisense CUGAACUGAGUUUAAAAGGCACC 2247 32772 FLT1:346U21 siNA inv
stab07 sense B AcGGAAAAuuuGAGucAAGTT B 2333 UGAACUGAGUUUAAAAGGCACCC
2248 32773 FLT1:347U21 siNA inv stab07 sense B
cAcGGAAAAuuuGAGucAATT B 2334 GAACUGAGUUUAAAAGGCACCCA 2249 32774
FLT1:348U21 siNA inv stab07 sense B ccAcGGAAAAuuuGAGucATT B 2335
ACUGAGUUUAAAAGGCACCCAGC 2250 32775 FLT1:350U21 siNA inv stab07
sense B AcccAcGGAAAAuuuGAGuTT B 2336 CUGAGUUUAAAAGGCACCCAGCA 2251
32776 FLT1:351U21 siNA inv stab07 sense B GAcccAcGGAAAAuuuGAGTT B
2337 UGAGUUUAAAAGGCACCCAGCAC 2252 32777 FLT1:352U21 siNA inv stab07
sense B cGAcccAcGGAAAAuuuGATT B 2338 GAGUUUAAAAGGCACCCAGCACA 2253
32778 FLT1:353U21 siNA inv stab07 sense B AcGAcccAcGGAAAAuuuGTT B
2339 CUGAACUGAGUUUAAAAGGCACC 2247 32779 FLT1:364L21 siNA (346C) inv
stab08 cuuGAcucAAAuuuuccGuTsT 2340 antisense
UGAACUGAGUUUAAAAGGCACCC 2248 32780 FLT1:365L21 siNA (347C) inv
stab08 uuGAcucAAAuuuuccGuGTsT 2341 antisense
GAACUGAGUUUAAAAGGCACCCA 2249 32781 FLT1:366L21 siNA (348C) inv
stab08 uGAcucAAAuuuuccGuGGTsT 2342 antisense
ACUGAGUUUAAAAGGCACCCAGC 2250 32782 FLT1:368L21 siNA (350C) inv
stab08 AcucAAAuuuuccGuGGGuTsT 2343 antisense
CUGAGUUUAAAAGGCACCCAGCA 2251 32783 FLT1:369L21 siNA (351C) inv
stab08 cucAAAuuuuccGuGGGucTsT 2344 antisense
UGAGUUUAAAAGGCACCCAGCAC 2252 32784 FLT1:370L21 siNA (352C) inv
stab08 ucAAAuuuuccGuGGGucGTsT 2345 antisense
GAGUUUAAAAGGCACCCAGCACA 2253 32785 FLT1:371L21 siNA (353C) inv
stab08 cAAAuuuuccGuGGGucGuTsT 2346 antisense
AGTTTAAAAGGCACCCAGCACATC 2254 32805 FLT1:373L21 siNA (354C) v1 5'p
pGUGCUGGGUGCCUUUUAAA 2347 antisense AGGCACCCAGC B
AGTTTAAAAGGCACCCAGCACATC 2254 32806 FLT1:373L21 siNA (354C) v2 5'p
pGUGCUGGGUGCCUUUAAA 2348 antisense GGCACCCAGC B
AGTTTAAAAGGCACC0AGCACATC 2254 32807 FLT1:373L21 siNA (354C) v3 5'p
pGUGCUGGGUGCCUUAAGGCACCC 2349 antisense AGC B
GCATATATATGATAAAGCATTCA 2255 32808 FLT1:1247L21 siNA (1229C) v1
5'p
pAAUGCUUUAUCAUAUAUAU 2350 antisense GAUAAAGC B
GCATATATATGATAAAGCATTCA 2255 32809 FLT1:1247L21 siNA (1229C) v2 5'p
pAAUGCUUUAUCAUAUAU 2351 antisense GAUAAAGC B
GCATATATATGATAAAGCATTCA 2255 32810 FLT1:1247L21 siNA (1229C) v3 5'p
pAAUGCUUUAUCAUAU GAUAAAGC 2352 antisense B GCATATATATGATAAAGCATTCA
2255 32811 FLT1:1247L21 siNA (1229C) v4 5'p pAAUGCUUUAUCAUAU 2353
antisense GAUAAAGCA B GCATATATATGATAAAGCATTCA 2255 32812
FLT1:1247L21 siNA (1229C) v5 5'p pAAUGCUUUAUCAUAUAU 2354 antisense
GAUAAAGCAUU B GCATATATATGATAAAGCATTCA 2255 32813 FLT1:1247L21 siNA
(1229C) v6 5'p pAAUGCUUUAUCAUAU 2355 antisense GAUAAAGCAUU B
AACUGAGUUUAAAAGGCACCCAG 2009 33056 FLT1:367L21 siNA (349C) v3 5'p
pGGGUGCCUUUUAAACUCAG 2356 antisense GAGUUUAAAAGG B
AACUGAGUUUAAAAGGCACCCAG 2009 33057 FLT1:367L21 siNA (349C) v4 5'p
pGGGUGCCUUUUAAACUC 2357 antisense GAGUUUAAAAGGCA B
AACUGAGUUUAAAAGGCACCCAG 2009 33058 FLT1:367L21 siNA (349C) v5 5'p
pGGGUGCCUUUUAAACU 2358 antisense AGUUUAAAAGG B
AACUGAGUUUAAAAGGCACCCAG 2009 33059 FLT1:367L21 siNA (349C) v6 5'p
pGGGUGCCUUUUAAACU 2359 antisense AGUUUAAAAGGC B
AACUGAGUUUAAAAGGCACCCAG 2009 33060 FLT1:367L21 siNA (349C) v7 5'p
pGGGUGCCUUUUAAACU 2360 antisense AGUUUAAAAGGCA B
AACUGAGUUUAAAAGGCACCCAG 2009 33061 FLT1:367L21 siNA (349C) v8 5'p
pGGGUGCCUUUUAAACU 2361 antisense AGUUUAAAAGGCAC B
AACUGAGUUUAAAAGGCACCCAG 2009 33062 FLT1:367L21 siNA (349C) v9 5'p
pGGGUGCCUUUUAAAC 2362 antisense GUUUAAAAGGC B
AACUGAGUUUAAAAGGCACCCAG 2009 33063 FLT1:367L21 siNA (349C) v10 5'p
pGGGUGCCUUUUAAAC 2363 antisense GUUUAAAAGGCA B
AACUGAGUUUAAAAGGCACCCAG 2009 33064 FLT1:367L21 siNA (349C) v11 5'p
pGGGUGCCUUUUAAAC 2364 antisense GUUUAAAAGGCAC B
AACUGAGUUUAAAAGGCACCCAG 2009 33121 FLT1:349U21 siNA stab22
CUGAGUUUAAAAGGCACCCTT B 2444 AACUGAGUUUAAAAGGCACCCAG 2009 33321
FLT1:367L21 siNA (349C) stab08 + 5' pGGGuGccuuuuAAAcucAGTsT 2445 P
AACUGAGUUUAAAAGGCACCCAG 2009 33338 FLT1:367L21 siNA (349C) stab08 +
5' L GGGuGccuuuuAAAcucAGTsT 2447 aminoL AACUGAGUUUAAAAGGCACCCAG
2009 33553 FLT1:367L21 siNA (349C) stab08 + 5' L
GGGuGccuuuuAAAcucAGTsT 2447 aminoL AACUGAGUUUAAAAGGCACCCAG 2009
33571 FLT1:367L21 siNA (349C) stab10 + 5'I IGGUGCCUUUUAAACUcAGTT
2448 CAUGCUGGACUGCUGGCAC 2244 33725 FLT1:3645U21 siNA stab07 B
cAuGcuGGAcuGcuGGcAcTT B 2449 AUGCUGGACUGGUGGCACA 2245 33726
FLT1:3646U21 siNA stab07 B AuGcuGGAcuGcuGGcAcATT B 2450
CAUGCUGGACUGCUGGCAC 2244 33731 FLT1:3663L21 siNA (3645C) stab08
GuGccAGcAGuccAGcAuGTsT 2451 AUGCUGGACUGCUGGCACA 2245 33732
FLT1:3664L21 siNA (3646C) stab08 uGuGccAGcAGuccAGcAuTsT 2452
CAUGCUGGACUGCUGGCAC 2244 33737 FLT1:3645U21 siNA stab09 B
CAUGCUGGACUGCUGGCACTT B 2453 AUGCUGGACUGCUGGCACA 2245 33738
FLT1:3646U21 siNA stab09 B AUGCUGGACUGCUGGCACATT B 2454
CAUGCUGGACUGCUGGCAC 2244 33743 FLT1:3663L21 siNA (3645C) stab10
GUGCCAGCAGUCCAGCAUGTsT 2455 AUGCUGGACUGCUGGCACA 2245 33744
FLT1:3664L21 siNA (3646C) stab10 UGUGCCAGCAGUCCAGCAUTsT 2456
CAUGCUGGACUGCUGGCAC 2244 33749 FLT1:3645U21 siNA inv stab07 B
cAcGGucGucAGGucGuAcTT B 2457 AUGCUGGACUGCUGGCACA 2245 33750
FLT1:3646U21 siNA inv stab07 B AcAcGGucGucAGGucGuATT B 2458
CAUGCUGGACUGCUGGCAC 2244 33755 FLT1:3663L21 siNA (3645C) inv stab08
GuAcGAccuGAcGAccGuGTsT 2459 AUGCUGGACUGCUGGCACA 2245 33756
FLT1:3664L21 siNA (3646C) inv stab08 uAcGAccuGAcGAccGuGuTsT 2460
CAUGCUGGACUGCUGGCAC 2244 33761 FLT1:3645U21 siNA inv stab09 B
CACGGUCGUCAGGUCGUACTT B 2461 AUGCUGGACUGCUGGCACA 2245 33762
FLT1:3646U21 siNA inv stab09 B ACACGGUCGUCAGGUCGUATT B 2462
CAUGCUGGACUGCUGGCAC 2244 33767 FLT1:3663L21 siNA (3645C) inv stab10
GUACGACCUGACGACCGUGTsT 2463 AUGCUGGACUGCUGGCACA 2245 33768
FLT1:3664L21 siNA (3646C) inv stab10 UACGACCUGACGACCGUGUTsT 2464
AGUUUAAAAGGCACCCAGCACAU 2438 34092 FLT1:373L18 siNA (354C) v4 5'p
pUGCUGGGUGCCUUUUAAA 2465 AGGCACCCAGC B AGUUUAAAAGGCACCCAGCACAU 2438
34093 FLT1:373L17 siNA (354C) v5 5'p pGCUGGGUGCCUUUUAAA 2466
AGGCACCCAGC B AGUUUAAAAGGCACCCAGCACAU 2438 34094 FLT1:373L17 siNA
(354C) v6 5'p pGCUGGGUGCCUUUUAAA 2467 AGGCACCCAGCT B
AGUUUAAAAGGCACCCAGCACAU 2438 34095 FLT1:373L17 siNA (354C) v7 5'p
pGCUGGGUGCCUUUUAAA 2468 AGGCACCCAG B AGUUUAAAAGGCACCCAGCACAU 2438
34096 FLT1:373L16 siNA (354C) v8 5'p pCUGGGUGCCUUUUAAA 2469
AGGCACCCAG B AGUUUAAAAGGCACCCAGCACAU 2438 34097 FLT1:373L16 siNA
(354C) v9 5'p pCUGGGUGCCUUUUAAA 2470 AGGCACCCA B
AGUUUAAAAGGCACCCAGCACAU 2438 34098 FLT1:373L15 siNA (354C) v10 5'p
pUGGGUGCCUUUUAAA 2471 AGGCACCCA B AGUUUAAAAGGCACCCAGCACAU 2438
34099 FLT1:373L15 siNA (354C) v11 5'p pUGGGUGCCUUUUAAA 2472
AGGCACCCAT B AGUUUAAAAGGCACCCAGCACAU 2438 34100 FLT1:373L15 siNA
(354C) v12 5'p pUGGGUGCCUUUUAAA 2473 AGGCACCCATT B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34101 FLT1:1247L21 siNA (1229C) v14
5'p pUGCUUUAUCAUAUAUAU 2474 GAUAAAGCA B GCAUAUAUAUGAUAAAGCAUUCA
2439 34102 FLT1:1247L21 siNA (1229C) v15 5'p pUGCUUUAUCAUAUAUAU
2475 GAUAAAGC B GCAUAUAUAUGAUAAAGCAUUCA 2439 34103 FLT1:1247L21
siNA (1229C) v16 5'p pGCUUUAUCAUAUAUAU 2476 GAUAAAGC B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34104 FLT1:1247L17 siNA (1229C) v5
AAUGCUUUAUCAUAUAU 2477 GAUAAAGCAUU B GCAUAUAUAUGAUAAAGCAUUCA 2439
34105 FLT1:1247L17 siNA (1229C) v7 5'p pAAUGCUUUAUCAUAUAU 2478
GAUAAAGCAUUT B GCAUAUAUAUGAUAAAGCAUUCA 2439 34106 FLT1:1247L17 siNA
(1229C) v8 5'p pAAUGCUUUAUCAUAUAU 2479 GAUAAAGCAUUTT B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34107 FLT1:1247L17 siNA (1229C) v9 5'p
pAAUGCUUUAUCAUAUAU 2480 GAUAAAGCAU B GCAUAUAUAUGAUAAAGCAUUCA 2439
34108 FLT1:1247L16 siNA (1229C) v10 5'p pAUGCUUUAUCAUAUAU 2481
GAUAAAGCAU B GCAUAUAUAUGAUAAAGCAUUCA 2439 34109 FLT1:1247L16 siNA
(1229C) v11 5'p pAUGCUUUAUCAUAUAU 2482 GAUAAAGCAUT B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34110 FLT1:1247L16 siNA (1229C) v12
5'p pAUGCUUUAUCAUAUAU 2483 GAUAAAGCAUTT B GCAUAUAUAUGAUAAAGCAUUCA
2439 34111 FLT1:1247L16 siNA (1229C) v13 5'p pAUGCUUUAUCAUAUAU 2484
GAUAAAGCA B GCAUAUAUAUGAUAAAGCAUUCA 2439 34112 FLT1:1247L17 siNA
(1229C) v14 5'p pAAUGCUUUAUCAUAUAU 2485 CUAUAAGCAUU B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34113 FLT1:1247L17 siNA (1229C) v15
5'p pAAUGCUUUUAGUUAUAU 2486 GAUAAAGCAUU B GCAUAUAUAUGAUAAAGCAUUCA
2439 34114 FLT1:1247L17 siNA (1229C) v16 5'p pAAUCCUUAAUCUUAUUU
2487 GAUAAAGCAUU B GCAUAUAUAUGAUAAAGCAUUCA 2439 34115 FLT1:1247L17
siNA (1229C) v17 5'p pAAuGcuuuAucAuAuAu 2488 GAuAAAGcAuu B
GCAUAUAUAUGAUAAAGCAUUCA 2439 34116 FLT1:1247L17 siNA (1229C) v18
5'p pAAuGcuuuAucAuAuAu 2489 GAuAAAGcAuu B AACUGAGUUUAAAAGGCACCCAG
2009 34487 FLT1:349U21 siNA stab09 w/block PS B 2490
CsUsGAGUUUsAsAsAsAsGGCACCs CsTsT B AACUGAGUUUAAAAGGCACCCAG 2009
34488 FLT1:367L21 siNA (349C) stab10 GGGsUsGsCsCsUUUUAAsAsCsUsCs
2491 w/block PS AGTsT AACUGAGUUUAAAAGGCACCCAG 2009 34489
FLT1:349U21 siNA stab09 inv w/block B 2492 PS
CsCsCACGGAsAsAsAsUsUUGAGUs CsTsT B AACUGAGUUUAAAAGGCACCCAG 2009
34490 FLT1:367L21 siNA (349C) stab10 inv
GACsUsCsAsAsAUUUUCsCsGsUsGs 2493 w/block PS GGTsT VEGFR2
UGACCUUGGAGCAUCUCAUCUGU 2001 KDR:3304U21 siNA stab04 sense B
AccuuGGAGcAucucAucuTT B 2052 UCACCUGUUUCCUGUAUGGAGGA 2003
KDR:3894U21 siNA stab04 sense B AccuGuuuccuGuAuGGAGTT B 2054
UGACCUUGGAGCAUCUCAUCUGU 2001 KDR:3322L21 siNA (3304C) stab05
AGAuGAGAuGcuccAAGGuTsT 2056 antisense UCACCUGUUUCCUGUAUGGAGGA 2003
KDR:3912L21 siNA (3894C) stab05 cuCcAuACAGGAAAcAGGuTsT 2058
antisense UGACCUUGGAGCAUCUCAUCUGU 2001 KDR:3304U21 siNA stab07
sense B AccuuGGAGcAucucAucuTT B 2060 UCACCUGUUUCCUGUAUGGAGGA 2003
32766 KDR:3894U21 siNA stab07 sense B AccuGuuuccuGuAuGGAGTT B 2062
UGACCUUGGAGCAUCUCAUCUGU 2001 KDR:3322L21 siNA (3304C) stab11
AGAuGAGAuGcuccAAGGuTsT 2064 antisense UUUGAGCAUGGAAGAGGAUUCUG 2002
KDR:3872L21 siNA (3854C) stab11 GAAuccucuuccAuGcucATsT 2065
antisense UCACCUGUUUCCUGUAUGGAGGA 2003 KDR:3912L21 siNA (3894C)
stab11 cuccAuAcAGGAAAcAGGuTsT 2066 antisense
GACAACACAGCAGGAAUCAGUCA 2004 KDR:3966L21 siNA (3948C) stab11
AcuGAuuccuGcuGuGuuGTsT 2067 antisense UGUCCACUUACCUGAGGAGCAAG 2017
30785 KDR:3076U21 siNA stab04 sense B uccAcuuAccuGAGGAGcATT B 2205
UUUGAGCAUGGAAGAGGAUUCUG 2002 30786 KDR:3854U21 siNA stab04 sense B
uGAGcAuGGAAGAGGAuucTT B 2053 AUGGUUCUUGCCUCAGAAGAGCU 2018 30787
KDR:4089U21 siNA stab04 sense B GGuucuuGccucAGAAGAGTT B 2206
UCUGAAGGCUCAAACCAGACAAG 2019 30788 KDR:4191U21 siNA stab04 sense B
uGAAGGcucAAAccAGAcATT B 2207 UGUCCACUUACCUGAGGAGCAAG 2017 30789
KDR:3094L21 siNA (3076C) stab05 uGcuccucAGGuAAGuGGATsT 2208
antisense UUUGAGCAUGGAAGAGGAUUCUG 2002 30790 KDR:3872L21 siNA
(3854C) stab05 GAAuccucuuccAuGcucATsT 2057 antisense
AUGGUUCUUGCCUCAGAAGAGCU 2018 30791 KDR:4107L21 siNA (4089C) stab05
cucuucuGAGGcAAGAAccTsT 2209 antisense UCUGAAGGCUCAAACCAGACAAG 2019
30792 KDR:4209L21 siNA (4191C) stab05 uGucuGGuuuGAGccuucATsT 2210
antisense UGUCCACUUACCUGAGGAGCAAG 2017 31426 KDR:3076U21 siNA sense
UCCACUUACCUGAGGAGCATT 2211 UUUGAGCAUGGAAGAGGAUUCUG 2002 31435
KDR:3854U21 siNA sense UGAGCAUGGAAGAGGAUUCTT 2045
AUGGUUCUUGCCUCAGAAGAGCU 2018 31428 KDR:4089U21 siNA sense
GGUUCUUGCCUCAGAAGAGTT 2212 UCUGAAGGCUCAAACCAGACAAG 2019 31429
KDR:4191U21 siNA sense UGAAGGCUCAAACCAGACATT 2213
UGUCCACUUACCUGAGGAGCAAG 2017 31430 KDR:3094L21 siNA (3076C)
antisense UGCUCCUCAGGUAAGUGGATT 2214 UUUGAGCAUGGAAGAGGAUUCUG 2002
31439 KDR:3872L21 siNA (3854C) antisense GAAUCCUCUUCCAUGCUCATT 2049
AUGGUUCUUGCCUCAGAAGAGCU 2018 31432 KDR:4107L21 siNA (4089C)
antisense CUCUUCUGAGGCAAGAACCTT 2215 UCUGAAGGCUCAAACCAGACAAG 2019
31433 KDR:4209L21 siNA (4191C) antisense UGUCUGGUUUGAGCCUUCATT 2216
UGACCUUGGAGCAUCUCAUCUGU 2001 31434 KDR:3304U21 siNA sense
ACCUUGGAGCAUCUCAUCUTT 2044 UCACCUGUUUCCUGUAUGGAGGA 2003 31436
KDR:3894U21 siNA sense ACCUGUUUCCUGUAUGGAGTT 2046
GACAACACAGCAGGAAUCAGUCA 2004 31437 KDR:3948U21 siNA sense
CAACACAGCAGGAAUCAGUTT 2047 UGACCUUGGAGCAUCUCAUCUGU 2001 31438
KDR:3322L21 siNA (3304C) antisense AGAUGAGAUGCUCCAAGGUTT 2048
UCACCUGUUUCCUGUAUGGAGGA 2003 31440 KDR:3912L21 siNA (3894C)
antisense CUCCAUACAGGAAACAGGUTT 2050 GACAACACAGCAGGAAUCAGUCA 2004
31441 KDR:3966L21 siNA (3948C) antisense ACUGAUUCCUGCUGUGUUGTT 2051
GACAACACAGCAGGAAUCAGUCA 2004 31856 KDR:3948U21 siNA stab04 sense B
cAAcAcAGcAGGAAucAGuTT B 2055 GACAACACAGCAGGAAUCAGUCA 2004 31857
KDR:3966L21 siNA (3948C) stab05 AcuGAuuccuGcuGuGuuGTsT 2059
antisense UUUGAGCAUGGAAGAGGAUUCUG 2002 31858 KDR:3854U21 siNA
stab07 sense B uGAGcAuGGAAGAGGAuucTT B 2061 GACAACACAGCAGGAAUCAGUCA
2004 31859 KDR:3948U21 siNA stab07 sense B cAAcAcAGcAGGAAucAGuTT B
2063 UUUGAGCAUGGAAGAGGAUUCUG 2002 31860 KDR:3872L21 siNA (3854C)
stab08 antisense GAAuccucuuccAuGcucATsT 2226
GACAACACAGCAGGAAUCAGUCA 2004 31861 KDR:3966L21 siNA (3948C) stab08
antisense AcuGAuuccuGcuGuGuuGTsT 2227 UUUGAGCAUGGAAGAGGAUUCUG 2002
31862 KDR:3854U21 siNA stab09 sense B UGAGCAUGGAAGAGGAUUCTT B 2228
GACAACACAGCAGGAAUCAGUCA 2004 31863 KDR:3948U21 siNA stab09 sense B
CAACACAGCAGGAAUCAGUTT B 2229 UUUGAGCAUGGAAGAGGAUUCUG 2002 31864
KDR:3872L21 siNA (3854C) stab10 GAAUCCUCUUCCAUGCUCATsT 2230
antisense GACAACACAGCAGGAAUCAGUCA 2004 31865 KDR:3966L21 siNA
(3948C) stab10 ACUGAUUCCUGCUGUGUUGTsT 2231 antisense
UUUGAGCAUGGAAGAGGAUUCUG 2002 31878 KDR:3854U21 siNA inv stab04
sense B cuuAGGAGAAGGuAcGAGuTT B 2232 GACAACACAGCAGGAAUCAGUCA 2004
31879 KDR:3948U21 siNA inv stab04 sense B uGAcuAAGGAcGAcAcAAcTT B
2233 UUUGAGCAUGGAAGAGGAUUCUG 2002 31880 KDR:3872L21 siNA (3854C)
inv AcucGuAccuucuccuAAGTsT 2234 stab05 antisense
GACAA0ACAGCAGGAAUCAGUCA 2004 31881 KDR:3966L21 siNA (3948C) inv
GuuGuGucGuccuuAGucATsT 2235 stab05 antisense
UUUGAGCAUGGAAGAGGAUUCUG 2002 31882 KDR:3854U21 siNA inv stab07
sense B cuuAGGAGAAGGuAcGAGuTT B 2236 GACAACACAGCAGGAAUCAGUCA 2004
31883 KDR:3948U21 siNA inv stab07 sense B uGAcuAAGGAcGAcAcAAcTT B
2237 UUUGAGCAUGGAAGAGGAUUCUG 2002 31884 KDR:3872L21 siNA (3854C)
inv AcucGuAccuucuccuAAGTsT 2238 stab08 antisense
GACAACACAGCAGGAAUCAGUCA 2004 31885 KDR:3966L21 siNA (3948C) inv
GuuGuGucGuccuuAGucATsT 2239 stab08 antisense
UUUGAGCAUGGAAGAGGAUUCUG 2002 31886 KDR:3854U21 siNA inv stab09
sense B CUUAGGAGAAGGUACGAGUTT B 2240 GACAACACAGCAGGAAUCAGUCA 2004
31887 KDR:3948U21 siNA inv stab09 sense B UGACUAAGGACGACACAACTT B
2241 UUUGAGCAUGGAAGAGGAUUCUG 2002 31888 KDR:3872L21 siNA (3854C)
inv ACUCGUACCUUCUCCUAAGTsT 2242 stab10 antisense
GACAACACAGCAGGAAUCAGUCA 2004 31889 KDR:3966L21 siNA (3948C) inv
GUUGUGUCGUCCUUAGUCATsT 2243 stab10 antisense CCUUAUGAUGCCAGCAAAU
2256 32238 KDR:2764U21 siNA sense CCUUAUGAUGCCAGCAAAUTT 2365
CUUAUGAUGCCAGCAAAUG 2257 32239 KDR:2765U21 siNA sense
CUUAUGAUGCCAGCAAAUGTT 2366 UUAUGAUGCCAGCAAAUGG 2258 32240
KDR:2766U21 siNA sense UUAUGAUGCCAGCAAAUGGTT 2367
UAUGAUGCCAGCAAAUGGG 2259 32241 KDR:2767U21 siNA sense
UAUGAUGCCAGCAAAUGGGTT 2368 AUGAUGCCAGCAAAUGGGA 2260 32242
KDR:2768U21 siNA sense AUGAUGCCAGCAAAUGGGATT 2369
CAGACCAUGCUGGACUGCU 2261 32243 KDR:3712U21 siNA sense
CAGACCAUGCUGGACUGCUTT 2370 AGACCAUGCUGGACUGCUG 2262 32244
KDR:3713U21 siNA sense AGACCAUGCUGGACUGCUGTT 2371
GACCAUGCUGGACUGCUGG 2263 32245 KDR:3714U21 siNA sense
GACCAUGCUGGACUGCUGGTT 2372 ACCAUGCUGGACUGCUGGC 2264 32246
KDR:3715U21 siNA sense ACCAUGCUGGACUGCUGGCTT 2373
CCAUGCUGGACUGCUGGCA 2265 32247 KDR:3716U21 siNA sense
CCAUGCUGGACUGCUGGCATT 2374 CAGGAUGGCAAAGACUACA 2266 32248
KDR:3811U21 siNA sense CAGGAUGGCAAAGACUACATT 2375
AGGAUGGCAAAGACUACAU 2267 32249 KDR:3812U21 siNA sense
AGGAUGGCAAAGACUACAUTT 2376 CCUUAUGAUGCCAGCAAAU 2256 32253
KDR:2782L21 siNA (2764C) antisense AUUUGCUGGCAUCAUAAGGTT 2377
CUUAUGAUGCCAGCAAAUG 2257 32254 KDR:2783L21 siNA (2765C) antisense
CAUUUGCUGGCAUCAUAAGTT 2378 UUAUGAUGCCAGCAAAUGG 2258 32255
KDR:2784L21 siNA (2766C) antisense CCAUUUGCUGGCAUCAUAATT 2379
UAUGAUGCCAGCAAAUGGG 2259 32256 KDR:2785L21 siNA (2767C) antisense
CCCAUUUGCUGGCAUCAUATT 2380 AUGAUGCCAGCAAAUGGGA 2260 32257
KDR:2786L21 siNA (2768C) antisense UCCCAUUUGCUGGCAUCAUTT 2381
CAGACCAUGCUGGACUGCU 2261 32258 KDR:3730L21 siNA (3712C) antisense
AGCAGUCCAGCAUGGUCUGTT 2382 AGACCAUGCUGGACUGCUG 2262 32259
KDR:3731L21 siNA (3713C) antisense CAGCAGUCCAGCAUGGUCUTT 2383
GACCAUGCUGGACUGCUGG 2263 32260 KDR:3732L21 siNA (3714C) antisense
CCAGCAGUCCAGCAUGGUCTT 2384 ACCAUGCUGGACUGCUGGC 2264 32261
KDR:3733L21 siNA (3715C) antisense GCCAGCAGUCCAGCAUGGUTT 2385
C0AUGCUGGACUGCUGGCA 2265 32262 KDR:3734L21 siNA (3716C) antisense
UGCCAGCAGUCCAGCAUGGIT 2386 CAGGAUGGCAAAGACUACA 2266 32263
KDR:3829L21 siNA (3811C) antisense UGUAGUCUUUGCCAUCCUGTT 2387
AGGAUGGCAAAGACUACAU 2267 32264 KDR:3830L21 siNA (3812C) antisense
AUGUAGUCUUUGCCAUCCUTT 2388 UGACCUUGGAGCAUCUCAUCUGU 2001 32310
KDR:3304U21 siNA stab09 sense B ACCUUGGAGCAUCUCAUCUTT B 2389
UCACCUGUUUCCUGUAUGGAGGA 2003 32311 KDR:3894U21 siNA stab09 sense B
ACCUGUUUCCUGUAUGGAGTT B 2390
UGACCUUGGAGCAUCUCAUCUGU 2001 32312 KDR:3322L21 siNA (3304C) stab10
AGAUGAGAUGCUCCAAGGUTsT 2391 antisense UCACCUGUUUCCUGUAUGGAGGA 2003
32313 KDR:3912L21 siNA (3894C) stab10 CUCCAUACAGGAAACAGGUTsT 2392
antisense UGACCUUGGAGCAUCUCAUCUGU 2001 32314 KDR:3304U21 siNA inv
stab09 sense B UCUACUCUACGAGGUUCCATT B 2393 UCACCUGUUUCCUGUAUGGAGGA
2003 32315 KDR:3894U21 siNA inv stab09 sense B
GAGGUAUGUCCUUUGUCCATT B 2394 UGACCUUGGAGCAUCUCAUCUGU 2001 32316
KDR:3322L21 siNA (3304C) inv UGGAACCUCGUAGAGUAGATsT 2395 stab10
antisense UCACCUGUUUCCUGUAUGGAGGA 2003 32317 KDR:3912L21 siNA
(3894C) inv UGGACAAAGGACAUACCUCTsT 2396 stab10 antisense
AACAGAAUUUCCUGGGACAGCAA 2268 32762 KDR:828U21 siNA stab07 sense B
cAGAAuuuccuGGGAcAGcTT B 2397 UGGAGCAUCUCAUCUGUUACAGC 2269 32763
KDR:3310U21 siNA stab07 sense B GAGcAucucAucuGuuAcATT B 2398
CACGUUUUCAGAGUUGGUGGAAC 2270 32764 KDR:3758U21 siNA stab07 sense B
cGuuuucAGAGuuGGuGGATT B 2399 CUCACCUGUUUCCUGUAUGGAGG 2271 32765
KDR:3893U21 siNA stab07 sense B cAccuGuuuccuGuAuGGATT B 2400
AACAGAAUUUCCUGGGACAGCAA 2268 32767 KDR:846L21 siNA (8280) stab08
GcuGucccAGGAAAuucuGTsT 2401 antisense UGGAGCAUCUCAUCUGUUACAGC 2269
32768 KDR:3328L21 siNA (3310C) stab08 uGuAAcAGAuGAGAuGcucTsT 2402
antisense CACGUUUUCAGAGUUGGUGGAAC 2270 32769 KDR:3776L21 siNA
(3758C) stab08 uccAccAAcucuGAAAAcGTsT 2403 antisense
CUCACCUGUUUCCUGUAUGGAGG 2271 32770 KDR:3911L21 siNA (3893C) stab08
uccAuAcAGGAAAcAGGuGTsT 2404 antisense UCACCUGUUUCCUGUAUGGAGGA 2003
32771 KDR:3912L21 siNA (3894C) stab08 cuccAuAcAGGAAAcAGGuTsT 2405
antisense AACAGAAUUUCCUGGGACAGCAA 2268 32786 KDR:828U21 siNA inv
stab07 sense B cGAcAGGGuccuuuAAGAcTT B 2406 UGGAGCAUCUCAUCUGUUACAGC
2269 32787 KDR:3310U21 siNA inv stab07 sense B
AcAuuGucuAcucuAcGAGTT B 2407 CACGUUUUCAGAGUUGGUGGAAC 2270 32788
KDR:3758U21 siNA inv stab07 sense B AGGuGGuuGAGAcuuuuGcTT B 2408
CUCACCUGUUUCCUGUAUGGAGG 2271 32789 KDR:3893U21 siNA inv stab07
sense B AGGuAuGuccuuuGuccAcTT B 2409 UCACCUGUUUCCUGUAUGGAGGA 2003
32790 KDR:3894U21 siNA inv stab07 sense B GAGGuAuGuccuuuGuccATT B
2410 AACAGAAUUUCCUGGGACAGCAA 2268 32791 KDR:846L21 siNA (828C) inv
stab08 GucuuAAAGGAcccuGucGTsT 2411 antisense
UGGAGCAUCUCAUCUGUUACAGC 2269 32792 KDR:3328L21 siNA (3310C) inv
cucGuAGAGuAGAcAAuGuTsT 2412 stab08 antisense
CACGUUUUCAGAGUUGGUGGAAC 2270 32793 KDR:3776L21 siNA (3758C) inv
GcAAAAGucucAAccAccuTsT 2413 stab08 antisense
CUCACCUGUUUCCUGUAUGGAGG 2271 32794 KDR:3911L21 siNA (3893C) inv
GuGGAcAAAGGAcAuAccuTsT 2414 stab08 antisense
UCACCUGUUUCCUGUAUGGAGGA 2003 32795 KDR:3912L21 siNA (3894C) inv
uGGAcAAAGGAcAuAccucTsT 2415 stab08 antisense
AACAGAAUUUCCUGGGACAGCAA 2268 32958 KDR:828U21 siNA stab09 sense B
CAGAAUUUCCUGGGACAGCTT B 2416 UGGAGCAUCUCAUCUGUUACAGC 2269 32959
KDR:3310U21 siNA stab09 sense B GAGCAUCUCAUCUGUUACATT B 2417
CACGUUUUCAGAGUUGGUGGAAC 2270 32960 KDR:3758U21 siNA stab09 sense B
CGUUUUCAGAGUUGGUGGATT B 2418 CUCACCUGUUUCCUGUAUGGAGG 2271 32961
KDR:3893U21 siNA stab09 sense B CACCUGUUUCCUGUAUGGATT B 2419
AACAGAAUUUCCUGGGACAGCAA 2268 32963 KDR:846L21 siNA (828C) stab10
GCUGUCCCAGGAAAUUCUGTsT 2420 antisense UGGAGCAUCUCAUCUGUUACAGC 2269
32964 KDR:3328L21 siNA (3310C) stab10 UGUAACAGAUGAGAUGCUCTsT 2421
antisense CACGUUUUCAGAGUUGGUGGAAC 2270 32965 KDR:3776L21 siNA
(3758C) stab10 UCCACCAACUCUGAAAACGTsT 2422 antisense
CUCACCUGUUUCCUGUAUGGAGG 2271 32966 KDR:3911L21 siNA (3893C) stab10
UCCAUACAGGAAACAGGUGTsT 2423 antisense AACAGAAUUUCCUGGGACAGCAA 2268
32988 KDR:828U21 siNA inv stab09 sense B CGACAGGGUCCUUUAAGACTT B
2424 UGGAGCAUCUCAUCUGUUACAGC 2269 32989 KDR:3310U21 siNA inv stab09
sense B ACAUUGUCUACUCUACGAGTT B 2425 CACGUUUUCAGAGUUGGUGGAAC 2270
32990 KDR:3758U21 siNA inv stab09 sense B AGGUGGUUGAGACUUUUGCTT B
2426 CUCACCUGUUUCCUGUAUGGAGG 2271 32991 KDR:3893U21 siNA inv stab09
sense B AGGUAUGUCCUUUGUCCACTT B 2427 AACAGAAUUUCCUGGGACAGCAA 2268
32993 KDR:846L21 siNA (828C) inv stab10 GUCUUAAAGGACCCUGUCGTsT 2428
antisense UGGAGCAUCUCAUCUGUUACAGC 2269 32994 KDR:3328L21 siNA
(3310C) inv CUCGUAGAGUAGACAAUGUTsT 2429 stab10 antisense
CACGUUUUCAGAGUUGGUGGAAC 2270 32995 KDR:3776L21 siNA (3758C) inv
GCAAAAGUCUCAACCACCUTsT 2430 stab10 antisense
CUCACCUGUUUCCUGUAUGGAGG 2271 32996 KDR:391 1121 siNA (3893C) inv
GUGGACAAAGGACAUACCUTsT 2431 stab10 antisense UAUGAUGCCAGCAAAUGGG
2259 33727 KDR:2767U21 siNA stab07 B uAuGAuGccAGcAAAuGGGTT B 2494
AUGAUGCCAGCAAAUGGGA 2260 33728 KDR:2768U21 siNA stab07 B
AuGAuGccAGcAAAuGGGATT B 2495 ACCAUGCUGGACUGCUGGC 2264 33729
KDR:3715U21 siNA stab07 B AccAuGcuGGAcuGcuGGcTT B 2496
CCAUGCUGGACUGCUGGCA 2265 33730 KDR:3716U21 siNA stab07 B
ccAuGcuGGAcuGcuGGcATT B 2497 UAUGAUGCCAGCAAAUGGG 2259 33733
KDR:2785L21 siNA (2767C) stab08 cccAuuuGcuGGcAucAuATsT 2498
AUGAUGCCAGCAAAUGGGA 2260 33734 KDR:2786L21 siNA (2768C) stab08
ucccAuuuGcuGGcAucAuTsT 2499 ACCAUGCUGGACUGCUGGC 2264 33735
KDR:3733L21 siNA (3715C) stab08 GccAGcAGuccAGcAuGGuTsT 2500
CCAUGCUGGACUGCUGGCA 2265 33736 KDR:3734L21 siNA (3716C) stab08
uGccAGcAGuccAGcAuGGTsT 2501 UAUGAUGCCAGCAAAUGGG 2259 33739
KDR:2767U21 siNA stab09 B UAUGAUGCCAG0AAAUGGGTT B 2502
AUGAUGCCAG0AAAUGGGA 2260 33740 KDR:2768U21 siNA stab09 B
AUGAUGCCAG0AAAUGGGATT B 2503 ACCAUGCUGGACUGCUGGC 2264 33741
KDR:3715U21 siNA stab09 B ACCAUGCUGGACUGCUGGCTT B 2504
CCAUGCUGGACUGCUGGCA 2265 33742 KDR:3716U21 siNA stab09 B
C0AUGCUGGACUGCUGGCATT B 2505 UAUGAUGCCAGCAAAUGGG 2259 33745
KDR:2785L21 siNA (2767C) stab10 CCCAUUUGCUGGCAU0AUATsT 2506
AUGAUGCCAGCAAAUGGGA 2260 33746 KDR:2786L21 siNA (2768C) stab10
UCCCAUUUGCUGGCAUCAUTsT 2507 ACCAUGCUGGACUGCUGGC 2264 33747
KDR:3733L21 siNA (3715C) stab10 GCCAGCAGUCCAGCAUGGUTsT 2508
CCAUGCUGGACUGCUGGCA 2265 33748 KDR:3734L21 siNA (3716C) stab10
UGC0AGCAGUCCAGCAUGGTsT 2509 UAUGAUGCCAGCAAAUGGG 2259 33751
KDR:2767U21 siNA inv stab07 B GGGuAAAcGAccGuAGuAuTT B 2510
AUGAUGCCAGCAAAUGGGA 2260 33752 KDR:2768U21 siNA inv stab07 B
AGGGuAAAcGAccGuAGuATT B 2511 ACCAUGCUGGACUGCUGGC 2264 33753
KDR:3715U21 siNA inv stab07 B cGGucGucAGGucGuAccATT B 2512
CCAUGCUGGACUGCUGGCA 2265 33754 KDR:3716U21 siNA inv stab07 B
AcGGucGucAGGucGuAccTT B 2513 UAUGAUGCCAGCAAAUGGG 2259 33757
KDR:2785L21 siNA (2767C) inv AuAcuAcGGucGuuuAcccTsT 2514 stab08
AUGAUGCCAGCAAAUGGGA 2260 33758 KDR:2786L21 siNA (2768C) inv
uAcuAcGGucGuuuAcccuTsT 2515 stab08 ACCAUGCUGGACUGCUGGC 2264 33759
KDR:3733L21 siNA (3715C) inv uGGuAcGAccuGAcGAccGTsT 2516 stab08
CCAUGCUGGACUGCUGGCA 2265 33760 KDR:3734L21 siNA (3716C) inv
GGuAcGAcCuGAcGAccGuTsT 2517 stab08 UAUGAUGCCAGCAAAUGGG 2259 33763
KDR:2767U21 siNA inv stab09 B GGGUAAACGACCGUAGUAUTT B 2518
AUGAUGCCAGCAAAUGGGA 2260 33764 KDR:2768U21 siNA inv stab09 B
AGGGUAAACGACCGUAGUATT B 2519 ACCAUGCUGGACUGCUGGC 2264 33765
KDR:3715U21 siNA inv stab09 B CGGUCGUCAGGUCGUACCATT B 2520
CCAUGCUGGACUGCUGGCA 2265 33766 KDR:3716U21 siNA inv stab09 B
ACGGUCGUCAGGUCGUACCTT B 2521 UAUGAUGCCAGCAAAUGGG 2259 33769
KDR:2785L21 siNA (2767C) inv AUACUACGGUCGUUUACCCTsT 2522 stab10
AUGAUGCCAGCAAAUGGGA 2260 33770 KDR:2786L21 siNA (2768C) inv
UACUACGGUCGUUUACCCUTsT 2523 stab10 ACCAUCCUGGACUGCUGGC 2264 33771
KDR:3733L21 siNA (3715C) inv UGGUACGACCUGACGACCGTsT 2524 stab10
CCAUGCUGGACUGCUGGCA 2265 33772 KDR:3734L21 siNA (3716C) inv
GGUACGACCUGACGACCGUTsT 2525 stab10 VEGFR3 AGCACUGCCACAAGAAGUACCUG
2005 31904 FLT4:2011U21 siNA sense CACUGCCACAAGAAGUACCTT 2068
CUGAAGCAGAGAGAGAGAAGGCA 2006 FLT4:3921U21 siNA sense
GAAGCAGAGAGAGAGAAGGTT 2069 AAAGAGGAACCAGGAGGACAAGA 2007
FLT4:4038U21 siNA sense AGAGGAACCAGGAGGACAATT 2070
GACAAGAGGAGCAUGAAAGUGGA 2008 FLT4:4054U21 siNA sense
CAAGAGGAGCAUGAAAGUGTT 2071 AGCACUGCCACAAGAAGUACCUG 2005 31908
FLT4:2029L21 siNA (2011C) GGUACUUCUUGUGGCAGUGTT 2072 antisense
CUGAAGCAGAGAGAGAGAAGGCA 2006 FLT4:3939L21 siNA (3921C)
CCUUCUCUCUCUCUGCUUCTT 2073 antisense AAAGAGGAACCAGGAGGACAAGA 2007
FLT4:4056L21 siNA (4038C) UUGUCCUCCUGGUUCCUCUTT 2074 antisense
GACAAGAGGAGCAUGAAAGUGGA 2008 FLT4:4072L21 siNA (4054C)
CACUUUCAUGCUCCUCUUGTT 2075 antisense AGCACUGCCACAAGAAGUACCUG 2005
FLT4:2011U21 siNA stab04 B cAcuGccAcAAGAAGuAccTT B 2076 sense
CUGAAGCAGAGAGAGAGAAGGCA 2006 FLT4:3921U21 siNA stab04 B
GAAGcAGAGAGAGAGAAGGTT B 2077 sense AAAGAGGAACCAGGAGGACAAGA 2007
FLT4:4038U21 siNA stab04 B AGAGGAAccAGGAGGAcAATT B 2078 sense
GACAAGAGGAGCAUGAAAGUGGA 2008 FLT4:4054U21 siNA stab04 B
cAAGAGGAGcAuGAAAGuGTT B 2079 sense AGCACUGCCACAAGAAGUACCUG 2005
FLT4:2029L21 siNA (2011C) GGuAcuucuuGuGGcAGuGTsT 2080 stab05
antisense CUGAAGCAGAGAGAGAGAAGGCA 2006 FLT4:3939L21 siNA (3921C)
ccuucucucucucuGcuucTsT 2081 stab05 antisense
AAAGAGGAACCAGGAGGACAAGA 2007 FLT4:4056L21 siNA (4038C)
uuGuccuccuGGuuccucuTsT 2082 stab05 antisense
GACAAGAGGAGCAUGAAAGUGGA 2008 FLT4:4072L21 siNA (4054C)
cAcuuucAuGcuccucuuGTsT 2083 stab05 antisense
AGCACUGCCACAAGAAGUACCUG 2005 FLT4:2011U21 siNA stab07 B
cAcuGccAcAAGAAGuAccTT B 2084 sense CUGAAGCAGAGAGAGAGAAGGCA 2006
FLT4:3921U21 siNA stab07 B GAAGcAGAGAGAGAGAAGGTT B 2085 sense
AAAGAGGAACCAGGAGGACAAGA 2007 FLT4:4038U21 siNA stab07 B
AGAGGAAccAGGAGGAcAATT B 2086 sense GACAAGAGGAGCAUGAAAGUGGA 2008
FLT4:4054U21 siNA stab07 B cAAGAGGAGcAuGAAAGuGTT B 2087 sense
AGCACUGCCACAAGAAGUACCUG 2005 FLT4:2029L21 siNA (2011C)
GGuAcuucuuGuGGcAGuGTsT 2088 stab11 antisense
CUGAAGCAGAGAGAGAGAAGGCA 2006 FLT4:3939L21 siNA (3921C)
ccuucucucucucuGcuucTsT 2089 stab11 antisense
AAAGAGGAACCAGGAGGACAAGA 2007 FLT4:4056L21 siNA (4038C)
uuGuccuccuGGuuccucuTsT 2090 stab11 antisense
GACAAGAGGAGCAUGAAAGUGGA 2008 FLT4:4072L21 siNA (4054C)
cAcuuucAuGcuccucuuGTsT 2091 stab11 antisense
ACUUCUAUGUGACCACCAUCCCC 2272 31902 FLT4:1666U21 siNA sense
UUCUAUGUGACCACCAUCCTT 2432 CAAGCACUGCCACAAGAAGUACC 2273 31903
FLT4:2009U21 siNA sense AGCACUGCCACAAGAAGUATT 2433
AGUACGGCAACCUCUCCAACUUC 2274 31905 FLT4:2815U21 siNA sense
UACGGCAACCUCUCCAACUTT 2434 ACUUCUAUGUGACCACCAUCCCC 2272 31906
FLT4:1684L21 siNA (1666C) GGAUGGUGGUCACAUAGAATT 2435 antisense
CAAGCACUGCCACAAGAAGUACC 2273 31907 FLT4:2027L21 siNA (2009C)
UACUUCUUGUGGCAGUGCUTT 2436 antisense AGUACGGCAACCUCUCCAACUUC 2274
31909 FLT4:2833L21 siNA (2815C) AGUUGGAGAGGUUGCCGUATT 2437
antisense CUGCCAUGUACAAGUGUGUGGUC 2440 34383 FLT4:1609U21 siNA
stab09 B GCCAUGUACAAGUGUGUGGTT B 2526 ACUUCUAUGUGACCACCAUCCCC 2272
34384 FLT4:1666U21 siNA stab09 B UUCUAUGUGACCACCAUCCTT B 2527
CAAGCACUGCCACAAGAAGUACC 2273 34385 FLT4:2009U21 siNA stab09 B
AGCACUGCCACAAGAAGUATT B 2528 AGCACUGCCACAAGAAGUACCUG 2005 34386
FLT4:2011U21 siNA stab09 B CACUGCCACAAGAAGUACCTT B 2529
ACUGCCACAAGAAGUACCUGUCG 2441 34387 FLT4:2014U21 siNA stab09 B
UGCCACAAGAAGUACCUGUTT B 2530 AGUACGGCAACCUCU0CAACUUC 2274 34388
FLT4:2815U21 siNA stab09 B UACGGCAACCUCUCCAACUTT B 2531
UGGUGAAGAUCUGUGACUUUGGC 2442 34389 FLT4:3172U21 siNA stab09 B
GUGAAGAUCUGUGACUUUGTT B 2532 GAAGAUCUGUGACUUUGGCCUUG 2443 34390
FLT4:3176U21 siNA stab09 B AGAUCUGUGACUUUGGCCUTT B 2533
CUGCCAUGUACAAGUGUGUGGUC 2440 34391 FLT4:1627L21 siNA (1609C)
CCACACACUUGUACAUGGCTsT 2534 stab10 ACUUCUAUGUGACCACCAUCCCC 2272
34392 FLT4:1684L21 siNA (1666C) GGAUGGUGGUCACAUAGAATsT 2535 stab10
CAAGCACUGCCACAAGAAGUACC 2273 34393 FLT4:2027L21 siNA (2009C)
UACUUCUUGUGGCAGUGCUTsT 2536 stab10 AGCACUGCCACAAGAAGUACCUG 2005
34394 FLT4:2029L21 siNA (2011C) GGUACUUCUUGUGGCAGUGTsT 2537 stab10
A0UGCCACAAGAAGUACCUGUCG 2441 34395 FLT4:2032L21 siNA (2014C)
ACAGGUACUUCUUGUGGCATsT 2538 stab10 AGUACGGCAACCUCUCCAACUUC 2274
34396 FLT4:2833L21 siNA (2815C) AGUUGGAGAGGUUGCCGUATsT 2539 stab10
UGGUGAAGAUCUGUGACUUUGGC 2442 34397 FLT4:3190L21 siNA (3172C)
CAAAGUCACAGAUCUUCACTsT 2540 stab10 GAAGAUCUGUGACUUUGGCCUUG 2443
34398 FLT4:3194L21 siNA (3176C) AGGCCAAAGUCACAGAUCUTsT 2541 stab10
CUGCCAUGUACAAGUGUGUGGUC 2440 34399 FLT4:1627L21 siNA (1609C)
ccAcAcAcuuGuAcAuGGcTsT 2542 stab08 ACUUCUAUGUGACCACCAUCCCC 2272
34400 FLT4:1684L21 siNA (1666C) GGAuGGuGGucAcAuAGAATsT 2543 stab08
CAAGCACUGCCACAAGAAGUACC 2273 34401 FLT4:2027L21 siNA (2009C)
uAcuucuuGuGGcAGuGcuTsT 2544 stab08 AGCACUGCCACAAGAAGUACCUG 2005
34402 FLT4:2029L21 siNA (2011C) GGuAcuucuuGuGGcAGuGTsT 2545 stab08
ACUGCCACAAGAAGUACCUGUCG 2441 34403 FLT4:2032L21 siNA (2014C)
AcAGGuAcuucuuGuGGcATsT 2546 stab08 AGUACGGCAACCUCUCCAACUUC 2274
34404 FLT4:2833L21 siNA (2815C) AGuuGGAGAGGuuGccGuATsT 2547 stab08
UGGUGAAGAUCUGUGACUUUGGC 2442 34405 FLT4:3190L21 siNA (3172C)
cAAAGucAcAGAucuucAcTsT 2548 stab08 GAAGAUCUGUGACUUUGGCCUUG 2443
34406 FLT4:3194L21 siNA (3176C) AGGccAAAGucAcAGAucuTsT 2549 stab08
VEGFR1 and VEGFR2 homologous sequences CAUGCUGGACUGCUGGCAC 2244
32235 FLT1:3645U21 siNA CAUGCUGGACUGCUGGCACTT 2275
AUGCUGGACUGCUGGCACA 2245 32236 FLT1:3646U21 siNA
AUGCUGGACUGCUGGCACATT 2276 UGCUGGACUGCUGGCACAG 2246 32237
FLT1:3647U21 siNA UGCUGGACUGCUGGCACAGTT 2277 CAUGCUGGACUGCUGGCAC
2244 32250 FLT1:3663L21 siNA (3645C) GUGCCAGCAGUCCAGCAUGTT 2278
AUGCUGGACUGCUGGCACA 2245 32251 FLT1:3664L21 siNA (3646C)
UGUGCCAGCAGUCCAGCAUTT 2279 UGCUGGACUGCUGGCACAG 2246 32252
FLT1:3665L21 siNA (3647C) CUGUGCCAGCAGUCCAGCATT 2280
CCUUAUGAUGCCAGCAAAU 2256 32238 KDR:2764U21 siNA
CCUUAUGAUGCCAGCAAAUTT 2365 CUUAUGAUGCCAGCAAAUG 2257 32239
KDR:2765U21 siNA CUUAUGAUGCCAGCAAAUGTT 2366 UUAUGAUGCCAGCAAAUGG
2258 32240 KDR:2766U21 siNA UUAUGAUGCCAGCAAAUGGTT 2367
UAUGAUGCCAGCAAAUGGG 2259 32241 KDR:2767U21 siNA
UAUGAUGCCAGCAAAUGGGTT 2368 AUGAUGCCAGCAAAUGGGA 2260 32242
KDR:2768U21 siNA AUGAUGCCAGCAAAUGGGATT 2369 CAGACCAUGCUGGACUGCU
2261 32243 KDR:3712U21 siNA CAGACCAUGCUGGACUGCUTT 2370
AGACCAUGCUGGACUGCUG 2262 32244 KDR:3713U21 siNA
AGACCAUGCUGGACUGCUGTT 2371 GACCAUGCUGGACUGCUGG 2263 32245
KDR:3714U21 siNA GACCAUGCUGGACUGCUGGTT 2372 ACCAUGCUGGACUGCUGGC
2264 32246 KDR:3715U21 siNA ACCAUGCUGGACUGCUGGCTT 2373
CCAUGCUGGACUGCUGGCA 2265 32247 KDR:3716U21 siNA
CCAUGCUGGACUGCUGGCATT 2374 CAGGAUGGCAAAGACUACA 2266 32248
KDR:3811U21 siNA CAGGAUGGCAAAGACUACATT 2375 AGGAUGGCAAAGACUACAU
2267 32249 KDR:3812U21 siNA AGGAUGGCAAAGACUACAUTT 2376
CCUUAUGAUGCCAGCAAAU 2256 32253 KDR:2782L21 siNA (2764C)
AUUUGCUGGCAUCAUAAGGTT 2377 CUUAUGAUGCCAGCAAAUG 2257 32254
KDR:2783L21 siNA (2765C) CAUUUGCUGGCAUCAUAAGTT 2378
UUAUGAUGCCAGCAAAUGG 2258 32255 KDR:2784L21 siNA (2766C)
CCAUUUGCUGGCAUCAUAATT 2379 UAUGAUGCCAGCAAAUGGG 2259 32256
KDR:2785L21 siNA (2767C) CCCAUUUGCUGGCAUCAUATT 2380
AUGAUGCCAGCAAAUGGGA 2260 32257 KDR:2786L21 siNA (2768C)
UCCCAUUUGCUGGCAUCAUTT 2381 CAGACCAUGCUGGACUGCU 2261 32258
KDR:3730L21 siNA (3712C) AGCAGUCCAGCAUGGUCUGTT 2382
AGACCAUGCUGGACUGCUG 2262 32259 KDR:3731L21 siNA (3713C)
CAGCAGUCCAGCAUGGUCUTT 2383 GACCAUGCUGGACUGCUGG 2263 32260
KDR:3732L21 siNA (3714C) CCAGCAGUCCAGCAUGGUCTT 2384
ACCAUGCUGGACUGCUGGC 2264 32261 KDR:3733L21 siNA (3715C)
GCCAGCAGUCCAGCAUGGUTT 2385 CCAUGCUGGACUGCUGGCA 2265 32262
KDR:3734L21 siNA (3716C) UGCCAGCAGUCCAGCAUGGTT 2386
CAGGAUGGCAAAGACUACA 2266 32263 KDR:3829L21 siNA (3811C)
UGUAGUCUUUGCCAUCCUGTT 2387 AGGAUGGCAAAGACUACAU 2267 32264
KDR:3830L21 siNA (3812C) AUGUAGUCUUUGCCAUCCUTT 2388
CAUGCUGGACUGCUGGCAC 2244 33725 FLT1:3645U21 siNA stab07 B
cAuGcuGGAcuGcuGGcAcTT B 2449 AUGCUGGACUGCUGGCACA 2245 33726
FLT1:3646U21 siNA stab07 B AuGcuGGAcuGcuGGcAcATT B 2450
CAUGCUGGACUGCUGGCAC 2244 33731 FLT1:3663L21 siNA (3645C) stab08
GuGccAGcAGuccAGcAuGTsT 2451 AUGCUGGACUGCUGGCACA 2245 33732
FLT1:3664L21 siNA (3646C) stab08 uGuGccAGcAGuccAGcAuTsT 2452
CAUGCUGGACUGCUGGCAC 2244 33737 FLT1:3645U21 siNA stab09 B
CAUGCUGGACUGCUGGCACTT B 2453 AUGCUGGACUGCUGGCACA 2245 33738
FLT1:3646U21 siNA stab09 B AUGCUGGACUGCUGGCACATT B 2454
CAUGCUGGACUGCUGGCAC 2244 33743 FLT1:3663L21 siNA (3645C) stab10
GUGCCAGCAGUCCAGCAUGTsT 2455 AUGCUGGACUGCUGGCACA 2245 33744
FLT1:3664L21 siNA (3646C) stab10 UGUGCCAGCAGUCCAGCAUTsT 2456
CAUGCUGGACUGCUGGCAC 2244 33749 FLT1:3645U21 siNA inv stab07 B
cAcGGuCGucAGGucGuAcTT B 2457 AUGCUGGACUGCUGGCACA 2245 33750
FLT1:3646U21 siNA inv stab07 B AcAcGGucGucAGGucGuATT B 2458
CAUGCUGGACUGCUGGCAC 2244 33755 FLT1:3663L21 siNA (3645C) inv
GuAcGAccuGAcGAccGuGTsT 2459 stab08 AUGCUGGACUGCUGGCACA 2245 33756
FLT1:3664L21 siNA (3646C) inv uAcGAccuGAcGAccGuGuTsT 2460 stab08
CAUGCUGGACUGCUGGCAC 2244 33761 FLT1:3645U21 siNA inv stab09 B
CACGGUCGUCAGGUCGUACTT B 2461 AUGCUGGACUGCUGGCACA 2245 33762
FLT1:3646U21 siNA inv stab09 B ACACGGUCGUCAGGUCGUATT B 2462
CAUGCUGGACUGCUGGCAC 2244 33767 FLT1:3663L21 siNA (3645C) inv
GUACGACCUGACGACCGUGTsT 2463 stab10 AUGCUGGACUGCUGGCACA 2245 33768
FLT1:3664L21 siNA (3646C) inv UACGACCUGACGACCGUGUTsT 2464 stab10
UAUGAUGCCAGCAAAUGGG 2259 33727 KDR:2767U21 siNA stab07 B
uAuGAuGccAGcAAAuGGGTT B 2494 AUGAUGCCAGCAAAUGGGA 2260 33728
KDR:2768U21 siNA stab07 B AuGAuGccAGcAAAuGGGATT B 2495
ACCAUGCUGGACUGCUGGC 2264 33729 KDR:3715U21 siNA stab07 B
AccAuGcuGGAcuGcuGGcTT B 2496 CCAUGCUGGACUGCUGGCA 2265 33730
KDR:3716U21 siNA stab07 B ccAuGcuGGAcuGcuGGcATT B 2497
UAUGAUGCCAGCAAAUGGG 2259 33733 KDR:2785L21 siNA (2767C) stab08
cccAuuuGcuGGcAucAuATsT 2498 AUGAUGCCAGCAAAUGGGA 2260 33734
KDR:2786L21 siNA (2768C) stab08 ucccAuuuGcuGGcAucAuTsT 2499
ACCAUGCUGGACUGCUGGC 2264 33735 KDR:3733L21 siNA (3715C) stab08
GccAGcAGuccAGcAuGGuTsT 2500 CCAUGCUGGACUGCUGGCA 2265 33736
KDR:3734L21 siNA (3716C) stab08 uGccAGcAGuccAGcAuGGTsT 2501
UAUGAUGCCAGCAAAUGGG 2259 33739 KDR:2767U21 siNA stab09 B
UAUGAUGCCAGCAAAUGGGTT B 2502 AUGAUGCCAGCAAAUGGGA 2260 33740
KDR:2768U21 siNA stab09 B AUGAUGCCAGCAAAUGGGATT B 2503
ACCAUGCUGGACUGCUGGC 2264 33741 KDR:3715U21 siNA stab09 B
ACCAUGCUGGACUGCUGGCTT B 2504 CCAUGCUGGACUGCUGGCA 2265 33742
KDR:3716U21 siNA stab09 B CCAUGCUGGACUGCUGGCATT B 2505
UAUGAUGCCAGCAAAUGGG 2259 33745 KDR:2785L21 siNA (2767C) stab10
CCCAUUUGCUGGCAUCAUATsT 2506 AUGAUGCCAGCAAAUGGGA 2260 33746
KDR:2786L21 siNA (2768C) stab10 UCCCAUUUGCUGGCAUCAUTsT 2507
ACCAUGCUGGACUGCUGGC 2264 33747 KDR:3733L21 siNA (3715C) stab10
GCCAGCAGUCCAGCAUGGUTsT 2508 CCAUGCUGGACUGCUGGCA 2265 33748
KDR:3734L21 siNA (3716C) stab10 UGCCAGCAGUCCAGCAUGGTsT 2509
UAUGAUGCCAGCAAAUGGG 2259 33751 KDR:2767U21 siNA inv stab07 B
GGGuAAAcGAccGuAGuAuTT B 2510 AUGAUGCCAGCAAAUGGGA 2260 33752
KDR:2768U21 siNA inv stab07 B AGGGuAAAcGAccGuAGuATT B 2511
ACCAUGCUGGACUGCUGGC 2264 33753 KDR:3715U21 siNA inv stab07 B
cGGucGucAGGucGuAccATT B 2512 CCAUGCUGGACUGCUGGCA 2265 33754
KDR:3716U21 siNA inv stab07 B AcGGucGucAGGucGuAccTT B 2513
UAUGAUGCCAGCAAAUGGG 2259 33757 KDR:2785L21 siNA (2767C) inv
AuAcuAcGGucGuuuAcccTsT 2514 stab08 AUGAUGCCAGCAAAUGGGA 2260 33758
KDR:2786L21 siNA (2768C) inv uAcuAcGGucGuuuAcccuTsT 2515 stab08
ACCAUGCUGGACUGCUGGC 2264 33759 KDR:3733L21 siNA (3715C) inv
uGGuAcGAccuGAcGAccGTsT 2516 stab08 CCAUGCUGGACUGCUGGCA 2265 33760
KDR:3734L21 siNA (3716C) inv GGuAcGAccuGAcGAccGuTsT 2517 stab08
UAUGAUGCCAGCAAAUGGG 2259 33763 KDR:2767U21 siNA inv stab09 B
GGGUAAACGACCGUAGUAUTT B 2518 AUGAUGCCAGCAAAUGGGA 2260 33764
KDR:2768U21 siNA inv stab09 B AGGGUAAACGACCGUAGUATT B 2519
ACCAUGCUGGACUGCUGGC 2264 33765 KDR:3715U21 siNA inv stab09 B
CGGUCGUCAGGUCGUACCATT B 2520 CCAUGCUGGACUGCUGGCA 2265 33766
KDR:3716U21 siNA inv stab09 B ACGGUCGUCAGGUCGUACCTT B 2521
UAUGAUGCCAGCAAAUGGG 2259 33769 KDR:2785L21 siNA (2767C) inv
AUACUACGGUCGUUUACCCTsT 2522 stab10 AUGAUGCCAGCAAAUGGGA 2260 33770
KDR:2786L21 siNA (2768C) inv UACUACGGUCGUUUACCCUTsT 2523 stab10
ACCAUGCUGGACUGCUGGC 2264 33771 KDR:3733L21 siNA (3715C) inv
UGGUACGACCUGACGACCGTsT 2524 stab10 CCAUGCUGGACUGCUGGCA 2265 33772
KDR:3734L21 siNA (3716C) inv GGUACGACCUGACGACCGUTsT 2525 stab10
Uppercase = ribonucleotide u,c = 2'-deoxy-2'-fluoro U,C Z = sbL:
symmetrical bifunctional linker T = thymidine B = inverted deoxy
abasic s = phosphorothioate linkage A = deoxy Adenosine G = deoxy
Guanosine A = 2'-C-methyl Adenosine Z = sbL: symmetrical
bifunctional linker H = chol2: capped Cholesterol TEG L = C18
phospholipid Q = L-uridine R = 5-bromo-deoxy-uridine G =
2'-O-methyl Guanosine X = nitroindole universal base Z =
nitropyrole universal base Y = 3',3'-inverted thymidine AA =
glyceryl N = 3'-O-methyl uridine P = L-thymidine Sequence
alignments between select Human (h), Rat (r), and Mouse (m) VEGFR1
(FLT1) and VEGFR2 (KDR) 23mer target Gene Pos Sequence SEQ ID hFLT1
3645 AUCAUGCUGGACUGCUGGCACAG 2572 hKDR 3717 AcCAUGCUGGACUGCUGGCACgG
2573 mFLT1 3422 AUCAUGUUGGAUUGCUGGCACAa 2574 mKDR 3615
AcCAUGCUGGACUGCUGGCAUga 2575 rFLT1 3632 AUCAUGCUGGAUUGCUGGCACAa
2576 rKDR 3650 AcCAUGCUGGAUUGCUGGCAUga 2577 hFLT1 3646
UCAUGCUGGACUGCUGGCACAGA 2578 hKDR 3718 cCAUGCUGGACUGCUGGCACgGg 2579
mFLT1 3423 UCAUGUUGGAUUGCUGGCACAaA 2580 mKDR 3616
cCAUGCUGGACUGCUGGCAUgag 2581 rFLT1 3633 UCAUGCUGGAUUGCUGGCACAaA
2582 rKDR 3651 cCAUGCUGGAUUGCUGGCAUgag 2583 hFLT1 3647
CAUGGUGGACUGCUGGCACAGAG 2584 hKDR 3719 CAUGCUGGACUGCUGGCACgGgG 2585
mFLT1 3424 CAUGUUGGAUUGCUGGCACAaAG 2586 mKDR 3617
CAUGCUGGACUGCUGGCAUgagG 2587 rFLT1 3634 CAUGCUGGAUUGCUGGCACAaAG
2588 rKDR 3652 CAUGCUGGAUUGCUGGCAUgagG 2589 hKDR 2764
UGCCUUAUGAUGCCAGCAAAUGG 2590 hFLT1 2689 UcCCUUAUGAUGCCAGCAAgUGG
2591 mFLT1 2469 UGCCcUAUGAUGCCAGCAAgUGG 2592 mKDR 2662
UGCCUUAUGAUGCCAGCAAgUGG 2593 rFLT1 2676 UGCCcUAUGAUGCCAGCAAgUGG
2594 rKDR 2697 UGCCUUAUGAUGCCAGCAAgUGG 2595 hKDR 2765
GCCUUAUGAUGCCAGCAAAUGGG 2596 hFLT1 2690 cCCUUAUGAUGCCAGCAAgUGGG
2597 mFLT1 2470 GCCcUAUGAUGCCAGCAAgUGGG 2598 mKDR 2663
GCCUUAUGAUGCCAGCAAgUGGG 2599 rFLT1 2677 GCCcUAUGAUGCCAGCAAgUGGG
2600 rKDR 2698 GCCUUAUGAUGCCAGCAAgUGGG 2601 hKDR 2766
CCUUAUGAUGCCAGCAAAUGGGA 2602 hFLT1 2691 CCUUAUGAUGCCAGCAAgUGGGA
2603 mFLT1 2471 CCcUAUGAUGCCAGCAAgUGGGA 2604 mKDR 2664
CCUUAUGAUGCCAGCAAgUGGGA 2605 rFLT1 2678 CCcUAUGAUGCCAGCAAgUGGGA
2606 rKDR 2699 CCUUAUGAUGCCAGCAAgUGGGA 2607 hKDR 2767
CUUAUGAUGCCAGCAAAUGGGAA 2608 hFLT1 2692 CUUAUGAUGCCAGCAAgUGGGAg
2609 mFLT1 2472 CcUAUGAUGCCAGCAAgUGGGAg 2610 mKDR 2665
CUUAUGAUGCCAGCAAgUGGGAA 2611 rFLT1 2679 CcUAUGAUGCCAGCAAgUGGGAg
2612 rKDR 2700 CUUAUGAUGCCAGCAAgUGGGAg 2613 hKDR 2768
UUAUGAUGCCAGCAAAUGGGAAU 2614 hFLT1 2693 UUAUGAUGCCAGCAAgUGGGAgU
2615 mFLT1 2473 cUAUGAUGCCAGCAAgUGGGAgU 2616 mKDR 2666
UUAUGAUGCCAGCAAgUGGGAAU 2617 rFLT1 2680 cUAUGAUGCCAGCAAgUGGGAgU
2618 rKDR 2701 UUAUGAUGCCAGCAAgUGGGAgU 2619 hKDR 3712
ACCAGACCAUGCUGGACUGCUGG 2620 hFLT1 3640 AUCAGAUCAUGCUGGACUGCUGG
2621 mFLT1 3417 ACCAaAUCAUGUUGGAUUGCUGG 2622 mKDR 3610
ACCAGACCAUGCUGGACUGCUGG 2623 rFLT1 3627 ACCAaAUCAUGCUGGAUUGCUGG
2624 rKDR 3645 ACCAaACCAUGCUGGAUUGCUGG 2625 hKDR 3713
CCAGACCAUGCUGGACUGCUGGC 2626 hFLT1 3641 UCAGAUCAUGCUGGACUGCUGGC
2627 mFLT1 3418 CCAaAUCAUGUUGGAUUGCUGGC 2628 mKDR 3611
CCAGACCAUGCUGGACUGCUGGC 2629 rFLT1 3628 CCAaAUCAUGCUGGAUUGCUGGC
2630 rKDR 3646 CCAaACCAUGCUGGAUUGCUGGC 2631 hKDR 3714
CAGACCAUGCUGGACUGCUGGCA 2632 hFLT1 3642 CAGAUCAUGCUGGACUGCUGGCA
2633 mFLT1 3419 CAaAUCAUGUUGGAUUGCUGGCA 2634 mKDR 3612
CAGACCAUGCUGGACUGCUGGCA 2635 rFLT1 3629 CAaAUCAUGCUGGAUUGCUGGCA
2636 rKDR 3647 CAaACCAUGCUGGAUUGCUGGCA 2637 hKDR 3715
AGACCAUGCUGGACUGCUGGCAC 2638 hFLT1 3643 AGAUCAUGCUGGACUGCUGGCAC
2639 mFLT1 3420 AaAUCAUGUUGGAUUGCUGGCAC 2640 mKDR 3613
AGACCAUGCUGGACUGCUGGCAU 2641 rFLT1 3630 AaAUCAUGCUGGAUUGCUGGCAC
2642 rKDR 3648 AaACCAUGCUGGAUUGCUGGCAU 2643 hKDR 3716
GACCAUGCUGGACUGCUGGCACG 2644 hFLT1 3644 GAUCAUGCUGGACUGCUGGCACa
2645 mFLT1 3421 aAUCAUGUUGGAUUGCUGGCACa 2646 mKDR 3614
GACCAUGCUGGACUGCUGGCAUG 2647 rFLT1 3631 aAUCAUGCUGGAUUGCUGGCACa
2648 rKDR 3649 aACCAUGCUGGAUUGCUGGCAUG 2649 hKDR 3811
AGCAGGAUGGCAAAGACUACAUU 2650 hFLT1 3739 AaCAGGAUGGUAAAGACUACAUc
2651 mFLT1 3516 AaCAGGAUGGgAAAGAUUACAUc 2652 mKDR 3709
AGCAGGAUGGCAAAGACUAUAUU 2653 rFLT1 3726 AaCAGGAUGGUAAAGACUACAUc
2654 rKDR 3744 AGCAGGAUGGCAAAGACUAUAUU 2655 hKDR 3812
GCAGGAUGGCAAAGACUACAUUG 2656 hFLT1 3740 aCAGGAUGGUAAAGACUACAUcc
2657 mFLT1 3517 aCAGGAUGGgAAAGAUUACAUcc 2658 mKDR 3710
GCAGGAUGGCAAAGACUAUAUUG 2659 rFLT1 3727 aCAGGAUGGUAAAGACUACAUcc
2660 rKDR 3745 GCAGGAUGGCAAAGACUAUAUUG 2661 Lower case nucleotides
represent mismatches
[0531] Sequence Alignments Between Select Human (h), Rat (r), and
Mouse (m) VEGFr1 (FLT1) and VEGFr2 (KDR) 19mer Target Sequences
4 Gene Pos Seq SEQ ID hFLT1 3645 CAUGCUGGACUGCUGGCAC 2662 hKDR 3717
CAUGCUGGACUGCUGGCAC 2663 mFLT1 3422 CAUGuUGGAuUGCUGGCAC 2664 mKDR
3615 CAUGCUGGACUGCUGGCAu 2665 rFLT1 3632 CAUGCUGGAuUGCUGGCAC 2666
rKDR 3650 CAUGCUGGAuUGCUGGCAu 2667 hFLT1 3646 AUGCUGGACUGCUGGCACA
2668 hKDR 3718 AUGCUGGACUGCUGGCACg 2669 mFLT1 3423
AUGuUGGAuUGCUGGCACA 2670 mKDR 3616 AUGCUGGACUGCUGGCAug 2671 rFLT1
3633 AUGCUGGAuUGCUGGCACA 2672 rKDR 3651 AUGCUGGAuUGCUGGCAug 2673
hFLT1 3647 UGCUGGACUGCUGGCACAG 2674 hKDR 3719 UGCUGGACUGCUGGCACgG
2675 mFLT1 3424 UGuUGGAuUGCUGGCACAa 2676 mKDR 3617
UGCUGGACUGCUGGCAuga 2677 rFLT1 3634 UGCUGGAuUGCUGGCACAa 2678 rKDR
3652 UGCUGGAuUGCUGGCAuga 2679 hKDR 2764 CCUUAUGAUGCCAGCAAAU 2680
hFLT1 2689 CCUUAUGAUGCCAGCAAgU 2681 mFLT1 2469 CCcUAUGAUGCCAGCAAgU
2682 mKDR 2662 CCUUAUGAUGCCAGCAAgU 2683 rFLT1 2676
CCcUAUGAUGCCAGCAAgU 2684 rKDR 2697 CCUUAUGAUGCCAGCAAgU 2685 hKDR
2765 CUUAUGAUGCCAGCAAAUG 2686 hFLT1 2690 CUUAUGAUGCCAGCAAgUG 2687
mFLT1 2470 CcUAUGAUGCCAGCAAgUG 2688 mKDR 2663 CUUAUGAUGCCAGCAAgUG
2689 rFLT1 2677 CcUAUGAUGCCAGCAAgUG 2690 rKDR 2698
CUUAUGAUGCCAGCAAgUG 2691 hKDR 2766 UUAUGAUGCCAGCAAAUGG 2692 hFLT1
2691 UUAUGAUGCCAGCAAgUGG 2693 mFLT1 2471 cUAUGAUGCCAGCAAgUGG 2694
mKDR 2664 UUAUGAUGCCAGCAAgUGG 2695 rFLT1 2678 cUAUGAUGCCAGCAAgUGG
2696 rKDR 2699 UUAUGAUGCCAGCAAgUGG 2697 hKDR 2767
UAUGAUGCCAGCAAAUGGG 2698 hFLT1 2692 UAUGAUGCCAGCAAgUGGG 2699 mFLT1
2472 UAUGAUGCCAGCAAgUGGG 2700 mKDR 2665 UAUGAUGCCAGCAAgUGGG 2701
rFLT1 2679 UAUGAUGCCAGCAAgUGGG 2702 rKDR 2700 UAUGAUGCCAGCAAgUGGG
2703 hKDR 2768 AUGAUGCCAGCAAAUGGGA 2704 hFLT1 2693
AUGAUGCCAGCAAgUGGGA 2705 mFLT1 2473 AUGAUGCCAGCAAgUGGGA 2706 mKDR
2666 AUGAUGCCAGCAAgUGGGA 2707 rFLT1 2680 AUGAUGCCAGCAAgUGGGA 2708
rKDR 2701 AUGAUGCCAGCAAgUGGGA 2709 hKDR 3712 CAGACCAUGCUGGACUGCU
2710 hFLT1 3640 CAGAuCAUGCUGGACUGCU 2711 mFLT1 3417
CAaAuCAUGuUGGAuUGCU 2712 mKDR 3610 CAGACCAUGCUGGACUGCU 2713 rFLT1
3627 CAaAuCAUGCUGGAuUGCU 2714 rKDR 3645 CAaACCAUGCUGGAuUGCU 2715
hKDR 3713 AGACCAUGCUGGACUGCUG 2716 hFLT1 3641 AGAuCAUGCUGGACUGCUG
2717 mFLT1 3418 AaAuCAUGuUGGAuUGCUG 2718 mKDR 3611
AGACCAUGCUGGACUGCUG 2719 rFLT1 3628 AaAuCAUGCUGGAuUGCUG 2720 rKDR
3646 AaACCAUGCUGGAuUGCUG 2721 hKDR 3714 GACCAUGCUGGACUGCUGG 2722
hFLT1 3642 GAuCAUGCUGGACUGCUGG 2723 mFLT1 3419 aAuCAUGuUGGAuUGCUGG
2724 mKDR 3612 GACCAUGCUGGACUGCUGG 2725 rFLT1 3629
aAuCAUGCUGGAuUGCUGG 2726 rKDR 3647 aACCAUGCUGGAuUGCUGG 2727 hKDR
3715 ACCAUGCUGGACUGCUGGC 2728 hFLT1 3643 AuCAUGCUGGACUGCUGGC 2729
mFLT1 3420 AuCAUGuUGGAuUGCUGGC 2730 mKDR 3613 ACCAUGCUGGACUGCUGGC
2731 rFLT1 3630 AuCAUGCUGGAuUGCUGGC 2732 rKDR 3648
ACCAUGCUGGAuUGCUGGC 2733 hKDR 3716 CCAUGCUGGACUGCUGGCA 2734 hFLT1
3644 uCAUGCUGGACUGCUGGCA 2735 mFLT1 3421 uCAUGuUGGAuUGCUGGCA 2736
mKDR 3614 CCAUGCUGGACUGCUGGCA 2737 rFLT1 3631 uCAUGCUGGAuUGCUGGCA
2738 rKDR 3649 CCAUGCUGGAuUGCUGGCA 2739 hKDR 3811
CAGGAUGGCAAAGACUACA 2740 hFLT1 3739 CAGGAUGGuAAAGACUACA 2741 mFLT1
3516 CAGGAUGGgAAAGAuUACA 2742 mKDR 3709 CAGGAUGGCAAAGACUAuA 2743
rFLT1 3726 CAGGAUGGuAAAGACUACA 2744 rKDR 3744 CAGGAUGGCAAAGACUAuA
2745 hKDR 3812 AGGAUGGCAAAGACUACAU 2746 hFLT1 3740
AGGAUGGuAAAGACUACAU 2747 mFLT1 3517 AGGAUGGgAAAGAuUACAU 2748 mKDR
3710 AGGAUGGCAAAGACUAuAU 2749 rFLT1 3727 AGGAUGGuAAAGACUACAU 2750
rKDR 3745 AGGAUGGCAAAGACUAuAU 2751
[0532]
5TABLE V A. 2.5 .mu.mol Synthesis Cycle ABI 394 Instrument Reagent
Equivalents Amount Wait Time* DNA Wait Time* 2'-O-methyl Wait
Time*RNA Phosphoramidites 6.5 163 .mu.L 45 sec 2.5 min 7.5 min
S-Ethyl Tetrazole 23.8 238 .mu.L 45 sec 2.5 min 7.5 min Acetic
Anhydride 100 233 .mu.L 5 sec 5 sec 5 sec N-Methyl 186 233 .mu.L 5
sec 5 sec 5 sec Imidazole TCA 176 2.3 mL 21 sec 21 sec 21 sec
Iodine 11.2 1.7 mL 45 sec 45 sec 45 sec Beaucage 12.9 645 .mu.L 100
sec 300 sec 300 sec Acetonitrile NA 6.67 mL NA NA NA B. 0.2 .mu.mol
Synthesis Cycle ABI 394 Instrument Reagent Equivalents Amount Wait
Time* DNA Wait Time* 2'-O-methyl Wait Time*RNA Phosphoramidites 15
31 .mu.L 45 sec 233 sec 465 sec S-Ethyl Tetrazole 38.7 31 .mu.L 45
sec 233 min 465 sec Acetic Anhydride 655 124 .mu.L 5 sec 5 sec 5
sec N-Methyl 1245 124 .mu.L 5 sec 5 sec 5 sec Imidazole TCA 700 732
.mu.L 10 sec 10 sec 10 sec Iodine 20.6 244 .mu.L 15 sec 15 sec 15
sec Beaucage 7.7 232 .mu.L 100 sec 300 sec 300 sec Acetonitrile NA
2.64 mL NA NA NA C. 0.2 .mu.mol Synthesis Cycle 96 well Instrument
Equivalents:DNA/ Amount: DNA/2'-O- Wait Time* 2'-O- Reagent
2'-O-methyl/Ribo methyl/Ribo Wait Time* DNA methyl Wait Time* Ribo
Phosphoramidites 22/33/66 40/60/120 .mu.L 60 sec 180 sec 360 sec
S-Ethyl Tetrazole 70/105/210 40/60/120 .mu.L 60 sec 180 min 360 sec
Acetic Anhydride 265/265/265 50/50/50 .mu.L 10 sec 10 sec 10 sec
N-Methyl 502/502/502 50/50/50 .mu.L 10 sec 10 sec 10 sec Imidazole
TCA 238/475/475 250/500/500 .mu.L 15 sec 15 sec 15 sec Iodine
6.8/6.8/6.8 80/80/80 .mu.L 30 sec 30 sec 30 sec Beaucage 34/51/51
80/120/120 100 sec 200 sec 200 sec Acetonitrile NA 1150/1150/1150
.mu.L NA NA NA Wait time does not include contact time during
delivery. Tandem synthesis utilizes double coupling of linker
molecule
[0533]
6TABLE VI Cell Number type/Location of Growth Group of tumor
Inoculum Animals Treatment Endpoints Period 1 4Tl-luciferase 1.0
.times. 10.sup.6 10 NA Tumors 15d cells/animal collected in right
flank and flash frozen for analysis of luciferase expression 2
4Tl-luciferase 1.0 .times. 10.sup.6 10 Saline, Tumor 21d
cells/animal Daily IV volume, in right flank injection, tumors 100
.mu.L flash frozen for IHC, expression of VEGFR- 1 and R2 and
endoglin 3 4Tl-luciferase 1.0 .times. 10.sup.6 10 349-9/10 Tumor
21d cells/animal ACTIVE, 30 volume, in right flank mg/kg/d, tumors
daily IV flash frozen for IHC, expression of VEGFR- 1 and R2 and
endoglin 4 4Tl-luciferase 1.0 .times. 10.sup.6 10 349-9/10 Tumor
21d cells/animal INVERTED, volume, in right flank 30 tumors mg/kg/d
flash daily IV frozen for IHC, expression of VEGFR- 1 and R2 and
endoglin
[0534]
7TABLE VII Solution on Stock VEGF Number of Injectate Conc. Group
Filter concentration Animals (1.2 .mu.L) Dose injectate 1 R&D
3.53 .mu.g/.mu.L 5 water 1.0 .mu.g 0.833 Systems .mu.g/.mu.L hVEGF
Each strand 2 R&D 3.53 .mu.g/.mu.L 5 siRNA 3645- 1.0 .mu.g
0.833 Systems 9/10-Active .mu.g/.mu.L hVEGF Each strand 3 R&D
3.53 .mu.g/.mu.L 5 siRNA 3646- 1.0 .mu.g 0.833 Systems 9/10-Active
.mu.g/.mu.L hVEGF Each strand 4 R&D 3.53 .mu.g/.mu.L 5 siRNA
3715- 1.0 .mu.g 0.833 Systems 9/10-Active .mu.g/.mu.L hVEGF Each
strand 5 R&D 3.53 .mu.g/.mu.L 5 siRNA 3716- 1.0 .mu.g 0.833
Systems 9/10-Active .mu.g/.mu.L hVEGF Each strand 6 R&D 3.53
.mu.g/.mu.L 5 siRNA 3645- 1.0 .mu.g 0.833 Systems 9/10-Inverted
.mu.g/.mu.L hVEGF Each strand 7 R&D 3.53 .mu.g/.mu.L 5 siRNA
3645- 1.0 .mu.g 0.833 Systems 9/10-Active .mu.g/.mu.L hVEGF Each
strand 8 R&D 3.53 .mu.g/.mu.L 5 siRNA 3646- 1.0 .mu.g 0.833
Systems 9/10-Active .mu.g/.mu.L hVEGF Each strand 9 R&D 3.53
.mu.g/.mu.L 5 siRNA 3715- 1.0 .mu.g 0.833 Systems 9/10-Active
.mu.g/.mu.L hVEGF Each strand 10 R&D 3.53 .mu.g/.mu.L 5 siRNA
3716- 1.0 .mu.g. 0.833 Systems 9/10-Active .mu.g/.mu.L hVEGF Each
strand 11 R&D 3.53 .mu.g/.mu.L 5 siRNA 3645- 1.0 .mu.g 0.833
Systems 9/10-Inverted .mu.g/.mu.L hVEGF Each strand 12 R&D 3.53
.mu.g/.mu.L 5 SiRNA 349- 1.0 .mu.g 0.833 Systems 9/10 Active
.mu.g/.mu.L hVEGF Each strand
* * * * *